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Uterine leiomyomas (fibroids) are common benign neoplasms arising 
from the smooth muscle layer of the uterus, the myometrium. Despite their 
prevalence in reproductive age women, little is understood of their 
pathobiology. The work in this thesis examined genetic and functional factors 
involved in the aetiology of sporadic leiomyomas, those in the hereditary 
leiomyomatosis and renal cell cancer syndrome, and leiomyomas from 
patients of Affican/Affo-Caribbean ethnicity, who develop more severe 
tumours at an earlier age. Work was carried out studying: the role of apoptosis 
in the tumours; mutations in the FH gene and mtDNA; and copy number 
change by microarray CGH.
The findings of this work demonstrated further differences between the 
pathobiology of HLRCC leiomyomas, compared to sporadic lesions, 
particularly with regard to the mechanisms of resistance to apoptosis of each 
tumour type. Furthermore, germline FH mutations, which cause HLRCC, 
were excluded as a major cause of overall uterine leiomyoma prevalence in 
both sporadic cases, and in Affican/Afro-Caribbean women.
A 1Mb resolution microarray CGH screen demonstrated a number of 
novel regions of copy number change, not previously reported, that may 
harbour novel genes involved in leiomyoma development. Furthermore, this 
study identified a minimal region of 7q deletion of 3.82Mb. Progressing from 
this, a tiling-path resolution CGH microarray specific for chromosome 7q was 
constructed and a number of tumours from different ethnicities were tested. 
This array narrowed the minimal region of deletion to ~273kb on 7q22.2, a 
region containing 2 genes, SRPK2 and MLL5, either of which couldpotentially be involved in uterine leiomyoma aetiology. The results from this 
array also demonstrated a common overlap in the pathobiology of uterine 
leiomyomas from Caucasian and African/Afro-Caribbean women, who 
demonstrated equal frequencies of 7q deletion.
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LI Uterine leiomyomas
Uterine leiomyomas (WHO International Classification of Diseases, 
Tenth Revision, Code D25), more commonly known as fibroids, are benign 
tumours arising from the smooth muscle layer of the uterus, the myometrium. 
They are frequently occurring tumours in women of reproductive age 
characterised by myometrial smooth muscle cell proliferation, and fibrosis 
(Walker and Stewart 2005).
1.1.1  Location and nomenclature
Uterine leiomyomas can occur throughout the myometrium, and are 
classified depending on their locality within the uterus. The most common 
form is the intramural form, where the tumour occurs within the wall of the 
uterus (Stewart 2001b). As the tumour grows, it may extend into the 
abdominal cavity, where it would then be classified as subserosal, or into the 
uterine cavity, where it would be classified as submucosal. Leiomyomas of the 
uterine cervix can also occur, but are uncommon (Wilkinson and Rollason
2001)(Figure 1.1). Pedunculated leiomyomas, where the tumour grows out 
from the myometrium, forming a polypoid structure, may also form from 
subserosal and submucosal leiomyomas (Stewart 2001b).
The location of a uterine leiomyoma influences the type of symptoms 
that affect a patient. For example, submucosal leiomyomas, which intrude into 
the uterine cavity, are most likely to cause menorrhagia due to interference 
with the endometrial lining. Submucosal leiomyomas are also associated with 
increased infertility, again due to the interference with the endometrial lining. 
Finally, pelvic pressure caused by an irregularly shaped, bulky uterus, can
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cause different symptoms depending on leiomyoma location. For example, 
anterior leiomyomas put pressure on the bladder, resulting in urinary 
symptoms, whereas posterior leiomyomas can put pressure on the colorectum, 
leading to constipation (Stewart 2001b).
While the histology of uterine leiomyomas from different locations 
appears similar, a number of molecular differences have been observed. These 
differences, which will be more thoroughly dealt with later on, are suggestive 
of a number of different pathways involved in leiomyoma tumorigenesis, and 
are also reflective of structural differences within the myometrium (Brosens et
Figure 1.1 Classification of uterine leiomyomas depending on their position 
within the uterus (from (Brosens et al.  1998)).
al. 1998),
Pedunculated
subserosal
Intramural
Submucosal
Cervical
Pedunculated
submucosal
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1.1.2  Histology and ultrastructure
Grossly, uterine leiomyomas are firm, pale tumours. They are not 
encapsulated, but are well circumscribed by a pseudo-capsule of compressed 
smooth muscle (Figure 1.2a). They vary considerably in size. Symptomatic 
lesions can be as small as 10mm, but tumours greater than 20cm diameter are 
not uncommon (Walker and Stewart 2005). Leiomyomas consist of interlacing 
fascicles of uniform spindle cells. There is abundant eosinophilic fibrillar 
cytoplasm with blunt-ended, cigar-shaped nuclei of uniform size and little or 
no mitotic activity. The cells are embedded in an extensive, eosinophilic, 
collagen matrix (Figure 1.2b) (Stewart 2001b).
Other histological forms of uterine leiomyomas also exist (Wilkinson 
and Rollason 2001). These include: cellular leiomyomata, which are defined 
as being significantly more cellular than the myometrium, but retain the 
fascicular growth of usual leiomyomas (Wilkinson and Rollason 2001); 
bizarre leiomyoma, which contain multinucleated, monolobed or 
mononucleated giant cells with unusual smooth muscle differentiation 
(Wilkinson and Rollason 2001); and leiomyomblastoma, which contains 
immature smooth muscle cells that mimic foetal uterine myocytes (Watanabe 
et al. 2003).
Ultrastructural studies of uterine leiomyomas have demonstrated a 
number of features distinguishing the tumour cells from the myometrium. 
Common features of the tumour cells include: 6-7nm actin myofilaments 
present in the cytoplasm aligned with the cell axis; sparse rough endoplasmic 
reticulum; few mitochondria, with morphological aberrations including 
swelling; and clustering of organelles to the ends of the nucleus, which is itself
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elongated along the long cell axis. The tumour cells are separated by variable- 
size masses of collagen, which have a diffuse and disorganised structure. An 
increase in the amount and aggregation of the intermediate filament protein 
desmin, has been observed in some leiomyoma cells (Eyden et al. 1992; 
Erlandson 1994; Richards et al.  1998; Eyden 2004).
b
Figure 1.2 a) Uterine leiomyomas from a single patient following surgical 
removal. The tumours occur in a range of sizes, and are removed from a 
variety of locations within the uterus, b) Haematoxylin and eosin stained 
section of a uterine leiomyoma (Original magnification, 400x). The 
leiomyoma cells can be seen running longitudinally and transversely in the 
tumour. The nuclei are elongated and the cells sit in an extensive collagen 
extracellular matrix.
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1.1.3  Epidemiology
Uterine leiomyomas are very common tumours, occurring in 
approximately 30% of reproductive-age women (Buttram and Reiter 1981). 
One study of serial sections of uteri has suggested that up to 77% of women 
have one or more uterine leiomyomas, albeit a majority 
asymptomatically(Cramer and Patel 1990). In the United States, uterine 
leiomyomas account for more than 26% of 650,000 hysterectomies annually 
(Pokras and Hufnagel 1988). The epidemiology of the tumours parallels the 
life-cycle changes in reproductive endocrinology. They have not been 
described in pre-pubescent girls, and generally occur in most women in their 
30’s to 40’s. The symptoms are relieved after the menopause (Stewart 2001b). 
This has lead to a widespread acceptance of the role of the gonadal steroid 
hormones oestrogen and progesterone in the pathobiology of uterine 
leiomyomas (Maruo et al. 2004).
Several epidemiological studies of women with uterine leiomyomas 
have been carried out in order to determine risk factors for these common 
tumours. From these studies, a number of both hormonal and non-hormonal 
factors have been suggested to be associated with an increased risk of 
developing leiomyomas. Hormonal factors affect a woman’s exposure to 
gonadal steroid hormones. These factors include early menarche (Faerstein et 
al. 2001a) (Marshall et al. 1998), increased menstrual cycle length (>30 days) 
(Chen et al. 2001), prolonged menstrual bleeding (>6 days) (Chen et al. 2001), 
and nulliparity (although this may be as a result of uterine leiomyoma-induced 
infertility) (Marshall et al. 1998; Chen et al. 2001).
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The role of oral contraceptives has also been explored. Initially 
conflicting results were published, with some groups claiming an increase in 
leiomyoma prevalence (Samadi et al.  1996), and others claiming a decrease 
(Ross et al. 1986b). Subsequent stratification of the results discovered an 
increase in leiomyoma growth in women exposed to oral contraceptives 
between the ages of 13 and 16 (Marshall et al.  1998), and a decrease in 
prevalence in women exposed to oral contraceptives later on (Marshall et al. 
1998). Conflicting results have also been obtained in studies examining the 
effects of increased body mass index (BMI), but it is generally thought that 
increased BMI leads to an increased risk of uterine leiomyomas (Ross et al. 
1986b) due to increased oestrogen production by adipose tissue (Glass 1989). 
Smoking has also been shown to reduce the risk of uterine leiomyomas, which 
may be due to a smoking-associated lowering of endogenous estrogens 
(MacMahon et al.  1982).
In addition to these hormonal factors, a number of non-hormonal risk 
factors have also been identified. These include : any history of hypertension, 
particularly when requiring medication; pelvic inflammatory disease; 
Chlamydia trachomatis infection; and infectious complications resulting from 
the use of an intrauterine contraceptive device (Faerstein et al. 2001b).
Genetic factors also been shown to play a role in uterine leiomyoma 
pathogenesis. Despite the high prevalence of these tumours in reproductive 
age women, a number of studies have confirmed familial susceptibility. 
Familial clustering has been well documented and it is accepted that female 
relatives of a patient with uterine leiomyomas are at an increased risk (Gross 
and Morton 2001). Furthermore, retrospective twin studies using hysterectomy
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data have shown that monozygotic twins have twice the twin-pair correlation 
for hysterectomy than dizygotic twins. While the data only examined the 
frequency of hysterectomies, the fact that uterine leiomyomas are the leading 
cause for hysterectomy was used to associate this with increased twin-pair 
correlation with familial effects of uterine leiomyomas (Treloar et al.  1992).
A number of Mendelian genetic syndromes have also been identified, 
in which uterine leiomyomas are a part of the tumour spectrum. These include 
hereditary leiomyomatosis and renal cell carcinoma (HLRCC) (Launonen et 
al. 2001), multiple endocrine neoplasia (MEN) (McKeeby et al. 2001) and 
Alport syndrome (Cochat et al.  1988). These will be discussed in greater depth 
later on.
Associations of fibroid prevalence with ethnicity have been observed. 
The most striking example occurs in patients of African or Afro-Caribbean 
ethnicity, who have been shown to develop uterine leiomyomas significantly 
more frequently, with greater multiplicity, at an earlier age of onset, and with 
an increased severity of disease, than Caucasian women or women of other 
ethnicities (Marshall et al. 1997). Prospective studies have demonstrated a 
three-fold greater frequency of leiomyomas in African and Afro-Caribbean 
women compared to white women (Kjerulff et al. 1993). A study by Marshall 
et al demonstrated that despite a higher prevalence of known risk factors in 
African and Afro-Caribbean women, these only accounted for a small 
proportion of the ethnicity-related differences in leiomyoma development 
(Marshall et al. 1997).
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1.1.4  Treatment of uterine leiomyomas
A variety of treatments have been used for uterine leiomyoma patients. 
Surgical intervention is a common treatment and generally takes two forms: 
hysterectomy, the only genuinely curative treatment; and myomectomy, where 
individual leiomyomas are surgically removed and the uterus is left intact 
(Stewart and Nowak 1998). This latter treatment is preferential for younger 
patients who may still wish to have children. However, recurrence of the 
tumours is common following this latter procedure, with one study reporting a 
10 year recurrence rate of 27% in a review of 622 patients (Candiani et al. 
1991). Less invasive surgical techniques have also been used for patients with 
milder symptoms, including hysteroscopic resection for submucosal 
leiomyomas projecting into the uterine cavity (Brandner et al. 2000), and 
laparoscopic (“keyhole”) myomectomy (Donnez et al.  1996).
A number of non-surgical treatments have also been used. The two 
major treatments are uterine artery embolization and Gonadotropin-releasing 
hormone (GnRH) analogue treatment. Both of these interventions are used 
prior to surgery to shrink tumours (Stewart 2001b). Uterine artery 
embolization involves blocking the blood supply to the tumour by injecting 
small particles which block the arteriole branches into the leiomyoma (Smith
2000). While the technique itself is modern, the principles of blocking the 
tumour blood supply to the tumour were described in 1906 in the textbook 
Operative Gynaecology in which the use of selective artery ligation was a 
complement to surgical myomectomy and hysterectomy (Kelly 1906).
GnRH analogues, such as leuprolide acetate and goserelin acetate, 
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and follicle stimulating hormone (FSH), which are responsible for the release 
of oestrogen and progesterone from the ovaries. GnRH analogues work by 
constitutively binding to GnRH receptors in the pituitary gland. Initially this 
causes an increase in LH and FSH release, but chronic treatment results in 
receptor desensitisation, inducing a pseudomenopausal state characterised by 
decreased oestrogen and progesterone (Flake et al. 2003). This results in 
shrinkage of uterine leiomyomas. GnRH analogues have been used 
extensively in the study of the molecular pathways of leiomyoma 
pathogenesis, more of which will be discussed later.
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1.2 Pathobiology of Uterine Leiomyomas
The epidemiology of uterine leiomyomas provides some clues as to 
their pathogenesis, particularly with respect to the reliance of tumorigenesis on 
the presence of the sex hormones oestrogen and progesterone (Gross and 
Morton 2001). However, beyond this, little is understood of the pathobiology 
of the tumours, and many questions, such as why do they occur so frequently, 
and how do the tumours arise in the first place, remain unanswered.
Further molecular clues to leiomyoma pathobiology have been 
identified through a vast number of molecular and genetic studies. However, 
despite the vast array of data, to date no complete picture of the mechanism of 
leiomyoma growth has emerged. Instead, diverse groups of involved cellular 
processes have been implicated.
It has been suggested that there are two distinct components to uterine 
leiomyoma development (Stewart 2001b): the transformation of normal 
myometrial smooth muscle cells into leiomyoma cells; and subsequent growth 
of these cells into clinically apparent tumours. The initial transformation is a 
common event, demonstrated by the high prevalence of microscopic 
leiomyomas (Cramer and Patel  1990; Kjerulff et al.  1993). Subsequent clonal 
expansion leads to the development of symptomatic leiomyomas (Stewart 
2001a).
1.2.1  A genetic basis for uterine leiomyoma development
A number of studies have identified an inherited basis for uterine 
leiomyoma pathogenesis in some patients (Ligon and Morton 2001). Many of 
the key players have been identified through genetic studies, either of
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inherited syndromes characterised by uterine leiomyomas, or through 
cytogenetic studies of somatic tumours.
1.2.1.1 Inherited uterine leiomyoma syndromes
As discussed above, strong evidence exists for inherited forms of 
uterine leiomyoma, starting from the observation of familial clustering (Gross 
and Morton 2001). Within the overall genetic contribution to uterine 
leiomyomas, several known inherited syndromes exist in humans and animals 
for which these tumours are a defined part of the clinical presentation. In a 
number of these syndromes, there is also associated renal disease, including 
cancers. This may reflect the fact that the uterus and kidneys both arise from 
the intermediate mesoderm (Strachan and Read 2004).
1.2.1.1.1 Hereditary Leiomyomatosis and Renal Cell Cancer
In 1958, Kloepfer and colleagues described a family with several 
members with cutaneous leiomyomas, benign tumours of the skin erector pili 
muscle, demonstrating autosomal dominant inheritance with incomplete 
penetrance (Kloepfer et al. 1958). These data were supported by the 
identification of other families with a similar condition (Rudner et al. 1964; 
Berendes et al.  1971). Reed and colleagues described a multiple uterine 
leiomyomas associated with the skin leiomyomas previously described 
(Walker and Reed 1972). Finally, Launonen et al described Finnish families 
with this condition and an increased risk of aggressive renal cancers of rare 
pathology (Launonen et al. 2001). The latter group named this condition 
Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC).
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A large study of a number of families with this condition lead to the 
discovery of linkage to chromosome Iq42.3-q43 (Alam et al. 2001), and the 
subsequent identification of germline inactivating mutations in the FH gene, 
encoding the Krebs’ cycle enzyme fumarate hydratase (FH) (Tomlinson et al.
2002). Subsequent activity assays of patient lymphoblastoid cell lines 
confirmed a reduction in FH activity in heterozygous patients, implying that 
loss of the wild-type copy of the gene would result in a loss of FH activity in 
,  the cell, and cessation of the Krebs cycle (Alam et al. 2003).
1.2.1.1.1.1  Pathogenic effects of FH mutations
The role of FH as a tumour suppressor gene suggested an apparent 
paradox of loss of energy production resulting in tumour growth. Several 
theories were initially proposed as to how tumorigenesis could come about 
including: i) pseudo-hypoxic drive, where hypoxia related signalling pathways 
are activated by the cessation of oxidative metabolism; ii) defective apoptosis 
caused by altered mitochondrial function; iii) stress pathway activation; iv) 
increased mutagenesis by the accumulation of reactive oxygen species 
(ROSs); and v) anabolic drive, where cessation of the Krebs cycle leads to an 
accumulation of biosynthetic building blocks, such as amino acids, fooling the 
cell into thinking it is in a nutrient-rich state and inducing proliferation 
(Pollard et al. 2003; Pollard et al. 2005a). These mechanisms may not be 
mutually exclusive.
The first clues as to the tumorigenic mechanism of HLRCC came 
through the discovery of increased microvessel density in HLRCC 
leiomyomas, with increased expression of pro-angiogenic vascular endothelial 
growth factor, and decreased expression of anti-angiogenic thrombospondin.
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The Bcl-2/adenovirus E1B 19kD protein interacting protein (BNIP3), which 
contains a hypoxia response element in its promoter, was also found to be 
upregulated in HLRCC leiomyomas (Pollard et al. 2005a). Thus, pseudo­
hypoxia was beginning to emerge as a candidate mechanism.
Subsequent in vitro work by Selak et al demonstrated that 
accumulation of succinate, the metabolite immediately preceding fumarate in 
the Krebs cycle, resulted in the stabilisation of Hypoxia inducible factor la 
(HIFla) through the direct product inhibition of the HIF prolyl-hydroxylase 
enzyme, which hydroxylates proline 402 or 564 of HIFla, targeting it for 
ubiquitylation and degradation by the proteasome (Selak et al. 2005). This 
mechanism was confirmed in vivo by the demonstration of accumulation of 
succinate and increased expression of HIFla in HLRCC tumours (Pollard et 
al. 2005c).
1.2.1.1.1.2  The Krebs cycle and tumorigenesis
HLRCC is not the only inherited tumour condition resulting from 
mutations in Krebs cycle enzymes. Hereditary paragangliomatosis and 
pheochromocytoma (HPGL), typified by carotid body tumours, is caused by 
mutations in 3 of the 4 genes encoding succinate dehydrogenase (SDH), the 
enzyme preceding FH in the Krebs cycle (Baysal et al. 2000). Mutations in 
this gene cause loss of enzyme activity and subsequent accumulation of 
succinate following loss of heterozygosity (Selak et al. 2005). The pathogenic 
mechanism of these tumours has been shown to be very similar to that of 
HLRCC (Pollard et al. 2005b).
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1.2.1.1.2 Multiple Endocrine Neoplasia type 1
Multiple endocrine neoplasia type 1  (MEN1) is an autosomal dominant 
tumour syndrome resulting in multiple tumours in the parathyroid and anterior 
pituitary glands and the enteropancreatic endocrine tissues. MEN 1  is caused 
by germline mutations in the MEN1 gene on chromosome 1  lql3 
(Chandrasekharappa et al.  1997). MEN1 patients have also been shown to 
develop multiple leiomyomas of the lungs, oesophagus and uterus (McKeeby 
et al. 2001).
The MEN1 gene encodes the menin protein, which plays a role in 
transcriptional regulation. It has been shown to interact with the transcription 
factor JunD, and loss of menin antagonises transforming growth factor p 
(TGFP) mediated cell growth inhibition (Kaji et al. 2001). As will be 
discussed later, the TGF(3 pathway plays an important role in uterine 
leiomyoma pathogenesis, and menin may cause uterine leiomyomas through 
that pathway.
1.2.1.1.3 Alport syndrome
The Alport syndrome is an X-linked condition resulting in renal failure 
due to mutations in collagen IV that affect the structure of the glomerular 
basement membrane. Alport syndrome has also been associated with diffuse 
leiomyomatosis, particularly of the vulva and oesophagus (Cochat et al. 1988). 
Alport syndrome with diffuse leiomyomatosis arises due to a large germline 
deletion encompassing the COL4A5 and COL4A6 genes on Xq22, encoding 
two collagen type IV isoforms which form an integral part of the basement 
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in the COL4A5 gene only (Heidet et al.  1995). Therefore, it has been proposed 
that COL4A6 plays a role in smooth muscle differentiation (Zhou et al. 1993).
1.2.1.2  Animal models of uterine leiomyomas
Several animal models of uterine leiomyomas have also been 
described. These have proved useful in functional studies of uterine 
leiomyomas, and the evaluation of novel therapies. Furthermore, the genes 
involved have provided new insights into uterine leiomyoma pathogenesis.
1.2.1.2.1  The Eker Rat
The Eker rat was a naturally arising model that was initially studied as 
one of the earliest autosomal dominant models of renal cancers (Eker et al. 
1981). They were used by Knudson to confirm his two-hit hypothesis (Yeung 
et al. 1994). Further breeding and pathology studies demonstrated frequent 
development of uterine leiomyomas and splenic hamengiosarcomas (Howe et 
al.  1995). The mutation that resulted in this phenotype was found to be a 
retroviral insertion disrupting the rat tuberous sclerosis complex 2 (Tsc2) gene, 
and loss or disruption of the wild-type copy has been demonstrated in virtually 
all uterine leiomyomas in this model (Yeung et al. 1995). Expression of the 
TSC2 gene product, Tuberin, has also been found to be decreased in human 
uterine leiomyomas (Wei et al. 2005). This gene is mutated in the human 
disease Tuberous Sclerosis, a hamartoma condition in which patients develop 
tuber-like growths on the brain and may also develop renal carcinoma and 
giant cell astrocytoma (Au et al.  1999).
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Tumour samples and cells lines derived from Eker rat leiomyomas 
have been used as a model system analogous to human leiomyomas in a 
number of studies. The tumours have a similar steroid hormone response to 
human leiomyomas, and also appear to be affected by similar factors, such as 
the protective effect of pregnancy on tumour onset (Walker et al. 2003). In 
addition, a number of molecular similarities have been observed, in particular 
aberrant expression of the High Mobility Group protein HMGA2, which, as 
will be discussed later, is of importance in the pathobiology of human uterine 
leiomyomas (Walker et al. 2003).
1.2.1.2.2  Birt-Hogg-Dube syndrome
Canine hereditary multifocal cystadenocarcinoma and nodular 
dermatofibrosis (RCND) is a naturally occurring inherited cancer syndrome 
first described in German Shepherd dogs. In addition to bilateral, multifocal 
kidney tumours, affected dogs also develop firm collagenous dermal nodules, 
and all affected females develop uterine leiomyomas (Jonasdottir et al. 2000). 
Linkage analysis identified a region on canine chromosome 5 which contained 
the orthologue to the human BHD gene, encoding the protein folliculin, 
mutations of which cause the human renal cancer syndrome Birt-Hogg-Dube 
(Lingaas et al. 2003). In humans, this syndrome also results in hair follicle 
hamartomas and benign lung cysts (Nickerson et al. 2002).
A recent study demonstrated identified the folliculin interacting protein 
1  (FNIP1) and an interaction with AMP-activated protein kinase (AMPK), a 
member of the mammalian target of rapamycin (mTOR) signalling pathway, 
which also involves the TSC2 protein that is mutated in the Eker rat (Baba et 
al. 2006). The mTOR pathway has also been shown to stimulate the
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translation of HIFla, and so the mechanisms in these animal models of 
uterine leiomyoma and HLRCC may converge (King et al. 2006).
1.2.1.3  Other inherited components in uterine leiomyoma pathogenesis
In addition to defined single-gene syndromes with high penetrance, 
familial clustering and ethnicity studies suggest that there are further genetic 
variants within the general population that increase the risk of developing 
uterine leiomyomas.
1.2,13.1  Prevalence of uterine leiomyomas in African/Afro-Caribbean 
women
The clearest association of any factor with increased prevalence of 
uterine leiomyomas has been shown to be African or Afro-Caribbean ethnicity 
(Marshall et al. 1997). Even after taking into account a high level of uterine 
leiomyoma risk factors, such as increased BMI, reproductive history and age 
of oral contraceptive use, ethnicity alone still imparted a relative risk of 3.25 
for the development of uterine leiomyomas (Marshall et al. 1997). This 
increased prevalence on the basis of ethnicity implies that an underlying 
genetic element results in this increased susceptibility.
In the past few years, a number of association studies have attempted 
to elucidate the underlying genetic elements causing this ethnic prevalence. 
Several studies have focused on the oestrogen receptor a gene. Sadan et al 
examined the variation of oestrogen and progesterone receptor levels in 
myometrium and leiomyomas of Caucasian and Negroid patients. They found 
no difference in receptor content between leiomyomas from the two ethnic
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groups, but they demonstrated decreased expression of both receptors in 
myometrium from the Negroid group (Sadan et al. 1988). However, a similar 
study by Amant et al failed to identify this change in expression (Amant et al.
2003).
More recently, intronic polymorphisms of the oestrogen receptor a 
(ERa) gene have been associated with increased prevalence of leiomyomas in 
African and Affo-Caribbean patients (Al-Hendy and Salama 2006b). They 
examined the distribution of a PvuII RFLP site within intron 1  close to the 
start of exon 2 of the ERa gene in 198 cases and 229 controls and determined 
that patients homozygous for an absence of this restriction site were 6.42 times 
more likely to develop uterine leiomyomas than patients of other genotypes 
(Confidence limits 2.04-20.16). This genotype, termed the PP genotype, was 
found to be more prevalent in African and Afro-Caribbean women (35%) than 
Caucasian (13%) or Hispanic (16%) women. Finally, they demonstrated that 
myometrial cells from women with the PP genotype exhibited greater 
proliferation in response to oestrogen stimulation than cells from other 
genotypes (Al-Hendy and Salama 2006b).
Other genetic loci have also been associated with uterine leiomyomas 
in African and Afro-Caribbean women. The Vall38Met coding polymorphism 
in the gene encoding Catechol-O-Methyltransferase (COMT), an important 
enzyme in oestrogen biosynthesis, was investigated and patients homozygous 
for the Val allele were found to have a 2.5 fold increased risk of uterine 
leiomyomas through increased activity of the enzyme (Confidence limits 
1.017-6.151). Again this genotype was more prevalent in African and Afro- 
Caribbean women (Al-Hendy and Salama 2006a).
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Polymorphisms of the promoter of the p450cl7a gene (CYP17), 
another oestrogen biosynthetic enzyme, have also been investigated as a 
possible important variant (Amant et al. 2004). This polymorphism is 
suspected to alter transcription of the gene, with the associated variant 
increasing expression. Results of this pilot study suggested that an association 
was present, and suggested the study be expanded to increase power.
1.2.1.3.2  Other genetic associations with uterine leiomyomas
Studies of genetic variants have also been carried out in women of 
other ethnicities in order to determine genetic factors that may increase 
susceptibility to uterine leiomyomas. In addition to its apparent role in ethnic 
determination of leiomyoma prevalence, the ERa gene has also been a target 
of association studies in other ethnic groups. A number of associations 
between polymorphisms of this gene and increased susceptibility to uterine 
leiomyomas have been described. For example, Hsieh et al identified an 
association between different lengths of a TA dinucleotide repeat upstream of 
the ESR1 gene (encoding ERa), demonstrating an increased prevalence of 
leiomyomas with shorter repeat lengths (Hsieh et al. 2003; Hsieh et al. 2006). 
However, several studies have shown no association of the same alleles with 
uterine leiomyomas (Massart et al. 2001; Denschlag et al. 2006). The general 
functional effect of the reportedly disease-associated alleles of the ERa gene 
is to increase sensitivity of a cell to oestrogen signalling, be it through 
increased receptor expression, or a coding polymorphism that alters ligand 
binding affinity. This increased sensitivity has been shown for at least one of
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these alleles in vitro (the PP allele, described above (Al-Hendy and Salama 
2006b)).
Other allele associations have also been studied, including alleles of 
the CYP17 and COMT genes tested for ethnic association. Whereas 
associations of certain alleles of these had been identified in African and Afro- 
Caribbean patients, as described above (Amant et al. 2004; Al-Hendy and 
Salama 2006a), Denschlag et al identified no such association in either gene 
,  (Denschlag et al. 2006).
Polymorphisms have also been studied in p53, where one study 
identified associations of uterine leiomyomas with the proline variant of the 
Arg72Pro polymorphism (Denschlag et al. 2005), whereas a separate group 
failed to identify an association of the same polymorphism (Hsieh et al. 2004), 
but did identify an association with a promoter polymorphism of tumour 
necrosis factor a (Hsieh et al. 2004).
Many other such associations have been made in the literature, often 
with conflicting results. This may derive from the high frequency of uterine 
leiomyomas in the general population. Potentially, a large, genome-wide 
association study with careful selection of controls may provide a more valid 
insight into genetic elements increasing the risk of uterine leiomyomas.
1.2.1.4  Somatic Genetics of uterine leiomyomas
Uterine leiomyomas frequently arise sporadically, and have been 
determined to occur asymptomatically in as many as 70% of reproductive age 
women (Cramer and Patel 1990). Tumour clonality has been determined by 
analysis of the X-linked polymorphic loci of glucose-6-phosphate (Linder and
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Gartler 1965) and the human androgen receptor (Fujimoto et al. 2000), which 
have both shown that uterine leiomyomas arise from a single cell or clone of 
cells. The somatic genetics of uterine leiomyomas have been extensively 
studied and both cytogenetic and sequence aberrations have been identified.
1.2.1.4.1  Cytogenetic aberrations
The most frequently described genetic changes in uterine leiomyomas 
are cytogenetic aberrations, where chromosomal structure is altered. Such 
changes have been observed in approximately 40% of studied tumours (Ligon 
and Morton 2001). A wide variety of changes have been observed, including: 
copy number changes, where regions of chromosomes are deleted or 
amplified; translocations, where two chromosomes break and are fused 
together; and other changes such as inversions or the presence of marker 
chromosomes (Ligon and Morton 2001).
While cytogenetic changes involving almost every chromosome have 
been reported, several relatively frequent, non-random changes have been 
extensively studied in order to provide clues to their role in leiomyoma 
pathogenesis. The most frequent of these changes are interstitial deletions of 
chromsome 7q, translocations between chromosomes 12 and 14, and 
rearrangements of 6p21 (Ligon and Morton 2001).
One study identified a difference in the frequency of chromosomal 
abnormalities in uterine leiomyomas depending on their location (Brosens et 
al.  1998). Submucosal leiomyomas had fewer abnormalities than subserosal 
and intramural leiomyomas. This difference could be explained by an apparent 
difference in hormonal regulation of submucosal leiomyomas. Higher levels 
of progesterone and oestrogen receptors have been reported in submucosal
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leiomyomas (Marugo et al.  1989), and the embryonic development of 
oestrogen receptors in the subendometrial myometrium also differs from the 
rest of the myometrium (Glatstein and Yeh 1995). Submucosal leiomyomas 
are also more effectively treated by GnRH analogues (Donnez et al. 1989). 
Therefore, it was suggested that leiomyomas with cytogenetic aberrations 
exhibited loss of dependency on sex hormones for growth (Brosens et al. 
1998), and the genes affected by these aberrations confer that growth 
,  independence.
1.2.1.4.1.1  The del(7q) group
Interstitial deletions of chromosome 7q, particularly involving bands 
q22-q32, are a frequently observed cytogenetic aberration in uterine 
leiomyomas, occurring in approximately 17% of karyotypically abnormal 
lesions (Xing et al. 1997). The high frequency and specificity of deletions in 
this region has lead to widespread speculation that a novel leiomyoma tumour 
suppressor gene is present there.
Observations of 7q deletions have frequently shown tumours to be 
mosaics, containing a number of karyotypically normal cells (Xing et al.
1997). Clonality studies have shown that all the cells in these mosaic tumours 
arose from the same cells (Xing et al. 1997). This has lead to speculation that 
deletions of 7q are a secondary event in leiomyoma pathogenesis, potentially 
an event that occurs as a later part of tumour progression (Xing et al. 1997).
7q deletions can occur as the sole abnormality, or in conjunction with 
other chromosomal changes. Leiomyomas with 7q deletions are smaller than 
those with other karyotypic abnormalities, such as t(12; 14), and have been 
reported to be smaller than karyotypically normal leiomyomas (Rein et al.
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1998). Furthermore, cultures of leiomyomas with del(7q) grow particularly 
poorly and frequently become enriched for karyotypically normal cells (Xing 
et al. 1997). The combination of decreased tumour size and poor in vitro 
growth has lead to speculation that a tumour suppressor gene on 7q22 may be 
involved in the regulation of cell growth, and deletion of this gene may inhibit 
cell growth (Xing et al.  1997). However, the possibility also exists that while 
deletion of this gene may inhibit cell growth, it may promote cell survival, 
although one study examining the effectiveness of GnRH analogue therapy on 
uterine leiomyomas with 7q LOH failed to find a protective effect (Takahashi 
et al. 2001a).
In addition to deletion, involvement of 7q22 has been reported in other 
cytogenetic abnormalities in leiomyomas, including inversions (Fan et al.
1990) and translocations (Sargent et al. 1994), thus implicating this band as 
the important region in these rearrangements. Uterine leiomyomas are the only 
solid tumour where 7q22 rearrangements occur consistently, although 
deletions are frequently observed in acute leukaemias (Flake et al. 2003) and 
translocations and deletions involving 7q22 have been described in other 
benign mesenchymal tumours, such as lipomas (Mandahl et al. 1988; Dal Cin 
et al.  1997).
The q22 band of chromosome 7 is a gene-dense region (Xing et al. 
1997). A number of genes in the 7q22 band have been studied as candidate 
tumour suppressors. The Cut-like homeobox gene (CUTL1) was found to be 
deleted and to have reduced expression in del(7q22) leiomyomas (Zeng et al. 
1997). This was an intriguing candidate since it encodes a transcriptional 
repressor that down-regulates the expression of the c-myc oncogene (Higgy et
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al. 1997). However, a later study by the same authors identified 
overexpression of N-terminally truncated versions of CUTL1 in leiomyomas, 
and so concluded that it was unlikely to be the candidate tumour suppressor 
(Moon et al. 2002). Other genes have also been studied, including pro­
collagen carboxy-terminal proteinase enhancer protein (PCOLCE), although 
no change in expression was identified (Ligon et al. 2002), and laminin B1 
(LAMB1) (Saito et al. 2005). However, no strong candidate gene has been 
identified.
Other studies have attempted to minimise the region of deletion in 
order to identify the predicted tumour suppressor. One study used a 
combination of karyotyping and loss of heterozygosity (LOH) analysis to 
minimise the region (Ishwad et al. 1995). They reported a minimal region of 
deletion between the markers D7S518 and D7S471, a region of approximately 
10Mb. A later study by the same group claimed to have further refined this 
region surrounding the marker D7S666 (Ishwad et al.  1997). However, the 
LOH map in this paper did not appear to support their conclusions, with LOH 
occurring in samples outside their minimum defined region in the samples 
used to define that region.
Another study also used LOH analysis to refine the deleted region to 
an approximately 1.5Mb region (van der Heijden et al.  1998), 4Mb distal from 
the region identified in the previous studies (Ishwad et al. 1997). A 
fluorescence in situ hybridisation (FISH) based study refined the region to 
approximately 11Mb (Vanni et al. 1999). More recently, Sell et al identified 
LOH at a single marker, D7S2446, giving a supposed minimal region of less 
than 500kb and containing 2 genes, Origin recognition complex subunit 5
54Chapter  1  Introduction
(ORC5L) and Lipoma HMGIC fusion partner-like 3 (.LHFPL3) (Sell et al.
2005). Again, however, this region differed from the locations of other 
minimal regions.
1.2.1.4.1.2  The t(12;14) group
Translocations involving chromosomes 12ql4-15 are also a frequently 
reported aberration, occurring in approximately 20% of karyotypically 
abnormal leiomyomas (Heim et al. 1988; Ligon and Morton 2001). The most 
frequent translocation partner is chromosome 14q24 (Ligon and Morton
2001). Mapping of the chromosome 12 breakpoint revealed the high mobility 
group gene HMGI-C (more recently called HMGA2) as the translocation 
partner (Schoenmakers et al. 1995). The involved gene on chromosome 14q24 
was identified as the DNA repair gene RAD51L (Schoenmakers et al.  1999). 
This translocation has been shown to fuse the two genes and produce an in­
frame fusion transcript (Takahashi et al. 2001b). However, fusion transcripts 
do not occur in all leiomyomas with t(12; 14) (Quade et al. 2003) and it is 
thought that they are not the principal means of pathogenesis occurring from 
this rearrangement.
Uterine leiomyomas with t(12; 14) have been shown to be significantly 
larger (Rein et al. 1998) and less responsive to GnRH analogue therapy 
(Takahashi et al. 2002) than karyotypically normal tumours, and those with 7q 
deletions. Thus it appears that leiomyomas with this karyotype attain 
independence from sex hormones.
HMGA2 has also been shown to translocate with other chromosomes 
in uterine leiomyomas, and a number of other fusion partners have been 
described, including: cytochrome c oxidase subunit 6C (COX6C) on
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chromosome 8q22-23 (Kurose et al. 2000); homo sapiens enhancer of invasion 
10 (HEI10) on chromosome 14ql 1  (Mine et al. 2001); and the aldehyde 
dehydrogenase gene (ALDH2) on 12q24 as the result of an inversion 
(Kazmierczak et al. 1995). There is also a suspected fusion partner on 
chromosome 5q22 in uterine lipoleiomyomas (Havel et al. 1989).
Furthermore, HMGA2 has also been involved in translocations observed in 
other benign mesenchymal tumours including lipomas, hamartomas and 
endometrial polyps (Tallini et al. 2000).
Expression of the HMGA2 protein is normally associated with foetal 
tissues, and its expression is switched off in adult tissues, bar the lung and 
kidney (Gattas et al. 1999). Analysis of HMGA2 expression in uterine 
leiomyomas demonstrated an increase in expression compared to matched 
myometrium, but only in samples with t( 12; 14) (Gross et al. 2003). HMGA2 
expression has also been shown to be increased in uterine leiomyomas from 
the Eker rat (Hunter et al. 2002) Therefore, it has been suggested that 
disruption of the HMGA2 gene exerts a pathogenic effect by increasing 
HMGA2 expression. This increased expression may come about because of 
mRNA truncation resulting from the translocation. It has been shown that the 
3’-UTR of the HMGA2 gene is responsible for controlling translation of the 
mRNA. Removal of the 3’-UTR, which occurs in uterine leiomyomas with 
t(12; 14) results in an increase in levels of translated protein (Borrmann et al. 
2001).
Very recently, a series of novel transcripts were identified within the 
HMGA2 gene transcribed from the complementary strand (Ingraham et al.
2006). Expression of these novel transcripts was also found to be upregulated
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in uterine leiomyomas. Their role is as yet undefined, although they are 
suspected of being non-coding RNA molecules, potentially with regulatory 
capacity.
HMGA2 is a nuclear phosphoprotein containing 3 DNA binding 
domains, and is thought to be an architectural transcription factor. It was 
originally discovered as a protein expressed at high levels following 
transformation of fibroblasts with an oncogenic virus (Giancotti et al.  1987).
,  It has recently been shown that HMGA2 overexpression results in pituitary 
tumorigenesis through interaction with the retinoblastoma tumour suppressor 
gene product pRB. It displaces the histone deacetylase HDAC1 from the DNA 
bound pRB/E2Fl, resulting in local histone and E2F1 acetylation, which 
switches on the expression of S-phase genes (Fedele et al. 2006). A similar 
mechanism may occur in leiomyoma cells with t(12;14).
1.2.1.4.1.3  The 6p21 group
Identification of the HMGA2 gene as the translocation partner involved 
in t( 12; 14) and the frequency of rearrangements of 6p21 in uterine 
leiomyomas and other benign mesenchymal tumours lead to the study of the 
known HMGA1 gene in this region. A single PAC clone containing HMGA1 
was found to span breakpoints in this region (Kazmierczak et al. 1996). 
Rearrangements of this region include t(6;10)(p21;q22) (Gross et al. 2004), 
and t(l;6)(q23;p21) and t(6;14)(p21;q24) (Ligon and Morton 2001). HMGA1 
expression has been shown to be increased in uterine leiomyomas with 
rearrangements of 6p21 (Tallini et al. 2000).
The mechanism of HMGA1-associated tumorigenesis is likely to be 
similar to that of HMGA2. Indeed, overexpression of truncated HMGA1 in
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mouse pre-adipocytes induced proliferation with increased E2F1 activity 
(Tallini et al. 2000), implying that HMGA1 and HMGA2 may have a similar 
effect on inducing cell proliferation through interaction with pRB.
1.2.1.4.1.4 Other cytogenetic aberrations
A whole host of other cytogenetic aberrations have been described in 
uterine leiomyomas. Many of these are recurrent changes, though not at the 
frequency of those described above. These include deletions of 3p 13-14 (Hu 
and Surti 1991), and rearrangements of the X chromosome such as 
inv(X)(p22;ql3) (Ozisik et al. 1992) and del(X)(pl 1) (Turc-Carel et al. 1988). 
Marker chromosomes, such as ring chromosome 1, have also been observed in 
leiomyomas, although always where other abnormalities are present (Nilbert 
et al. 1988).
A translocation of chromosomes 10 and 17 was shown to disrupt the 
histone deacetylase MORF (Moore et al. 2004). Disruption of this gene may 
be related to HMGA pathogenesis due to the involvement of histone 
acetylation. Deletions have also been observed of lq42.3, the cytogenetic 
location of the FH gene, indicating that this gene might have a role to play in 
sporadic leiomyma development (Gattas et al. 1999).
1.2.1.4.2  Somatic mutations in uterine leiomyomas
Screening for somatic sequence variants has also been carried out in a 
number of genes, including FH, TP53, MDM2, KRAS, and CUTL1 (Hall et al. 
1997; Barker et al. 2002; Kiuru et al. 2002; Patrikis et al. 2003).
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Some FH mutations were observed in sporadic uterine leiomyomas but at a 
very low frequency (Kiuru et al. 2002). Activating KRAS mutations were 
observed in 3/20 uterine leiomyomas screened in one study (Hall et al. 1997), 
but none were found in the other (Patrikis et al. 2003). No somatic mutations 
were identified in any of the other genes screened.
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1.2.2  Mechanisms and pathways of leiomyoma growth
In addition to the genetic studies carried out on uterine leiomyoma 
patients, numerous studies have been carried out in an attempt to elucidate the 
mechanisms and signalling pathways involved in leiomyoma pathogenesis in 
order to identify targets for clinical intervention. A variety of cell signalling 
pathways and associated growth factors have been implicated in uterine 
leiomyoma pathogenesis (Maruo et al. 2004). Strong evidence exists for the 
roles of oestrogen, progesterone, transforming growth factor p (TGF|3), 
platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and 
vascular endothelial growth factor (VEGF) among others (Maruo et al. 2004). 
These pathways have effects on a number of mechanisms important to 
leiomyoma pathogenesis, including cell proliferation, extracellular matrix 
deposition, resistance to apoptosis and angiogenesis (Maruo et al. 2004).
1.2.2.1  Sex hormone signalling
As is eluded to above, the epidemiology of uterine leiomyomas 
suggests a strong, if not essential involvement of the female sex hormones 
oestrogen and progesterone in tumour formation, particularly due to the 
observed regression of the tumours following the menopause, and the 
successful use of GnRH analogues, which induce a hormonally 
pseudomenopausal state, in shrinking uterine leiomyomas prior to surgery 
(Stewart 2001b).
The levels of oestrogen and progesterone vary with the stage of the 28 
day menstrual cycle. In the follicular phase of the cycle, from day 0 to day 13, 
progesterone and oestrogen levels are initially low during menstruation. The
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level of oestrogen begins to accumulate before peaking approximately 1  day 
prior to ovulation before regressing slightly. Following ovulation, the cycle 
enters the luteal phase. Levels of both progesterone, produced by the corpus 
luteum in the ovary, and oestrogen begin to rise, peaking at approximately 5-7 
days following ovulation. The levels of both hormones then regress back to 
the basal level on about day 28 as the menstruation begins to occur (Hacker 
and Moore 1998). Leiomyomas have been shown to be most proliferative in 
the luteal phase of the cycle, when there is abundant oestrogen and 
progesterone (Figure 1.3) (Walker and Stewart 2005).
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Figure 1.3 Hormone levels and endometrial histology during the menstrual 
cycle. (Adapted from
https ://webapp. walgreens. com/cePharmacy/programsHTML/reproductive. htm 
1, Figure 3)
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1,2.2.1.1  Oestrogen signalling
Oestrogen has been shown to act on two receptors, ERa and ER(3.
Both receptors are expressed in the myometrium and leiomyoma, with ERa 
being the more prevalent form. Expression of both receptors has been shown 
to be increased in uterine leiomyomas compared to the host myometrium at 
the mRNA level (Benassayag et al.  1999), with the increase in ERa 
expression more notable. This increased expression would increase the 
sensitivity of a leiomyoma cell to oestrogen signalling.
Levels of circulating oestrogen do not differ between women with and 
without uterine leiomyomas, nor are leiomyomas associated with conditions 
resulting in elevated oestrogen, such as polycystic ovarian syndrome (Buttram 
1986). However, local oestrogen levels may be elevated since several studies 
have identified increased expression of aromatase p450, an oestrogen 
synthetase, in leiomyomas (Bulun et al.  1994; Shozu et al. 2002). Therefore, in 
situ oestrogen synthesis may affect leiomyoma growth through an 
autocrine/paracrine mechanism (Sumitani et al. 2000). Aromatase p450 
expression is reduced upon treatment with GnRH analogues (Shozu et al. 
2001). Furthermore, Shozu et al demonstrated shrinkage of a uterine 
leiomyoma upon treatment with the aromatase inhibitor, Fadrazole, reporting a 
71% loss in tumour volume in 8 weeks (Shozu et al. 2003).
Barbarisi et al examined the effects of oestrogen signalling on cultured 
leiomyoma cells (Barbarisi et al. 2001). They found that oestrogen triggers a 
rapid and transient activation of the mitogen-activated protein kinase (MAPK) 
pathway. Furthermore, tyrosine phosphorylation of some intracellular 
pathways, including phosphoplipase C y (PLCy), phosphatidyl-inositide-3-
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kinase (PI-3-K) and the GTPase activating protein (GAP) was observed, 
indicative of activation of a transmembrane receptor tyrosine kinase. The 
activating ligand was discovered to be platelet derived growth factor (PDGF) 
(Barbarisi et al. 2001). Further details of this will be discussed later.
A number of oestrogen regulated genes have been reported as being 
overexpressed in uterine leiomyomas, including collagens I and III, and the 
progesterone receptor (Maruo et al. 2004). Oestrogen is also thought to induce 
,  the expression of other growth factors in leiomyoma cells including IGF-I and 
its receptor, the epidermal growth factor receptor (EGFR) and prolactin 
(Watters et al. 2000). It has also been shown to alter the expression of a 
number of other important cell factors, including downregulation of the p53 
tumour suppressor (Gao et al. 2002), and upregulation of the proliferative 
marker proliferating cell nuclear antigen (PCNA) (Maruo et al. 2003).
1.2.2.1.2  Progesterone signalling
The effects of progesterone signalling in leiomyomas are less clear, 
and studies have produced conflicting results. Although two peaks of 
oestrogen production occur during the menstrual cycle, the greatest level of 
proliferation is observed in the luteal phase, when not only oestrogen, but also 
progesterone levels peak (Hacker and Moore 1998; Walker and Stewart 2005). 
Progesterone receptor (PR) expression is also increased in uterine leiomyomas 
(Sadan et al. 1987), and several studies have been published implicating 
progesterone in uterine leiomyoma pathogenesis. The progesterone analogue 
medroxyprogesterone acetate significantly increases mitotic activity in 
leiomyomas (Tiltman 1985), and the progesterone antagonist RU-486 reduces 
the size of leiomyomas and PR expression (Murphy et al. 1995). Progestins
63Chapter 1  Introduction
have also been shown to inhibit the therapeutic effects of GnRH 
analogues(Friedman et al. 1988). To confuse matters, progestins have been 
demonstrated to transdominantly suppress ER signalling in Eker rat 
leiomyomas, resulting in down regulation of oestrogen-induced PR expression 
(Hodges et al. 2002).
PR, like ER, exists in two forms, PR-A and PR-B, each of which 
possesses a distinct biological function. PR-B is a transcriptional activator of 
progesterone responsive genes, whereas PR-A is a repressor of PR-B 
transcriptional activity in certain cell contexts. Expression of both PRs is 
higher in leiomyomas than myometrium, with a dominance of PR-A over PR- 
B (Viville et al. 1997; Nisolle et al. 1999), although one of these studies failed 
to find an increase in mRNA level. Another study demonstrated relative 
overexpression of PR-B on the cell surface (Fujimoto et al. 1998). This pattern 
of expression may represent a proliferating phenotype for leiomyoma growth, 
allowing a majority of progesterone to be bound by the transcription- 
activating PR-B, before it reaches the intracellular PR-A.
The more specific downstream effects of progesterone in uterine 
leiomyomas have also been studied. Maruo et al studied the effects of 
progesterone on growth factor expression in cultured leiomyoma cells. They 
demonstrated an increase in the expression of EGF, which complemented the 
increase in EGFR by oestrogen signalling. They also demonstrated an increase 
in PCNA expression which, in vivo, is most highly expressed in the 
progesterone dominated luteal phase of the menstrual cycle, and is also 
upregulated by oestrogen (Maruo et al. 2003). The expression of IGF-I, which 
induces proliferation, was also examined in this study. The results showed a
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significant decrease in IGF-I mRNA upon treatment with progesterone or 
combined progesterone and oestrogen treatment, with no effect on expression 
caused by oestrogen alone (Maruo et al. 2003). This finding differs from the 
results of Burroughs et al in studies using Eker rat leiomyomas, who 
demonstrated a 7.5-fold increase in IGF-I mRNA upon treatment with 
oestrogen (Burroughs et al. 2002).
The progesterone response of the expression of two apoptosis-related 
proteins, the apoptosis inducing tumour necrosis factor a (TNFa), and the 
anti-apoptotic B-cell lymphoma 2 (Bcl-2), has also been studied. These studies 
have identified increased expression of Bcl-2 (Matsuo et al. 1997), and 
decreased expression of TNFa (Kurachi et al. 2001) in response to 
progesterone. This implies that progesterone is a pro-survival signal for 
leiomyoma cells, but also has an anti-proliferative effect.
This anti-proliferative effect of progesterone may explain why uterine 
leiomyomas very rarely grow during pregnancy, but remain the same size or 
shrink over the course of the pregnancy (Phelan 1995), since progesterone 
concentrations increase throughout the course of the pregnancy to levels 
higher than observed during the menstrual cycle (Hacker and Moore 1998).
Overall there appears to be complex interplay between oestrogen and 
progesterone signalling in uterine leiomyomas. Ultimately, the two hormones 
almost certainly exhibit a combined effect, resulting in leiomyoma growth. 
However, the exact mechanism of how this occurs has yet to be fully 
discovered.
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1.2.2.2  Platelet-derived growth factor signalling
Platelet-derived growth factor (PDGF) is a potent smooth muscle cell 
mitogen, acting through a receptor tyrosine kinase to activate the MAPK 
pathway, resulting in increased DNA synthesis and cell proliferation (Ross et 
al.  1986a). Expression of PDGF and its receptor has been described in 
leiomyoma cells, suggesting an autocrine/paracrine signalling mechanism 
(Palman et al. 1992). As described above, PDGF expression in leiomyoma 
•  ■  cells is stimulated by oestrogen, and it appears that expression of PDGF by 
these cells is at least one of the means by which oestrogen induces cell 
proliferation (Barbarisi et al. 2001). In cultured cells, treatment with oestrogen 
induces PDGF expression and cell proliferation. Addition of antibodies 
against PDGF to the culture media to sequester secreted PDGF inhibited 
oestrogen-induced cell proliferation (Barbarisi et al. 2001). In addition, PDGF 
expression is downregulated by GnRH analogues, implying an in vivo 
relationship between the sex hormones and PDGF expression (Di Lieto et al. 
2005). The PDGF-R receptor is overexpressed in cultured leiomyoma cells 
compared to myometrium, but has a lower affinity for the ligand (Fayed et al. 
1989).
PDGF expression has also been shown to be modulated by TGF|3-1. In 
smooth muscle cells, low levels of TGF|3-1 stimulate PDGF secretion, 
whereas at higher concentrations it down-regulates PDGF-R expression. This 
bimodal effect is also observed in leiomyoma cells, where low levels of 
TGFp-1 induces cell proliferation, but increasing levels remove this 
stimulatory effect (Battegay et al. 1990; Arici and Sozen 2003).
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PDGF consists of two polypeptide chains, A and B, and can exist as a 
heterodimer, or as a homodimer of either chain. The activity of PDGF is 
dependent on which dimer is formed (Ross et al.  1986a). Differing reports 
exist in the literature as to which dimer is dominant in uterine leiomyomas, 
with one study showing an increase in PDGF-A mRNA expression in 
leiomyoma cells, (Mendoza et al. 1990) whereas two other studies show no 
difference in the expression of PDGF-A and PDGF-B between myometrium 
,  and leiomyomas (Boehm et al.  1990; Mangrulkar et al. 1995).
1.2.2.3  Epidermal growth factor signalling
Epidermal growth factor (EGF) is also a mitogenic factor that has been 
shown to play an important role in leiomyoma growth. Stimulation of cultured 
leiomyoma cells with either oestrogen or EGF results in an increase in cell 
proliferation, but treatment with both factors is not additive (Maruo et al. 
2004). This indicates that, as is the case for PDGF, EGF expression may be a 
downstream effect of oestrogen signalling. This turns out to be the case since, 
as is described above, oestrogen and progesterone are responsible for 
increased expression of EGF-R and EGF respectively in uterine leiomyoma 
cells (Watters et al. 2000). Since both EGF and its receptor are expressed in 
leiomyomas, an autocrine/paracrine signalling mechanism again appears to be 
involved (Maruo et al. 2004).
EGF again acts through a classical MAPK pathway to induce cell 
proliferation (Shushan et al. 2004). It has been shown to stimulate expression 
of PCNA (Shimomura et al. 1998), which correlates with increased expression 
of PCNA in the luteal phase of the menstrual cycle (Zaslawski et al. 2001). In 
addition, the EGF receptor antagonist AG1478 has been shown to suppress
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leiomyoma cell growth, further indicating an important role of this growth 
factor in leiomyoma pathogenesis (Shushan et al. 2004).
1.2.2.4  Transforming Growth Factor p signalling
Uterine leiomyomas are flbrotic tumours with increased levels of 
extracellular matrix and therefore studies of the transforming growth factor (3  
(TGFp) pathway have been carried out, since this pathway has been shown to 
increase the expression of ECM proteins such as collagen (Lee and Nowak
2001). The TGFp pathway has been shown to be involved in a variety of 
cellular roles, including stimulation or inhibition of cell growth, 
differentiation, and the aforementioned increase in ECM deposition (Lee and 
Nowak 2001). Due to this latter role, TGFp plays an important role in wound 
healing. However, excessive TGFp production or signalling has been shown 
to result in tissue fibrosis. In particular, TGFp may be involved in keloid 
formation (Liu et al. 2004).
Three isoforms of TGFp, (TGFp-1, TGFp-2 and TGFp-3) have been 
detected in human myometrium and leiomyomas, as well as the 3 receptors 
(TGFpR-1, TGFpR-2, and TGFpR-3), although TGFp-2 is the least abundant 
(Maruo et al. 2004). Increased expression of TGFp-3 has been reported in 
uterine leiomyomas (Lee and Nowak 2001), whereas changes in expression of 
TGFp-1 are less clear, with 3 different reports providing 3 different results 
(Lee and Nowak 2001; Arici and Sozen 2003; Chegini et al. 2003). The 
highest levels of TGFP-3 have been observed in mid-luteal phase, and in vitro 
experiments have demonstrated both oestrogen and progesterone-induced 
TGFP-3 expression (Arici and Sozen 2003).
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Binding of a TGFp ligand to its receptor results in phosphorylation of 
the Smad proteins Smad2 or Smad3, which then translocate to the nucleus, 
resulting in altered gene transcription. The inhibitory Smad, Smad 7, helps to 
modulate signalling. As well as Smad activation, TGFp can also activate the 
MAPK pathway (Chegini et al. 2003). Stimulation of cultured myometrium 
cells with TGFp-1 and TGFP-3 results in inhibition of cell proliferation (Lee 
and Nowak 2001). However, in cultured leiomyoma cells, TGFp-3 resulted in 
an increase in cellular proliferation (Lee and Nowak 2001). This proliferation 
is reduced following treatment with GnRH analogues, suggesting that 
oestrogen signalling may be closely tied in with TGFp signalling (Lee and 
Nowak 2001). In addition, expression of Smad3, phosphorylated Smad3, 
TGFpR-1 and TGFpR-3 are increased in leiomyomas compared to normal 
myometrium (Chegini et al. 2003). GnRH analogue treatment results in a 
reduction of the expression of these proteins in both myometrium and 
leiomyoma cells, with a concurrent increase in inhibitory Smad7 (Chegini et 
al. 2003). In addition to the increased cell proliferation, TGFp-1 and -3 both 
increase fibronectin mRNA levels in cultured leiomyoma cells (Arici and 
Sozen 2000).
A recent study used a microarray-based approach to examine the 
effects of TGFp-1 stimulation on cultured leiomyoma and myometrium cells. 
Grouping of differentially expressed genes by gene ontology demonstrated 
that a majority of genes with altered expression were involved in 
transcriptional regulation, cell cycle regulation, extracellular matrix and signal 
transduction (Luo et al. 2005).
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TGFj3-l may also be involved in the regulation of other growth factors 
involved in leiomyoma pathogenesis, such as the regulation of PDGF 
expression described above (Battegay et al.  1990; Arici and Sozen 2003). 
Therefore, it appears that TGFp has several roles in leiomyoma pathogenesis: 
the stimulation of cell proliferation; increased ECM synthesis; and the 
regulation of other mitogenic growth factors.
The role of TGFp may be important in relation to the increased 
prevalence of uterine leiomyomas in African and Afro-Caribbean women. A 
recent study identified decreased expression of the collagen binding protein 
dermatopontin in uterine leiomyomas. Reduced expression of dermatopontin 
is also observed in keloids, a fibrotic disease that occurs 3 times more 
frequently in African and Afro-Caribbean women than Caucasian women. 
Dermatopontin interacts with TGFp to downregulate its growth-inhibitory 
action (Catherino et al. 2004)
1.2.2.5  Insulin-like growth factor I signalling
Another implicated growth factor in leiomyoma pathogenesis is the 
insulin-like growth factor I (IGF-I). This is an anabolic growth factor, 
responsible for cell growth and differentiation. Studies using the Eker rat 
model demonstrated a 7.5-fold increase in IGF-I expression in leiomyomas 
compared to normal tissue, but an inverse change in IGF-I receptor expression 
(Burroughs et al. 2002). Increases in IGF-I and IGF-II expression have been 
reported in human leiomyomas (Boehm et al. 1990). However, unlike the Eker 
rat, human leiomomyas have shown an increase in IGF-I receptor expression 
in leiomyomas (Chandrasekhar et al.  1992). Again an autocrine/paracrine 
mechanism appears to be apparent.
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Studies in cultured cells have further refined the role of IGF-I, 
demonstrating an increase in cell numbers and proliferation rate. An increase 
in PCNA expression was observed upon treatment with IGF-I (Gao et al.
2001). Furthermore, IGF-I also increases expression of anti-apoptotic Bcl-2 
and reduces the cell’s susceptibility to apoptosis (Gao et al. 2001).
The expression of IGF-I is related to the signalling by sex hormones.
As described above, oestrogen induces the expression of both IGF-I and its 
receptor, whereas progesterone reduces IGF-I expression (Maruo et al. 2003; 
Maruo et al. 2004). In addition, GnRH analogue treatment results in a decrease 
in IGF-I and IGF-I receptor expression (Maruo et al. 2004). It has been shown 
that IGF-I mediates oestrogen action in the animal uterus (Burroughs et al.
2002), and it has been demonstrated that it can replicate the mitogenic and PR 
expression responses exerted by oestrogen (Murphy et al. 1987).
1.2.2.6  The mTOR pathway
The mTOR pathway has been heavily implicated in leiomyoma 
pathogenesis, particularly due to the Eker rat model and Birt-Hogg-Dube 
syndrome (Walker et al. 2003; Baba et al. 2006). Expression of the TSC2 
gene, mutations of which cause the Eker rat phenotype, is decreased in 
approximately half of sporadic leiomyomas, (Wei et al. 2005), and has been 
associated with up-regulation of EGF (Wei et al. 2006a). Another member of 
this pathway, Akt/protein kinase B, was also up-regulated and found to be 
phosphorylated during the luteal phase of the cycle (Kovacs et al. 2003). 
Inactivating phosphorylation of the PTEN tumour suppressor, which is also a 
member of this pathway, occurs in uterine leiomyomas in the luteal phase 
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activated during the luteal phase of the cycle. PDGF expression leads to 
activation of PI3K, which is at the head of the mTOR pathway (Barbarisi et al. 
2001). One of the effects of this pathway is the stimulation of the translation 
of HIFla (King et al. 2006), therefore, leiomyomas with activation of this 
pathway could follow a similar pathogenic route to HLRCC, Eker rat and 
BHD uterine leiomyomas.
1.2.2.7  Resistance to apoptosis
Deficiency in apoptosis has been described as one of the fundamental 
features of a tumour cell (Hanahan and Weinberg 2000), and this has also 
been observed to be true for uterine leiomyomas. A number of studies have 
identified aberrant expression of apoptosis-related proteins in uterine 
leiomyomas. Of particular focus has been the role of Bcl-2 family members. 
Members of this family of homologous proteins are responsible for the 
regulation of mitochondrial apoptosis (Kirkin et al. 2004). They can be 
divided into two groups: the anti-apoptotic proteins, such as Bcl-2, Mcl-1 and 
B c1-xl; and the pro-apoptotic members, such as Bax, Bak and Bad. These 
proteins act to control the integrity of the outer mitochondrial membrane. In 
response to apoptotic stimuli, factors such as cytochrome c and Smac/Diablo 
are released into the cytoplasm, resulting in caspase activiation and apoptosis 
(Kirkin et al. 2004).
As is mentioned above, Bcl-2 expression is upregulated in leiomyoma 
cells in response to progesterone stimulation (Maruo et al. 2004). 
Immunohistochemical studies have also identified increased levels of Bcl-2 
protein in vivo, particularly in the luteal phase, but also in the follicular phase 
of the menstrual cycle (Matsuo et al. 1997; Dixon et al. 2002; Wu et al. 2002;
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Kovacs et al. 2003). This increase in Bcl-2 levels was only observed in 
leiomyomas from pre-menopausal women (Wu et al. 2002). Increased 
expression of Bcl-2 has been shown to be sufficient to inhibit apoptosis 
(Kirkin et al. 2004). Studies examining the expression of pro-apoptotic Bax 
have produced conflicting results; some studies have demonstrated a decrease 
in Bax expression in leiomyomas (Dixon et al. 2002; Zhang et al. 2005), while 
others have shown no change (Kovacs et al. 2003) or increases in Bax 
'  expression (Wu et al. 2002). The role of other Bcl-2 family members has also 
been examined in uterine leiomyomas. No changes in expression have been 
observed in expression of anti-apoptotic Bcl-x and Mcl-1, or in pro-apoptotic 
Bak (Wu et al. 2002).
The expression of other apoptosis-related factors has also been studied. 
Expression of tumour necrosis factor a (TNFa) was decreased in cultured 
leiomyoma cells following progesterone stimulation (Matsuo et al. 1999). 
However, TNFa expression is higher in leiomyoma cells than myometrium 
cells (Kurachi et al. 2001), and therefore, the increased expression of Bcl-2 
may be important in protecting leiomyoma cells from apoptosis.
The p53 tumour suppressor protein is a frequent target of mutation and 
inactivation in tumour cells, given its pivotal role in regulation of the cell 
cycle, particularly in response to DNA damage (Meek 2004). p53 content in 
leiomyomas is greater in the follicular phase than the luteal phase of the 
menstrual cycle, and has been shown to be decreased by oestrogen in 
leiomyoma cells (Gao et al. 2002), but no difference in p53 content has been 
observed between myometrium and leiomyoma. GnRH analogue treatment
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was shown to up-regulate p53 in leiomyomas, possibly as a result of oestrogen 
depletion (Gao et al. 2002).
1.2.2.8  Angiogenesis
The role of angiogenesis in uterine leiomyomas also appears to be 
important. As discussed above, FH mutations in HLRCC patients initiate a 
pseudo-hypoxic response, resulting in the upregulation of vascular endothelial 
growth factor (VEGF) expression, and increased microvessel density in 
uterine leiomyomas from these patients compared to their host myometrium 
(Pollard et al. 2005a). However, vessel density in non-syndromal leiomyomas 
has been found to be lower than in the myometrium (Poncelet et al. 2002; 
Pollard et al. 2005a).
Despite this decreased vessel density, the successful treatment of 
uterine leiomyomas by uterine artery embolisation suggests that the vascular 
structure of the leiomyoma is vital for growth of the tumour and the provision 
of nutrients and oxygen (Stewart and Nowak 1998).
VEGF expression has been studied in uterine leiomyomas and the 
myometrium. VEGF mRNA and immunoreactivity has been identified in both 
myometrium and leiomyoma. In the myometrium, VEGF expression is 
slightly higher in the follicular phase, presumably as a part of the new 
formation of endometrium. However, no menstrual cycle related changes are 
observed in leiomyomas. VEGF levels were found not to differ between 
myometrium and leiomyomas, nor are they affected by GnRH analogues, 
suggesting that VEGF expression is not mediated by sex hormones (Harrison- 
Woolrych et al. 1995).
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Expression of the anti-angiogenic factor thrombospondin was also 
found to be downregulated in HLRCC leiomyomas (Pollard et al. 2005a). 
Microarray expression studies of sporadic uterine leiomyomas have found a 
similar result (Tsibris et al. 2002).
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1.3  Aims of this thesis
The work in this thesis is intended to tackle several genetic and 
functional issues related to both inherited and sporadic uterine leiomyomata. 
The first part examines the pathobiology of HLRCC uterine leiomyomas. The 
frequency and spectrum of germline FH mutations in uterine leiomyoma 
patients was determined, and in silico methods were used to analyse their 
functional effects on protein structure. Studies were also undertaken on two of 
the potential mechanisms of HLRCC pathogenesis, by examining defects in 
apoptosis and aberrant ultrastructural features in HLRCC uterine leiomyomas. 
The potential role of ROS-driven mutagenesis was also studied by examining 
the frequency of mutations in the vulnerable mitochondrial genome (mtDNA).
The second part of the thesis examines genetic factors in the 
pathogenesis of sporadic uterine leiomyomas. Initially, the role of germline 
FH variants in predisposition to leiomyomas in the general population was 
determined. Then the focus shifted on to the identification of large-scale 
somatic genetic changes in sporadic uterine leiomyomas, with particular 
emphasis on deletions of chromosome 7q. Finally, the possible role of somatic 
mtDNA mutations in uterine leiomyoma pathogenesis was assessed.
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2.1 Study Samples
The different samples used in this study came from a number of 
different centres depending on the study. All samples were obtained with full 
ethical consent.
2.1.1 Hereditary Leiomyomatosis and Renal Cell cancer Samples
HLRCC samples were obtained as a part of the ongoing study into this 
condition. Samples were obtained from a number of clinical collaborators and 
consisted of blood or DNA samples in all cases, and archival pathology blocks 
in a number of cases. For one patient, surgery was attended and fresh frozen 
samples of uterine leiomyomas, as well as tissue fixed for paraffin embedding, 
were obtained.
As a study sample for the frequency of FH gene mutations in uterine 
leiomyoma patients, 100 blood samples were collected from patients attending 
the uterine leiomyoma clinic at St. Mary’s hospital, Paddington, London.
2.1.2 Sporadic Uterine leiomyomas samples
Frozen sporadic uterine leiomyoma tissue samples were collected from 
the tissue banks at the Addenbrookes Hospital, Cambridge and the 
Hammersmith Hospital, London. Where possible, ethnicity and age data were 
collected. Samples were also collected from the North Middlesex Hospital in 
London in collaboration with Mr Stanley Okolo, and archival paraffin- 
embedded tissue samples of sporadic uterine leiomyomas were supplied by Dr 
Sanjiv Manek at the John Radcliffe Hospital, Oxford. All samples were 
anonymised.
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2.1.3  South African Uterine leiomyoma samples
In collaboration with Prof Zephne van der Spuy at the University of 
Cape Town, South Africa, blood and tissue samples from sporadic uterine 
leiomyoma patients was collected. DNA was extracted from blood and tissue 
samples by Dr Jacquie Greenberg of the Division of Human Genetics at the 
University of Cape Town. Clerking sheets supplied with each sample gave 
details of ethnicity, age of onset, family history, and diagnosis, but without 
details of patient names.
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2.2  Nucleic acid extraction
2.2.1 Fresh tissue and cell line DNA extraction
DNA extraction was carried out using the Qiagen QIAamp DNA mini 
kit (Qiagen, Crawley, UK) as per the manufacturer’s instructions. DNA was 
extracted from 30mg of fresh frozen tissue and resuspended in 400pil TE 
buffer.
2.2.2 Genomic DNA extraction from whole blood
DNA was extracted from whole blood taken into EDTA vacutainer 
tubes (BD, Oxford, UK) by two methods. Automatic extraction of DNA was 
carried out by using charged magnetic beads, using the Chemagen blood DNA 
extraction kit and magnetic robot as per the manufacturer’s instructions 
(Chemagen, Germany).
Manual extraction of DNA was carried out using an ammonium 
acetate extraction method. Blood samples (~10ml) were transferred into a 
50ml falcon tube. Ice cold water was added to a final volume of 50ml to 
osmotically lyse cells. The tubes were spun at 2300 rpm in a Jouan CR412 
centrifuge (Thermo-Scientific, Waltham, MA, USA) for 20 mins at 4°C, and 
the supernatant was discarded into Virkon, leaving a white nuclear pellet. The 
pellet was washed with 0.1% Nonidet P-40 in water and centrifuged at 2300 
rpm for 20 mins at 4°C. The supernatant was discarded and 3ml nuclei lysis 
buffer (lOmM Tris-HCl, 400mM NaCl, 2mM EDTA, autoclaved) was added 
to the pellet, which was subsequently resuspended by vortexing. 200pl of 10% 
SDS and 600[xl Proteinase K solution (2mg/ml proteinase K in 2mM EDTA,
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1% SDS (Autoclaved before addition of proteinase K)) was added to the tube, 
which was mixed by inversion and incubated overnight at 55°C to digest 
nucleosomal protein.
The following day, 1ml saturated ammonium acetate was added to the 
tube to precipitate remaining protein. The tube was then mixed by vigorous 
shaking for 15s, and left to stand at RT for 10-15 mins before centrifugation at 
2300 rpm for 20 mins at RT. The supernatant was transferred to a new tube, 
taking care not to transfer any of the precipitated protein. The DNA was 
precipitated by the addition of 2 volumes of 100% ethanol and spooled out of 
solution using an inoculation loop into 80% ethanol, where it was washed for 
1  hour at room temperature. The DNA was then spooled out of the 80% 
ethanol and dissolved in 300pil TE buffer.
2.2.3  DNA extraction from cell pellets
DNA was extracted from cell pellets using a high-salt method. 3xl07  
cells were pelleted into a 50ml falcon tube by centrifugation at 1000 rpm in a 
Jouan CR412 centrifuge. The cell pellet was resuspended in 2ml SE buffer 
(75mM NaCl, 25mM EDTA, 1% SDS, filter sterilised) per 107  cells. 20p,l of 
RNase A (lOmg/ml, Qiagen) was added to the cells, which were then 
incubated at 37°C for lhr. Proteinase K was then added to a final 
concentration of 200pg/ml (10p,l of a 20mg/ml stock per 1ml SE buffer used) 
and incubated overnight at 55°C. Prewarmed 5M NaCl was added to a final 
concentration of 1.5M (300pl 5M NaCl per 1ml SE buffer used). One volume 
of chloroform was added and mixed for 30 mins at RT with rotation, followed 
by centrifugation at 2000 rpm for 10 minutes at RT. The top layer was
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transferred to a new 50ml tube using a wide bore pipette, and an equal volume 
of isopropanol was added to precipitate the DNA. The DNA was spooled into 
80% ethanol and washed for lhr at RT. The DNA was removed from the 80% 
ethanol and dissolved in TE buffer.
2.2.4  BAC DNA extraction
Stabs of BAC clones were obtained from BACPAC resources 
(Childrens’s hospital, Oakland, CA, USA). Clones were streaked onto LB- 
Agar plates containing 25p,g/ml Chloramphenicol and grown overnight at 
37°C. A single clone was picked and grown overnight in 5ml LB containing 
25p,g/ml chloramphenicol at 37°C in a shaking incubator. The culture was 
centrifuged at 3000 rpm for 10 mins and the supernatant was discarded. The 
pellet was resuspended in 300pl buffer PI (See 2.12) and transferred to a 
1.5ml microfuge tube. 300pl buffer P2 was added followed by gentle shaking 
and incubation at room temperature for 5 mins to lyse the bacteria. 300|il 
buffer P3 was added and mixed to precipitate bacterial genomic DNA and 
protein. The tubes were incubated on ice for 5 mins.
The lysate was centrifuged at 10,000 rpm for 10 mins at 4°C to pellet 
the precipitated DNA and protein. The supernatant was then transferred to a 
new tube and the BAC DNA was precipitated by adding 800pil of ice-cold 
isopropanol. The tube was incubated on ice for 5 mins and the precipitated 
DNA was pelleted by centrifugation at maximum speed (13,000 rpm) for 15 
mins. The supernatant was discarded and the pellet was washed with 500pil 
70% ice-cold ethanol and centrifuged at maximum speed for 5 mins. The
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supernatant was discarded and the pellet allowed to air dry before being 
resuspended in 50pl UV-treated TE buffer.
2.2.5  DNA quantification
DNA was quantified by Spectrophotometry at 260 and 280nm blanked 
against the buffer in which the DNA sample was dissolved using a nanodrop 
instrument (Nanodrop technologies, Wilmington, DE, USA). In order to 
calculate the concentration, the absorbance at 260nm was multiplied by 500 to 
give the concentration in ng/pl. The ratio of absorbance at 260/280 nm was 
used to calculate the purity of the DNA. A ratio of 1.8-1.9 indicated clean 
DNA; a ratio below this indicated protein contamination, and a ratio above 
this indicated, amongst other contaminants, RNA contamination.
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2.3  Polymerase Chain Reaction (PCR)
The polymerase chain reaction (PCR) is a means of amplifying 
fragments (amplimers) of DNA from a template. The amplimer is determined 
by oligonucleotide primers specific to the each end of the region to be 
amplified (Strachan and Read 2004). Work in this thesis used standard PCR 
and two specialised PCR protocols for microarray construction: Degenerate 
oligonucleotide primer (DOP) PCR, and aminolinking PCR.
2.3.1 Primer design
Primer design was carried out using the Primer3 program (Rozen and 
Skaletsky 2000). Primers were ordered from Sigma-Genosys. Primer 
sequences for genomic microsatellite markers were obtained from the UCSC 
genome browser (Hinrichs et al. 2006). All primer stocks were diluted to 
20pM in UV-treated water.
2.3.2 Standard PCR
For products for mutation analysis and sequencing, which involved 
PCR products of less than lkb, a standard PCR protocol was used. A typical 
PCR reaction mixture is shown in Table 2.1. Dimethylsulfoxide (DMSO) was 
included in the reaction mixture to reduce template and primer secondary 
structure. Thermal cycling was carried out on an MJ research Tetrad thermal 
cycler in 96 or 48-well plates.
84Chapter 2 Materials and Methods
Table 2.1 Standard PCR reaction mix
Component Volume in 25pl reaction Final concentration
Promega PCR Buffer 
(lOx)
2.5pl lx
dNTPs (2.5mM dATP, 
dCTP, dGTP, dTTP)
2pl 0.2mM of each dNTP
MgCl2 (25mM) 1.5pl 1.5mM
DMSO 1.25pl 5%
Forward primer (20pM) 0.25pl 200nM
Reverse primer (20pM) 0.25pl 200nM
Taq polymerase (5U/pl) 0.25pl 1.25U/reaction
DNA template 25ng lng/pl
Water To 25 pi -
2.3.2.1  Standard PCR thermal cycler programs
All thermal cycler programs were carried out on an MJ Research 
Tetrad thermal cycler. Two standard programs were used for PCR, EJ55 and 
AR55. All primer pairs worked with these cycling conditions.
EJ55
Temperature Time (mins) Cycles
94°C 5:00 lx
94°C 0:30 35x
55°C 0:30
72°C 0:30
72°C 7:00 lx
4°C Hold lx
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AR55
Temperature Time (mins) Cycles
94°C 5:00 lx
94°C 1:00 35x
55°C 1:00
72°C 1:00
72°C 7:00 lx
4°C Hold lx
2.3.3  Degenerate oligonucleotide PCR (DOP-PCR)
Degenerate oliogonucleotide PCR (DOP-PCR) is the amplification of 
whole genomic, or BAC clone DNA using a degenerate primer containing a 
specific hexamer, a random hexamer, and a restriction-site linker sequence 
(Telenius et al.  1992). In this thesis, it was used for the amplification of BAC 
clones in the construction of the 7q tiling path array. Three DOP primers were 
used, designed to preferentially amplify human genomic DNA over 
background E.coli DNA contaminating the BAC from the purification 
procedure (Fiegler et al. 2003) (Table 2.2).
Table 2.2 DOP-PCR and aminolink primer sequences (From (Fiegler et al. 
2003))
Primer Name Primer Sequence
DOP-1 CCGACTCGAGNNNNNNCTAGAA
DOP-2 CCG  ACTCG  AGNNNNNNT  AGG  AG
DOP-3 CCGACTCGAGNNNNNNTTCTAG
Aminolink GGAAACAGCCCGACTCGAG*
*This primer has a C6-aminolinker at the 5’ end
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The DOP-PCR reaction was carried out using a different buffer (lOx 
buffer = lOOmM Tris-HCl (pH 8.4), 20mM NaCl, 500mM KC1, 1  mg/ml 
Gelatin) and different conditions to standard PCR. All plastics, buffers and 
water were UV sterilised before the reaction was set up due to the sensitivity 
of the procedure to contamination. The reaction mix was set up as below, one 
reaction was carried out for each DOP primer:
DOP-PCR reaction mix
Component Volume (50pl reaction) Final Concentration
lOx DOP Buffer 5 pi lx
dNTPs (As above) 4pl 0.2mM each
MgCl2 (25mM) 5 pi 2.5mM
W1 (1% stock) 2.5pl 0.05%
Primer (20pM stock) 5 pi 2pM
Taq polymerase (5U/pl) 0.5 pi 2.5U/50pl
DNA (lng/pl) 2.5pl -
Water To 50pl -
The thermal cycling conditions were as below:
Temperature Time (mins) Cycles
94°C 3:00 lx
94 °C 1:30 lOx
30°C 2:30
72°C 3:00
94°C 1:00 3 Ox
62°C 1:30
72°C 2:00
72°C 8:00 lx
15°C Hold lx
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2.3.4  Aminolinking PCR
Aminolinking PCR was carried out using the DOP-PCR products to 
attach a C6-aminolink moiety to allow the amplified products to attach to the 
Codelink slides. A different buffer (lOx aminolink buffer = 500mM KC1, 
25mM MgCb, 50mM Tris-HCl (pH 8.5)) was used for this reaction, and the 
same UV sterilisation procedures were used prior to setting up this reaction. 
The reaction mix is shown below, this protocol is taken from (Fiegler et al. 
2003):
Component Volume (60pl reaction) Final Concentration
lOx Aminolink buffer 6pl lx
dNTPs (2.5mM each) 6pl 0.25mM each
Aminolink primer 
(200ng/pl)
3 pi 4ng/pl
Taq polymerase (5U/pl) 0.6pl 3U/60pl
Water 42.4pl -
Pooled DOP-PCR 
products
2pl
And the thermal cycling conditions were as follows:
Temperature Time (mins) Cycles
95°C 10:00 lx
95°C 1:00 35x
60°C 1:30
72°C 7:00
72°C 10:00 lx
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2.4  Electrophoresis
Electrophoresis of DNA, RNA and protein samples allows the 
separation of molecules on the basis of size. This separation is useful for 
analytical purposes, for example, ensuring a PCR reaction is successful and 
the product is the correct size, and for extraction of specific samples, for 
example gel purification of DNA fragments for cloning. Analysis of DNA 
samples in this thesis was carried out by agarose gel electrophoresis.
2.4.1  Agarose gel electrophoresis
Analytical electophoresis was carried out using agarose gels prepared 
with lx Tris-Borate-EDTA (TBE), and run in the same buffer. Different 
percentages of gels were used for different product lengths. Typically, a 2% 
gel was used for products of between 150 and lOOObp; a 1% gel was used for 
product lengths up to 3kb; a 0.8% gel was used for very long products; and a 
3% gel was used for products under 150bp.
Gels were prepared by boiling agarose powder in lx TBE buffer until 
it was dissolved. The gel was allowed to cool to approximately 60°C before 
addition of ethidium bromide to a concentration of lOOng/ml. Gels were cast 
and run using the Biorad mini-sub cell electrophoresis system.  lOpl of PCR 
product was mixed with 2pi of 5x Orange G loading buffer (50% Glycerol, 
50mM EDTA, 0.2% Orange G), which migrates at approximately 50bp.
Gels over 1% were run at 120V, with the time dependent on the size of 
the product, typically 20 minutes for 300bp. Gels of 1% and under were run at 
100  V, again with the length of time dependent on the size of the product. Gels
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were visualised under UV light using a UVP transilluminator  and captured 
using a CCD camera coupled to Labworks software (UVP, Cambridge, UK).
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2.5  Mutation screening techniques
2.5.1 Single stranded conformational polymorphism analysis 
(SSCP)
SSCP analysis detects alterations in the electrophoretic mobility of 
single strands of DNA, which have a tendency to fold into complex structures 
stabilised by hydrogen bonding (Strachan and Read 2004). The difference in 
mobility of these structures can be indicative of single base mutations in a 
DNA sample. For SSCP analysis, PCR products to be screened were amplified 
using both forward and reverse labelled primers using a standard PCR 
protocol. These products were then denatured and snap-cooled to produce 
single-strand structures. The products were detected by capillary 
electrophoresis using an ABI 3100 genetic analyser (Applied Biosystems) and 
analysed using GENESCAN and GENOTYPER software (Applied 
Biosystems).
2.5.2 Melting curve analysis
Another means of mutation detection used was meltpoint analysis 
using LCgreen (Wittwer et al. 2003). The basis of this method is the analysis 
of the melting profile of a DNA molecule. The LCgreen dye (Idaho 
technology), which is incorporated into the PCR reaction mixture, binds to 
double stranded DNA and fluoresces. As the DNA is slowly melted over a 
temperature gradient, the LCgreen dissociates from the now single-stranded 
DNA and no longer fluoresces. The melting curve produced by this
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dissociation is dependent upon the sequence of the PCR product, and 
differences in melting curves are indicative of DNA variants.
Melting curve analysis was carried out by amplifying DNA using 
unlabelled primers in a lOpil standard PCR protocol, with the addition of lpl 
of lOx LCgreen reagent, layered with mineral oil in an opaque PCR plate. The 
melting curves of the samples were analysed using the Lightcycler instrument 
(Idaho technologies). Samples with differences in the melting curve, 
visualised with the instrument’s software, were selected for sequencing.
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2.6DNA sequencing
DNA sequencing was carried out using the Big Dye Terminator kit 
v3.1 (Applied Biosystems). 5pi of PCR product amplified using unlabelled 
primers was treated with 2pi ExoSap-IT (GE) to remove single-stranded DNA 
from the first PCR reaction as per the manufacturer’s instructions. Samples 
were then diluted to approximately 2.5ng/ul, estimated using the gel run for 
the PCR reaction. 4pl of diluted PCR product was used in a sequencing
reaction mix as follows:
Component Volume
BDT v3.1 8 pi
Primer (20pM) lpl
Water 7 pi
Diluted PCR product 4 pi
Using the following thermal cycler conditions
Temperature Time (mins) No. Cycles
96°C 1:00 lx
96°C 0:10
25x 30°C 0:05
60°C 4:00
4°C Forever lx
The sequencing reaction was cleaned up using Dye-Ex columns 
(Qiagen) and analysed using an ABI 3730 genetic analyser (Applied 
Biosystems). Sequences were analysed using 4peaks software (Netherlands 
Cancer Institute).
93Chapter 2 Materials and Methods
2.7  Microsatellite Loss of heterozygosity analysis
Loss of heterozygosity (LOH) analysis was carried out by PCR 
amplification of labelled markers using a short-range PCR protocol. Primer 
sequences and conditions for each marker are detailed in the relevant chapter. 
Dye-labelled PCR products were detected on an ABI 3100 genetic analyser 
(Applied biosystems) and analysed using GENESCAN and GENOTYPER 
software (Applied Biosystems). In order to assess LOH, the ratio of the areas 
under the peak were calculated. LOH was called if the ratio of the areas under 
the peaks in one sample were greater than 2x or less than 0.5x the ratio of the 
areas in the control. Where a single peak was observed in the normal sample, 
the marker was deemed non-informative for that sample.
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2,8  Histology and Immunohistochemistry
2.8.1 Fixation and paraffin embedding of tissue samples
Tissue samples were collected and fixed in neutral buffered formalin 
(NBF) overnight at room temperature. Samples were then transferred to 70% 
ethanol before paraffin embedding. Embedding of samples and cutting of 
sections was carried out by the Cancer Research UK histopathology unit. 
Briefly, samples were placed in a histology cassette and dehydrated by taking 
through 3 changes of 70%, 80%, 95% and 100% ethanol, followed by 3 
changes of xylene, and finally 4 changes of paraffin wax. The tissue was 
embedded in paraffin wax and allowed to set overnight.
Serial 4pm sections were cut using a microtome and mounted onto 
plain glass slides. One section from each block was dewaxed and rehydrated 
by two 10 minute washes in xylene, followed by 10 minute washes in 100%, 
90% and 70% ethanol, and water. Sections were stained using haemotoxylin 
and eosin, and dehydrated through graded alcohols and xylene. Coverslips 
were mounted using DepEx.
2.8.2 Immunohistochemistry
Immunohistochemistry was carried out on 4pm cut sections mounted 
onto glass slides. Sections were dewaxed and dehydrated by two 10 minute 
washes in xylene, followed by 10 minute washes in 100%, 90% and 70% 
ethanol before being transferred to water. Endogenous peroxidase activity was 
blocked by incubation in 3% hydrogen peroxide in methanol for 30 minutes.
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Antigen retrieval was carried out by pressure cooking the slides at 16psi in 
0.01M sodium citrate buffer (lOmM) for 3 minutes, and were subsequently 
transferred to PBS.
Sections were pre-blocked using 1.5% serum in PBS for 30 minutes. 
The serum used depended on the source of the secondary antibody used. For 
mouse derived primary antibodies, whole horse serum was used; and for rabbit 
derived primary antibodies, whole goat serum was used. The sections were 
then incubated with the primary antibody at an appropriate dilution in PBS for 
1  hour at room temperature, before being washed twice with PBS. Antibody- 
antigen binding was detected using biotinylated secondary antibodies at a 
dilution of 1:200 in PBS for 30 minutes at room temperature. Goat-derived 
anti-rabbit IgG (BA-1000, Vector laboratories) was used for rabbit-derived 
primary antibodies, and horse-derived anti-mouse IgG (BA-2080, Vector 
laboratories) was used for mouse-derived primary antibodies. Sections were 
again washed twice in PBS and were incubated with a streptavidin-horseradish 
peroxidase complex (Dako), diluted 1:200 in PBS, for 30 minutes. Following 
this, the sections were washed twice more in PBS.
Sites of peroxidase activity were detected by incubation with 3-3’- 
diaminobenzidine (Dab, Sigma-Aldrich) for 5 minutes. The reaction was 
quenched by flushing the sections with water. Slides were subsequently 
counterstained for 15 seconds in Mayer’s haematoxylin before being 
dehydrated through 2 minute washes in 70%, 90% and 100% ethanol, and 
xylene. Coverslips were mounted using DepEx.
Patterns of staining were evaluated as absent (-), weak (+), moderate 
(++), strong (+++) and very strong (++++) by semi-quantitative observation of
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20 high power fields for all antibodies with cytosplasmic staining. Staining of 
nuclear markers, such as PCNA, was assessed by percentage of stained nuclei: 
<10% (-), 10-25% (+), 25-50% (++), 50-75% (+++), and >75% (++++). 
Scoring was undertaken blind by two independent observers under the 
guidance of histopathologists.
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2.9  Electron Microscopy
All electron microscopy procedures, including tissue preparation, 
staining and electron microscopy, were carried out by Mr Bart Wagner at the 
Northern General Hospital, Sheffield, UK.
Samples were collected fresh from surgery and fixed in 2.5% (v/v) 
glutaraldehyde in phosphate buffer (pH7.4). Fixed samples were diced into 
1mm3  cubes, rinsed in distilled water, transferred into 1% aqueous osmium 
tetraoxide and embedded in TAAB Emix resin. Sections of 0.6pm were cut, 
mounted on glass slides, and stained in 1% toluidine blue in 1% sodium 
tetraborate for 30s on a hot plate at 140°C. After checking the histology of the 
samples, they were sectioned with a diamond knife in a Leic Ultracut E 
ultramicrotome, with interference colour gold of approximately 95nm. 
Sections were stained by immersion for 3 min in 99% alcoholic saturated 
uranyl water, 3 min in Reynolds lead citrate and thres washes in distilled 
water, and examined by a Philips 400 transmission electron microscope.
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2.10  Fluorescent in-situ hybridisation (FISH)
Probe was prepared from isolated BAC DNA (2.2.4) and labelled 
using the Invitrogen Nick Translation kit. 500ng of DNA was diluted to a total 
volume of 17pl in nuclease free water. This was mixed with 2.5pil of lOx 
dNTP (low dUTP) mix from the kit, and 0.5 pi dUTP-Rhodamine (red) or 
dUTP-Fluorescein (green) (Roche) and 5pl of Nick Translationenzyme mix. 
The reaction was incubated at 16°C for 2hrs and stopped with 2.5pi stop 
buffer.
The probe was then precipitated by combining lOpl of the labelling 
reaction mixture with 5pi Cot-1 DNA (lmg/ml, Roche), 2pl Salmon sperm 
DNA (lOmg/ml), 2pl of 3M sodium acetate (pH 5.2) and 50pl of cold ethanol. 
The probe was left to precipitate overnight at -20°C.
Purchased normal metaphase spread slides were prepared for 
hybridisation by incubation in 70% deionised formamide/2xSSC at 65 °C for 2 
mins, followed by a wash in 70% ice-cold ethanol for 3 mins and subsequent 3 
min washes in 90% and 100% ethanol at room temperature. The slide was 
then allowed to air dry.
The precipitated probe was pelleted by centrifugation at top speed in a 
microcentrifuge at 4°C for 15 mins. The supernatant was removed and the 
pellet allowed to air dry before resuspension in 5pi hybridisation buffer (50% 
deionised formamide, 10% Dextran sulphate, 0.1% Tween-20, 2x SSC,  lOmM 
Tris (pH 7.4)). The hybridisation mixture was vortexed to mix and incubated 
at 70°C for 5 mins, with occasional vortexing to resuspend the pellet. The 
probe was then placed at 37°C for V 2  hr to compete.
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Following this incubation, 5 pi of rhodamine-labelled probe was 
spotted onto one half of the metaphase slide, followed by 5 pi of fluorescein- 
labelled probe on top (the other half was used for a different pair of probes). A 
22x22mm cover slip was gently dropped onto the hybridisation mix and the 
edges were sealed with rubber cement. The slide was placed in a box 
humidified with 50% formamide/2xSSC overnight at 37°C.
Washing of the slide was carried out the following day. All washing 
steps were carried out at 42°C using solutions pre-warmed to that temperature. 
The cover slip was carefully removed from each slide, and the slide was 
washed 3 times for 5 mins each in 50% formamide/2xSSC, followed by 3 x 5 
mins washes in 2xSSC. The slides were then washed in lxPBS/0.1% Tween- 
20 at room temperature for 5mins. Finally, the slides were washed in 70%, 
90% and 100% ethanol at room temperature for 3 mins each, before being 
allowed to air dry. The slides were counterstained with DAPI and captured 
using a cooled CCD camera (Photometries) attached to a Zeiss Axioplan 2 
Imaging microscope and SmartCapture 2 software (Applied Imaging).
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2.11  Microarray techniques
2.11.1 Microarray CGH
2.11.1.1 Microarrays
Two different CGH arrays were used in experiments in this thesis. The 
first was a 1Mb resolution array designed by Nigel Carter’s group at the 
Wellcome Trust Sanger Centre in Cambridge. This array consisted of 3125 
human Bacterial Artificial Chromosome (BAC) clones, amplified by 
degenerate oligonucleotide primer PCR (DOP-PCR) and printed in duplicate 
on to glass slides. In addition, 6 BAC clones from Drosophila melanogaster 
were also printed onto the array as a control for background hybridisation.
The BAC clones were selected from the Golden Path at a spacing of 
approximately 1Mb, excluding the short arms of the acrocentric chromosomes. 
Clones FISH-mapped to a single location or localised to known oncogenes and 
tumour suppressors were preferred, but the selection was arbitrary in a 
majority of cases (Fiegler et al. 2003).
The second microarray used was a tile-path resolution array for 
chromosome 7q, designed and prepared as described in Chapter 7.
2.11.1.2 Array printing and preparation
Array printing was carried out by Cordelia Langford at the Wellcome 
Trust Sanger Centre in Cambridge. Aminolinked PCR products were diluted 
into lx printing buffer (250mM Sodium Phosphate pH 9.0, 0.000001% N- 
Laurylsarcosine) and filtered through 0.22pm filter plates (Millipore), before
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re-arraying into 384-well plates. The DNA products were printed onto 
Codelink™ activated slides (GE healthcare) using a Microgrid II array spotter 
(Biorobotics).
Printed slides were transferred to a humid chamber at room 
temperature for 72 hours to drive the covalent attachment of the DNA to the 
slides. They were then immersed in 1% w/v ammonium hydroxide for 5 min, 
0.1% sodium dodecyl sulphate for 5 min, and rinsed in water. The bound 
DNA was denatured by immersing the slides in water at 95 °C for 2 min, 
before being rinsed in ice-cold water and dried by centrifugation.
2.11.1.3  DNA labelling and purification
500ng of normal (‘Reference’) and tumour (‘Test’) DNAs were 
labelled using Cy3-dCTP and Cy5-dCTP (Amersham) respectively, using the 
Bioprime array CGH labelling kit (Invitrogen), according to the 
manufacturer’s instructions. Briefly, DNA was diluted to a volume of 21 pi in 
nuclease-free water and combined with 20pl random octamer primers in 2.5x 
buffer (125mM Tris-Hcl (pH 6.8), 12.5mM MgCh, 25mM |3-mercaptoethanol, 
750pg/ml random octamers). The sample was incubated at 100°C for 10 
minutes and immediately cooled on ice. 5 pi of dNTP mix (1.2mM dATP, 
dGTP and dCTP, 0.6mM dCTP), 3pi of Cy3- or Cy5-dCTP (lpM) and lpl of 
Exo-Klenow fragment (40U/pl) were mixed with the cooled sample. The 
samples were incubated overnight at 37°C. Reactions were stopped by the 
addition of 5pi 0.5M EDTA.
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Labelled DNA was purified using Microspin G-50 columns 
(Amersham) according to the manufacturer’s protocol. DNA samples were run 
on a 2% TBE-agarose gel at 120V for 20mins to check DNA labelling. 
Successfully labelled samples produced a low-molecular weight smear (~50- 
200bp) when viewed under UV light.
2.11.1.4  DNA precipitation and hybridisation
A seal was formed around the edge of the arrayed area on printed 
slides using 2 layers of adhesive PCR film (ABgene, cat no. AB-0558), cut 
with reference to a ‘dummy’ printed slide.
Labelled test and reference DNA samples were combined and 
precipitated with 135pg Cot-1 DNA (Roche) in 0.1 volumes 3M sodium 
acetate (pH 5.2) and 2.5 volumes of ice-cold ethanol at -80°C for 30 minutes. 
Concurrently, lOpg of Herring sperm DNA was precipitated with 135pg Cot-1 
DNA. Precipitated DNA was pelleted by centrifugation at 16,000g for 15 
minutes. The resultant pellet was washed with 80% ice-cold ethanol and re­
pelleted at 16,000g for 5 minutes. The supernatant was removed and the pellet 
dried.
The labelled pellet was re-suspended in 80pl hybridisation buffer (50% 
deionised formamide, 10% Dextran sulphate, 0.1% Tween-20, 2x SSC, lOmM 
Tris (pH 7.4)) and 8pl yeast tRNA (lOOpg/pl, Invitrogen). The herring-sperm 
pellet was re-suspended in 180pl hybridisation buffer. Both samples were 
heated at 80°C and frequently mixed by vortex until the pellets were re­
suspended. The labelled DNA sample was then placed at 37°C for 1 hour to
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allow the labelled samples to compete with the C0t-1 DNA, blocking repetitive 
sequences. The re-suspended herring sperm DNA mixture was carefully 
pipetted onto the prepared slide to pre-hybridise for 1  hour at 37°C in a humid 
chamber formed of a slide box containing 3MM paper (Whatman) soaked in 
40% formamide/2x SSC.
Following competition, the labelled DNA sample was added to the pre­
hybridised array. The humidity chamber was sealed with electrical tape and 
the array was incubated at 37°C with gentle rocking for 48 hours.
2.11.1.5  Array washing and scanning
All wash stages were carried out in reduced lighting. Arrays were 
removed from the humidity chamber and placed in wash buffer 1  (2x 
SSC/0.1% Tween-20) in a coplin jar at room temperature. The seal was 
carefully removed after about 30 seconds. The arrays were washed in this 
solution with rocking for 5 minutes. Arrays were then washed in wash buffer 1  
at 65°C for 5 mins before being transferred to wash buffer B (0.2x SSC). 
Arrays were washed 4 times in wash buffer 2 (lx 2min, 3x 20mins) at room 
temperature before being transferred to wash buffer 3 (lx PBS, 0.1% Tween- 
20), for 5 minutes, then wash buffer 4 (lx PBS) for 5 minutes, and a final brief 
wash in ddF^O. The arrays were dried by centrifugation at ~500g for 5 
minutes in slide boxes lined with bleach-free paper towels and stored at room 
temperature in black boxes before scanning.
Arrays were scanned using a Scanarray confocal scanner and software 
(Perkin-Elmer). Each array was pre-scanned to and settings adjusted to ensure 
even signal from both the Cy3 and Cy5 channels. Arrays were then scanned at
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lO^im resolution, and TIFF image files of each channel saved for analysis. 
Details of downstream analysis of image files can be found in 2.13.2.
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2.11.2  Mitochondrial DNA resequencing array
The mtDNA resequencing array allows a complete mtDNA sequence 
to be derived from high-quality DNA samples. The arrays are able to identify 
heteroplasmy, and are over-tiled to take into account common variants, 
identified on the FBI mtDNA database. The resequencing protocol was 
divided into three sections: the first involved PCR amplification of specific 
mtDNA fragments; the second involved the labelling of samples, hybridisation 
and washing of the arrays; and the final stage involved scanning and data 
analysis.
2.11.2.1  PCR amplification of mtDNA fragments.
The mitochondrial genome of each sample was amplified into two long 
fragments, using specific primers designed by Affymetrix (Table 2.3). 
Amplification was carried out using TaKaRa LA Taq by a modified 
procedure. In addition to the test DNA sample, a 7.5kb control PCR and a 
negative control for each primer set were also run.
All PCR preparation procedures were carried out on ice after UV 
sterilisation. Primer stocks were diluted to lOOpM in 0.1 x TE. A primer pair 
stock was created by diluting lOOpl of forward and reverse primer in 800pl of 
O.lx TE, giving a final concentration of lOpM for each primer. For each 
reaction, 6pl of primer pair stock was diluted in 14pl of molecular biology 
grade water.  lOOng of genomic DNA sample was diluted to 5ng/pl in 
molecular biology grade water, giving a total volume of 20pl This was 
combined with the 20pl primer pair mix. A lOOpl reaction volume was 
prepared with final concentrations of lx LA PCR buffer, 2.5mM MgCL,
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400pM dNTPs and 5U LA Taq enzyme. The reaction was run to the cycle 
shown in Table 2.4, and resulting products analysed on a 0.8% TBE-agarose 
gel run for 1  hour at 100V.
Table 2.3 Primers for amplification of mtDNA fragments.
Primer
Name
Forward Primer Fragment
Size
Mitol-2F ACATAGCACATTACAGTCAAATCCCTTCTCGTCCC 9307bp
Mitol-2R ATTGCTAGGGTGGCGCTTCCAATTAGGTGC
Mito3F TCATTTTTATTGCCACAACTAACCTCCTCGGACTC 7814bp
Mito3R CGTGATGTCTTATTTAAGGGGAACGTGTGGGCTAT
Table 2.4 Thermal cycler program for mtDNA fragment amplification.
Temperature Time Cycles
94°C 2 minutes lx
94°C 15 seconds 3 Ox
68°C 1  minute/kb product size
68°C 5 minutes + 1  minute/kb lx
4°C HOLD
107Chapter 2 Materials and Methods
2.11.2.2 PCR product quantification, pooling, fragmentation, labelling 
and hybridisation
PCR products were purified using the Qiaquick PCR purification kit 
(Qiagen), and eluted in 30pl buffer EB. The concentration of each fragment, 
including the positive control, was calculated as described (2.2.5). Each 
fragment, including the positive control was diluted to a final concentration of 
250pM and combined. Subsequent steps, including fragmentation, labelling, 
and hybridisation were carried out by the manufacturer’s recommended 
protocol.
2.11.2.3 Array washing, scanning and data analysis.
Hybridised arrays were washed and scanned by the manufacturers 
protocol using an Affymetrix fluidics station and scanner. Sequence data was 
derived using the software GSEQ (Affymetrix). Analysis was carried out as an 
overall batch analysis of every array run from a manufactured batch using a 
diploid data analysis model in order to detect heteroplasmy. Data was 
exported as FASTA DNA sequence files, and a delimited file detailing 
identified changes.
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2.12  Formulation of  standard media and solutions
2.12.1 Buffers and saline
2.12.1.1 Phosphate Buffered Saline (lx)
Component Mass for 11 (Cone) Notes
NaCl 8g(137mM) Check pH = 7.4 
Autoclave KC1 0.25g (2.7mM)
Na2HP04 1.43g (Total 1  OmM P04)
KH2P04 0.25g
2.12.1.2 1M Tris (Various pH values)
Component Mass for 11 (1M) Notes
Tris base 121.14g pH as desired using HC1 
Autoclave
2.12.1.3 0.5M EDTA (pH 8.0)
Component Mass for 11 (0.5M) Notes
Na-EDTA 184. lg pH to 8.0 with 1M NaOH 
Autoclave
2.12.1.4 TE Buffer (lx)
Component Vol for 11 (Cone) Notes
1M Tris (pH 8.0) 10ml (1 OmM) 0.2pm filter and UV 
sterilise for 15min 0.5mM EDTA (pH 8.0) 2ml (ImM)
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2.12.1.5 SSC Buffer (20x)
Component Mass for 11 (Cone) Notes
NaCl 175.32g (3M) pH to 7.0 with 1M NaOH 
Autoclave Na-Citrate 88.23g (0.3M)
2.12.1.6 TBE Buffer (lOx)
Component Mass for 11 (Cone) Notes
Tris base 108g (0.89M) pH should be 8.3, requiring 
no adjustment 
Autoclave
Boric Acid 55g (0.89M)
Na-EDTA 9.3g (0.02M)
2.12.2  Bacteriological Media
2.12.2.1  L-Broth
Component Mass for 11 Notes
Bacto-tryptone 10g Autoclave
Yeast Extract 5g
NaCl 10g
2.12.2.2  L-Broth Agar (For 1 litre)
As for L-Broth, add 15g agar per litre.
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2.12.2.3  Buffers for BAC DNA extraction 
PI
Component Volume for 11 (Cone) Notes
1M Tris (pH 8.0) 50mls (50mM) Filter sterilise, store at 
4°C 0.5M EDTA (pH 8.0) 20mls (lOmM)
RNase A (lOmg/ml) lOmls (100^g/ml)
P2
Component Volume for 11 (Cone) Notes
lMNaOH 200mls (0.2M) Filter sterilise, store at 
RT 20% SDS 50mls (1%)
P3
Component Mass for 11 (Cone) Notes
Potassium Acetate 294.5g (3M) pH to 5.5, autoclave, 
store at 4°C
111Chapter 2 Materials and Methods
2.13  Data Analysis
2.13.1  Statistical Analysis
Statistical analysis was carried out using the software R (Team 2006). 
This provides a framework to carry out a number of statistical calculations. 
Individual significance values and tests utilised are described in each chapter.
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2.13.2  Microarray CGH data analysis
2.13.2.1 Rationale
All microarray based experiments produce large quantities of data, 
which must be dealt with in a robust manner in order to obtain valid and 
significant results. Probably the two most important issue facing researchers in 
this field are: 1) Normalisation of the data, where raw ratios are transformed to 
a, defined baseline, accounting for artefacts of the experimental procedure, 
such as uneven hybridisations or differences in the brightness of individual 
images; and 2) The selection of significant regions of change for further study. 
The approaches used for both of these issues are described below, along with 
the additional data analysis steps.
2.13.2.2 Data analysis
Fiegler et al broke down array data analysis into several individual 
stages (Fiegler et al. 2003):
i)  Overlaying image files and data-point quantification:
Individual output files for each fluorescent dye channel are 
overlaid, and the intensity of individual spots is calculated.
ii)  Data rejection: Individual spots are accepted or rejected on the 
basis of spot quality and the level of background hybridisation. 
Data is then normalised to the number of copies of test genome 
per copy of reference genome.
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iii)  Normalisation: Accepted data values are normalised across the
array to give a ratio of the number of test genomes per copy of 
the reference genome.
iii)  Duplicate rejection: Variability of data for duplicated spots of 
clones is compared, and excessively variable data is rejected.
iv)  Identification of significant changes: Final calculated log2 
ratios are used to identify regions of altered copy number in the 
test DNA sample with respect to the reference sample.
2.13.2.2.1 Overlaying Image Files
Scanned microarrays were overlaid and quantified using the freeware 
Spot (Jain et al. 2002). The software overlays the Cy3 and Cy5 array images, 
and calculates intensity values for each spot on the array using a local 
histogram method. This method takes into account non-circular spot 
morphologies, which may occur as a result of printing, providing accurate 
intensity values for each spot.
2.13.2.2.2 Drosophila clone-based rejection
In addition to the human BAC clones, the array contains 6 clones from 
Drosophila melanogaster. These clones were known not to hybridise to 
human DNA, and so were used as a measure of non-specific hybridisation. 
Individual spots were accepted or rejected after comparison with the 
Drosophila clone values. For an individual spot to be accepted, the reference 
(Cy3) intensity was required to be greater than twice the median reference
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intensity of the Drosophila clones. This stage of rejection was only carried out 
using the reference intensities, since in the case of a homozygous deletion of a 
particular region, the test (Cy5) intensity would be expected to be at the level 
of background hybridisation, thus additional rejection on the basis of this 
parameter could lead to the exclusion of particularly interesting data.
2.13.2.2.3  Normalisation
The process of normalisation adjusts for systematic differences in the 
relative intensity of each channel, such that the normalised ratio identifies the 
number of test genomes per single copy of the reference genome. In early 
experiments using the arrays, data analysis was carried out in a Microsoft 
Excel spreadsheet written by Heike Fiegler in Nigel Carter’s group at the 
Wellcome Trust Sanger Institute. (Fiegler et al. 2003)
This method of analysis normalised the data by block, or print-tip 
normalisation. The median of the accepted test/reference ratios for each block 
was calculated, and each ratio was divided by this median. As a comparison, a 
global normalisation, using the median accepted ratio for the whole array, was 
carried out. The use of block normalisation accounted for local differences on 
the array, which global normalisation could not account for, and hence 
reduced the spread of data and made changes more pronounced (Figure 2.1).
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Figure 2.1 Comparison of global and block normalisation of array CGH data.
In this example output of chromosome 2, block normalised data (B) | *
demonstrates less spread than globally normalised data (A). This allows 
genuine changes to be more easily identified.
A study of published literature regarding microarray normalisation 
revealed a further factor found to affect data in cDNA expression array 
experiments (Yang et al. 2002). Variation between the Cy3 and Cy5 channels 
was found to not always be constant, but to change as a function of signal 
intensity. To see if this was the case for BAC-based CGH arrays, an MA plot 
was drawn (Figure 2.2a), whereby the spot intensity (A = \og\o(Test*Ref), 
where Test and Ref  are the raw signal intensities of the Cy5 and Cy3 channels 
respectively) is plotted against the raw log2 ratios (M = \ogi(Test/Ref)). An 
MA plot was also drawn to compare the intensity to block normalised log2 
ratios (Figure 2.2b). In a number of samples, particularly those with a broad 
spread of data, a distinctive curve pattern of data was observed. As the 
intensity of a spot increased, so did the log2 ratio. Even after block 
normalisation, this pattern remained. Therefore, an alternative form of 
normalisation to overcome this effect was necessary.
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Figure 2.2 MA plots of array CGH data. Plotting intensity (A) against raw 
log2 ratios (M) shows a distinctive curve pattern indicative of intensity- 
dependent effects on the log2 ratios (a). This curved pattern remains even after 
block median normalisation (b).
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Intensity dependent effects on log2 ratios can be corrected by 
generating a best-fit curve through the data and treating this curve as the new 
zero line. The log2 ratio (M) is shifted by a quantity c = c(A), which is 
dependent on the intensity (A):
M = log2 (Test/Ref) -> log2 (Test/ReJ) -  c(A) = log2 (Test/(k(A) *Ref)
In order to estimate c(A), the LOWESS (/ocally weighted scatterplot 
smoothing) function, found in the software package R (Team 2006), was used 
. This is a local scatterplot smoothing function that uses a proportion of the 
data (determined by the variable/ )  around each value of x (in this case the 
intensity) to draw a smooth line of best fit through the data (Cleveland 1981). 
The output from the LOWESS function gives a smoothed log2 value for each 
original intensity value. This smoothed log2 value is then used as c(A) to 
normalise the original log2 ratios by subtraction from the original value. The 
resulting MA plot (Figure 2.3b) shows that intensity-dependent effects on the 
log2 ratio have been corrected.
Several values of/   were tested in order to find the best smoothing, 
most accurately reflecting the data. As the value of/  decreases, less data is 
used for smoothing at a particular point. While this can lead to more accurate 
smoothing, local outliers can affect the smoothed data. A value of 0 (orange 
line in Figure 2.3a), did not use enough local data and gave a rough line 
affected by local outliers in the data, whereas higher values off  such as 0.3 
and 0.4 (green and blue lines in Figure 2.3a respectively) gave a smooth line, 
but did not reflect the fit of the data at intensities with sparse data, in this case 
at lower spot intensities. The best fit for global lowess correction was obtained
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using a value for/of 0.2 (red line in Figure 2.3a), which produced a smooth 
line, unaffected by outliers, which reflected the data at lower intensities.
Global lowess corrected M A plot
Figure 2.3 Global lowess correction of 1Mb array CGH data. (A) Raw MA 
plot with lowess smoothed lines using different values of/: 0=orange; 
0.2=red; 0.3=green; 0.4=blue. The lowest value of/  gives a rough line skewed 
by outliers, whereas the higher values do not accurately reflect the data at a 
lower intensity value. A value of 0.2 gave the most accurate smoothing. After 
normalisation by subtraction (B), the corrected MA plot shows that intensity 
dependent effects on the log2 ratio have been removed.
As for the median ratio-based method of normalisation (Fiegler et al. 
2003), it was decided to normalise each block on the array individually. This 
would account for differences in hybridisation across the array. A separate 
lowess line was calculated for each block, and used to normalise log2 ratios 
within that block. This method reduced the spread of the normalised data 
compared to lowess normalisation across the entire array. For example, in the 
dataset used in Figure 2.3, the raw data had a standard deviation of 0.3254.
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Global lowess normalised data had a standard deviation of 0.1218, whereas 
block lowess normalised data had a standard deviation of 0.1081. Therefore, 
block normalisation reduced the spread of the data.
One further consideration of block LOWESS normalisation is the 
effect on the f   value due to the reduced number of data points per block, 
compared to the whole array. It was found that increasing the value of/   to 0.25 
for block normalisation produced smoothed lines of the most accurate fit.
2.13.2.2.4  Duplicate rejection
Following normalisation, duplicate clone spots on the array are 
compared to ensure that each spotted clone is giving an identical hybridisation 
ratio. This is carried out by taking the median of the normalised Test/Ref  ratios 
of the duplicates and assessing the deviation of the original ratios from this 
median. If duplicates lie outside the greater of 10% or 0.1 of this median, then 
the entire clone is rejected, if not, this median is used to calculate the final 
log2 ratio for the clone.
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2.13.2.2.5  Identification of significant changes
2.13.2.2.5.1 Rationale
The ultimate aim of microarray CGH experiments is the identification of 
regions of copy number change, and where these regions begin and end. 
Accurate breakpoint identification can help to identify and minimise regions 
harbouring genes of interest and importance in a tumour type. The initial 
stages of analysis, from overlaying image files through to normalisation and 
duplicate rejection, are concerned with producing the best possible data in 
order that false changes are minimised, and actual changes are retained. This 
gives the best possible platform for identifying significant changes that may 
have biological relevance.
2.13.2.2.5.2 Problems faced in identifying changes
Theoretically, the output log2 ratios for each clone are representative of 
the number of copies of the test genome per copy of the reference genome. For 
example, a diploid tumour losing one copy of chromosome 15 would give a 
ratio of 0.5, one copy of the tumour genome per 2 copies of the reference 
genome, and an expected log2 ratio of -1. Therefore, identification of copy 
number changes should be a case of simply observing which clones are at the 
theoretical log2 ratio.
However, these theoretical thresholds are rarely met. In theory, only two 
factors should have an effect on the thresholds: contaminating normal DNA, 
which would dilute the change; and tumour ploidy, where copy number 
change in a polyploid tumour, for example loss of one chromosome in 3 in a
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triploid tumour, results in a smaller log2 ratio difference. To account for both 
of these factors, one requires accurate information regarding the ploidy status 
of the tumour, and the amount of contaminating normal, to adjust thresholds, 
neither of which are easy to determine.
Yee-Loi Wan of our lab carried out experiments examining the effects 
of contaminating normal on the 16q CGH profile of the breast cancer cell line, 
MPE-600. This is a diploid cell line with a single copy loss of 16q. Since the 
DNA came from a pure population of cells, a log2 ratio of -1 would be 
expected with no contaminating normal present. However, the mean log2 ratio 
of clones in the deleted region was consistently less than the expected ratio 
(Figure 2.4).
These differences are likely to be due to a number of factors inherent 
within the experimental and analytical procedure. The theoretical threshold 
requires absolute accuracy throughout the preparation of the arrays, the 
hybridisation, washing and analysis. In a procedure involving such a large 
number of stages, variation is very likely to occur such that theoretical values 
are not observed. These variations can occur at the stage of clone 
amplification, printing, array hybridisation, washing, and data analysis. It is 
important to note, however, that although the threshold values are not met, the 
values observed in the experiment in Figure 2.4 are consistently the same 
proportion below the theoretical value. Thus, the data from the arrays is valid 
for identifying copy number variation.
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The effect of contaminating normal on mean log ratios of a known loss
Measure of copy number (100 = 2 copies) 0.5
< /> o
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■  Experimental values -0.5L
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Percentage copy number (100%  =  2 copies,  50%  =  1  copy)
Figure 2.4 Effect of contaminating normal on known loss. Contamination of 
MPE-600 DNA with a known loss of 16q with normal DNA reduces the 
observed log2 ratio. The experimental log2 ratios always fail to reach the 
expected values, even where there is no contaminating normal. The difference 
between the expected and actual results appears proportionally the same 
through different levels of contaminating normal.
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2.13.2.2.6Identifying significant changes
Since theoretical thresholds are rarely met, and require presumed 
knowledge of tumour ploidy and normal tissue content, a different method of 
identifying significant changes was required. A series of 7 normal-normal 
hybridisations, both sex-matched and sex-mismatched, were used to derive the 
method.
A box plot of the final, normalised log2 ratios for each chromosome 
following a normal-normal hybridisation reveals differences in the spread of 
data within each chromosome (Figure 2.5a). These differences were conserved 
between control experiments. For example, chromosome 19 frequently 
showed a greater spread of data than other chromosomes. Thus, the 
distribution of data for each chromosome was different to the distribution for 
the overall array. Therefore, thresholds derived from the distribution of the 
whole array would not be as accurate for individual chromosomes, leading to 
false positive and negative calls of copy number change.
In order to overcome this, the data was rescaled in order to transform the 
data for each chromosome onto the same distribution as the whole array. 
Scaling factors were derived by calculating the ratio of the chromosome 
interquartile range (IQR) to the autosome IQR. The mean ratio for each 
chromosome from seven control hybridisations was used as a scaling factor. 
Log2 ratios were scaled on a per chromosome basis by dividing each ratio by 
the appropriate scaling factor (Table 2.5). This resulted in a more comparable 
spread of data between chromosomes (Figure 2.5b), reducing the potential for 
false positives or negatives. This scaling was not carried out on the sex 
chromosomes.
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Boxplot of individual Chromosome Normalised Log2 ratios pre scaling
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Figure 2.5 Box plots of the spread of normalised log2 ratios from a normal 
male vs. female hybridisation, a) Pre-scaling, there is a greater variability in 
the spread of data between chromosomes, particularly in chromosome 19. b) 
After rescaling of the data, the distribution of data between each chromosome 
is more even
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Table 2.5 Scaling factors for individual autosomes derived from chromosome 
interquartile ranges from 7 normal-normal hybridisations
Chromosome Scaling Factor Chromosome Scaling Factor
1 0.965973938 12 0.995602788
2 0.910571526 13 0.902563854
3 1.004879797 14 0.950534457
4 0.938298957 15 0.883567966
5 0.878673476 16 0.991388402
6 0.918211228 17 1.077342838
7 1.006211423 18 0.949672773
8 0.892522767 19 1.467918832
9 0.861630166 20 1.008651688
10 0.92227046 21 1.175069821
11 0.97822635 22 1.058064909
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A histogram of the scaled, normalised data (Figure 2.6) demonstrates 
that the log2 ratios are normally distributed about a median of approximately 
0. For each array, the median (Md) and standard deviation (a) of the scaled 
log2 ratios of the autosomal clones were calculated. Since most regions of 
copy number change are greater than one clone in length, less stringent 
thresholds were set for consecutive clone changes. Therefore, three thresholds 
were initially set based on the 2-sided z-score for three probability values: For 
a single clone change, the threshold was Md±3.291*a (p=0.001); for 3 
consecutive clones, the threshold was Md±2.576*a (p=0.01); and for 5 
consecutive clones, the threshold was Md±1.960*cr.
Distribution of block lowess normalised Log2 Ratios
0.0 
Log2 Ratio
0.5 -0.5 -1.0
Figure 2.6 Frequency distribution of normalised log2 ratios. The normalised 
log2 ratios follow a normal distribution about a median of 0.
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In addition to the raw log2 ratio, a 3 and 5 clone local median was 
calculated for each clone. These medians were compared to the 3 and 5-clone 
thresholds respectively. If the local median lay outside its respective threshold, 
the clones used to calculate that median were all considered to have a copy 
number change. Since a local median of clones is used, rather than a mean, a 
majority of clones used to calculate a local median must be above the 
respective threshold.
Changes were identified using the single clone threshold first, followed 
by the 3-clone threshold, and finally the 5-clone threshold. If a particular clone 
had a copy number change called at a more stringent threshold, it was not 
considered at a less stringent threshold. This is summarised in (Figure 2.7). 
This removes the possibility of false calls. For example, if 2 of 3 consecutive 
clones have a change that is detected at the 1  clone threshold, taking a 3 clone 
median of these clones would increase the area of copy number change by one 
clone either side, since the median of these clones would be skewed by the 2 
consecutive changes at the 1  clone threshold and would be greater than the 3 
clone gain threshold.
Finally, the assumption was made that if a clone appeared to not have 
any change, but was flanked by clones with identical called changes, then that 
clone would also be called changed. This assumption was already made when 
calculating local medians, since only a majority, not all, of the clones used to 
calculate the local median are required to exceed the respective threshold. This 
takes into account some clones that may be flanked by clones with copy 
number changes.
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Final scaled Log2 Ratios
Calculate Loss and Gain 
Thresholds (TSL1,3,5, 
TSG1,3.5) and 3 & 5 clone 
medians <Md3. Md5)
Is the single 
done Log2 
ratio < T8L1 
or> TSG1?
Yes
Call single done as 
significantly lost or gained.
No
Yes Is Md3 
< TSL3 or 
> TSG3?
Call clones used to 
calculate median as 
significantly lost or gained.
No
Yes
Is Md5
< TSL5 or 
> TSG5?
Call clones used to 
calculate median as 
significantly lost or gained.
No
Call no significant copy 
number change.
Figure 2.7 Flowchart for selecting significant copy number changes. Once a 
particular clone has been called lost or gained, it is not considered at lower 
thresholds.
The final analysis program, which carries out analysis using the file 
derived from UCSF Spot (Jain et al. 2002), was written in R (Team 2006). 
This carries out the analysis described above in one process with user- 
definable parameters of the /   value for lowess normalisation, and the multiple 
of Drosophila clone intensities used for initial spot rejection.
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2.13.2.2.7 Testing significant changes using the HCT116 cell line
In order to test that the data analysis was identifying significant 
changes, data from a hybridisation of normal female DNA to the colon cancer 
cell line HCT116 was used (Langer et al. 2005). This is a microsatellite 
unstable cell line with a stable karyotype of:
45 (43-45), X, YxO, 10x1, der( 10)dup( 10)(q?)t( 10:16), 16x1, 
der(16)t(8;16), 18x1, der(18)t(17;18).
This cell line contains a number of characterised copy number changes, which 
can be used to test the method. The HCT116 Spot output file was run using a 
Drosophila rejection multiple of 2 and an/value of 0.25. A plot of the results 
and calls is shown in (Figure 2.8).
The outcome of the analysis demonstrated accurate identification of 
expected copy number changes. The duplicated region in the derivative 
chromosome 10 was identified, and demonstrated that the duplicated region is 
interstitial, with a small deletion of the lOqter. The other known karyotypic 
changes were also identified.
Furthermore, two distinct small regions of copy number change were 
identified, a copy number gain of 3 clones on chromosome 5q, and a deletion 
of 2 clones on chromosome 16p. Although other single clone changes were 
also present, many of these were clones known to ‘misbehave’ in 
hybridisation and produce unexpected results, possibly due to homologous 
content to other chromosomes.
The analysis did not miss regions which could have been identified by 
eye, nor did it identify any ‘false positive’ regions. Thus it can be deemed an 
accurate and sensitive method for analysis of microarray CGH data.
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Figure 2.8 Chromosome output plots for the HCT116 colon cancer cell line. 
Individual chromosome plots are shown after normalisation and analysis. 
Scaled, normalised log2 ratios are shown as black circles on each plot. The 
copy number change call is shown as a red line, a change of 1  indicates a gain, 
a change of-1 indicates a deletion, and 0 indicates no change. (Continued on 
following two pages)
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2.13.2.3  Data analysis discussion
Current literature contains many and varied methods and algorithms for 
the generation and analysis of genomic microarray data. Each with its own 
advantages and disadvantages, and often designed for a particular researcher’s 
individual needs. The approaches taken are diverse. The simplest involve 
using 2 standard deviations from the median as a threshold (Sharp et al. 2005). 
Others have devised ‘smoothing’ algorithms, which present the data as 
different levels of copy number, and so are useful for identifying different 
levels of change, for example in polyploidy tumours (Jong et al. 2004). And 
other groups have used more complex models, including Hidden Markov 
chains as a basis for their analysis (Chen et al. 2005).
The rationale behind this method was to devise a method of data 
generation and analysis that was simple to use and understand, but at the same 
time sensitive and specific. The devised method is not unique, it has taken 
elements of a number of analyses, and combined them to produce a 
comprehensive analysis program (Yang et al. 2002; Fiegler et al. 2003; 
Mulholland et al. 2006). Testing the method using a known cell line 
demonstrated both sensitivity and specificity in identifying known changes in 
a pure population of DNA.
As with all data analysis methods there are distinct advantages and 
disadvantages of this method. One particular disadvantage could be a 
difficulty in identifying significant changes in a sample with a large amount of 
copy number variation, since multiple changes would increase the spread of 
the array data, and thus artificially increase the thresholds, and possibly miss 
significant changes. Furthermore, the method cannot identify which changes
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are biologically genuine, rather than as a result of aberrant clone behaviour. 
Recent reports have identified large-scale copy number variation in the human 
genome between individuals, and this must be taken into account when 
identifying regions of change.
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3.1  Introduction
The inherited multiple tumour syndrome hereditary leiomyomatosis and 
renal cell cancer (HLRCC) is caused by germline mutations in the FT/gene 
encoding the Krebs’ cycle enzyme fumarate hydratase (FH). A wide variety of 
pathogenic variants were identified in the initial set of families in which the 
mutations were discovered, including whole gene deletions, missense and 
nonsense changes (Tomlinson et al. 2002). All the mutations have been shown 
to serve the same purpose, reducing the activity of the FH protein, by activity 
assays of patient lymphoblastoid cell lines (Alam et al. 2003).
While heterozygous germline mutations in FH result in HLRCC, bi- 
allelic mutations cause the fumarase deficiency syndrome, characterised by 
gross developmental delay and death within the first decade (Rustin et al. 
1997).
The aim of the work in this Chapter was to examine the frequency of 
germline FH mutations in a cohort of sporadic uterine leiomyoma patients to 
examine the contribution they make to leiomyoma prevalence. Within this, the 
association of FH mutations with ethnicity was also examined in order to 
assess the contribution of FH mutations in the earlier-onset and more 
prevalent uterine leiomyomas in African and Afro-Caribbean patients than 
Caucasian patients. In addition, patients with HLRCC and related syndromes 
were also screened to identify novel mutations. A series of cancer cell lines 
was also screened to assess the role of FH mutations in the common cancers.
In silico functional analysis of all known HLRCC and FH deficiency 
mutations was carried out in order to assist with the identification of the 
potential pathogenic effects of novel identified germline mutations. This
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analysis involved examining the structural distribution and interactions of FH 
missense mutations, given prior knowledge of effects on activity. As a part of 
this, the distribution of HLRCC and FH deficiency mutations was studied to 
examine the significance of differences in the mutation spectra of these two 
conditions. Other novel mutations, including missense changes to the 
mitochondrial targeting sequence, splice site mutations and non-coding 
variants were also examined in order to assess their pathogenicity.
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3,2 Materials and Methods
3.2.1 Sample Collection
All fresh tumour and blood/normal DNA samples from patients with 
diagnosed uterine leiomyomas were screened for mutations. In total 334 
unselected samples from sporadic leiomyoma patients were screened. Within 
this sample cohort, 232 patients provided ethnicity data: 75 patients were of 
African or Afro-Caribbean ethnicity, 55 patients were Caucasian, and 102 
patients were of other ethnicities. In addition, 26 selected samples with 
features of HLRCC were provided by clinical collaborators and screened for 
mutations.
3.2.2 Cancer cell line screening
In order to assess the role of FH mutations in a variety of cancers, an 
array of 70 cancer cell lines was screened. These cell lines (Table 3.1) 
represented a variety of tissue types, including colon, breast, lung and 
pancreas.
3.2.3 Mutation screening and DNA sequencing
Initial mutation screening was carried out by fluorescent SSCP
analysis, as described in Chapter 2 (2.5.1). Screening was carried out on PCR
products amplified using FAM-labelled primers using the described conditions
(Table 3.2). Samples with a change from the majority (assumed to be
homozygous normal), such as those shown in Figure 3.1, were selected for
sequencing. In addition, one apparently normal sample was also sequenced to
ensure that it was representative of a normal sample. Sequencing was carried
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out by re-amplification of the fragment with unlabelled primers by the same 
PCR conditions, followed by sequencing (2.6). Observed changes were 
analysed using DNA strider software to identify amino acid change.
7600 7100 7200 7300 7400 7500 6900
Normal
7000
-400
-300
-200
-100
Heterozygous change
-300
-200
-100
Figure 3.1 Example of a change observed by SSCP. There is an obvious 
difference between the normal sample, which has only two peaks, indicative 
of homozygosity, and the apparent heterozygous change, which has 4 peaks.
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Table 3.1 Cell lines screened for FH mutations
Cell Line Tissue Cell Line Tissue
U87 Astrocytoma A459 Lung
K562 B-cell lymphocyte CaLu-1 Lung
HT1376 Bladder A549 Lung
L88 Bone marrow SKMES Lung
MDA-
MB488 Breast LUDLU-1 Lung
BT-20 Breast NCI-H2170 Lung
MDA-
MB231 Breast T84 Lung
MCF-7 Breast NCIH69 Lung
MDA-
MB415 Breast NCI-H520 Lung
SKBR3 Breast MOLT4 Lymphocyte
T47D Breast IM9 Lymphocyte
MDA-
MB361 Breast U937 Lymphoma
MDAMB435 Breast P3HR1 Lymphoma
ZR-75 Breast SK23 Melanoma
MDA-
MB157 Breast DX3 Myeloma
JAMA-2 Breast NB100 Neuroblastoma
Hela S3 Cervical Carcinoma NFS-10-B7 Neurofibrosarcoma
HT29 Colon SCC15 Oral carcinoma
Colo741 Colon SKOV3 Ovarian
SW620 Colon TR175 Ovarian
Colo320 Colon Paca-3 Pancreas
LoVo Colon Hs766T Pancreas
Caco2 Colon HPAF Pancreas
HCT116 Colon PANC-1 Pancreas
HCA-7 Colon CF Pac-1 Pancreas
A431
Epithelial
Carcinoma Detroit 562 Pharynx
U118 Glioblastoma DU 145 Prostate
SCC25 Head and neck PC3 Prostate
TRI26 Head and neck 786PRC9 Renal
TRI46 Human Buccal RCC-VHL Renal
KG1 Leukemia NCI-H1385
Squamous cell 
carcinoma
HL60 Leukemia SCC-4
Squamous cell 
carcinoma
ML-1 Leukemia Jurkat T-cell
PLC/PRF/S Liver
NTERA.scl
.dl Testicular
HepG2 Liver JAR Trophoblast
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Table 3.2 Primer sequences for amplification of FH exons. Exon 5 was split 
into two fragments due to its length. Primers were labelled with FAM. Primers 
from (Tomlinson et al. 2002) were used for screening.
Primer
Name
Primer Sequence Product
Length
PCR
program1 ,2
Exon 0 F GTGTGAGGCTGTTGATTGGA 258 EJ55
Exon 0 R CTGCGCTCACCATTCGAG
Exon 1  F GAT  GCG  ATT  ACTTTT  G  ATCCTG 261 EJ55
Exon 1  R T  G  ACTC  AT  G  AAT  AC AGCCTACTT  C
Exon 2 F CTTTTGCATCTGCCAAAATAA 264 AR55
Exon 2 R TGCCAGAGCATATCGTCATC
Exon 3 F CTCTGTGGCATAATCAGCATT 300 AR55
Exon 3 R CAATCTCAGGTATGCTTTTCAA
Exon 4 F TTT  GTTTTT  GTTGCCTCTG  ATTT 295 EJ55
Exon 4 R ATTGGCCATTTGTACCAAGC
Exon 5a F TTTGCTCATCATAAGATTTGAAGT 300 AR55
Exon 5a R CCTTTTCTGCAAAGCCAATTC
Exon 5b F TGC  AAT  G  AC AAG  AAT  AAAAGCT G 215 AR55
Exon 5b R T  C  AAG  AC  AGG  AAC  ACTC  AG  A  A  AA
Exon 6 F TTTAACTT GTTC  ACCC ATCT  AGG  A 293 AR55
Exon 6 R GGACCTAGTCAAGTTTTAGCTCCA
Exon 7 F ATGGTTGGGCCTTGCTTTAT 300 EJ55
Exon 7 R CCAAGATAATAAGCCTTTGGTCA
Exon 8 F AAAGATTAAAAATGTGTTACACTCAGC 234 EJ55
Exon 8 R TCCACTTGTCTCTTAAAAATGGTTT
Exon 9 F GCTAACCCATATGTCGTCTTTTT 250 EJ55
Exon 9 R CGTTTTT  A  AG  AAAT GGG  AGTCTG
Details of programs can be found in Chapter 2 (2.3.2.1)
2 All PCR reactions contained  1.5mM MgCl2 and 5% v/v DMSO in a 25pl reaction 
with 25ng template genomic DNA
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3.2.4  Mutation functional and structural analysis
In order to assess the potential pathogenic effects of novel mutations, a 
number of strategies were undertaken. Initially, the functional effects of 
observed missense mutations were initially predicted using the PolyPhen 
program, which predicts the functional effects of coding SNPs on a protein 
(Ramensky et al. 2002) . Analysis of other mutations was carried out on an 
individual basis, dependent on the type of mutation..
In addition, several FH sequences were aligned using the ClustalW 
multiple alignment tool (Thompson et al. 1994) visualised with JalView 
(Clamp et al. 2004), in order to visualise conservation of residues across 
species. FH protein sequences for this alignment were obtained from the 
Entrez protein database (http://www.ncbi.nlm.nih.gov/entrez) for 8 species 
(Table 3.3)
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Table 3.3 Species and ID numbers for FH protein
alignment in ClustalX
sequences used for multiple
Species FH protein Entrez ID
Homo sapiens NP_000134.2
Mus musculus NP  034339.1
Danio rerio NP_957257.1
Caenorhabditis elegans 017214
Drosophila melanogaster AAS14209.1
Arabidopsis thaliana BAB08741.1
Saccharomyces cerevisiae P08417
Escherichia coli AP  002232.1
The locations of missense mutations on the structure of the FH protein 
were studied to examine the relationship between the physical location of a 
mutated residue, particularly to identify any physical clustering of mutations 
resulting in renal cell carcinoma and to examine any differences in the 
distribution of mutations resulting in HLRCC and FH deficiency.
The locations of mutations were modelled onto the structure of E. coli 
fumarase C (Protein data bank ID 1FUO) (Weaver et al. 1995) using UCSF 
Chimera (Pettersen et al. 2004). The protein is a homotetramer with 2 2 2 
symmetry (Weaver et al. 1995). However, the deposited database structure is a 
homodimer. In order to model the tetrameric structure, the unit cell function of 
Chimera was utilised to produce an accurate interaction of two homodimers 
(Figure 3.6). The role of individual residues mutated in HLRCC patients, and
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the possible effects of the mutations, were determined by several criteria by 
examination of the equivalent E. coli residue:
i)  Examination of interactions with other residues. This 
includes examining the hydrophobic, electrostatic and 
hydrogen bonding interactions with other residues. Mutations 
removing such interactions can potentially destabilise protein 
folding and enzyme function.
ii)  Steric effects. This examines changes in both the size and the 
torsion angles imposed by the mutated residue compared to 
the original residue.
iii)  Active site residues. The catalytic mechanism of FH is now 
well understood, and the active site residues have been 
identified. Mutations to these residues, or in the proximity of 
them, would have an adverse effect on protein function.
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3.3 Results
3.3.1  FH mutation screening
In total, 360 patients with uterine leiomyomas, including 26 patients 
provided on the basis of an HLRCC or apparently related phenotype, and 70 
cancer cell lines were screened for FH mutations. Screening of patient and 
tumour samples identified 24 DNA sequence variants in 97 patients, and 9 cell 
line samples (Table 3.4). 7 of these variants, occurring in 55 patients and 8 
cell lines, were synonymous coding SNPs. 11 variants, observed in 25 patients 
and 1  cell line, were missense changes. 4 variants, observed in 17 patients, 
were insertion/deletion mutations, 2 of which occurred in coding regions, and 
the remaining 2 were intronic. One variant in one patient altered the splice 
acceptor site of exon 3, and finally, one variant in one patient occurred 25 
bases upstream of the transcriptional start (Table 3.4, Figure 3.2, Figure 3.3).
16 of these variants have not been previously reported in the literature 
or SNP databases (Shown in Figure 3.2, Figure 3.3). 4 of the remaining 
changes (Q142R, K187R, R190H and G354R) are known HLRCC mutations 
(Alam et al. 2003). One mutation (ins434K) has been previously associated 
with FH deficiency (Coughlin et al. 1998), and more recently with ovarian 
mucinous cystadenoma (Ylisaukko-oja et al. 2006). The final 3 
polymorphisms are reported synonymous SNPs in the dbSNP database 
(Sherry et al. 2001)(A60A = rsl0926501, P266P = rsl049719, and C391C = 
rsl2087951).
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Table 3.4 All identified FH sequence changes
Exon1 Mutation type Nucleotide
Position2
Wild type 
codon/sequence3
Mutated
codon/sequence3
Amino Acid 
Change4
No.
samples
0 Non-coding* -25 aaccggc aacgggc N/A 1
0 Missense* 36 TAC CAC Y2H 7
0 Missense* 69 CCC GCC P13A 1
0 Missense* 85 CCA CTA P18L 5
0 Missense* 126 GCC ACC A32T 1
0 Synonymous* 137 TCG TCA S35S 3
0 Synonymous* 149 CCG CCA P39P 5
1 Synonymous* 260 ACG ACA T33T 1
2 Synonymous SNP 341 GCC GCT A60A 16
3 Splice acceptor* 441-2 cagGTA cggGTA N/A 1
3 Missense* 558 CAT CCT H133P 1
3 Missense 586 CAG CGG Q142R 2
3 lbp insertion* 588+27 TTTGGT TTTTGGT N/A 9
4 Missense 721 AAG AGG K187R 1
4 1 bp deletion* 727 GGACGT GACGT G189fsX211 1
4 Missense 730 CGT CAT R190H 2
6 Synonymous 959 CCG CCA P266P 24
6 Missense* 1045 ATA ACA I295T 1
7 2bp deletion* 1141-35 TTTAGTC TTGTC N/A 4
7 Missense 1221 GGA AGA G354R 1
8 Synonymous 1334 TGC TGT C391C 7
8 Synonymous* 1370 AAT AAC N403N 8
9 3 bp insertion 1461 CAAAAAT CAAAAAAAAT ins434K 3
9 Missense SNP* 1504 TAT TGT Y448C 1
indicates the primer set in which the change was identified
2Numbered from FH  mRNA (Genbank accession NM  000143)
3Capital letters indicate coding bases, lowercase letters indicate intronic/other regions
4Amino acids in exon 0, encoding the mitochondrial signal sequence, are labelled separately 
from those in the cytosolic protein, due to historical mis-assignment of the first codon. 
*Represents novel changes identified in this study
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Y 2 H * P 1 3 A * P 1 8 L *
H 1 3 3 P I2 9 5 T
Y448C
A  C  A
Figure 3.2 Novel non-synonymous coding changes identified in this study. 
The location each polymorphism is indicated by an arrow. Mutations 
highlighted with * are variants in the mitochondrial targeting sequence.Chapter 3 Fumarate Hydratase (FH) mutations in Hereditary Leiomyomatosis and Renal Cell
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Synonymous coding variants
S35S* P39P*
N403N
Other variants
25bp upstream from ts start exon 3 splice acceptor
7  C
1141-35 delTA G189fsX211
A  A  A  A  T  A C  7  C  7  7  7
T33T
588+27 1  bp insertion_______
ins434K
Figure 3.3 Novel synonymous coding variants and other novel variants 
observed in this study. Variants marked with * occur in the mitochondrial 
targeting sequence. Positions of intronic variants are relative to the nearest 
mRNA position.
149Chapter 3 Fumarate Hvdratase (FH) mutations in Hereditary Leiomyomatosis and Renal Cell
Cancer (HLRCC)
3.3.2  Functional effects of novel polymorphisms
A number of novel changes were identified in this study of uncertain 
pathogenic potential. Previous studies have used FH activity in 
lymphoblastoid cell lines as a measure of the pathogencity of a mutation 
(Alam et al. 2003; Pithukpakorn et al. 2006). However, the samples in this 
study were all received as DNA samples, and so activity assays could not be 
carried out. Therefore, an in silico approach was used to identify the possible 
effects of the novel mutations on FH function.
3.3.2.1  Analysis of novel missense mutations
The online PolyPhen tool was initially used to predict the effects of the 
coding missense mutations. The results (Table 3.5) predicted the effects for 
the cytosolic missense mutations, but failed to predict the effects of the exon 0 
mutations due to insufficient similar protein sequences in the database. The 
results predicted that 2 of the novel missense changes, H133P and Y448C, 
were probably damaging to the protein, while the third, I295T, was probably 
benign. H133P was identified in a tumour sample, rather than a constitutional 
DNA sample, and the K187R mutation, which was among the original 
identified FH mutations in HLRCC (Tomlinson et al. 2002), was also 
identified in this tumour. Therefore, it is likely that H133P represents the 
second ‘hit’ in an HLRCC leiomyoma. Furthermore, HI33 has been identified 
as an active site residue in the FH protein (Weaver and Banaszak 1996), and 
so mutation of this residue should have a deleterious effect on the protein 
activity.
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The prediction of Y448C as potentially damaging is a surprising result 
for a number of reasons. As is shown in the next section, Y448 is not very 
well conserved between species, although the shape of the residue is 
conserved. Secondly, the patient with the mutation was 62 years old when she 
was diagnosed with uterine leiomyomas. Generally, HLRCC patients present 
in their 20’s and 30’s (Alam et al. 2005a), although there is one recent report 
of a patient with an R58X mutation presenting at 55 years of age (Varol et al. 
2006). Therefore, in order to further examine the potential pathogenic effect of 
this mutation, analysis in the context of sequence conservation and structure 
was carried out (See 3.3.4). A similar analysis was carried out on the I295T 
mutation.
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Table 3.5 Predicted effects of novel missense mutation by PolyPhen
Mutation Predicted Effect Comments
Y2H Unknown No data for prediction
P13A Unknown No data for prediction
P18L Unknown No data for prediction
A32T Unknown No data for prediction
H133P Probably Damaging Mutation disrupts ligand binding site
I295T Benign No predicted effect of substitution
Y448C Probably Damaging Predicted on basis of alignment
3.3.2.2  Further analysis of exon 0 missense mutations
The region encoded by exon 0 contains a 43-residue region that targets 
FH to the mitochondrial matrix. Once the protein has been transported into the 
matrix, this region is cleaved by specific proteases, leaving the final functional 
protein. These sequences are sufficient to target a protein to the mitochondria 
by fusing them to non-mitochondrial proteins (Roise and Schatz 1988). While 
little homology exists between signalling sequences of different mitochondrial 
proteins, the signal sequences share common features. Firstly, the sequence 
contains a mixture of positively charged and hydrophobic residues along its 
length, with a strong bias against negatively charged residues. Secondly, the 
sequences are amphiphilic, and projection of the sequence onto a helical wheel 
results in a pronounced segregation of charged and hydrophobic residues to 
either face of the wheel, forming an amphipathic helix (Roise and Schatz 
1988).
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This positively charged amphipathic helix is sufficient in itself to 
target a protein to the mitochondrial matrix, since artificially constructed 
amphiphilic signal sequences, with no homology to known mitochondrial 
signal sequences, are able to target a protein to the mitochondria (Roise and 
Schatz 1988). The first 18 residues of the FH signal sequence follow this 
pattern (Figure 3.4a). However, subsequent residues form a hydrophobic helix 
prior to the start of the cleaved final protein (Figure 3.4b). The effects of each 
missense mutation on the amphiphilicty of the predicted helix were assessed. 
None of the mutations affected the amphipathic nature of the helix, and so are 
assumed not to affect the mitochondrial targeting ability of the sequence. To 
confirm this, the mitochondrial leader sequence was used as the basis for a 
BLAST search against other eukaryotic FH signal sequences. None of the sites 
of mutation were conserved between species. Therefore, it can be concluded 
that the four exon 0 missense mutations, Y2H, P13A, P18L, and A32T, are 
probably benign.
3.3.2.3  Functional effects of other novel coding mutations
In addition to the 7 novel missense changes, two novel nonsense 
mutations were identified, G189fsX211  and ins434K. The latter mutation has 
previously been described in FH deficiency patients (Coughlin et al.  1998), 
and more recently in ovarian mucinous cystadenoma (Ylisaukko-oja et al. 
2006), and so is known to affect FH activity. Therefore, it can be added to the 
spectrum of HLRCC mutations. G189fsX211  joins a list of 21 nonsense 
mutations reported to date in HLRCC and FH deficiency patients (Coughlin et
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al.  1998; Kiuru et al. 2002; Tomlinson et al. 2002; Alam et al. 2003; Martinez- 
Mir et al. 2003; Toro et al. 2003; Chuang et al. 2005; Badeloe et al. 2006; 
Chuang et al. 2006a; Wei et al. 2006b). It has previously been shown that 
truncated FH proteins are unstable, affecting FH activity by reducing the 
available enzyme (Alam et al. 2003). Since truncating mutations have been 
observed throughout the protein, it can be assumed that the protein resulting 
from this mutation is also unstable, and so the mutation is pathogenic.
3.3.2.4  Functional effects of novel non-coding mutations
The final 4 novel mutations comprised variants in non-coding regions 
of the gene that have not been reported in publicly available databases. Three 
of these mutations occured within the introns close to the exon boundary, and 
the fourth occured 25bp upstream of the transcription start. Of the intronic 
mutations, one mutated the fully conserved AG motif of the splice acceptor 
site in exon 3 to GG. This mutation would abolish splicing of this exon, 
resulting in deletion of exon 3 from the final mRNA. Including this variant, 5 
splice donor and acceptor mutations have been reported in HLRCC and FH 
deficiency patients, all of which affect the conserved GT and AG motifs 
defining the splice donor and acceptor sites (Chuang et al. 2005; Badeloe et al. 
2006; Wei et al. 2006b).
In order to assess the effects of the other non-coding mutations, the 
comparative genomics track of the UCSC genome browser was used to 
examine the conservation of these regions between species. Regions of high 
sequence conservation have been shown to represent potentially important
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regulatory regions, including transcription factor and enhancer binding sites 
and the splice branch sites, which occur approximately 30bp upstream from 
the splice acceptor site.
The intronic insertion downstream from the exon 3 splice donor site 
(588+27) occurs in a region of little conservation between species, and is at 
the wrong end of the intron to affect the branch site. Therefore, it is likely that 
this polymorphism is a novel insertion-deletion SNP and pathogenically 
benign. The second intronic polymorphism, a 2bp deletion 35bp upstream of 
the exon 7 splice acceptor site, is highly conserved and adjacent to the branch 
site, but the deletion does not appear to affect this site. Again, this mutation 
appears to be benign.
The final non-coding mutation, 25bp upstream from the transcription 
start, occurs in the middle of a CpG island that encompasses all of exon 0. The 
mutation is a transversion of a C to a G, which removes one CpG group, but 
creates a new one lbp downstream. Analysis of this sequence showed that the 
nucleotide is not well conserved between species. The program FPROM 
(Solovyev et al. 2006) was used to identify promoter sequences in the locality 
of this base, and found no promoter sequences. Therefore, it is most likely that 
this mutation is benign.
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Figure 3.4 Helical wheel projection of the first 36 residues of the FH 
mitochondrial signal sequence. The first 18 residues (a) form a positively 
charged amphipathic a-helix, whereas the second 18 residues (b) form a 
hydrophobic helix, with the exception of two serine residues. The residues 
affected by the observed mutations are highlighted with ♦. None of the 
observed mutations affect the amphipathic nature of either helix, and so the 
mutations are likely to be benign.
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3.3.3  Multiple sequence alignment
A wide variety of missense mutations have now been described in 
HLRCC and FH deficiency patients in the literature (Table 3.7). In order to 
further understand the potential role of the two remaining novel missense 
mutations of uncertain pathogenicity, I295T and Y448C, the sequence 
conservation of these residues was examined alongside the conservation of 
known HLRCC and FH deficiency missense mutations.
An alignment was carried out using the ClustalW alignment tool (Thompson 
et al.  1994), and visualised and coloured using Jalview (Clamp et al. 
2004)(Figure 3.5). Despite the selection of species being evolutionarily 
diverse, a very high level of homology exists, particularly when the 
mitochondrial signal sequence is not taken into account (Table 3.6).
Mapping the locations of known missense mutations onto this 
alignment demonstrated that every reported missense mutation (Table 3.7) 
altered a residue that was conserved throughout species, either exactly, or by 
shape and type. 1295 was found to be conserved exactly across species, and to 
reside in a block of very highly conserved residues. Y448 was less well 
conserved, and it appeared that the hydrophobicity of the phenyl group was 
more necessary than any interactions due to the hydroxyl group since this 
residue was replaced with hydrophobic residues of a similar bulk in other 
species, such as phenylalanine and valine. Therefore, based on sequence 
conservation, I295T appears to be a more likely pathogenic mutation than 
Y448C.
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Table 3.6 Homology of FH polypeptide sequences from different species to 
human cytosolic FH. Alignment and assessment of homology was carried out 
using BLAST (Tatusova and Madden 1999).
Species % Identical residues to 
human FH
% homologous 
residues to human FH
Mus musculus 96% (451/467) 98% (460/467)
Danio rerio 87% (410/467) 94% (443/467)
Caenorhabditis elegans 76% (352/460) 86% (399/460)
Drosophila 68% (316/458) 81% (372/458)
melanogaster
Arabidopsis thaliana 71% (327/460) 82% (380/460)
Saccharomyces 67% (313/464) 81% (376/464)
cerevisiae
Escherichia coli 60% (280/462) 76% (354/462)
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Table 3.7 All reported HLRCC and FH deficiency missense mutations
HLRCC Missense 
Mutations
Exon WT 
codon.
Mutant
codon
Nucleotide 
Position on 
mRNA 
(NM  000143)
WT
residue
Amino
Acid
Position
Mutant
Residue
Reference
2 AAC ACC 352 N 64 T (Tomlinson 
et al. 2002)
2 GCT CCT 381 A 74 P (Tomlinson 
et al. 2002)
3 TTA TCA 427 L 89 S (Wei et al. 
2006b)
3 CAT CGT 436 H 92 R (Chuang et 
al. 2005)
3 CAG AAG 456 Q 99 K (Badeloe et 
al. 2006)
3 AGC ATC 505 s 115 I (Martinez- 
Mir et al. 
2003)
3 AGA GGA 510 R 117 G (Wei et al. 
2006b)
3 CAT CGT 571 H 137 R (Tomlinson 
et al. 2002)
3 CAG CGG 586 Q 142 R (Tomlinson 
et al. 2002)
4 TCA TTA 592 s 144 L (Toro et al. 
2003)
4 AAT AGT 595 N 145 S (Toro et al. 
2003)
4 CCC CTC 607 P 149 L (Chuang et 
al. 2005)
4 ATG ACG 616 M 152 T (Toro et al. 
2003)
4 CAC CGC 619 H 153 R (Kiuru et al. 
2002)
4 ATC ACC 718 I 186 T (Alam et al. 
2003)
4 AAG AGG 721 K 187 R (Tomlinson 
et al. 2002)
4 CGT CAT 730 R 190 H (Tomlinson 
et al. 2002)
4 CGT TGT 729 R 190 C (Wei et al. 
2006b)
4 CGT CTT 730 R 190 L (Toro et al. 
2003)
5 GCT ACT 852 A 231 T (Ylisaukko- 
oja et al. 
2006)
5 GGT GTT 877 G 239 V (Tomlinson 
et al. 2002)
6 AAT TAT 960 N 267 Y (Alam et al. 
2005b)
6 CAT TAT 984 H 275 Y (Toro et al. 
2003)
6 GTT GAT 997 V 279 D (Toro et al. 
2003)
6 ACT CCT 1023 T 287 P (Chuang et 
al. 2006a)
6 CTG CCG 1036 L 292 P (Toro et al. 
2003)
6 AAT GAT 1050 N 297 D (Toro et al. 
2003)
6 AAT AAA 1052 N 297 K (Wei et al. 
2006b)
6 GAA AAA 1095 E 312 K (Alam et al. 
2003)
6 AAT AAA 1115 N 318 K (Alam et al. 
2003)
6 AGC GGC 1125 S 322 G (Wei et al.
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6 AGT AAT 1129 S 323 N (Alam et al. 
2003)
7 GCC GAC 1186 A 342 D (Wei et al. 
2006b)
7 GTC CTC 1212 V 351 L (Martinez- 
Mir et al. 
2003)
7 GGA AGA 1221 G 354 R (Alam et al. 
2003)
8 TCA CCA 1287 S 376 P (Wei et al. 
2006b)
8 CAG CCG 1348 Q 396 P (Wei et al. 
2006b)
9 ATG ATA 1394 M 411 I (Carvajal- 
Carmona et 
al. 2006)
9 TAT TGT 1426 Y 422 C (Toro et al. 
2003)
9 CTG CCG 1552 L 464 P (Alam et al. 
2003)
FH Deficiency Missense Mutations
3 CCT CGT 553 P 131 R (Alam et al. 
2003)
5 GCT ACT 954 A 265 T (Coughlin et 
al.  1998)
6 CAT CTT 985 H 275 L (Deschauer 
et al. 2006)
6 GAA CAA 1116 E 319 Q (Bourgeron 
et al.  1994)
7 CAG CCG 1159 Q 333 P (Phillips et 
al. 2006)
8 GAT GTT 1306 D 382 V (Coughlin et 
al.  1998)
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Figure 3.5 Multiple sequence alignment of FH protein sequences from different species carried out using the 
CLustalW multiple alignment tool. Locations of HLRCC and FH deficiency (highlighted by *) missense mutations
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Os are highlighted by black boxes. The location of the I295T and Y448C mutations are highlighted by **. The red bar
marks the end of the mitochondrial signal sequence
C
h
a
p
t
e
r
 
3
 
F
u
m
a
r
a
t
e
 
H
y
d
r
a
t
a
s
e
 
(
F
H
)
 
m
u
t
a
t
i
o
n
s
 
i
n
 
H
e
r
e
d
i
t
a
r
y
 
L
e
i
o
m
y
o
m
a
t
o
s
i
s
 
a
n
d
 
R
e
n
a
l
 
C
e
l
lChapter 3 Fumarate Hydratase (FFO mutations in Hereditary Leiomyomatosis and Renal Cell
Cancer (HLRCC)
3.3.4  Structural effects of FH mutations
In order to assess the effects of germline FH mutations on the structure 
and activity of the fumarate hydratase protein, known mutations were mapped 
onto the structure of E.coli fumarase C (Weaver et al. 1995). This protein has 
very high homology and similar reaction kinetics to the human FH protein, 
and thus was considered a suitable structure for modelling mutations (Weaver 
et al. 1995).
E.coli Fum C is a tetrameric protein comprised of 4 identical 50kDa 
monomers (Figure 3.6). Each monomer contains three distinct domains: two 
globular domains at either end of the molecule, separated by a 5 a-helical 
bundle. The association of this helical domain results in tetramer formation. 
The enzyme has four active sites (Figure 3.6 -  yellow arrows). The solution 
of the crystal structure of E.coli FumC, demonstrated two ligand binding sites 
in the active site region, deemed A and B (Weaver et al. 1995). The A site is 
formed from residues from 3 monomers and was shown to be the catalytic site 
by site-directed mutagenesis experiments (Weaver and Banaszak 1996). The 
role of the B site, which is formed from a single monomer, is less clear, since 
it is apparently not required for catalysis, since mutation of one of the 
substrate binding residues does not affect FH activity. It was initially 
suggested to be an allosteric site, responsible for the increased activation of 
the enzyme at high substrate concentrations (Rose 1997), although this was 
found not to be physiologically viable since activation by common anions, 
including other Krebs cycle intermediates such as citrate, would obscure this 
effect in vivo (Rose and Weaver 2004).
162Chapter 3 Fumarate Hydratase (FH) mutations in Hereditary Leiomyomatosis and Renal Cell
Cancer (HLRCQ
Rose and Weaver suggested that the B-site is an integral part of the 
active site, involved in the transfer of substrate to the catalytic A-site. They 
showed that while mutation of substrate binding residues in the B-site does not 
affect enzyme activity, it does alter the rate limiting step of the reaction. 
Instead of being rate-limited in the enzyme recycling to a basic form ready to 
bind the next molecule of fumarate, the rate-limiting step becomes the release 
of substrate from the enzyme (Rose and Weaver 2004).
Figure 3.6 Homotetrameric structure of E. coli Fum C. Each subunit is 
coloured separately. The yellow arrows indicate the approximate locations of 
the 4 pairs of A and B-sites of the enzyme. The model was made using UCSF 
Chimera.
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3.3.4.1  Distribution and effects of known HLRCC mutations
To date, 43 separate missense mutations have been identified in 
patients with HLRCC, and a further 7 missense mutations have been found in 
FH deficiency patients (Table 3.7). In order to further understand the effects 
of these mutations on the FH protein, and how they may affect the activity of 
the protein, the location of each mutation was mapped onto the structure of 
E.coli FumC. Initially, the mutations were mapped onto a single monomer to 
identify clustering to any particular domain (Figure 3.7). It was observed that 
mutations clustered more to the globular domains, particularly the larger N- 
terminal globular domain.
Since the globular domains of the FH monomer are responsible for 
active site formation, it was decided to examine the location of the mutations 
in the context of an active site. The results (Figure 3.8) showed that the 
majority of missense mutations in the globular domains were physically close 
to the active site, and many were within close proximity to the two ligand 
binding sites. Thus, mutations in the globular domains of FH are likely to 
disrupt active site formation, and so catalysis. In addition, the locations of FH 
deficiency missense mutations did not cluster differently to HLRCC 
mutations.
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Figure 3.7 Location of HLRCC and FH deficiency missense mutations on a 
monomer of E.coli FumC. HLRCC missense mutations (white) and FH 
deficiency mutations (green, blue = both HLRCC and FH deficiency) cluster 
to either end of the monomer with fewer mutations occurring in the helical 
bundle. The monomer is viewed from both sides to show the location of all 
mutations.
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Figure 3.8 Clustering of HLRCC and FH deficiency missense mutations to 
the active site region of FH. In this model, FH was co-crystallised with citrate 
and malate, which occupy the active site (Weaver et al.  1995). Focusing on a 
single active site, formed from 3 monomers, HLRCC and FH deficiency 
missense mutations (white) were found to be physically close to the two 
ligand binding sites in each FH active site. Purple residues represent catalytic 
A-site residues, with blue residues being mutated in HLRCC and/or FH 
deficiency. Green residues form the ligand binding B-site, with yellow 
residues found mutated in HLRCC and/or FH deficiency. The tetramer is 
shown for reference with the region of interest boxed.
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In order to more closely observe how particular mutations can affect 
the activity of the protein, the 4 known HLRCC mutations observed in this 
study (Q142R, K187R, R190H and G354R), which have previously been 
shown to reduce FH activity in lymphoblastoid cell lines from HLRCC 
patients (Alam et al. 2003), were examined in more detail. These 4 mutations 
cover the 3 domains of the FH monomer.
2 HLRCC mutations of Q142 have been reported to date, one missense 
change, Q142R (Tomlinson et al. 2002), and one nonsense change, Q142X 
(Martinez-Mir et al. 2003). This residue occurs in the large N-terminal 
globular domain, very close to the active site. The E.coli equivalent, Q138, 
forms a number of H-bond interactions with both main chain carboxyl groups 
and side chains of nearby residues (Figure 3.9a). Also involved in these 
interactions is N59, the human equivalent of which, N64, is mutated in 
HLRCC patients. The residues within the N-terminal globular domain form a 
mesh of H-bond and salt bridge interactions which align the residues of the 
nearby catalytic and ligand binding sites. Therefore, mutations that disrupt 
these interactions, such as Q142R and N64T, would lead to alterations in the 
structure of the active site, and so would, at the very least, disrupt, if not 
completely remove, enzyme activity.
R190 and K187 (R186 and K183 in E.coli respectively) are both 
highly conserved in FH proteins across species. They are also physically close 
within the protein, occurring in the smaller C-terminal globular domain. To 
date, 3 separate missense mutations have been reported at R190 (R190H, 
R190L, R190C) in both HLRCC and FH deficiency patients (Gellera et al. 
1990; Tomlinson et al. 2002; Toro et al. 2003; Wei et al. 2006b). K187R has
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also been observed in both patient groups (Coughlin et al. 1998; Tomlinson et 
al. 2002). Examining the interactions of the E.coli equivalent residues (Figure 
3.9b) demonstrated salt bridge and H-bond interactions between these 
residues, and E308, the E.coli equivalent of E312, which has also been 
reported as mutated in HLRCC patients (Alam et al. 2003). Overall the pattern 
of salt bridge and H-bonding interactions draws together residues from 3 
monomers, and is likely to be important in both forming and stabilising the 
catalytic site, since 2 active site residues are adjacent to this interaction. 
Furthermore, mutation of either of these residues would disrupt interactions 
between monomers, and so affect tetramer formation.
G354 (G350 in E.coli) occurs in the central a-helical bundle, away 
from the active site of the enzyme. The residue faces into the centre of the 
monomer bundle, in a very hydrophobic region with close packing of residues 
(Figure 3.10). Mutation of this residue to arginine would have a massive 
effect on helix packing due to this residue being firstly very large, which 
would disrupt the close packing of the residues, and secondly very 
hydrophilic. Therefore, this mutation is likely to destabilise the entire 
monomer, reducing the available monomers for tetramer formation, and thus 
the overall activity of the enzyme.
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Figure 3.9 Interactions of E.coli equivalents of Q142 (a - Q138) and R190 (b - 
R186). Fine lines between residues indicate predicted H-bond and salt bridge 
interactions. The full protein is shown for reference with the region of interest 
highlighted. For a detailed description, see the main text.
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Figure 3.10 Interactions of G350 (E.coli equivalent of G354). G350 is on the 
inside of an a-helix within the central 5-helix bundle in a closely packed 
hydrophobic region. Nearby residues, such as F361, M364 and V365 are 
shown as spacefill models to emphasise this close packing. Mutation to an 
arginine would disrupt this close packing, and so would disrupt the helical 
bundle within the monomer.
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Each of these mutations demonstrates the three possible effects of FH 
defects on the protein, each contributing to a reduction in activity in a different 
manner. Firstly, a mutation may affect the active site, either by local 
disruption, for example due to the Q142R or N64T mutations, or by mutation 
of an active site residue, such as the N145S mutation. Monomers with such 
mutations would be able to form into full tetramers, but would lack function at 
active sites formed by the mutated subunit.
Secondly, the mutation may affect interactions with other subunits, as 
is the case for the R190H and K187R mutations. Monomers with such 
mutations may or may not be able to form tetramers, but the interactions 
between the subunits would be compromised, which could possibly lead to a 
dominant negative effect. Such an effect has previously been reported for the 
R190H and K187R mutations, which showed an approximately 80% reduction 
of FH activity, instead of the expected 50% (Alam et al. 2003).
The final group of mutations appear to disrupt the structure of the 
monomer before tetramer formation occurs, such as G354R. Therefore, it is 
predicted that these subunits will not form into tetramers. Therefore, all the 
FH homotetramers would contain wild type monomers, but the reduced 
overall amount of FH would lead to a reduction in enzyme activity.
In each of these scenarios, a second hit affecting the enzyme would 
result in a complete loss of FH activity within a cell. And it is this loss of 
activity that appears to be the trigger for tumorigenesis in HLRCC.
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3.3.4.2  Structural effects of novel mutations
The three novel missense mutations, H133P, I295T and Y448C were 
mapped onto the structure in an attempt to better understand their potential 
effect on the protein. The equivalent E. coli residues for each of these residues 
are H129 (for H133), Y444 (for Y448) and 1291 (for 1295).
PolyPhen had already predicted a disruptive effect of the H133P 
mutation on the protein due to ligand binding. These interactions, shown in 
Figure 3.11, bind the malate ligand to the non-catalytic B-site of the enzyme. 
Mutation of this residue to a proline would completely remove this interaction. 
This is not the end of the story with this residue, however, since Weaver et al 
have carried out studies using an H129N E.coli FumC mutant. They 
demonstrated that this mutation does not have an effect on FH activity, 
although it does alter the rate-limiting step of the enzyme (Weaver et al.
1997). However, one of the important characteristics of the B-site is the n- 
helical structure, which involves residues H129 to N135 (Weaver 2000).
While the H129N mutation removes the interaction with malate, it may not 
destabilise the iz helix. The restricted structure of proline would have a 
destabilising effect on this helix, and so may yet have a derogatory effect on 
enzyme activity, and if so this effect probably occurs through reducing access 
of the substrate to the active A-site.
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Figure 3.11 Ligand binding interaction of HI29 in E.coli FH. This residue 
forms salt bridge interactions with co-crystallised malate in the B-site of the 
enzyme. The malate also interacts with R126 (not conserved in humans) and 
the main chain amide groups of residues 131 and 132. Shown residues are 
coloured in standard atomic colours.
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1291 sits in a hydrophobic pocket at the core of the 5 helix bundle 
(Figure 3.12a) and is closely surrounded by other hydrophobic residues. The 
effects of mutation of this residue to a threonine are not clear cut. The 
mutation would not disrupt helix packing by increasing the bulk of the residue, 
since isoleucine and threonine are of a similar size. However, the addition of a 
polar group into the hydrophobic pocket may destabilise the helix packing, 
and so compromise enzyme activity although this might not have the effect of 
a charged amino acid such as the effect of the G354R mutation described 
above. Therefore, the effects of this mutation remain elusive.
Y444 is positioned at the edge of the protein away from the active site 
(Figure 3.12b). It appears to show H-bond and salt bridge interactions with 
two nearby residues, K420 (K424 in humans) and E423 (K427 in humans, 
which would retain this interaction). K420 and E423 are part of an cx-helix 
which appears to interact with a looped region from another subunit. Thus 
Y444 may stabilise inter-subunit packing. Mutation of this residue to a 
cysteine would remove these interactions, since although the thiol group is 
polar, the smaller size of the residue would increase the distance between the 
potentially interacting atoms. This disruption could affect inter-subunit 
interactions by the a-helix.
The results of this fail to conclusively suggest a pathogenic role for 
either the I295T or Y448C mutations, while the role of the H133P mutation 
also remains controversial based on the work of Weaver et al (Weaver et al. 
1997). Both I295T and Y448C elude to a possible effect on enzyme activity. 
However, to confirm this, more studies would need to be carried out. These 
will be discussed later on.
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Figure 3.12 Location and interactions of the two novel missense mutations 
I295T (a) and Y448C (b). For a description of the interactions, see main text.
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3.3.5 Frequency of pathogenic FH mutations in uterine leiomyoma 
patients
In assessing the frequency of pathogenic FH mutations, the three novel 
missense mutations, the pathogenic effects of which were uncertain, H133P, 
I295T and Y448C, were considered to be pathogenic.
3.3.5.1 Frequency of FH mutations in uterine leiomyoma patients
In order to assess the frequency of FH mutations in patients with 
uterine leiomyomas, 334 uterine leiomyoma patients from a variety of sample 
groups were screened. This set excluded patients sent specifically to the 
laboratory for HLRCC mutation testing. The screen identified pathogenic FH 
mutations in 7/335 (2.1%) of unselected leiomyoma cases. Therefore, the 
occurrence of germline FH mutations in uterine leiomyoma cases is very rare, 
and is not a significant cause of uterine leiomyoma onset.
In patients with HLRCC related symptoms sent to the laboratory for 
FH screening, 6/26 (23%) patients showed sequence mutations in the FH 
gene.
3.3.5.2 Frequency of FH mutations in Afro-Caribbean patients
Within the group of unselected uterine leiomyoma cases, ethnicity was 
reported for 232 samples (Table 3.8). The patients were grouped into three 
categories of ethnicity: African and Afro-Caribbean; Caucasian; and other 
(patients with reported ethnicities who were neither Caucasian nor 
African/Afro-Caribbean). Patients of African and Afro-Caribbean ethnicity 
were found to be significantly younger (p<0.001, Wilcoxon-signed rank test)
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than Caucasian patients and those of other ethnicities at the time of sample 
collection. Six of the FH mutations identified in this study were from patients 
with reported ethnicities. Three of these, R190H, ins434K and K187R/H133P 
were observed in Caucasian patients, and 3,1295T, and 2 occurrences of 
ins434K, were observed in patients of other ethnicities. Therefore, despite the 
younger age of leiomyomas in African and Afro-Caribbean patients, which 
mimics the younger age of onset in HLRCC patients, mutations in FH do not 
appear to play an important role in the earlier onset of leiomyomas in these 
patients.
Table 3.8 Distribution of patients by ethnicity and number of FH mutations.
Ethnic
Group
Number of 
samples
Age of onset (yrs) No. FH 
mutations Mean SD
African/Afro-
Caribbean
75 40.831 7.01 O 2
Caucasian 55 46.151 7.38 32
Other 102 45.571 6.63 32
African/Afro-Caribbean patients are significantly younger than Caucasian 
and other patients (pO.OOl Wilcoxon signed-rank test).
2No significant difference in the frequency of FH mutations in African/Afro- 
Caribbean patients, and Caucasian/other patients (p=0.18, Fisher’s exact test).
3.3.5.3  FH mutations in cancer cell lines
In order to assess the effects of FH mutations on a variety of cancers, a 
panel of 70 cancer cell lines was screened. Only one missense change was
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identified in all the samples, an exon 0 A32T mutation in cell line DU145. 
However, no definitively pathogenic mutations in FH were identified.
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3.4  Discussion
The work in this Chapter aimed to examine the frequency of 
pathogenic and potentially pathogenic FH mutations in sporadic uterine 
leiomyoma patients and in cancer cell lines. In addition, further possible 
HLRCC patients were screened in order to identify novel mutations to expand 
the mutation spectrum. The frequency of FH mutations in different ethnic 
groups was also studied. In addition to this, the function of FH mutations, 
particularly in relation to common patterns of mutation and the effects of these 
mutations on protein structure, was studied in silico.
Overall it was found that the prevalence of FH mutations in uterine 
leiomyoma patients was very low, in this study occurring with a frequency of 
2.1%. Therefore, HLRCC plays only a very small part in the overall 
prevalence of uterine leiomyomas in the general population. Previous work by 
Barker et al demonstrated a low frequency of allelic imbalance of FH 
sporadic uterine leiomyomas, but no somatic mutations, in 129 leiomyomas 
from 21 patients (Barker et al. 2002).
Interestingly, only 6/26 (23% of) patients with HLRCC-like features 
were identified to have germline FH mutations. In several cases, FH screening 
was requested for patients with early onset renal cancer of different pathology 
to the papilliary carcinomas associated with HLRCC (Alam et al. 2003), but 
no other HLRCC-like symptoms, where screening for other predisposition 
genes, such as VHL, had not shown any mutation. However, this still does not 
account for a number of patients with almost certain HLRCC, including 
uterine and skin leiomyomas and renal cancer, that did not demonstrate a
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mutation. When FH was initially identified as the gene responsible for 
HLRCC, 12/50 (24%) of families had no detectable mutations in FH 
(Tomlinson et al 2002; Alam et al. 2003). Yet, for 3 of these families, FH 
activity was reduced by approximately 50% (Alam et al. 2003). Therefore, 
screening techniques were missing some pathogenic alterations.
This would also suggest that pathogenic alterations have been missed 
in this study, and that the actual frequency of germline FH mutations in 
uterine leiomyoma patients may be higher than is reported here. It is likely 
that novel sequence variants exist which result in the observed reduction of 
FH activity in patients without apparent FH mutations. In order to identify 
these mutations, a number of different screening techniques could be used 
which have not been used to date. Screening for deletions of individual exons 
has not been carried out. Deletion of one or more exons would render the 
translated protein enzymatically useless. In order to test for this, techniques 
such as multiplex amplifiable probe hybridisation (MAPH) and multiplex 
ligation dependent probe amplification (MLPA) could be used (Sellner and 
Taylor 2004).
A number of splice site mutations have been reported in HLRCC 
patients, including a novel mutation in this study. Thus defects in splicing of 
the precursor RNA appear to have a detrimental effect on the protein. In order 
to test for variants affecting splicing, an mRNA-based approach could be used 
to detect different length transcripts. Furthermore, changes in mRNA 
expression could also have an effect on enzyme activity, therefore, testing 
expression by quantitative PCR could also identify novel changes.
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Unfortunately, RNA was unavailable for a number of these studies and so this 
could not be carried out.
Assuming from the initial study that 24% of FH mutations were novel 
variants not able to be detected by the techniques used in this study, this would 
only increase the number of identified mutations by 2 or 3 in total, leading to 
an increase in prevalence of FH mutations in uterine leiomyoma patients to 
2.8%. Therefore, FH mutations can still be considered to play only a small 
part in uterine leiomyoma prevalence in the general population.
The prevalence of FH mutations in African and Afro-Caribbean 
patients was also studied to examine the possible role that these mutations 
may play in the multiple uterine leiomyoma phenotype observed in these 
patients. Despite these patients having a lower age of onset than Caucasian 
patients or patients of other ethnicities, as is observed in HLRCC patients, no 
Y77 mutations were identified, fewer than in Caucasian and other patients. 
Therefore, it can be concluded that FH mutations are not responsible for the 
earlier onset and greater multiplicity of uterine leiomyomas in African and 
Afro-Caribbean patients.
The 70 cell lines screened appeared to contain no FH mutations. This 
could be a result of either of two things. Firstly, FH mutations may not 
contribute to the pathogenesis of the variety of cancers represented by the cell 
lines. Secondly, since a cell line contains a pure population of cells, 
homozygous FH mutations may have been missed by SSCP. Therefore, a 
screen carried out by sequencing the FY/gene directly could have provide a 
better idea of the prevalence of FH mutations in these cell lines.
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A number of novel mutations were identified in this study. The gold 
standard for assessing FH mutations pathogenicity is to study FH activity in 
patients’ cells (Alam et al. 2003; Pithukpakorn et al. 2006). This option was 
not available due to the methods of sample collection for this study and so 
alternative in silico approaches were taken. These studies resulted in the 
probable exclusion of all the exon 0 missense mutations as pathogenic, based 
on their minimal effect on the amphiphilic nature of the mitochondrial leader 
sequence. In addition, the intronic sequences, excluding the splice acceptor 
sequence of exon 3, were also provisionally excluded as pathogenic mutations. 
The results for the novel coding missense mutations, H133P, I295T and 
Y448C, and the pre-transcription start mutation were not as conclusive.
In order to obtain a definitive answer for the effects of these variants 
on FH activity, and so to assess their pathogenicity, further studies would need 
to be carried out. Fusing the mutant leader sequence to a fluorescent reporter 
protein such as GFP and examining the subcellular localisation of the resultant 
molecule could assess the effects of the exon 0 mutations. The effects of novel 
missense mutations could be assessed by site-directed mutagenesis to obtain 
mutant FTFcDNA at each of those locations and measuring the enzyme 
activity of in vitro transcribed mutant protein compared to wild-type protein. 
The effects of intronic mutations could be assessed by examining splice 
variants in mRNA. Finally, the effect of the pre-transcription start mutation 
could be assessed by expression analyses of FH in tissues with and without the 
novel mutation.
In conclusion, FH mutations appear to be a rare, but important, 
hereditary cause of uterine leiomyomas, and are not responsible for the
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multiple leiomyoma phenotype observed in African and Afro-Caribbean 
patients. The spectrum of mutations demonstrated that highly conserved 
residues were more likely to be mutated in HLRCC and FH deficiency 
patients, which are more likely to result in loss of function of the enzyme 
resulting in disease.
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4.1  Introduction
In HLRCC, FH acts as a classical tumour suppressor gene, requiring 
complete loss of activity for tumorigenesis to occur (Alam et al. 2003). This 
results in subsequent disruption of the Krebs cycle, since no other 
energetically viable pathway exists to convert fumarate to malate in human 
cells. The emergence of pseudo-hypoxia as an important mechanism in 
HLRCC tumour pathogenesis still leaves several questions related to tumour 
pathogenesis (Pollard et al. 2005a; Pollard et al. 2005b; Selak et al. 2005). One 
such question regards the resistance to apoptosis of HLRCC tumour cells.
One of the roles of the hypoxic response, involving HIF1  -a, is to protect 
a cell undergoing short-term hypoxia, with the expectation of eventual 
reoxygenation. However, normal cells exposed to chronic hypoxia eventually 
die (Jung et al. 2001). Tumour formation in HLRCC suggests that this cell 
death does not occur in cells with complete loss of wild-type FH, despite 
constitutive activation of HIFla (Isaacs et al. 2005; Pollard et al. 2005b). The 
question, therefore, regards the mechanisms utilised by HLRCC cells to stay 
alive.
Ultrastructural studies of sporadic uterine leiomyomas have 
demonstrated a number of distinguishing features distinguishing them from 
the myometrium, including alterations of intermediate filaments (Richards et 
al. 1998) and extracellular matrix (Leppert et al. 2004). This is discussed in 
greater depth in chapter 1  (1.1.2). Tumours from the HLRCC-related tumour 
syndrome hereditary paragangliomatosis and phaeochromocytoma (HPGL), 
resulting from mutations in three of the genes encoding subunits of the 
succinate dehydrogenase (SDH) complex, have also been examined
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ultrastructurally and have demonstrated an increased number of mitochondria 
in the cytoplasm of tumour cells from these patients (Douwes Dekker et al. 
2003).
The work in this chapter examines the expression and distribution of 
several markers related to apoptosis and cell proliferation in order to examine 
the involvement of these mechanisms in HLRCC and sporadic leiomyoma 
pathogenesis. Particular focus is paid to markers previously shown to be 
related to uterine leiomyoma pathology or the resistance of hypoxic cells to 
apoptosis. Furthermore, ultrastructural studies of HLRCC and sporadic 
leiomyomas were carried out in order to identify potential novel differences 
between the two species of leiomyomas, which may provide clues to 
mechanisms of pathogenesis.
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4.2 Materials and Methods
4.2.1 Immunohistochemistry
Immunohistochemistry was carried out as described in Chapter 2 
(2.8.2) on 9 uterine leiomyomas and 4 myometrium samples from 8 HLRCC 
individuals with known germline FH mutations, 13 uterine leiomyomas and 
matched myometrium from 13 sporadic cases (women without germline FH 
mutations and no evidence of cutaneous leiomyomatosis), and a further 4 
sporadic uterine leiomyomas. Seven antibodies against markers of apoptosis 
and proliferation, and one against a cytoskeletal protein were used (Table 4.1). 
Bcl-2, Bax and PCNA were all chosen due to previous reports of altered 
expression in sporadic uterine leiomyomas (Dixon et al. 2002; Wu et al. 2002; 
Kovacs et al. 2003). The Bcl-2 family members Bcl-x and Bak, and the 
Inhibitor of apoptosis (IAP) family members Survivin and c-IAP-2 have all 
been associated with resistance of hypoxic cells to apoptosis (Dong et al.
2002; Dong et al. 2003; Dong and Wang 2004; Yang et al. 2004; Sasabe et al. 
2005). Desmin expression was studied as a result of ultrastructural 
observations. All samples were confirmed as either myometrium or 
leiomyoma based on serial haematoxylin and eosin stained sections (Figure
4.1 A). Intensity of staining was calculated by semi-quantitative observation as 
described in chapter 2 (2.8.2).
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Table 4.1 Details of antibodies used for immunohistochemistry
Antigen Source Dilution Positive Control Supplier
Bcl-2 Mouse 1:25 Tonsil Dako
Bak Rabbit 1:40 Tonsil Abeam
B c1-Xl/s Rabbit 1:100 Normal Colon Dako
cIAP-2 Rabbit 1:50 Tonsil Santa Cruz
Bax Rabbit 1:200 Breast Carcinoma Santa Cruz
Proliferating Cell Nuclear Mouse 1:1000 Tonsil Dako
Antigen (PCNA)
Survivin Rabbit 1:2000 Melanoma Abeam
Desmin Mouse 1:50 Myometrium Dako
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4.2.2 Electron Microscopy
Four uterine leiomyomas from one HLRCC individual with a known 
germline FH mutation, and 2 uterine leiomyomas and matched myometrium 
from 2 sporadic cases were collected fresh from surgery and fixed in 
glutaraldehyde phosphate buffer. Electron microscopy was carried out as 
described in Chapter 2 (2.9).
4.2.3 Tissue cell density
Tissue cellularity was assessed on haematoxylin and eosin stained 
paraffin sections by nuclear density. Nuclei were counted in 10 random 
625p,m2 sections of a 10 x 10 graticule in 10 random, high power, fields.
4.2.4 Data Analysis
Results for immunohistochemistry were collated and analysed using the 
Mann-Whitney U test using R. A p-value of less than 0.05 was considered 
significant.
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4.3  Expression of apoptotic proteins in HLRCC and sporadic 
uterine leiomyomas
Immunohistochemistry was carried out on myometrium and uterine 
leiomyomas from HLRCC and sporadic cases to examine the expression of 
proteins involved in apoptosis, and of the proliferative marker PCNA. A 
summary of results is shown in Table 4.2, and examples of staining are shown 
in Figure 4.1. Increased expression of Bcl-2 and PCNA was observed in both 
HLRCC (p=0.049 and p=0.033 respectively, Mann-Whitney) and sporadic 
(p=0.015 and p=0.048 respectively, Mann-Whitney) leiomyomas (Figure 4.IB 
and C) compared to normal myometrium from HLRCC or sporadic 
leiomyoma patients as appropriate.
Furthermore, HLRCC leiomyomas showed an increase in expression 
of Bcl-x (p=0.015, Mann-Whitney, Figure 4.ID) and a concurrent decrease in 
the expression of Bak (p=0.048, Mann-Whitney, Figure 4.2), changes not 
observed in sporadic cases. For Bak, HLRCC myometrium also demonstrated 
decreased expression compared to non-HLRCC myometrium (p=0.0072, 
Mann-Whitney, Figure 4.2). Expression levels of Bax, Survivin and C-IAP2 
were not significantly altered.
190Table 4.2 Summary of immunohistochemistry results for apoptotic and proliferative markers in HLRCC and non-HLRCC myometrium 
and uterine leiomyomas. Data are shown as the median score followed by the range of values and the number of samples. Where all data 
had the same score, no range is shown.
Antibody
Tissue Bcl-21 Survivin1 C-IAP21 Bak1 Bax1 Bcl-x1 PCNA2
HLRCC Myometrium 0 (0-1) (n=3) 0 (0-1) (n=2) 1  (n=2) 1 (1-2) (n=4)5 2 (2-3) (n=4) 1 (n=3) 1   (1-2) (n=2)
Non-HLRCC Myometrium 1  (0-2) (n=13) 2(1-4) (n=9) 2 (1-3) (n=13) 3 (2-4) (n=10) 2 (1-3) (n=12) 2(1-3) (n=ll) 2(0-3) (n=10)
HLRCC Uterine Leiomyoma 2 (0-2) (n=9)3 2 (0-3) (n=9) 1  (1-3) (n=9) 1   (0-1) (n=7)4 2 (1-4) (n=9) 3 (1-3) (n=9)3 4 (2-4) (n=9)3
Sporadic Uterine Leiomyoma 1   (0-2) (n=13)3 3(1-4) (n=13) 2(1-2) (n=14) 3 (2-4) (n=14) 2 (1-3) (n=14) 3(1-4) (n=13) 2 (2-4)
/---1  ->\3
Scored by semi-quantitative observation: Absent (0), weak (1), moderate (2), strong (3), and very strong (4). 
2Scored by frequency of nuclear staining: <10% (0), 10-25% (1), 25-50% (2), 50-75% (3), >75% (4).
3Significantly greater in leiomyomas than myometrium (P<0.05).
4Significantly less in leiomyomas than myometrium (P<0.05).
Significantly less in HLRCC myometrium than non-HLRCC myometium (P<0.05).
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Figure 4.1 Representative heamatoxylin and eosin-stained sections (A) and 
examples of immunohistochemistry for Bcl-2 (B), PCNA (C), and Bcl-x (D). 
An increase in Bcl-2 staining and PCNA is observed in HLRCC and sporadic 
leiomyomas compared to myometrium (B,C). Increased Bcl-x is also observed 
in HLRCC leiomyomas compared to myometrium (D)
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Figure 4.2 Immunohistochemistry against the pro-apoptotic protein Bak. A 
decrease in expression was observed in HLRCC myometrium compared to 
non-HLRCC myometrium, in HLRCC leiomyomas compared to sporadic 
leiomyomas, and in HLRCC leiomyoma compared to HLRCC myometrium.
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4.4  Ultrastructural Aberrations in HLRCC and sporadic uterine 
leiomyomas
4.4.1  Ultrastructural observations
Ultrastructural observations of non-HLRCC myometrium, and HLRCC 
and sporadic leiomyomas by transmission electron microscopy revealed a 
number of interesting differences between the three tissue types. Overall tissue 
appearance differed between the tissue types. Myometrium (Figure 4.3a) 
showed an ordered structure; cells were closely packed in a common 
orientation with evenly sized, light nuclei. The HLRCC leiomyomas 
demonstrated some breakdown of this order (Figure 4.3b); cells appeared to be 
more compact and failed to align along a common axis, nuclei were electron 
dense and of uneven shape and size. Ultrastructure of sporadic leiomyomas 
showed an even greater breakdown in order (Figure 4.3c); cells were clustered 
in islands within an extensive collagen matrix. Nuclei again appeared more 
electron dense than in the myometrium, and demonstrated irregular 
architecture.
The electron micrographs also appeared to reveal a difference between 
the cellularity of the HLRCC and sporadic leiomyomas, due to the increased 
collagen matrix in the latter. This was confirmed by counting cell density in 
haematoxylin and eosin stained paraffin sections. The patchy nature of 
sporadic uterine leiomyoma tissue increased the range of cell densities 
observed compared to myometrium and sporadic leiomyomas, which were 
more homogeneous. To overcome this effect, minimum observed cell density 
was used for statistical analysis. HLRCC leiomyomas (median density=26
194Chapter 4 Apoptosis and Ultrastructure of HLRCC and sporadic uterine leiomvoma
nuclei/field, IQR=31.6) had a greater cell density than sporadic leiomyomas 
(median minimum density=14, IQR=4.25, p=0.031, Mann-Whitney) and 
myometrium (median minimum density=13, IQR=8.25, p=0.01, Mann- 
Whitney).
Ultrastructural differences were also observed in the ultrastructure of 
the collagen matrix. In myometrium, collagen fibrils were organised into tight 
bundles (Figure 4.3d). Collagen fibrils in HLRCC leiomyomas showed some 
disorganisation; bundling of the fibrils appeared less tight than in the 
myometrium (Figure 4.3e). Collagen in sporadic leiomyomas appeared very 
disorganised; fibrils failed to bundle and appeared randomly scattered 
throughout the matrix (Figure 4.3f).
The most striking intracellular difference observed was the variation of 
order and distribution of intermediate filament structure. In both sporadic and 
HLRCC leiomyomas, intermediate filaments formed disordered structures in 
the cytoplasm (Figure 4.3h-k), losing the common polarity observed in the 
myometrium (Figure 4.3g), and forcing myofilament structures and other 
organelles to the cell periphery. These variations also differed between species 
of leiomyoma: in sporadic tumours the intermediate filaments were spread 
diffusely throughout the cytoplasm (Figure 4.3j,k); whereas in HLRCC 
leiomyomas, they formed large, ‘thumbprint’-like aggregates (Figure 4.3h,i).
HLRCC leiomyomas also demonstrated other interesting changes. 
These included the presence of autophagosomes in several cells (Figure 4.31), 
and some differences in mitochondrial morphology, including swelling, loss of 
membranes, and the presence of matrical densities (Figure 4.3m). However, 
equivalent mitochondrial changes were also observed in normal myometrium
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fixed and processed at the same time, so the relevance of these changes could 
not be confirmed.
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Figure 4.3 Ultrastructural observations of myometrium and HLRCC and 
sporadic leiomyomas. A scale bar is shown in all micrographs for size 
comparison, a) Myometrium -  The tissue is well structured with a common 
alignment of cells, light, even structured nuclei, and an ordered extracellular 
matrix. (ECM). b) HLRCC leiomyoma - A breakdown of order is apparent, 
there is an increased cell density and a less ordered ECM and nuclear 
structure. Large filamentous deposits are evident in the cytoplasm.
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Figure 4.3 (Cont’d) c) Sporadic leiomyoma -  The tissue shows extensive 
breakdown of order, with small islands of cells within an extensive collagen 
matrix. The ECM appears highly disordered, and the cell cytoplasm appears 
packed with filamentous deposits, and the nuclei are dark and lacking even 
structure, d) Collagen ECM of myometium -  The ECM in myometrium is 
highly ordered, the collagen fibrils form neat bundles of defined orientation.
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Figure 4.3 (Cont’d) e) ECM in HLRCC leiomyoma -  While some orientation 
is evident, the structure is disjointed. The collagen fibrils appear to form less 
tight bundles, compared to the neat bundles observed in the myometrium, f) 
ECM in sporadic leiomyoma -  Evidence of collagen fibril orientation and 
structure appears completely lost. The fibrils fail to form bundles and appear 
randomly scattered between cells.
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Figure 4.3 (Cont’d) g) Filament structures in myometrium - Filaments in the 
myometrium are well ordered, running parallel to the cell’s long axis, with 
frequently and regularly interspersed dense bodies along the filaments, h & i) 
Aggregation of filaments in HLRCC leiomyomas -  A majority of cells in 
HLRCC leiomyomas contained ‘thumbprint’-like accumulations of 
intermediate filaments, spiralling within the cell. These aggregates forced 
myofilament dense bodies and other organelles to the cell periphery.
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Figure 4.3 (Cont’d) j & k) Filament structures in sporadic leiomyomas -  As 
in HLRCC leiomyomas, filament structures are broken down. The cytosplasm 
is packed with a jumble of intermediate filaments, without the spiralling 
pattern observed in HLRCC tumours, which again force organelles and 
contractile elements to the cell periphery. 1) Autophagosomes in HLRCC 
leiomyomas -  Autophagosomes were observed in a few cells inboth HLRCC 
and sporadic leiomyomas.
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Figure 4.3 (Cont’d) m) Mitochondrial swelling observed in HLRCC 
leiomyoma -  A number of mitochondria in HLRCC tumour cells were 
observed to have swollen mitochondria. In this case, the swollen mitochondria 
is surrounded by several apparently normal mitochondria. In some cases the 
cristae appeared lost. Swollen mitochondria were also observed in the 
myometrium and sporadic leiomyoma samples. Consequently, this swelling 
may be a result of fixation rather than tumorigenesis.
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4.4.2  Desmin Immunohistochemistry
In order to identify proteins implicated in the ‘thumbprint’ aggregates 
of intermediate filaments observed in HLRCC leiomyoma ultrastructure, 
immunohistochemistry was carried out for the muscle intermediate filament 
protein Desmin (Figure 4.4). Immunostaining for Desmin mimicked the 
patterns observed by electron microscopy. In the myometrium, staining was 
diffuse, with no evidence of filament aggregation, and appeared ordered. 
Staining in sporadic leiomyomas was also diffuse, but lacked order and had 
evidence of some aggregation. Finally, staining in HLRCC leiomyomas was 
limited to large aggregates of about the same size as those observed 
ultrastructurally, with little staining elsewhere in the cell.
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Figure 4.4 Immunohistochemical staining for the intermediate filament 
protein Desmin. Staining in myometrium shows ordered staining in line with 
the observed ordered smooth muscle structure. Staining in HLRCC 
leiomyomas reveals aggregates (arrowed) of a similar scale to those observed 
by electron microscopy. Staining in sporadic leiomyomas appears disordered 
with less evidence of aggregation than the HLRCC leiomyomas.
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4.5 Discussion
4.5.1  HLRCC and sporadic leiomyomas demonstrate a tendency to 
resist apoptosis
Aberrations in apoptotic mechanisms that promote cell survival have 
long been considered as vital for tumour growth and development (Hanahan 
and Weinberg 2000). The work in this chapter examined the expression of a 
number of apoptosis related proteins in HLRCC and sporadic uterine 
leiomyomas, and identified distinct changes likely to increase cellular 
resistance to apoptotic stimuli. In both HLRCC and sporadic leiomyomas, 
consistent increases in the expression of anti-apoptotic Bcl-2, and the 
proliferative marker PCNA were observed, with the latter being increased to a 
greater extent in HLRCC leiomyomas. The results for sporadic tumours are in 
agreement with previous studies, which have observed an increase in Bcl-2 
and PCNA in sporadic leiomyomas (Dixon et al. 2002; Kovacs et al. 2003).
Furthermore, changes in two other markers were identified solely in 
HLRCC leiomyomas: an increase in expression of anti-apoptotic Bcl-x; and a 
concurrent decrease in expression of pro-apoptotic Bak. The observed changes 
imply that both HLRCC and sporadic leiomyoma cells have acquired an 
increased resistance to apoptosis compared to the host myometrium. However, 
the difference in the pattern of marker expression implies that perhaps separate 
mechanisms are followed to come to the same outcome. The alterations in 
Bcl-x and Bak may also imply a greater resistance to apoptosis, and the 
increased expression of PCNA implies a greater rate of proliferation in 
HLRCC compared to sporadic leiomyomas. In addition, alterations in the level
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of Bak between myometrium from HLRCC and non-HLRCC patients is 
intriguing, and may point to a reduced basal level of apoptosis in these cells.
Expression of the other studied apoptotic factors, Survivin and cIAP2, 
did not significantly differ in either HLRCC or sporadic uterine leiomyomas, 
despite previous associations with hypoxia. This could imply that they require 
further regulation in addition to hypoxia, or that the hypoxic response 
observed in other cell types does not apply to leiomyoma cells. The lack of 
altered expression of Bax was not as surprising given previous differing 
results of expression analyses in leiomyomas (Dixon et al. 2002; Wu et al. 
2002; Kovacs et al. 2003).
As previously described, current evidence suggests that pseudo- 
hypoxic drive is the key mechanism of pathogenesis in both HLRCC and 
HPGL tumours (Isaacs et al. 2005; Pollard et al. 2005a; Pollard et al. 2005b; 
Selak et al. 2005). However, cells exposed to chronic hypoxia eventually 
undergo apoptosis, should other mechanisms to increase the cell’s oxygen 
supply fail, such as the release of angiogenic factors (Jung et al. 2001).
Interplay between hypoxia and apoptosis exists as a result of VEGF 
signalling. Several studies have demonstrated that VEGF acts as a survival 
factor in endothelial cells by increasing expression of Bcl-2 (Nor et al. 1999; 
Cai et al. 2003). This activation occurs via the PI-3-K and MAPK pathways, 
and has been shown to occur in response to HIFl-a activation (Trisciuoglio et 
al. 2005).
Although cells from HLRCC and HPGL tumours both appear to 
undergo chronic hypoxia, the work in this chapter demonstrates an apparent 
increase in resistance to apoptosis by increased expression of anti-apoptotic
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markers. The highly vascular nature of HLRCC leiomyomas suggests that a 
ready supply of oxygen is available to the cell. Therefore, it is likely that 
alternative mechanisms of oxygen sensing override the pro-apoptotic effects 
of the chronic hypoxia signal from HIFl-a, and increase the expression of 
anti-apoptotic proteins to compensate.
In vitro evidence already exists for this theory, in a study carried out 
by Sasabe and colleagues, who examined the role of artificially activated 
HIFl-a in oral squamous cell carcinoma cells. They cultured cells expressing 
the activated HIFl-a in both normoxic and hypoxic environments for 24hrs 
and examined the expression of apoptosis-related proteins. They discovered 
increased expression of Bcl-2 and B c1-xl, in cells cultured in both conditions, 
but with a greater increase in cells cultured under normoxic conditions.
Control cells under hypoxic conditions showed a decrease in Bcl-2 and B c1-xl 
expression, and an increase in expression of pro-apoptotic Bax and Bak 
(Sasabe et al. 2005).
In addition to this work, Dong and Wang discovered that cells 
surviving repeated rounds of hypoxia and reoxygenation demonstrated an 
increase in B c1-xl, suggesting a role for this protein in the protection of cells 
from hypoxic injury (Dong and Wang 2004). In both of these studies, 
increases in expression of identical proteins to those in this chapter were 
observed.
4.5.2  Ultrastructural features of HLRCC and sporadic leiomyomas
Previous ultrastructural observations of sporadic leiomyomas have 
demonstrated a number of aberrations. HLRCC and sporadic leiomyomas
appear ultrastructurally distinct, but still with certain similarities beteen cells.
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One such difference is the increased cell density in HLRCC leiomyomas, 
which lack the more expansive collagen matrix observed in the sporadic 
leiomyomas. This increased density may be due to increased cell proliferation, 
which appears evident due to the greater increase in the expression of PCNA 
in HLRCC leiomyomas than their sporadic counterparts, thus the cells are 
proliferating too quickly to lay down the more expansive extracellular matrix 
observed in sporadic leiomyomas. Another hypothesis is an alternative role of 
TGFp in the pathogenesis of HLRCC and sporadic leiomyomas. It has 
previously been demonstrated that TGF|3-3 signalling in uterine leiomyomas 
results in accumulation of extracellular matrix through increased expression of 
proteins such as collagen . The reduced amount of matrix in HLRCC 
leiomyomas may be due to a reduction in TGF[3-3 signalling. However, 
TGFp-3 expression has been shown to be activated by HIFla in trophoblast 
cells (Nishi et al. 2004).
The disrupted collagen structure in HLRCC leiomyomas is of 
particular interest due to similar post-translational modifications of the 
collagen precursors (pro-collagen) and HIFl-a. Both proteins are modified by 
prolyl-4-hydroxlyases (P4H): for HIFl-a, to target it for destruction; and for 
collagen, to stabilise the formation of the distinctive collagen triple-helix 
(Myllyharju 2003). The reaction for both targets, despite being carried out by 
different enzymes, is identical. It is possible that succinate inhibits collagen 
P4H in the same way as HIFl-a P4H, which could result in disrupted collagen 
structure. However, without proline hydroxylation, the collagen triple helix 
has a melting temperature of approximately 21°C, and so is not 
physiologically viable (Mizuno et al. 2004).
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One study of HT1080 fibroblasts under hypoxia has shown an increase 
in the expression of the collagen P4D-a subunit possibly to overcome the 
inhibition of the enzyme by reduced oxygen levels (Fahling et al. 2004). Since 
collagen fibrils are observed in HLRCC leiomyomas, this is likely to be true. 
The same study also showed a decrease in matrix metalloproteinase 
expression under hypoxia.
Fibrosis by increased deposition of extracellular matrix is a defining 
characteristic of uterine leiomyomas (Maruo et al. 2004). Studies on sporadic 
leiomyomas, the results of which are repeated here, demonstrate breakdown of 
order in the formation of collagen fibres (Leppert et al. 2004). There is also 
ultrastructural evidence for differing compositions of collagen isoforms in 
fibrils from myometrium and sporadic leiomyomas (Leppert et al. 2004). 
Furthermore, patients with Alport syndrome, which occurs due to germline 
deletions in the COL4A5 and COL4A6 genes, which encode collagen IV, a 
basement membrane collagen, exhibit diffuse leiomyomatosis, particularly of 
the oesophagus and vulva (Cochat et al. 1988). The true importance of the role 
of collagen in leiomyoma pathogenesis has yet to be determined, but certainly 
changes in collagen ultrastructure are among the more distinct observations in 
both sporadic and HLRCC tumours.
Disorganised cytoskeletal structures are also well characterised in 
sporadic leiomyomas. In both sporadic and HLRCC leiomyomas, disorganised 
intermediate filament structures, staining positive for desmin, are observed. In 
HLRCC leiomyomas, these disorganised filaments form distinct ‘thumbprint’ 
aggregates within the cytoplasm, whereas in sporadic leiomyomas these 
aggregates are more diffusely spread throughout the cytoplasm. Previous
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studies have demonstrated a wide variety of cytoskeletal aberrations in 
sporadic leiomyomas, from small numbers of loosely distributed filaments, to 
large aggregates. Such a variety was observed in this study. In HLRCC 
leiomyomas, the desmin aggregates were larger and occurred more frequently. 
Furthermore, they had a more defined structure than the diffuse aggregates in 
sporadic leiomyomas.
The significance of this breakdown in intermediate filament structure 
is not understood. It may represent an imbalance in the control of the 
equilibrium of synthesis and turnover of cytoskeletal proteins, particularly 
desmin, which plays an important role in global intermediate filament 
organisation in the cell (Paramio and Jorcano 2002). It would also suggest that 
the leiomyoma cells have lost their contractile ability, since no defined 
polarity is observed in the filaments. This loss of contracile ability has been 
previously described in uterine leiomyomas (Tsibris et al. 2002). Where these 
accumulations have been observed before, it has been hypothesised that they 
are a secondary effect of tumour growth, rather than a mechanism of 
pathogenesis  (Eydenetal. 1992).
The presence of autophagosomes in some cells in HLRCC leiomyomas 
may be a cellular response to a shortage of energy, due to the cessation of the 
Krebs cycle (Lum et al. 2005). However, the levels of autophagy, the process 
whereby a cell consumes itself by the formation of lysosomes during periods 
of extreme energy and nutrient shortage (Lum et al. 2005), has been described 
as being naturally increased in muscle cells, and the observation of 
autophagosomes in only a small number of cells may be representative of 
normal tissue turnover (Gevers 1984).
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Previous ultrastructural studies of HPGL tumours demonstrated an 
apparent increase in the numbers of mitochondria and aberrations in 
mitochondrial morphology. In these tumours, the cytoplasm appears packed 
with mitochondria (Douwes Dekker et al. 2003). In HLRCC tumours, 
morphological aberrations were observed in the mitochondria, including 
mitochondrial swelling, and reductions in the numbers of cristae. However, 
these aberrations were also observed in samples of mitochondria fixed 
simultaneously. Since mitochondria are notoriously difficult to fix for electron 
microscopy, it is not possible to confirm whether the changes observed in 
HLRCC leiomyomas are a result of pathogenesis, or an artefact of tissue 
fixation. Furthermore, the numbers of mitochondria did not appear to be 
increased in the HLRCC or sporadic leiomyomas compared to the 
myometrium.
4.5.3  Conclusions
The results described in this chapter suggest important differences in 
the pathways, and ultrastructure of HLRCC and sporadic uterine leiomyomas. 
These differences imply distinct mechanisms of pathogenesis resulting in a 
similar outcome. Apoptosis plays an important role in the development of both 
HLRCC and sporadic tumours, with increased expression of pro-survival 
factors occurring in both. However, different patterns of expression suggest 
that different pathways are followed to arrive at a similar outcome. A similar 
situation is observed ultrastructurally, whereby similar cell and tissue features, 
such as collagen and intermediate filament structure, are both affected by the 
process of tumorigenesis, but with slightly differing outcomes. Therefore, the
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data show that the pathogenesis of HLRCC and sporadic leiomyomas only 
partially overlaps.
Resistance to apoptosis appears to be important in HLRCC 
leiomyomas, as it is in many other tumour types (Hanahan and Weinberg 
2000). The pattern of expression of different factors involved in apoptosis 
mimics those observed in other studies examining resistance of apoptosis in 
cells exposed to hypoxia (Dong and Wang 2004; Sasabe et al. 2005). 
Therefore, alternative mechanisms of oxygen sensing, which detect the 
continued presence of molecular oxygen in the cell, despite the chronic 
hypoxia signal from the continued stabilisation of HIFl-a, are likely to play a 
vital role in the pathogenesis of HLRCC tumours. This may also have 
implications for related tumour conditions such as HPGL and VHL. The 
identification of these pathways may provide suitable targets for 
pharmacological intervention, which could lead to reduction in the tumour 
cells resistance to apoptosis.
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Chapter 5 
Analysis of the mitochondrial 
genome in HLRCC and 
sporadic uterine leiomyomata
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5.1 Introduction
5.1.1 Anatomy of the mitochondrial genome
In addition to the nuclear genome, eukaryotic cells contain specific 
organelle genomes, perhaps the best known examples of which are the 
mitochondrial and chloroplast genomes. The human mitochondrial genome 
(mtDNA) is a circular molecule of approximately 16.6kbp (Figure 5.1) 
(Anderson et al. 1981; Andrews et al. 1999). It contains 37 genes encoding 13 
polypeptides, 2 rRNAs and 22 tRNAs. The 13 polypeptide genes (Table 5.1) 
encode components of the oxidative phosphorylation pathway. The rRNAs 
and tRNAs are used for translation of the mtDNA polypeptide genes, which 
utilise a slightly different genetic code to the nuclear genome (Anderson et al. 
1981).
A single mtDNA molecule can be divided into two distinct regions: the 
coding region, containing the polypeptide and RNA genes; and the D-loop 
region, which contains all the control elements of the molecule, including 
replication and transcription origins. The D-loop is the most variable region of 
the mtDNA molecule, particularly within the two hypervariable segments 
(HVS) (Clayton 1992; Brandon et al. 2005).
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Figure 5.1 The mitochondrial genome, including the location of polypeptide, 
rRNA and tRNA genes (Taken from www.mitomap.org (Brandon et al. 
2005)).
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Table 5.1 Polypeptide genes encoded by the mitochondrial genome
Gene Name OXPHOS complex Encoding strand
ND1 NADH Dehydrogenase (Complex I) H-strand
ND2 NADH Dehydrogenase (Complex I) H-strand
COl Cytochrome c Oxidase (Complex IV) H-strand
C02 Cytochrome c Oxidase (Complex IV) H-strand
ATP8 ATP synthase F0 (Complex V) H-strand
ATP6 ATP synthase F0 (Complex V) H-strand
C03 Cytochrome c Oxidase (Complex IV) H-strand
ND3 NADH Dehydrogenase (Complex I) H-strand
ND4L NADH Dehydrogenase (Complex I) H-strand
ND4 NADH Dehydrogenase (Complex I) H-strand
ND5 NADH Dehydrogenase (Complex I) H-strand
ND6 NADH Dehydrogenase (Complex I) L-strand
CYTB Cytochrome b-ci complex (Complex III) H-strand
Replication and transcription within the mitochondrial genome also 
differ from their nDNA equivalents. Replication occurs independently of S- 
phase in the rest of the cell (Lightowlers et al. 1997). There are two theories of 
mtDNA replication: the first is a more conventional leading and lagging strand 
replication, as observed in plasmid replication in bacteria (Holt et al. 2000). 
The second involves separate replication origins for each strand of the 
molecule. Firstly, the purine-rich H (heavy) strand is synthesised, using the 
pyrimidine-rich L (light) strand as a template, with an origin within the D-loop
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region. Once approximately 2/3 of the H-strand has been synthesised, 
displacement of a particular site forms a stem-loop structure which acts as a 
primase recognition site for L-strand synthesis (Brown et al. 2005).
Mitochondrial transcription occurs as a polygenic synthesis from core 
promoters for H and L-strand transcription. H-strand transcription, which 
occurs in the opposite direction to traditional mtDNA base numbering and 
encodes a majority of the encoded genes, is terminated after transcription of 
the complete genome. The resulting RNA molecule is then processed to 
produce either mRNAs, rRNAs or tRNAs. Since a number of genes overlap, 
the processing of the transcript determines the level of each RNA species. 
Processing of the RNA results in the completion of the coding sequence of 
some genes. For example, the stop codon of the ND2 gene is completed by 
poly-adenylation of the processed mRNA (Clayton 1992).
5.1.2  Mitochondrial Genetics
Mitochondrial genetics is different from the Mendelian genetics of the 
nuclear genome in a number of aspects. Firstly, while the nuclear genome is 
diploid in a cell, with only two copies of each chromosome, the mitochondrial 
genome exists in multiple copies, often several thousand, in a single cell 
(Penta et al. 2001). This gives rise to an important concept of mitochondrial 
genetics -  homoplasmy and heteroplasmy. Homoplasmy occurs when all the 
copies of the mitochondrial genome are identical. Heteroplasmy occurs when 
there is a mixture of two or more mitochondrial genotypes (Lightowlers et al. 
1997). This has implications for the effects of mtDNA mutations in disease, as 
will be discussed later on.
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A further difference occurs in the mode of inheritance; mtDNA 
inheritance is uniparental, coming only from the mother (Case and Wallace 
1981). While a few reports exist detailing paternal inheritance, paternal 
mtDNA has been found not to transmit to subsequent generations (Gustafson 
2002), even with assisted reproduction techniques such as intracytoplasmic 
sperm injection (Sutovsky et al. 2004). This uniparental inheritance has been a 
useful characteristic for evolutionary geneticists, who have used ethnic 
variations in mtDNA to trace human evolution and geographical divergence, 
and have identified a number of separate mitochondrial haplogroups (Wallace 
et al. 1999). For example, most Western Europeans belong to haplogroup H 
(Helena), while Native American and East Eurasian peoples are strongly 
representative of haplogroup A (Malhi et al. 2004).
The reference sequence for mtDNA is the revised Cambridge 
Reference sequence (Anderson et al. 1981; Andrews et al. 1999). Originally 
sequenced by Fred Sanger and colleagues (Anderson et al. 1981), it was 
updated following improvements in sequencing technology (Andrews et al. 
1999). This sequence belongs to haplogroup H2b, and other haplogroups are 
defined by their deviations from this sequence (Carelli et al. 2006).
5.1.3  Mitochondrial mutations and disease
As with the nuclear genome, mutations in mtDNA have been 
associated with a number of disorders (Taylor and Turnbull 2005). Many of 
these disorders are inherited, such as Lebers’s hereditary optic neuropathy 
(characterised by optic nerve dysfunction leading to blindness in young 
adults), which results from hetero- or homoplasmic mutations in three of the
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genes encoding Complex I subunits (ND1, ND4, and ND6) (Man et al. 2002), 
and MERRF (Myoclonic Epilepsy with Ragged Red Fibres), which is a result 
of heteroplasmic mutations in the Leucine tRNA gene (Enriquez et al. 1995). 
There is also thought to be an involvement of mtDNA in age-related disorders 
such as diabetes (Martin Negrier et al. 1998).
The nature of mitochondrial genome inheritance, and its multiple 
copies within the cell, complicate the inheritance of a disease gene, 
particularly in disorders requiring heteroplasmic mutations. In a number of 
these conditions, an affected patient’s mother may be a carrier of an mtDNA- 
encoded disease without herself demonstrating any symptoms. Similarly, 
affected patients’ siblings may be unaffected or have less severe disease, 
despite inheriting the same mtDNA as the affected sibling. This discrepancy 
leads to the suggestion that a threshold of mutant mtDNAs must be inherited 
in order for a disorder to present. Theoretically, a child should be 
heteroplasmic for a mutation at the same level as the mother. However, a 
genetic bottleneck occurs at the point of oocyte maturation, where a selected 
proportion of mtDNA molecules are transmitted into each primary oocyte. 
Oocyte maturation is associated with a rapid replication of this mtDNA 
population. This bottleneck can lead to a random shift in mutational load 
between individuals resulting in the observed familial discrepancies (Taylor 
and Turnbull 2005).
The proximity of the mitochondrial genome to the functioning electron 
transport chain increases its susceptibility to oxidative damage (Beckman and 
Ames 1999). Furthermore, the lack of the protective nucleosome structure 
observed in nDNA increases its susceptibility even further (Beckman and
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Ames 1999). As a consequence, it has become the focus of study for somatic 
mutations, in particular in tumour and cancer syndromes.
Mutations in the mitochondrial genome have also been observed in a 
variety of cancers (Table 5.2). The first of these reports, by Polyak et al, 
identified homoplasmic changes in 7 out of 10 studied colorectal cancer cell 
lines. These changes were somatic and absent in matched patient tissue, yet 
their selection to homoplasmy (Polyak et al. 1998). The significance of this 
homoplasmy is not known, it may confer a growth advantage on the cell, 
however, mathematical modelling has demonstrated that genetic drift can lead 
to homoplasmy without phenotypic selection (Elson et al. 2001).
Since Polyak et aVs landmark study, somatic mutations have been 
identified in a variety of tumour types, including breast (Bianchi et al. 1995), 
prostate (Petros et al. 2005), kidney (Horton et al. 1996), and gastric cancers 
(Alonso et al. 1997). Somatic mutations have been described in the D-loop 
region, in all 22 tRNAs, both rRNAs and all 13 polypeptide encoding genes 
(Chatterjee et al. 2006). Associations have also been made with hereditary 
tumour types, in particular multiple lipomas associated with MERFF (Holme 
et al.  1993), and an increased incidence of breast cancer in African-American 
women carrying the G10398A polymorphism (Canter et al. 2005).
In addition to point mutations, mitochondrial genomic instability has 
been observed in tumours (Bianchi et al. 2001). A number of poly-C tracts 
occur within the D-loop and coding regions and these can be polymorphic 
through slippage (Bianchi et al. 2001). Larger deletions have also been 
described in the literature, including a 4977bp deletion, shown to be
220Chapter 5 Analysis of the mitochondrial genome in HLRCC and sporadic uterine
leiomyomata
heteroplasmic in breast cancers, and shorter deletions that have been described 
in colorectal cancers among others (Bianchi et al. 1995).
A study by Aikhionbare et al examined the potential of mtDNA 
mutations as prognostic markers in colorectal cancer patients by studying the 
accumulation of mtDNA mutations in normal, pre-cancerous (adenomatous 
polyps) and cancer specimens by RFLP analysis. The study identified 38 
sequence variants, none of which were tumour specific. However, the 
accumulation of mtDNA mutations correlated with tumour progression, 
suggesting mtDNA mutation accumulation as a potential prognostic marker 
(Aikhionbare et al. 2004).
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Table 5.2 A selection of cancer sites and associated somatic mDNA mutations 
(Data from (Chatterjee et al. 2006)).
Cancer Site Mutated Genes Mutation types
Bladder CYTB, ND3 Deletion (CYTB), Missense 
(ND3)
Colon CYTB, ND5, ND4L, 
C03, C02, COl, ND1
Missense (CYTB, ND5, ND4L, 
C03, C02, ND1)
Truncation (COl)
Frameshift (ND1, ND5) 
Deletion (ND1)
Pancreas CYTB, ND6, ND4, 
ND3, C03, ATP6, 
C02, COl, ND2, ND1
Missense (CYTB, ND6, ND4, 
C03, ATP6, C02, COl, ND2, 
ND1)
Ovary CYTB Nonsense
Thyroid CYTB, ND6, ND5, 
ND4, ND4L, ND3, 
C03, ATP6, C02, 
ND2, ND1
Missense (CYTB, ND6, ND5, 
ND4, ND3, C02, ND2, ND1) 
Deletion (CYTB, C02)
Breast ND5, ND4 Missense (ND5, ND4) 
4977bp deletion (Various)
Prostate ND5, COl, ND1 Missense (ND5, COl, ND1)
Head and Neck ND4 Missense
Medulloblastoma ND4L Missense
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5.1.4  Difficulties and controversies of mtDNA screening
The association of particular mtDNA mutations with diseases, 
particularly cancer, has been the subject of much controversy. Salas et al 
recently published a scathing paper on the role of mtDNA mutations in cancer 
(Salas et al. 2005). They attacked a number of studies of inherited and somatic 
mtDNA mutations in cancer. A number of their points are valid, particularly 
-regarding association studies of cancers with mtDNA mutations. The huge 
number of phylogenetic differences between the different haplogroups makes 
a traditional case-control study very difficult, since cases and controls with 
matching ethnicities may not have identical mtDNA haplogroups. For 
example, in Western Europe, although haplogroup H is predominant, 
representing approximately 50% of the population, the remaining 50% are 
represented by at least 7 other haplogroups. This study was designed to 
represent the situation in approximately 1500AD, before the European 
expansion, and so all these other haplogroups are likely to be from Caucasians 
(Torroni et al.  1996). Therefore, ethnicity does not necessarily denote mtDNA 
haplogroup.
Salas et al also attacked the concept of haplotype shifting, where the 
mtDNA of a patient of one haplogroup acquires homoplasmic mutations that 
result in a shift to a SNP defining a different haplogroup (Salas et al. 2005). 
This haplotype shift can occur at a single nucleotide position, or several 
nucleotides in a mtDNA molecule can mutate to SNPs indicative of the same 
haplogroup. It is this latter effect, where a whole mtDNA molecule appears to 
shift from one haplotype to another unrelated haplotype that draws the most
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criticism (Salas et al. 2005). For example, a report by Jeronimo et al where 
one case accumulated 18 somatic mutations, each indicative of haplogroup W 
(a Western European haplogroup (Torroni et al. 1996)), was highly suggestive 
of sample contamination (Jeronimo et al. 2001). However, this phenomenon of 
haplotype shifting has been demonstrated for single nucleotides. Linnartz et al 
described a patient with myelodysplasic syndrome (MDS) with mtDNA 
haplotype U. They tracked the slow progression of MDS to acute leukaemia 
demonstrating a low-level early heteroplasmy, which reached 50% when the 
cells were in transformation, and became a homoplasmic haplotype shift when 
the leukaemia arose (Linnartz et al. 2004). The significance of this haplotype 
shifting is unknown, since many mutations that occur as a part of this shift 
occur in the germline of many people of other haplogroups, with no apparent 
increase in cancer prevalence within those groups. It may represent an 
example of genetic drift (Elson et al. 2001).
The controversies described above have arisen partly due to the great 
care required in designing a screening strategy. Many studies have been 
carried out on the basis that mtDNA copy number is far in excess of nDNA 
copy number. However, highly homologous (>99%) mitochondrial 
pseudogene regions are present within the nuclear genome, which may present 
false heteroplasmy (Parr et al. 2006). The regions of greatest homology are 
observed on chromosomes 1, 5 and 17. Therefore, great care must be taken in 
designing PCR primers for mitochondrial genome screening in order to only 
amplify true mtDNA. The best approach for primer design is a long-range 
PCR taking advantage of the fact that none of the pseudogene regions
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encompasses the entire mtDNA molecule. Therefore, it is possible to design 
primers that completely exclude the possibility of pseudogene amplification.
In addition to their role in disease, mtDNA mutations have been shown 
to accumulate as a result of natural aging (Chomyn and Attardi 2003), and are 
thought to play a role in muscle degradation and other effects of aging 
(Chomyn and Attardi 2003).
5.1.5 The Affymetrix Mitochip for the analysis of mtDNA sequences
The Affymetrix human mitochondrial resequencing array is a tool 
allowing the sequencing of the entire mitochondrial genome in one 
experiment. The array was originally conceived by Maitra et al and consists of 
a series of 8 25-mer oligonucleotide probes for each base position within the 
mitochondrial genome, 4 probes for each strand. Each probe is varied at the 
central position to incorporate each possible nucleotide, A,G,C or T. Labelled 
amplified mtDNA is hybridised to the array and stringently washed to allow 
discrimination between alleles (Maitra et al. 2004; Zhou et al. 2006).
In order to account for common variation, the D-loop region is 
overtiled with 245 common variants observed in the FBI database of 
mitochondrial mutations (Fox 1996). This overtiling particularly takes into 
account polymorphisms within 25 base pairs of each other, which would occur 
on the same arrayed oligonucleotide (Zhou et al. 2006).
5.1.6 Aims of this chapter
Given that mutations in FH result in uterine leiomyoma formation due 
to a blockage in oxidative metabolism at the level of the Krebs cycle, and the 
absence of FH mutations in sporadic leiomyomas, it was decided to
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investigate the potential role of the mitochondrial genome (mtDNA) in 
sporadic leiomyoma pathogenesis. As mentioned above, the mitochondrial 
genome is highly susceptible to damage and mutation. This high mutation 
frequency, coupled with the high prevalence of uterine leiomyomas, makes it 
an important screening target. It was also decided to use mtDNA mutations as 
an indirect measure of reactive oxygen species (ROS) in the mitochondria, and 
to use this to examine the difference in ROS production in HLRCC uterine 
leiomyomas, which have a known mitochondrial defect, and sporadic uterine 
leiomyomas.
The aims of the work in this chapter were:
i)  To investigate the presence of mtDNA mutations in sporadic 
uterine leiomyomas, and to assess the potential pathogenic role 
of any observed changes.
ii)  To compare the frequency and spectrum of mtDNA changes in 
sporadic uterine leiomyomas with HLRCC leiomyomas to 
assess the presence of high-energy species in HLRCC 
mitochondria.
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5.2  Materials and Methods
5.2.1 Sample Collection
Thirteen pairs of matched normal (blood or myometrium) and 
leiomyoma DNA samples were selected at random from the pool of sporadic 
uterine leiomyoma samples without germline FH mutations. In addition, 3 
HLRCC leiomyomas from a patient with a K187R germline mutation, and 
known LOH, plus the patient’s germline DNA, derived from a blood sample 
were also chosen for analysis.
5.2.2 Affymetrix mtDNA resequencing array protocol
Samples were analysed using the Affymetrix mtDNA resequencing 
array v2.0. Since this protocol requires a single long-PCR amplification, rather 
than nested PCR, sequence artefacts as a result of multiple PCR steps are 
minimised.
The procedure is described in Chapter 2 (2.11.2). Data from these 
arrays were analysed as a single batch using a quality score threshold of 3 and 
a diploid genome model in order to identify regions of heteroplasmy. Tumour 
and normal samples were compared alongside each other as described in the 
Affymetrix recommendations for analysis 
(http ://www. affymetrix. com/Auth/support/technical/other/ 
mito_support_docs.pdf). In order to identify changes in the tumour with 
respect to the normal, a number of criteria were applied:
i)  Changes were discarded if they occurred within or flanking a
stretch of no-calls in both tumour and normal DNA.
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ii)  Where a region was over-tiled, changes were accepted or 
discarded on the basis of occurring in all the over-tiled 
fragments for the same position.
5.2.3  Analysis of detected mutations
Observed mutations were compared to known polymorphisms reported 
in the Mitomap database (Brandon et al. 2005) and within the literature. 
Phylogenetic analysis of mutations to identify instances of haplotype 
switching were carried out with reference to the Mitomap phylogenetic tree 
(Brandon et al. 2005). Protein missense mutations were analysed using the 
PolyPhen tool to identify the effects of amino acid polymorphisms on the 
overall function of the protein (Ramensky et al. 2002).
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5.3  Results
5.3.1  Resequencing analysis of mtDNA from uterine leiomyoma and 
matched normal samples
In total, 30 hybridisation experiments were carried on 16 tumour 
samples from 14 patients. Hybridisations were successful for 28/30 arrays 
analysed. Two arrays, 200103 leiomyoma, and 200144 myometrium, had very 
low call rates Table 5.3. While the overall call rates for each array appeared 
low (median = 68.75%), the call rates for the coding regions, containing all the 
polypeptide and RNA genes, but not the D-loop, was far higher (Median = 
91.98%). This discrepancy is due to the overtiling of the D-loop region for 
common polymorphisms, since many of these overtiled regions will not 
hybridise DNA in a particular sample, thus increasing the number of ‘no- 
calls’.
Mutations relative to the normal mitochondrial genome were observed 
in 6 sample pairs, AHF2, 000357, TB02 0341, 200061, TB03 0152, and TB04 
0107 (Table 5.4). The remaining 8 analysed sample pairs contained no 
mutations following analysis by the criteria described above. In total, 26 
mutations were observed. A majority (81%) of the observed mutations were 
transversions, with only 19% transitions. The maximum number of mutations 
observed in a single sample was 6 (Table 5.4), which occurred in 2 samples 
(000357 and TB02 0341). The remaining samples contained 5 (AHF2), 4 
(200061 and TB04 0107) and 1  mutation (TB03 0152). Of all 26 mutations, 
only one, in sample TB03 0152, was homoplasmic.  18 of the mutations 
occurred in protein coding genes, but only 12 of these were missense changes
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(Table 5.5). 3 mutations occurred in genes encoding tRNAs (1 in each of 
tRNA-Ile, tRNA-Val and tRNA-Gly) although none of these mutations 
occurred in the anticodon region of the molecule. One mutation occurred in 
the 16S rRNA, and 4 mutations occurred in the D-loop region. No consistent 
sites of mutation were observed.
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Table 5.3 Individual array call rates and number of mutations observed.
Sample
Name1
Normal Call Rate Leiomyoma Call Rate Number of 
mutations Total Coding2 Total Coding2
000357 72.79% 94.73% 70.94% 93.40% 6
100179 63.60% 84.84% 68.41% 92.17% 0
200061 53.71% 74.30% 58.36% 80.01% 4
200103 59.71% 80.18% 26.61%3 35.58% N/A
200144 39.60%3 53.56% 6 6 .0 2 % 85.36% N/A
AH 60.14% 78.30% 63.93%
(AHF2)
82.32% 5
69.09%
(AHF4)
91.79% 0
72.95%
(AHF5)
94.65% 0
FG4 70.28% 93.79% 71.91% 94.41% 0
TB02 0341 62.82% 87.27% 62.01% 84.86% 6
TB02 0431 74.60% 95.15% 74.90% 95.09% 0
TB03 0152 70.20% 94.04% 70.77% 94.10% 1
TB03 0413 74.63% 95.31% 73.15% 94.52% 0
TB03 0438 74.56% 95.29% 74.90% 95.42% 0
TB03 0566 65.54% 89.42% 70.58% 92.50% 0
TB04 0107 67.74% 89.51% 64.72% 86.40% 4
Sample name refers to the patient
2Coding region call rates were calculated from position 577 (tRNA-Phe) to 
16023 (tRNA-Pro) containing all the coded polypeptides and RNAs
3Call rates were considered too low and samples were not analysed
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Table 5.4 Observed differences between normal and tumour mtDNA in 
uterine leiomyomas. The reference is the revised Cambridge Reference 
Sequence (Andrews et al. 1999).
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Table 5.5 Number and type of mutations observed in mtDNA protein-coding 
regions. Genes are ordered as they appear on the mtDNA
Gene Missense Mutations Silent Mutations
ND1 1 1
ND2 1 0
COX1 0 1
COX2 2 0
ATP6 1 0
COX3 1 0
ND4L 1 0
ND4 2 1
ND5 2 1
CYTB 1 2
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5.3.2  Haplotype shifting
In order to assess whether any mutations were present as 
polymorphisms in a different mtDNA haplogroup, the mutations were 
compared against known polymorphisms for different haplogroups (Brandon 
et al. 2005) (Table 5.6). Of the 26 observed mutations, 9 occurred at sites of 
known haplogroup polymorphisms, although only 5 of these matched the 
reported polymorphisms.
Table 5.6 Observed mutations in positions of known mtDNA haplogroup 
polymorphisms.
Site of mutation Observed
Mutation
Reported
Polymorphism
Haplogroups with
reported
polymorphism
152 T-C T-C T2, Kl, H2
1656 A -C A -G H4, H6
2217 C -A C -T K2
3511* A -G A -G H2, HI 6
3798 C-A C -T M2 7
8 6 6 8 T-C T-C H10, Lie
9813* T-A T-A Kl
11062 C -T C -T D2
16126 T -G T-C T3,T2,T1, J4, J3, 
J2, J1
♦Polymorphisms result in protein missense mutation
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5.3.3  Functional effects of observed mtDNA mutations
In order to assess the functional effects of the observed coding 
mutations on the proteins, analysis of each mutation was carried out using the 
PolyPhen tool (Ramensky et al. 2002). Results of this analysis (Table 5.7) 
suggested that 9 of the 12 missense mutations had a potentially damaging 
effect on the encoded protein, two mutations were likely to be benign, and the 
. effect of one mutation was unknown due to a lack of homologous sequences.
Table 5.7 PolyPhen predictions of effects of observed mtDNA mutations
Sample Gene Mutation Polyphen
Prediction
Remarks
AHF2 COX2 P208S Probably
Damaging
Close to functional site
AHF2 ATP6 W48R Probably
Damaging
Original Trp highly 
conserved
AHF2 ND5 M7I Unknown No alignment with other 
sequences
000357 ND5 S305T Probably
Damaging
Original Ser highly 
conserved
000357 ND2 A101S Benign Original Ala not well 
conserved, mutation 
conserves shape
TB02 0341 COX2 N203H Probably
Damaging
Close to functional site and 
other chains
TB02 0341 ND4 G311V Probably
Damaging
Original Gly highly 
conserved
TB02 0341 CYTB L102Q Possibly
Damaging
Highly conserved Leu, 
mutation close to ligand
200061 ND1 T69A Benign Original Thr not well 
conserved, mutation 
conserves shape
200061 COX3 F203I Probably
Damaging
Close to ligand, close to other 
chains
TB04 0107 ND4L Y89C Probably
Damaging
Residues of similar type 
highly conserved
TB04 0107 ND4 I100N Probably
Damaging
Conserved size and 
hydrophobic ity
235Chapter 5 Analysis o f the mitochondrial genome in HLRCC and sporadic uterine
leiomyomata
In order to assess the potential pathogenic effects of mutations in the 
rRNA and tRNA genes, the structures of these molecules were studied to 
identify altered interactions within the molecule (Figure 5.2). These results 
showed that the mutations in nucleotides 10054, affecting tRNA-Gly (Figure 
5.2a) , and 4272, affecting tRNA-Ile (Figure 5.2b), both disrupt secondary 
structural interactions within the tRNA molecule, and may, therefore, have a 
detrimental affect on translation. The mutation of nucleotide 1656, affecting 
tRNA-Val (Figure 5.2c) does not affect secondary structural interactions. 
However, mutations in the looped regions of mitochondrial tRNA molecules 
have been described in a number of mitochondrial diseases, such as MELAS 
(mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like 
episodes) (Goto et al. 1994).
The observed 16S rRNA mutation has not been previously reported, 
nor have any confirmed pathogenic mutations been reported within the 16S 
rRNA. Analysis of the secondary structural interactions (Figure 5.2d) showed 
that this base does not pair with any other base within the rRNA molecule. 
Any further pathogenic effect cannot be confirmed.
The function of mutations in the D-loop region are more difficult to 
ascertain. Only one of these mutations, T152C has been previously described 
and is associated with haplogroups T2, Kl and H2 (Brandon et al. 2005). 
There has also been a report of this mutation occurring in a patient with 
ovarian carcinoma (Liu et al. 2001). The other observed mutations have not 
been previously described, and do not occur in any described functional 
elements of the D-loop. Therefore, their function remains unknown.
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Figure 5.2 Analysis of the secondary structure of tRNA and rRNA molecules 
affected by observed mtDNA mutations in uterine leiomyomas, a & b) 
Mutations in the tRNA-Gly and tRNA-lle molecules disrupt base-pairing 
interactions within the molecule. Mutations affecting tRNA-Val (c) and the 
16S rRNA (d) do not affect these interactions. RNA structures were obtained 
from the mtSNP database (Chuang et al. 2006b).
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5.3.4  mtDNA mutations in HLRCC uterine leiomyomas
The total number of observed mutations in the 3 HLRCC leiomyomas 
was compared to the numbers observed in sporadic leiomyomas by a 
Wilcoxon signed-rank test in R. The number of mutations observed in 
HLRCC leiomyomas was not greater than those observed in sporadic uterine 
leiomyomas (p=0.8627).
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5.4  Discussion
Reports of mtDNA mutations in a number of different tumour types 
occur frequently in the literature (Chatterjee et al. 2006). Here, mtDNA 
mutations have been identified in 6/14 (43%) uterine leiomyoma samples from 
both sporadic and familial cases. The true pathogenic effects of these 
mutations have not been established. There is no common theme linking the 
mutations, be it a shift to a common haplogroup, or mutations in similar genes 
or of similar types. Therefore, it is unclear whether the mutations are 
causative, or an effect of tumour growth leading to increased mutagenesis.
The consequences of mtDNA mutations have been hotly debated. In 
tumour cells, the mitochondria appear to be under persistent oxidative stress, 
signified by the presence of high levels of ROS (Brown and Bicknell 2001). 
This stress arises due to hypoxic conditions at the centre of the tumour 
(Knowles and Harris 2001). This stress could be the cause of frequently 
observed mtDNA mutations in tumours. The question of whether these 
mutations then provide a growth advantage to the tumour cell is as yet 
undetermined. The accumulation of mutations may be a result of a vicious 
cycle. Initially, tumour hypoxia leads to an increase of ROS in the cell, which 
damage mtDNA. This leads to changes in the electron transport chain, which 
could further increase the ROS in the mitochondria, which further damages 
mtDNA, and so on. ROS are known to function as secondary messenger 
molecules within the cell, influencing metabolism, gene expression, and cell 
proliferation, among others (Gamaley and Klyubin 1999).
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This has implications for leiomyoma pathogenesis. It was interesting to 
note that 5/6 samples with mutations had accumulated several changes (Table 
5.4). It is possible that the vicious cycle of mutation described above is 
occurring in these tumours. The predicted increasing levels of ROS in the cell 
could act as secondary messengers increasing cell proliferation and tumour 
growth (Gamaley and Klyubin 1999), and also increase the likelihood of 
further genetic aberration, possibly cytogenetic changes to the nuclear 
genome.
It is also possible that mtDNA mutations arose as a consequence of 
cell aging due to proliferative growth, in a similar manner to the accumulation 
of mtDNA mutations as a consequence of aging (Chomyn and Attardi 2003). 
Unfortunately, data regarding the size of the samples used in this study was 
not taken, which could have been used to examine the correlation between 
tumour size, as a measure of tumour age, and mtDNA mutation frequency.
5.4.1  mtDNA mutations in HLRCC uterine leiomyomas
It was predicted that the deleterious effects on Krebs cycle metabolism 
of the FH mutations observed in HLRCC patients would transfer to the 
electron transport chain, resulting in an increase in ROS production, and so an 
increase in mtDNA mutations. However, the results of this study showed 
mutations in only one familial sample, AHF2, and no significant difference in 
mtDNA mutation prevalence between sporadic and familial samples.
It appears, therefore, that the initial assumption was wrong, and that 
blocking of the Krebs cycle may not have a significant effect on ROS 
production through aberrant effects on the electron transport chain. This could
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imply that it is still functioning in some capacity, perhaps using NADH 
produced from other cellular processes such as the pentose phosphate pathway 
(Wood 1986).
The mutations observed in the one HLRCC leiomyoma may have 
arisen in a similar manner to those observed in the other leiomyoma samples. 
Again, it would be interesting to see if there was a correlation between tumour 
size and mtDNA mutation frequency.
5.4.2  The Mitochip -  conceptually flawed?
The conclusions drawn from this study are entirely dependent on the 
sensitivity and specificity of the screening method. While the Mitochip allows 
the sequencing of an entire mtDNA molecule in one experiment, some 
difficulties with the array perhaps point to conceptual flaws, both within the 
array design, and within resequencing technology as a whole. One of the 
major problems encountered with using the Mitochip was the high number of 
no-calling bases. In the two samples with such a low call rate that the sample 
pairs were excluded from analysis (200103 leiomyoma and 200144 normal), 
the low call rate was due to a weak signal. However, in a number of other 
arrays, weak signal accounted for only a small amount of reduction in call 
rate. During analysis of the different sets of data, regions of no call were 
observed to occur in blocks, rather than randomly spread throughout the data 
set. More importantly, these blocks occurred at the same point in both tumour 
and matched normal samples.
Resequencing arrays are designed on the principles of allelic 
discrimination -  being able to discriminate between a single base at a
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particular point (Maitra et al. 2004). Each arrayed 25 base oligonucleotide 
consists of the base of interest flanked by 12 bases either side. This central 
base varies for each of the 4 DNA bases, and is also present as a reversed 
sequence. In a hybridisation experiment, sample DNA is hybridised to the 
array (Figure 5.3a). The flanking sequences either side of the base of interest 
will hybridise as well, despite the mismatch at the central base. In order to 
identify the appropriate base(s), a stringent enough washing procedure to 
allow allelic discrimination at a single base mismatch must be used. This 
removes the mismatched DNA, resulting in the correct base(s) being called.
However, this procedure falls down when a homoplasmic mutation 
occurs. For the oligo defining the base where the mutation occurs, the 
situation in Figure 5.3a occurs, and the mutation is called. However, for the 
12 bases tiled either side of the mutation, the situation in Figure 5.3b occurs, 
and a mismatch occurs in the flanking bases to the base of interest. The 
washing procedure removes the mismatched bases, and hence no base is called 
at positions flanking a mutation.
This difficulty is compounded by the massive variability in the 
mitochondrial genomes of different ethnic groups, which would lead to a 
succession of no-calls in bases varying from the reference sequence. This has 
been approached in the D-loop region by overtiling 245 of the most common 
haplotype variants observed in the FBI database (Fox 1996). However, a 
number of common, haplotype-defining SNPs occur within the coding region, 
from bases 577 to 16023. This region has not been overtiled on the Mitochip, 
which was created from the rCRS, representing haplogroup H2 (Andrews et 
al. 1999). Thus, mtDNAs from different haplogroups will contain a number of
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coding region SNPs not tiled for on the array, and long runs of ‘no-call’ bases 
will frequently occur, as was observed in the results from this chapter.
In theory, these affected bases should be called in the middle of a run 
of no-calls. However, in practice this did not occur and made calling 
mutations in the coding region very difficult. In most cases, the runs of no­
called bases were observed in both the constitutional and tumour DNA, 
indicating the patient was not from haplogroup H2. Only heteroplasmic 
mutations not flanked by no-calls could be reliably called.
A further limitation of the Mitochip is its inability to identify deletion 
mutations. A number of common deletion polymorphisms, particularly within 
poly-C tracts, have been reported (Bianchi et al. 2001). Furthermore, there is 
no means of detecting well characterised large deletions, such as the 4977 
deletion (Bianchi et al. 2001). Therefore, further screening procedures should 
be carried out to complement the Mitochip in order to obtain the fullest 
mtDNA profile.
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Figure 5.3 Problems with mutation detection using the resequencing arrays, a) 
Where the flanking sequence of the labelled DNA matches the sequence tiled 
onto the array, a perfect match occurs for one variant, which remains 
hybridised following washing, leading to a base call, b) A polymorphism at a 
single base would lead to imperfect hybridisation to probes representing bases 
either side of the polymorphism. These would be removed by washing, 
leading to no base being called.
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5.4.3  Conclusions
Mutations of mtDNA in tumours have proven to be a controversial 
issue, with many arguments and opinions on the role of these mutations, and 
even their existence, in tumour progression (Bianchi et al. 2001; Penta et al. 
2001; Salas et al. 2005). In this chapter, the potential effects of mtDNA 
mutations in leiomyoma pathogenesis have been examined using the Mitochip 
resequencing array. While mutations were detected in 6/14 samples, the role 
of these changes is unclear and it is possible that they are background changes.
Conversely, they may represent an important new mechanism of 
leiomyoma pathogenesis, particularly regarding the involvement of ROS 
signalling. The lack of difference in mtDNA mutation frequency between 
HLRCC and sporadic uterine leiomyomas suggests that they may not arise due 
to Krebs cycle dysfunction in HLRCC leiomyomas.
The role of these mutations is still undefined, and further molecular 
studies on the potential effects of these mutations and their role in 
tumorigenesis would need to be carried out to ascertain whether they are a 
cause of pathogenesis, or an effect of tumour growth.
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6.1 Introduction
6.1.1 Copy number changes and tumorigenesis
Mutations at the gene level are one means of altering gene function in 
order to promote tumorigenesis. Examples include activating mutations proto­
oncogenes, such as KRAS2, leading to their constitutive activation (Feig et al. 
1984) and mutations in tumour suppressor genes, such as FH, as observed in 
Chapter 3, which lead to their inactivation (Tomlinson et al. 2002). However, 
such changes can also occur as a result of copy number variation, where 
specific regions of the genome are amplified or deleted, usually on a scale of 
tens of kb or more.
Traditionally, amplified regions tend to indicate the presence of 
oncogenes (Kashiwagi and Uchida 2000), where the presence of increased 
copies of the gene increases the expression, and effect of a gene. For example, 
the ERBB2 oncogene is frequently found amplified in breast cancer 
(Kallioniemi et al. 1992). In contrast, deleted regions are often taken to be 
indicative of tumour suppressor genes (Kashiwagi and Uchida 2000). In this 
case, one copy of the gene may be inactivated by mutation, and the second 
copy deleted from the genome, or both copies may be deleted as a 
homozygous deletion. For example, Grafstrom et al identified frequent 
homozygous deletions of the INK4 locus on chromosome 9p21  in cutaneous 
melanoma (Grafstrom et al. 2005).
The locations of copy number changes in tumours are frequently 
studied as potential markers of novel genes involved in the development of a 
particular tumour. Additionally, such changes may be associated with a
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patient’s prognosis - the deletion of INK4 described above is associated with 
decreased survival (Grafstrom et al. 2005) -  and the identification of novel 
involved genes in these regions can help with both an understanding of the 
pathobiology of a particular tumour, and with the development of therapeutic 
strategies for patients with tumours containing such changes (Grafstrom et al. 
2005).
A number of regions of frequent copy number change, with as yet 
unidentified target genes, have been identified. For example, deletions of 
chromosome 16q are common in ductal and lobular breast cancers (Rakha et 
al. 2006). To date one associated tumour suppressor, E-cadherin, has been 
identified in lobular tumours, yet no associated gene has been identified for 
ductal tumours (Rakha et al. 2006). In colorectal cancer, loss of 4q is a 
frequently recurring event associated with poor prognosis (De Angelis et al.
2 0 0 1 ), and so identification of the involved gene or genes in this region could 
help to improve patient therapies.
6.1.2  Copy number variation in the human genome
In addition to the copy number changes observed in tumours, much 
recent focus has been given to natural copy number variation between 
individuals (Sebat et al. 2004; Sharp et al. 2005). Several studies have 
identified a number of sites throughout the genome where polymorphic 
deletions, insertions or inversions of genetic material are observed in 
constitutional DNA (Sebat et al. 2004; Sharp et al. 2005). These copy number 
polymorphisms (CNPs) can be associated with genes that define specific traits. 
For example, Sebat et al identified a triplication of the neuropeptide-Y
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receptor (.PPYR1), which is directly involved in the regulation of food intake 
and body weight (Sebat et al. 2004). Differences in CNPs have also been 
observed in different ethnic backgrounds (Sharp et al. 2005).
The presence of these CNPs has been found to be associated with the 
presence of segmental duplications, particularly intrachromosomal 
duplications (Sharp et al. 2005). These are regions of repeated sequence >lkb 
in length and of >90% identity, thought to be recently duplicated in 
evolutionary history (Samonte and Eichler 2002). Their high homology could 
be an important means of genetic recombination, leading to the observed 
variation in copy number (Sharp et al. 2005), although it is possible that they 
arise as a result of genetic recombination.
6.1.3  Microarray comparative genomic hybridisation (array-CGH)
The identification of copy number changes was originally carried out 
by karyotyping of metaphase chromosomes stained with Giemsa, Quinacrine 
or Chromomycin among others (Strachan and Read 2004). This method is 
time-consuming and requires a highly skilled eye, and the resolution was 
limited to very large copy number changes over several cytogenetic bands. 
Furthermore, chromosomes can only be obtained from growing cell lines, 
which places a limit on samples that can be analysed. However, it does allow 
the detection of other cytogenetic abnormalities, such as translocations, 
inversions and the presence of marker chromosomes. Furthermore, fluorescent 
in-situ hybridisation (FISH) can be used to examine the copy number of 
individual BAC clones to identify breakpoints once a region is identified 
(Gorman and Roylance 2006).
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A later development was comparative genomic hybridisation (CGH), 
where normal and tumour DNA samples were labelled with different 
fluorescent dyes and competitively hybridised to normal metaphase 
chromosomes. The ratio of normal to tumour DNA was used as a measure of 
comparative copy number (Gorman and Roy lance 2006). This technique 
increases the number of samples available for study, since there is no need to 
grow cell lines to obtain metaphase spreads. However, it is unable to detect 
abnormalities other than copy number change and the resolution, while more 
precise than karyotyping of metaphase spreads, is still limited to 
approximately 10Mb (Gorman and Roy lance 2006).
A number of other techniques are available to measure copy number 
change at a very high resolution. Multiplex amplifiable probe hybridisation 
(MAPH) can compare gene dosage at the exon level. Patient DNA is spotted 
onto a nylon membrane and hybridised to a mixture of DNA probes, each 
specific for one exon or region with identical DNA ends for priming. After 
washing, the hybridised probes are amplified using a single primer pair, 
producing a series of different size products, which are then analysed by 
capillary gel electrophoresis (Sellner and Taylor 2004). Multiplex ligation 
dependent probe amplification (MLPA) is a similar technique, this time using 
a mixture of PCR primers in a single multiplex reaction to detect copy number 
differences between regions such as exons (Sellner and Taylor 2004). 
Quantitative real-time PCR using probes specific for the region of interest can 
also be used (Lehmann and Kreipe 2001). While these methods offer very 
high resolution detection of copy number change, they require presumed
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knowledge of specific regions or genes involved and cannot be used as a 
general screening technique for whole genome copy number change.
In recent years, CGH has been superseded by microarray-based CGH, 
where DNA is hybridised to individual arrayed DNA probes, such as 
oligonucleotide probes (Pollack et al. 1999) and bacterial artificial 
chromosomes (BACs) (Cai et al. 2002), immobilised onto a glass slide. This 
has dramatically improved the resolution of the technique to allow detection of 
sub-megabase copy number changes that would previously have been missed 
by conventional CGH, while still retaining the ability to screen the entire 
genome in one experiment (Albertson and Pinkel 2003). Currently, this is the 
technique of choice for detecting copy number changes.
6.1.4  Copy number variation in uterine leiomyomas
Cytogenetic abnormalities are the most frequently observed changes 
within sporadic uterine leiomyomas, occurring in approximately 40% of 
observed cases (Ligon and Morton 2001). A large number of these 
abnormalities have been described in the literature, and affect many different 
chromosomes, although a number of non-random aberrations have been 
frequently reported (For a more detailed overview, see section 1.2.1.4.1) 
(Ligon and Morton 2001).
The work in this Chapter aimed to examine genome-wide copy number 
changes in uterine leiomyomas using 1Mb resolution microarray CGH. The 
overall aim of this project was to attempt to refine previously reported regions 
and to identify new regions of copy number change. In addition to this, genes 
within these regions were identified and compared to known protagonists of
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leiomyoma pathogenesis to examine the relevance of particular genetic 
pathways, particularly given that some cytogenetic alterations appear to impart 
resistance to GnRH analogue therapy, implying that the tumours are able to 
grow independently from the sex hormones oestrogen and progesterone 
(Brosens et al.  1998).
Uterine leiomyomas from three different patient cohorts were studied: 
HLRCC cutaneous and uterine leiomyomas were studied in an attempt to 
identify novel copy number changes separate from the FH locus at lq42 that 
could give clues as to other regions and pathways involved in the pathogenesis 
of these tumours; uterine leiomyomas from African and Afro-Caribbean 
patients were studied to see if copy number changes could give potential clues 
to the location of specific genetic loci predisposing to leiomyoma formation; 
and finally sporadic leiomyomas were studied to identify novel regions of 
copy number change, and to refine the locations of previously known copy 
number change.
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6.2  Materials and Methods
6.2.1 Samples
Microarray CGH was carried out on 40 samples in total. Of these, 3 
were HLRCC leiomyomas (2 uterine and 1  skin), 14 were sporadic uterine 
leiomyomas from Caucasian patients, 10 were similar sporadic samples but 
with known LOH on chromosome 7, 3 were from leiomyoma cell lines and 13 
were from patients of African or Affo-Caribbean origin.
Where matched germline DNA was available for a sample, this was 
used as a normal control. Where this was not available, a sample of 5 pooled 
normal female DNAs was used as a control.
6.2.2 1Mb resolution microarray CGH
Microarray CGH, carried out using 1Mb resolution BAC microarrays, 
and subsequent data analysis and calling of copy number changes was carried 
out as described in Chapter 2 (2.11.1, 2.13.2)..
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6.3  Results
6.3.1 Microarray CGH results
1Mb resolution microarray CGH was carried out on 42 samples. Of 
these, 37 produced useful results and 5 samples failed. Overall, 34 changes 
were observed throughout all the samples. In 23 samples, no copy number 
changes were observed. The maximum number of changes in one sample was 
6.
6.3.2 Analysis of HLRCC leiomyomas
3 HLRCC leiomyoma samples (2 uterine and 1  skin) were analysed by 
microarray CGH to examine potential copy number changes specific to this 
tumour syndrome. Only 1  change was observed, a deletion of Iq41-q43 
(Figure 6.1). This deletion contains the FH gene, and the deletion in this 
tumour was highly likely to be the ‘second-hit’ leading to tumorigenesis. This 
was confirmed by sequence analysis of the patient, who had a germ line 
K187R mutation (Alam et al. 2003), which showed no wild-type allele in the 
FH DNA sequence. In the 2 other tumours analysed, no copy number changes 
were observed although LOH had previously been confirmed by sequencing.
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Figure 6.1 del(l)(q41-q43) in HLRCC uterine leiomyoma AHF2. The 
ideogram shows the location of the deletion, which encompasses the FH gene. 
The output plot shows the CGH profile for the entire chromosome plus results 
of the copy number change calling analysis.
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6.3.3  Analysis of sporadic uterine leiomyomas
A majority of the observed copy number changes occurred in sporadic 
uterine leiomyoma samples. 16/24 (67%) samples contained at least one copy 
number change. By far the most frequently observed change involved 
deletions of chromosome 7q, occurring in 9/24 (38%) of samples. Changes 
were also observed in chromosomes 1, 3, 5, 6 , 8, 9,  11,  12,  13, 14, 15, 19, 20, 
21 and 22. 8 samples showed no copy number changes, with 4 of these due to 
experimental failure Detailed lists of the copy number changes are shown in 
Table 6.1 and Table 6.2.
6.3.3.1  Chromosome 7 changes
9 samples demonstrated copy number changes on chromosome 7q 
(Table 6.1). 7 of these were samples selected for further study following LOH 
analysis of microsatellite markers by collaborators in Finland, where 165 
samples from 91 patients were screened. One sample with 7q LOH (51 Ml) 
did not show any copy number change of chromosome 7, but did have a 
number of other copy number changes (discussed in 6 .3.3.2). For the final 2 
samples with 7q LOH, the experiment failed. 2 further samples from cell lines 
also showed deletions of 7q.
A minimum overlapping area of deletion of 3.92Mb was observed in 
all samples bar one (Figure 6.2a). The edges of this region were defined by 
two samples, 38M5 and 9M5 (Figure 6.2b), and was delimited proximally by 
clone RP11-148A10 (position -  104,084,406bp (UCSC)), and distally by 
clone RP11-5N18 (position -  108,002,467bp (UCSC)). This region contains 
approximately 28 known genes, and a number of transcripts (Figure 6.2c).
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The minimum region of deletion excluded a number of previously 
proposed genes such as CUTL1 (Zeng et al.  1997), PCOLCE (Ligon et al.
2002), and ORC5L (Ligon and Morton 2001); all of which are proximal to this 
minimum region. This region does contain a number of interesting candidates. 
LHFPL3 (Lipoma HMGIC fusion partner-like 3) is a gene with high identity 
to the LHFP gene family, which are fusion partners of HMGIC in 
translocations observed in lipomas (Petit et al. 1999). The frequency of 
HMGIC translocations in sporadic uterine leiomyomas suggests that this may 
be a strong candidate (Ligon and Morton 2001). Several candidate genes 
encoding important cell signalling pathway members, such as PIK3CG 
(phosphoinositide-3-kinase, catalytic subunit gamma) and PRKAR2B (cAMP- 
dependent protein-kinase regulatory subunit type 2 (3). Deletion of the former 
would reduce PI3K signalling and disrupt the mTOR pathway. This could 
explain the effects on slowing cell growth of deletions of 7q (Xing et al. 1997; 
Takahashi et al. 2001a). Conversely, deletion of PRKAR2B, which inhibits the 
activity of cAMP-dependent protein kinase, could increase cell signalling 
through G-protein coupled pathways. This kinase also localises to the 
centrosomes, and dissociation is PRKAR2B is required to allow the onset of 
mitosis (Takahashi et al. 1999).
In addition to the minimal region of overlap observed in 8/9 samples 
with 7 q deletions, two alternative regions of deletion were also observed, both 
in sample 29M2 (Figure 6.3). The first region was a single clone deletion at 
approximately 100Mb along chromosome 7. This region contains several 
genes thought to be candidates for the 7q tumour suppressor, including 
CUTL1, PCOLCE and ORC5L. However, it is also the location of copy
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number variation in the human genome (Sebat et al. 2004; Sharp et al. 2005). 
For this sample no normal DNA was provided by collaborators and so a 
pooled normal was used. The single clone contains the polymorphic 
microsatellite marker D7S518. No LOH had been detected at this 
microsatellite in 29M2, and so it is possible that this single clone deletion is 
due to a copy number polymorphism.
The larger deletion in this sample spans the region q31.33-q34 and is 
approximately 17.5Mb long (Figure 6.3). A number of genes are encoded 
within this region, including a subunit of the mitochondrial electron transport 
chain enzyme NADH dehydrogenase (NDUFB2) and the B-Raf proto­
oncogene (BRAF). The latter appears to be the only gene in this region with 
any relation to known leiomyoma signalling pathways, being a modulator of 
receptor tyrosine kinase signalling (Chan et al. 2003). However, the effects of 
deletion of this gene, when it is normally activated in tumours (Chan et al.
2003), are unknown.
Deletion of this region has been previously reported, along with other 
rearrangements of 7q34, in uterine leiomyomas (Fan et al. 1990; Vanni et al. 
1991). However, it is reported rarely in comparison to the observed deletions 
of 7q22.
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Table 6.1 Summary of chromosome 7 copy number changes observed by 1Mb 
microarray CGH
Breakpoint l 1 Breakpoint 21
Sample Clone Position
(Mb)2
Clone Position
(Mb)2
Length
(Mb)
Change
28M1 (1st 
Change)
ptel 0 RP5-1091E21 55.04 55.04 Del
28M1 (2n d  
Change)
RP5-1136A10 80.53 RP11-384A20 121.37 40.84 Del
Awaki RP4-784G16 82.50 RP11-56305 114.02 31.52 Del
9CR ptel ptel Whole Del
29M2 (1st 
Change)3
RP11-506M12 99.64 RP11-401L13 102.51 2.87 Del
29M2 (2n d  
Change)
RP11-420H19 124.83 RP11-282G13 142.31 17.48 Del
38M5 RP11-148A10* 104.08 RP11-264K23 123.71 19.63 Del
38M1 RP4-672011 103.09 RP11-264K23 123.71 20,62 Del
14M8 RP5-1084H12 91.08 RP11-328M22 112.28 21.20 Del
11M1 RP5-1084H12 91.08 RP11-36B6 130.08 39.00 Del
9M5 RP5-1145A22 97.17 RP11-5N18' 108.00 10.84 Del
Denotes clones delimiting the smallest region of deletion.
'Breakpoint clones are defined as the first clones not considered lost flanking the change. 
Positions are defined as the position of the end of the breakpoint clone closest to the change. 
Positions are from the UCSC genome browser.
3This change was unverified by LOH analysis.
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Figure 6.2 Deletions on chromosome 7 in sporadic uterine leiomyomas, (a) A 
summary of observed chromosome 7 deletions in 8 samples is shown against 
the chromosome ideogram, (b) The minimum region of overlap, occurring in 7 
of the 8 samples, is 3.92Mb and is delimited by the samples 38M5 and 9M5; 
(c) this region contains approximately 28 known genes.
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Figure 6.3 Plot of chromosome 7 from sample 29M2. This sample contains 2 
apparent deletions. The larger deletion occurs in 7q31.33-q34, a novel region 
of deletion in uterine leiomyomas. The single clone deletion at approximately 
100Mb occurs in a region of known copy number variation in the human 
genome and so its significance as a deletion is unknown.
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6.3.3.2  Changes observed in other chromosomes in sporadic uterine 
leiomyomas.
In addition to the observed deletions of chromosome 7q, several other 
copy number changes were also observed (Table 6.2, Figure 6.4 - Figure 
6.7). Changes varied from whole chromosome gains or deletions, to more 
discrete regions of copy number change, with one sample demonstrating an 
apparent homozygous deletion on 19ql2. Only 3 regions demonstrated 
overlapping copy number changes: deletion of chromosome  1 2q2 1 .2-q2 2, 
deletion of chromosome 22, and an interstitial deletion on 5p. There was also 
an apparent 3.5Mb homozygous deletion observed on 19ql2 in sample 28M1.
Analysis of these other chromosome changes brought to light 
limitations of the analysis method (2.13.2). In particular, two changes obvious 
by eye were not identified, a deletion of chromosome 3 in sample 38M5 
(Figure 6.4), and a gain of chromosome 19 in sample 51M1 (Figure 6.6). In 
these cases, a call was made by eye, and is indicated in the relevant diagram. 
Generally, these limitations were only observed where there were a number of 
changes involving many clones (for example, 51M1), leading to an increased 
standard deviation, and thus more stringent thresholds for copy number 
change.
In order to identify novel changes, a search was made for the location 
and type of each change in the Mitelman database of chromosomal aberrations 
(Mitelman et al. 2006). 24/27 (89%) of copy number changes observed in this 
study occurred within or overlapping with previously reported regions of copy 
number change by karyotyping studies. The three unique changes were the 
two deletions on 5p and the small gain on chromosome 13.
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A number of small copy number changes were identified in this study. 
These regions were compared to reported regions of copy number 
polymorphism (CNP) (Sebat et al. 2004; Sharp et al. 2005). One change, on 
chromosome 5 in sample TB03 0111, mapped to a region containing two 
deletion and duplication CNPs, and so this change may be due to these CNPs.
Of the remaining small changes, two observed in sample 28M1 are of 
particular interest: amplification of 2 1q2 2.1 1, and an apparent homozygous 
deletion of 19ql2. While similar changes have been previously reported in 
these regions in uterine leiomyomas, the deletion of 19ql2 was reported as a 
heterozygous occurrence (Meloni et al. 1992).
The amplified region of chromosome 21 contains a number of 
potentially interesting genes that could be involved in leiomyoma 
pathogenesis. There are a number of cytokine receptors, particularly 
interleukin and interferon receptors. Of perhaps more interest is the cluster of 
keratin-associated proteins in the region. It has been hypothesised that uterine 
leiomyomas may form in response to injury, in a similar manner to keloids 
(Catherino et al. 2004). Keratin expression is upregulated in keloids (Prathiba 
et al. 2 0 0 1), and the amplification of keratin-associated proteins in this sample 
may provide further evidence of a link between the two.
The homozygous deletion of 19ql2 does not provide as interesting 
candidates. Two genes, CCNE1 (Cyclin El) and UQCRFS1 (Ubiquinol- 
cytochrome c reductase) catch the eye. The former due to its intrinsic 
involvement in the cell cycle (Koff et al. 1991), and the latter due to its 
involvement in mitochondrial metabolism (Duncan et al. 1994). However, the 
deletion of cyclin El, which is required to allow a cell to progress from G1 to
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S-phase (Koff et al. 1991), would appear to have a detrimental effect on cell 
growth.
The additional small regions of copy number change also produced 
potentially interesting candidates. For example, the region of gain on 
chromosome 13 in sample TB02 0336 contained the MYCBP2 gene, which 
regulates the Myc proto-oncogene, and also inhibits TSC2, the mutated gene 
in the Eker rat model of uterine leiomyomas (Murthy et al. 2004).
Balanced translocations involving chromosomes 6p, 12q and 14q are 
frequent cytogenetic events in uterine leioymomas, involving rearrangements 
of the high mobility group (HMG) genes on chromosomes 6p and 12q, and 
RAD51L as a translocation partner on chromosome 14q (Ligon and Morton
2001). This study found a total of 8 changes in 6 samples in each of these 
chromosomes. This included the frequently reported trisomy 12 (Ligon and 
Morton 2001), which occurred in sample 51M1, and interstitial gains and 
deletions in other samples.
Only one of these changes, the deletion of chromosome 14q23.3-24.3 
in sample TB03 0560, covered the regions involved in the common 
translocations. RAD51L, which is a translocation partner of HMGA2 on 12q 
(Takahashi et al. 2001b), maps to the proximal breakpoint of this deletion 
(Figure 6.8). Therefore, it is likely that a translocation has taken place in this 
sample, additionally resulting in a loss of some genetic material from the 
breakpoint on chromosome 14. This deletion also removes a single copy of the 
TGFB3 gene encoding TGF|3-3, which is involved in leiomyoma 
pathogenesis, although it is frequently seen upregulated (Tsibris et al. 2002).
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It has been hypothesised that uterine leiomyomas with cytogenetic 
changes are able to grow independently of oestrogen stimulation (Brosens et 
al. 1998). Therefore, in order to identify potential candidate genes in the 
regions of copy number change observed in this study with the potential to 
allow oestrogen-independent tumour growth, the locations of a number of 
genes involved in oestrogen biosynthesis and oestrogen signalling were 
compared to the locations of copy number change. Only one gene, SPEN (also 
known as MINT), which encodes a transcriptional regulator involved in a 
multi-protein complex containing, among others, BRCA1, which inhibits 
oestrogen signalling (Yang et al. 2005), was identified in regions of copy 
number change in this study. This gene maps to lp36, which is deleted in 
sample 200094A.
The locations of components of other pathways that have been 
implicated in leiomyoma pathogenesis were also studied, including the 
progesterone, TGFp and bFGF pathways. Some genes involved in these 
pathways did map to the locations of various copy number changes: such as 
the progestin receptor PAQR7, which occurs on the deleted region of lp (Zhu 
et al. 2003); and a number of FGF genes on chromosome 8, which were 
amplified as a part of a whole chromosome gain in one sample, and deleted in 
another sample. However, the involvement of these genes is purely 
speculative and could only be confirmed with further refinement of the region, 
and expression studies of individual genes.
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Table 6.2 Summary of all non-7q copy number changes observed in sporadic 
uterine leiomyomas
Proximal Breakpoint Distal Breakpoint
Chrm Sample Clone Position
(Mb)
Clone Position
(Mb)
Length
(Mb)
Change
1 200094A pter 0 RP1-
118J21
40.00 40.00 Del
3 38M5 RP11-
108A8
63.66 pcen 90.60 26.94 Del
5 38M1 RP11-
32D12
9.60 RP11-
215G15
10.64 1.05 Del
5 200049A pter 0 RP11-
28P24
19.64 19.64 Del
5 200049A RP11-
12D3
90.96 CTD-
2332G20
141.85 50.89 Del
5 TB03 0111 RP11-
421A17
67.68 RP11-
11516
71.66 3.98 Del
6 200094A RP11-
685G11
105.15 RP11-
368P1
142.22 37.07 Del
8 51M1 pter 0 qter 146.27 Whole Gain
8 28M1 pter 0 CTD-
2115H11
43.32 43.32 Del
9 51M1 pter 0 qter 140.27 Whole Gain
11 200103B RP11-
569N5
68.07 RP11-
46D24
79.64 11.56 Del
11 200103B RP11-56J3 107.61 RP11-
485A5
123.30 15.70 Del
12 51M1 pter 0 qter 132.35 Whole Gain
12 38M5 RP11-
362A1
80.92 RP11-
74K11
93.05 12.12 Del
12 38M1 RP11-
362A1
80.92 RP11-
435E3
94.13 13.21 Del
13 TB02 0336 RP11-
309H15
72.69 RP11-
38E20
77.79 5.10 Gain
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Proximal Breakpoint Distal Breakpoint
Chrm Sample Clone Position
(Mb)
Clone Position
(Mb)
Length
(Mb)
Change
14 TB03 0560 RP11-
125H8
66.87 RP11-
368K8
75.21 8.34 Del
14 Awaki RP11-
98N22
19.73 RP11-
159L20
30.16 10.43 Del
14 Awaki RP11-
346L24
49.05 RP11-
304L20
54.38 5.33 Gain
14 51M1 pter 0 qter 106.37 Whole Gain
15 200103B qcen 17.00 RP11-
519G16
43.41 26.41 Del
19 28M1 CTD-
2043116
33.40 CTC-
416D1
36.89 3.49 Del
(Homo)
19 51M1 pter 0 qter 63.81 63.81 Gain
20 51M1 pter 0 qter 62.44 Whole Gain
21 28M1 RP11-
175P11
29.81 RP1-
245P17
34.48 4.68 Gain
22 200103B pter 0 qter 49.69 Whole Del
22 Awaki pter 0 qter 49.69 Whole Del
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Figure 6.4 Examples of copy number changes -  chromosomes 1,3,5,6 . The 
ideogram summarises all observed changes (red bar = deletion, green bar = 
amplification). The plot shows an example output from one sample with the 
actual log2 values (black) and the called change (red). If a change has been 
identified by eye, this is shown as a blue line.
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Figure 6.5 Summary of chromosome changes continued - chromosomes, 
8,9,11,12.
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Figure 6 .6 Summary of chromosome changes continued - chromosomes 
13,14,15,19.
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Figure 6.7 Summary of chromosome changes continued -  chromosomes 
20,21,22.
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Figure 6 .8 Deletion of chromosome 14 in sample TB03 0560. The deletion 
breakpoint (arrowed) is in the same region as the RAD51L gene (boxed) 
frequently involved in translocations in sporadic uterine leiomyomas.
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6.3.4  Analysis of uterine leiomyomas from African and Afro- 
Caribbean patients
13 uterine leiomyomas samples from patients of African and Afro- 
Caribbean ethnicity were analysed in order to identify any regions of copy 
number change that may be indicative of the inherent element predisposing 
these ethnic groups to multiple uterine leiomyomas.
Following screening of the samples, only one change was identified, 
del(17)(ql2-q21.2) in sample ER FI, a deletion of 6.5Mb flanked by clones 
RP11-47L3 (30,685,983 (UCSC)) and RP11-156E6 (37,192,545 (UCSC)) 
(Figure 6.9a). No other changes were observed. This region has previously 
been reported as being deleted in a conventional CGH study (Levy et al. 
2000).
The deleted region, despite being only 6.5Mb long, contains a large 
number of genes (Figure 6.9b). However, there are a few interesting 
candidates in the region. Firstly, there is a cluster of keratin genes towards the 
distal end of the breakpoint. As previously mentioned, there is thought to be 
some overlap in the pathogenic mechanisms of keloids and leiomyomas 
(Catherino et al. 2004). Keloids, which show overexpression of keratins, are 
particularly common in patients of African and Afro-Caribbean ethnicity 
(Catherino et al. 2004). Thus, although the region is deleted, the presence of a 
keratin gene cluster in this region may be significant to leiomyoma 
pathogenesis.
The second interesting candidate is the SMARCE1 gene, encoding a 
protein related to the SWI/SNF chromatin remodelling complex. The product
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of this gene has been shown to be required for the transcription of oestrogen 
responsive genes (Belandia et al. 2002). Finally, 1Mb distal to the region is the 
BRCA1 tumour suppressor gene, which predisposes to breast cancer.
Although no studies have been carried out examining the role of BRCA1 in 
uterine leiomyomas, the role of this gene in oestrogen signalling could imply 
some involvement in leiomoyma pathogenesis (Trauernicht and Boyer 2003).
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Figure 6.9 del(17)(ql2-q21.2) in sample ER FI, a uterine leiomyoma from an 
Affo-Caribbean patient. A 6.5Mb region is deleted in this sample. No other 
copy number changes were observed in 1 2 other tumours of similar origin, b) 
The UCSC genome browser shows a number of genes within this region that 
could have the effect of a tumour suppressor.
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6.4  Discussion
1Mb CGH analysis of a selection of sporadic uterine leiomyoma 
demonstrated a number of copy number changes across a wide-distribution of 
chromosomes, mimicking previous results.
6.4.1  Copy number changes in HLRCC uterine leiomyomas
Copy number analysis of HLRCC leiomyomas was carried out in order 
to identify further chromosomal regions of potential importance. A single 
deletion of lq was observed in a 1/3 HLRCC leiomyoma samples. This 
deletion contained the FHtumour suppressor and was the second ‘hit’ in this 
tumour, removing the patient’s wildtype copy of FH. No other changes were 
observed. Furthermore, no deletions of lq42 were observed in sporadic uterine 
leiomyomas in this study.
Rearrangments of lq42 in uterine leiomyomas have been previously 
reported in a number of studies, prior to the discovery of FH as the HLRCC 
tumour suppressor, but they are rare as the sole abnormality, occurring in 
3/797 (0.37%) of karyotyped tumours in one study (Dal Cin and Morton
2002). In some cases, rearrangments of lq42 have been identified in addition 
to other karyotypic changes, including t(12:14), and del(2)(q31) (Dal Cin and 
Morton 2002). A further study by Gross et al used FISH to examine deletions 
of the FH locus in uterine leiomyomas with rearrangements of lq42, and 
found that in 9 /11  tumours, only one copy of FH was present, suggesting a 
role of FH in the pathogenesis of those tumours. Again, other karyotypic 
changes were observed in addition to the rearrangement of lq42 (Gross et al.
2004).
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These results suggest that other karyotypic abnormalities may occur in 
HLRCC uterine leiomyomas. However, in this study, the potential for 
discovering these was limited by the very small sample size of tumours tested. 
Furthermore, a number of additional rearrangements observed in uterine 
leiomyomas with lq42 rearrangements were balanced changes, such as 
translocations and inversions, which cannot be detected by array CGH (Gross 
et al. 2004). A more thorough study, requiring not just copy number analysis, 
but also more traditional karyotyping, would give a more thorough overview 
of additional cytogenetic changes occurring in HLRCC uterine leiomyomas, 
which may augment the effects of the FH tumour suppressor.
6.4.2  Copy number changes in sporadic uterine leiomyomas
Copy number changes appeared as a frequent event in the sporadic 
uterine leiomyomas. In this study, 9/17 (53%) sporadic leiomyomas, 
excluding those with knowledge of LOH, exhibited copy number changes.
This frequency is higher than the reported frequency of approximately 40% 
for leiomyomas with karyotype alterations, but may reflect the increased 
sensistivity of the array CGH method for identifying copy number changes.
6.4.2.1  Chromsome 7q deletions
The role of 7q deletions in leiomyoma pathobiology is confusing. 
While the frequent deletions observed have lead many to propose a novel 
tumour suppressor in the deleted region (van der Heijden et al. 1998), studies 
of the size of tumours with 7q deletions (Rein et al. 1998), their growth 
behaviour in culture (Xing et al. 1997), and lack of resistance to GnRH 
analogue treatment (Takahashi et al. 2001a) suggest otherwise. However, the
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high frequency of these deletions suggests that there is a role for these 
deletions in uterine leiomyoma pathobiology.
The minimum region of deletion at 7q22.1  obtained in this Chapter 
confirms results obtained in the FISH studies of Vanni et al, the CGH studies 
of Levy et al, and the LOH study of ven der Heijden et al and reduces the 
minimal region of deletion within the boundaries of the regions observed in 
these studies (van der Heijden et al. 1998; Vanni et al. 1999; Levy et al. 2000). 
A number of interesting genes occur in this region that could explain the 
behaviour of uterine leiomyomas with 7q deletions, including PIK3CG, and 
PRKAR2B. However, the minimum regions defined by two LOH-based 
studies, at markers D7S666 (Ishwad et al. 1997) and D7S2446 (Sell et al.
2005), lie outside of the minimum region defined by this study.
It is possible that the different implied and demonstrated minimal 
regions of deletion are suggestive of several loci on 7q22 being important for 
uterine leiomyoma development, a hypothesis that has previously been 
postulated (Ishwad et al. 1997). However, most studies of 7q deletions aimed 
at defining the region at the highest resolution have been carried out by LOH 
analysis, and this presents a number of problems. Firstly, the assumption that 
LOH of 7q automatically implies deletion is made in many of these studies 
(van der Heijden et al. 1998; Sell et al. 2005). In this study, one sample,
51M1, demonstrated LOH across a number of markers in the chromosome. 
However, when this sample was analysed by array-CGH, no changes in copy 
number were observed. Thus, validation of LOH as a deletion is important.
Secondly, there is a demonstrated unreliability in the method of 
microsatellite LOH analysis for detecting deletions. The paper by Ishwad et al
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identified uterine leiomyomas with cytogenetically visible deletions of 
chromosome 7q, and then analysed these tumours for LOH. The resulting 
LOH map shows a confusing and inconsistent pattern of loss and retention of 
heterozygosity, the results suggest a wider minimum region than that 
suggested by the authors (Ishwad et al. 1997). This confusing pattern of LOH 
in samples with known deletions suggests that LOH analysis is not a reliable 
means of their detection. Thus, great care should be taken, where a single 
marker is observed to have LOH, to validate this result by other methods as 
much as possible.
An alternative region of deletion was also observed at 7q34 in one 
sample. Deletion of 7q34 has been previously reported (Fan et al. 1990; Vanni 
et al.  1991), and it is not inconceivable that leiomyomas with this particular 
copy number change represent a separate cytogenetic group to those with 
deletions of 7q22.
6.4.2.2 Other observed copy number changes
Copy number changes affecting other chromosomes were also 
observed in sporadic leiomyomas in this study. Some of these changes were 
observed in the same samples as those with 7q deletions and may complement 
the effects of the deletion. There was some overlap between copy number 
changes observed in other chromosomes in leiomyomas with and without 7q 
deletions, and the low number of samples tested means that the significance of 
any difference in distribution cannot yet be verified. Grouping of other copy 
number changes was not observed, but again this is probably due to the low
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number of samples tested. While a number of interesting regions were 
identified, no obvious candidate genes were present in these regions.
6.4.3  Copy number changes in African and Afro-Caribbean uterine 
leiomyomas
While a number of karytoyping studies have been carried out on 
uterine leiomyomas in general, to date, no study has specifically examined an 
association between specific karyotypic changes and ethnicity. Here, 13 
uterine leiomyomas from patients of African and Afro-Caribbean origin were 
examined by microarray CGH to identify any specific copy number changes 
associated with ethnicity. In all the samples, one change was identified, a 
deletion of 17q 12-21.1 in sample ER FI. A small deletion of this region has 
been previously reported by CGH studies of uterine leiomyomas.
As described above, this region contains several interesting genes, 
particularly the cluster of keratin genes, which may be important in the 
increased frequency of uterine leiomyomas in African and Afro-Caribbean 
patients, and may also be related to increased prevalence of keloids in patients 
of this ethnicity. However, the presence of only one copy number change in 13 
samples does not imply a significant association of this region with ethnic 
predisposition to uterine leiomyomas. In order to further confirm this 
association, a far greater number of samples would need to be studied.
It is important to remember that in addition to copy number change, a 
number of other balanced cytogenetic aberrations occur in leiomyomas, which 
are undetectable by microarray CGH. A full study of the distribution of 
karyotypic abnormalities in uterine leiomyoma patients of African/Afro-
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Caribbean and Caucasian ethnicity would require karyotyping studies to 
complement microarray CGH to determine the association of cytogenetic 
changes beyond copy number changes.
6.4.4  Discussion
The work in this chapter has examined copy number changes in uterine 
leiomyomas from a variety of backgrounds, including HLRCC, sporadic and 
Afro-Caribbean leiomyomas. A number of copy number changes have been 
identified, in particular on chromosome 7q in sporadic leiomyomas, where the 
region of demonstrated deletion was minimised to 3.92Mb. However, no 
obvious strong candidate genes for leiomyoma pathobiology have arisen from 
these regions based on prior knowledge of known pathways of leiomyoma 
pathogenesis.
The use of high resolution copy-number analysis techniques such as 
microarray CGH has the potential to identify a number of novel regions of 
copy number change involved in the pathobiology of uterine leiomyomas. The 
increased resolution may demonstrate a greater number of copy number 
changes than have previously been described, and could also implicate many 
more genes and pathways in leiomyoma pathogenesis.
Other than the region of deletion of chromosome 7q, few other 
overlapping regions of copy number change were identified. Unfortunately, a 
very limited quantity of 1Mb arrays was available for this study. An increased 
number of samples studied would allow potentially more regions to be 
identified, and, perhaps more importantly, would allow known regions of copy
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number change to be refined and potentially important genes in leiomyoma 
pathogenesis to be identified.
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7.1  Introduction
Work in the previous chapter identified a number of deletions of 
chromosome 7q, as expected from the literature. This initial mapping 
demonstrated a minimum deleted region of 3.92Mbp. The CGH results were 
shown to provide more reliable information about deletions than LOH 
analysis. However, the limited resolution of these arrays means that at least 
800kb of sequence was unaccounted for per megabase on the array, and so 
finer mapping of the deleted region was not possible and small homozygous 
deletions were likely to be missed. It was, therefore, decided to pursue the 
novel leiomyoma gene on chromosome 7q by increasing the resolution of the 
analysis and constructing a tiling-path resolution genomic microarray. This 
would allow finer mapping of the deleted region, and also potentially allow 
the identification of homozygous deletions that may harbour the proposed 
gene. The work in this chapter details the construction and validation of the 7q 
tiling-path array.
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7.2  Materials and Methods
7.2.1 Selection of BAC clones
Three sets of BAC clones were selected for the array: 1067 clones 
covering chromosome 7q; 554 control clones representing the rest of the 
genome at approximately 4.5Mb intervals; and 8 clones from Drosophila 
melanogaster as a control for non-specific hybridisation. Specific lists of the 
clones can be found in Appendix 1.
7.2.1.1 7q Tiling Path Clones
BAC clones mapping to chromosome 7q were used from the “32k” 
BAC re-array set produced by BACPAC resources (Children’s Hospital, 
Oakland, CA, USA). This set comprises 32,433 BAC clones with an average 
resolution of 43kb. The clones were selected from the RPCI-11/13 and 
Caltech-D clone libraries using the fingerprint map of the human genome. 
They were selected to provide complete genome coverage at high resolution. 
Selected clones were enriched for those that had end sequence and full 
sequence data. All selected clones were fingerprinted by Hind III digestion, 
and overlapping clones were selected on the basis of greater than 3 conserved 
restriction fragments between clones. Clone localisation was carried out using 
a combination of end-sequence co-ordinates, fingerprinting and assembly co­
ordinates from NCBI release 8 of the human genome (Osoegawa et al. 2001). 
This library was selected due to its availability as prepared DNA.
Selection of 7q clones was based on mapping data from human 
genome 15 (hgl5). From this data, 1104 clones mapped to 7q, and these 
clones were amplified and printed. Clone data were updated by the clone
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suppliers following the release of hgl7. Re-examination of the clones printed 
on the array showed that of the 1104 clones originally selected, 1067 
continued to map to 7q; 19 mapped to different chromosomes and were 
incorporated into the control set;  12 were un-positioned; and 6 were re­
mapped to 7p. A further 15 clones were added to the 7q set from the control 
set, giving 1082 clones in the final clone set. This set had a median centre to 
centre clone spacing of 87.1 kb, and a resolution (median unique length of 
sequence per clone) of 57.0kb. A summary of the 7q clone set following re­
mapping is shown in Table 7.1 and a list of all the clones amplified and 
printed on the array can be found in Appendix 1.
286Chapter 7 Construction and validation of a chromosome 7a tiling path genomic microarrav
Table 7.1 Summary of 7q tiling path clone set
Total number of clones 
Median clone length
Total clone length
Length of 7q covered by array
Chromosome arm coverage
Total gaps
Total gap distance
Median gap
Median clone midpoint distance
Median clone overlap
Median unique sequence per clone
1,082
164,949bp (Range 18,857- 
313,512bp)
175,036,319bp 
97,722,464bp 
1.79x genome 
83
4,463,104bp
27,883bp (Range 5-503,465bp) 
87,053bp
77,83lbp (Range 295-22l,150bp) 
56,985bp
1 Median unique sequence is derived from the 613 clones containing sequence 
unique to that clone. 469 clones contained no unique sequence.
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7.2.1.2  Control Clones
BAC clones for the control set were selected from those used to 
construct the Sanger Centre’s 1Mb resolution microarray used in the previous 
chapter (Fiegler et al. 2003). 554 clones were picked at approximately 4.5Mb 
intervals throughout the genome, excluding the Y chromosome and 
chromosome 7p. The latter was excluded to prevent effects of whole 
chromosome 7 loss on normalisation. Performance of these clones was 
assessed by analysis of normal-normal hybridisations to the 1Mb genomic 
microarray, and information about the clones provided by Nigel Carter’s 
group at the Wellcome Trust Sanger Institute. Clones found to have 
inconsistent results in hybridisation, or to cross-hybridise in FISH experiments 
(carried out by Nigel Carter’s group), were removed from the control set and 
replaced with adjacent clones that fulfilled the criteria. DNA for these clones 
was extracted by Regina Regan at the Wellcome Trust Centre for Human 
Genetics in Oxford.
In addition to the control clones, 19 of the original 7q were found to 
map to other chromosomes. These clones were also included in the control set 
giving a total of 573 clones. The number of control clones per chromosome is 
shown in Table 7.2 and a complete list of the clones in the control set can be 
found in Appendix 1.
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Table 7.2 Summary of the control clone set
Total Clones
Median mid-point spacing
573
4.41Mb
Chromosome No. Clones Chromosome No. Clones
1 48 13 22
2 41 14 22
3 44 15 19
4 38 16 19
5 37 17 2 2
6 33 18 18
8 1 25 19 11
9 23 20 15
10 25 21 7
11 23 22 10
12 25 X 30
*No control clones were chosen from 7p
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7.2.1.3 Drosophila Clones
In addition to the human clones, eight BAC clones from Drosophila 
melanogaster were selected as a control for non-specific hybridisation (Table 
7.3). These clones were used as FISH probes on normal human chromosomes, 
and were found not to map to any point in the genome (Figure 7.1). More 
information about these clones can be found in Appendix 1.
Table 7.3 Drosophila control clones
Clone ID Drosophila Chromosome 
mapping
FISH result against 
human
RP98-10P9 3L-66E4 No hybridisation
RP98-5L4 X No hybridisation
RP98-38L1 X No hybridisation
RP98-3G6 3L No hybridisation
RP98-33N24 X No hybridisation
RP98-44K7 3L-74C1 No hybridisation
RP98-9C21 3L-9C21 No hybridisation
RP98-7P15 X No hybridisation
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Figure 7.1 Fluorescence in-situ hybridisaton of the control Drosophila BAC 
clones to normal human chromosomes. Drosophila BACs, labelled orange, 
did not hybridise to normal human chromosomes. A 16q specific BAC (green) 
was included as an experimental control.
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7.2.2  Clone Amplification and Array printing
7.2.2.1  Degenerate oligonucleotide primer (DOP) PCR
Amplification of BAC DNA was carried out by three separate DOP- 
PCR reactions using the three primers designed by Fiegler et al to 
preferentially amplify human DNA over E.coli DNA (Fiegler et al. 2003). 
Buffers, primer sequences and cycling conditions are as described in Materials 
and Methods (2.3.3). 2.5p,l of clone DNA at approximately lng/fxl was used 
for each PCR reaction. Amplification was checked by agarose gel 
electrophoresis and compared to a no-template blank (Figure 7.2). Any 
product detected in this blank implied contamination and necessitated 
repeating the PCR reaction since contaminating total genomic DNA could 
dilute the hybridisation ratio of the clone in a hybridisation experiment. PCR 
products for each DOP primer were then pooled for the aminolinking reaction.
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Figure 7.2 Example of DOP 1  primer amplified BAC DNA. Amplification 
produces a distinct pattern of bands for each clone. Equally important is the 
presence of a blank (Lane 3) indicating no contamination in the PCR 
reactions.
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7.2.2.2  Aminolinking PCR
A further PCR step amplified the pooled DOP-PCR products using a 
primer with a 5’ C-6 aminolink moiety to allow the amplified clone DNA to 
be covalently attached to the Codelink slides. The protocol and primer 
sequences are described in materials and methods (2.3.4). As for the DOP- 
PCR, a no-template control was included, and any contamination witnessed 
after electrophoresis required a repeat of the PCR.
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Figure 7.3 Example of a gel following aminolinking PCR. PCR products form 
a smear of approximately 100-1200bp. The no-template control in lane 4 
indicates no contamination of the PCR reaction.
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7.2.2.3  Array printing
Array printing was carried out by Cordelia Langford and Oliver Dovey 
at the Wellcome Trust Sanger Institue as described in Chapter 2 (2.11.1.2). 
The arrays were printed in 24 blocks of 18 spots by 18 spots. Each block 
contained a combination of control, 7q and Drosophila clones. Within each 
block, each clone was printed twice, with the upper 9 by 18 spots being the 
duplicate of the lower 9 by 18 spots (Figure 7.4). In addition, each clone was 
in duplicate on another block. Therefore, each clone was printed 
in quadruplicate.
Figure 7.4 Printed layout of the 7q tiling-path array. The array consists of 24 
subarray blocks, each containing 324 spots. The top half of each block is the 
duplicate of the bottom half.
i
also present 
on the array
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7.3 Array Validation
To ensure the validity of the arrays, and their usefulness for analysis, 
several stages of validation were carried out. Firstly, test arrays were printed 
using a small number of the final clone set. Following printing of complete 
arrays, several normal-normal and sex-mismatched hybridisations were 
carried out. Finally, hybridisation of samples with known changes was carried 
out. All three methods of validation ensured the final arrays were robust and 
producing reliable data.
7.3.1  Test array printing
The first stage of validation involved printing a set of test arrays using 
amplified DNA from control plates 1  and 2 (192 spots in total). The reasons 
for this were twofold: to ensure that the amplification and aminolinking 
methods allowed the DNA to attach to the slide; and to ensure that the blank 
controls didn’t hybridise DNA once printed onto the array.
The array consisted of 192 spots, 188 containing BAC DNA and 4 
blanks. Pooled female DNA was labelled and competitively hybridised to the 
array against itself. The arrays were washed and scanned as previously 
described (2.11.1).
Visual inspection of the scanned images showed the arrays to be 
strongly hybridised, with very low background. Furthermore, empty spots 
printed from the no template PCR reactions showed no evidence of 
hybridisation above the background (Figure 7.5).
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The array images were overlaid and quantified using UCSF Spot (Jain 
et al. 2002) and analysed in Microsoft Excel. A summary of the Cy3 and Cy5 
hybridisation signals for BAC and blank spots is shown in Table 7.4. Cy3 and 
Cy5 intensity values for all printed spots were strongly positively correlated, 
with an R2=0.916 (Figure 7.6) with very few outliers. After lowess correction, 
the median log2 ratio for each BAC spot was -0.006950494, with a standard 
deviation of 0.1228517.
Figure 7.5 Cy5 image of hybridised spots from the test print array. This 
magnification of a single row containing 7 clone spots and 1  blank spot shows 
that DNA hybridises evenly to the clone spots, with no hybridisation to the 
blanks.
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Table 7.4 Summary of hybridisation intensities to BAC clone and empty spots 
on the printing test array. Values are shown as the median, followed by the 
range of data.
Cy3 Cy5
BAC clone 
spots 
(n=188)
Foreground Intensity 4801.9 (1125.5- 
13301.5)
9366.4 (1607.8- 
28908.9)
Background Intensity 0.065 (0-269) 10.7 (0-101.8)
Foreground Standard 
Deviation
597.1 (245.2- 
1431.1)
633.4 (222.2-2017.3)
Blank spots 
(n=4)
Spot Intensity 816.4 (639.9- 
958.0)
398.1 (369.9-505.8)
Background Intensity 0 0
Foreground Standard 
Deviation
160.7 (139.2- 
203.2)
73.9 (69.9-109.0)
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Figure 7.6 Correlation between Cy3 and Cy5 intensity values for the test print 
array. Values were highly positively correlated with an R2  value of 0.916.
7.3.2  Normal-Normal hybridisations
The test array printing confirmed that the amplified DNA was 
attaching satisfactorily to the slide, and that empty positions were not 
hybridising to samples. As a result, the remaining DNA plates were amplified 
and full arrays were printed as described in 7.2.2.3. The first stage of 
validation was to hybridise several slides using ‘normal’ DNA to ensure that 
no deleterious hybridisation was occurring.
7.3.2.1 Data analysis considerations
The basic method for analysis of the array data was similar to that 
involved for the 1Mb array (2.13.2). However, a number of factors needed to 
be considered given the content of the array. In particular, since the majority
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of clones on the array were from chromosome 7q, consideration of 
normalisation was required. The array was designed with a number of control 
clones from the other autosomes, and chromosome X to act as a comparison to 
the ratios observed for the 7q clones. As for the 1Mb CGH array, a lowess 
normalisation was used for data analysis. Initially, an attempt was made to 
normalise using only the control clones, however, this was too technically 
demanding an approach. Therefore, it was decided to normalise using all the 
clones on the array. Following this, data were adjusted to set the median ratio 
of the control clones as 0. This meant that copy number changes involving a 
majority of the clones on the array, such as deletion of the whole arm of 7q, 
would still be detectable.
The method for calling changes was based on similar principles to the 
1Mb array (2.13.2). However, only the clones from the control set (ie non-7q 
clones) were used to define the thresholds for significant changes. Analysis of 
the normal-normal hybridisations {132.2) demonstrated no difference in the 
spread of data between the 7q clones and the autosomal control clones, so no 
rescaling of the data was required (Table 7.5).
13.2.2  Sex match and mismatch
The initial array testing was to ensure that normal-normal 
hybridisations showed no deleterious effects, and to exclude clones 
consistently producing unexpected values. 6 hybridisations were carried out: 4 
were sex-matched, and 2 were sex-mismatched. Normalised Log2 ratios for 
each array were obtained as for the 1Mb resolution arrays. Block-lowess 
normalisation was used and the data for each array was collated.
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5 of the 6 hybridisations carried out showed strong hybridisations and 
tight data on chromosome 7q (Figure 7.7). Hybridisation results for 
chromosome X on the sex-mismatch experiments showed copy number 
changes of these chromosomes and so demonstrated the ability of the array to 
detect single-copy chromosome changes (Figure 7.8). This demonstrated that 
no normal contamination was present in the printed, amplified clones.
Results from these hybridisations were also used to exclude clones 
consistently producing unexpected results. A clone was excluded if it fulfilled 
one of several criteria:
i)  The clone failed to produce a result in >50% of hybridisations.
ii)  Unexpected ratios, such as significant loss or gain, were obtained 
in >50% of hybridisations.
iii)  Unexpected ratios occurred as a result of sex-mismatch 
hybridisations, indicating strong homology with either the X or Y 
chromosomes. For a clone to be excluded, unexpected ratios would 
have to occur in both sex-mismatch experiments.
iv)  A combination of the above.
In total,  88 clones fulfilled these criteria, all from the 7q set, and were 
excluded from further analysis. Excluded clones can be found in Appendix 1.
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Table 7.5 Median and standard deviations of control and 7q clones in the 
control experiments
1095-4
F-M
1242-
18F-F
1095-5
M-F
1095-6
F-F
1238-9
F-F
1095- 
12 F-F
Control Clones 
Median (excl 
X)
-0.0134 0.0026 0.0032 -0.0023 -0.0237 -0.0052
Control clones
Standard
Deviation
0.0688 0.0418 0.0709 0.0774 0.06680 0.0347
7q Clones 
Median
0.0060 0.0003 -0.0108 0.0097 0.0063 0.0018
7q Clones
Standard
Deviation
0.0685 0.0393 0.0691 0.0906 0.0710 0.0393
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Position (bp)
Figure 7.7 Chromosome 7q results of normal-normal hybridisation. A 
majority of hybridisations produced tight data with little variation around the 
baseline (Log2 = 0).
Chromosome X
o
G C
I   °
Figure 7.8 Chromosome X results for sex-mismatch hybridisations on the 7q 
tilepath array. Hybridisations were carried out with a male reference (red) and 
a female reference (blue). Clear expected differences were observed and were 
consistent for both hybridisations.
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7.3.2.3  Genomic features affecting hybridisation.
Although 5 of the 6 control hybridisations produced expected results, 
with good quality data (Figure 7.7), one of the experimental controls (1095-6) 
produced a less even spread of data, with certain regions of chromosome 7q, 
particularly at 60-75Mb and 100Mb, showing a broader spread of data than 
other regions (Figure 7.9a). This particular experiment involved hybridising 
identical test and reference DNA samples. The hybridisation to the array was 
strong, with no unusual artefacts, and a large proportion of data points were 
retained, indicating good agreement of ratios between clones. Furthermore, the 
standard deviation of data for the control clones was comparable to the other 
control hybridisations (Table 7.5). These regions of broader data spread 
further appeared in several later experiments, particularly where no deletions 
were evident.
In an attempt to identify the reasons for this unusual pattern of 
hybridisation, a number of features of chromosome 7 were investigated for an 
association with these regions. Following analysis of data obtained from the 
March 2006 assembly of the UCSC genome browser (Hinrichs et al. 2006), 
two features of genome structure appeared to associate with these regions: 
local GC content and density of segmental duplications (Figure 7.9b and c).
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Position (bp)
Figure 7.9 Unexpected hybridisation ratios from a female-female 
hybridisation (a). The unexpected ratios correlate with both an increase in the 
local GC content (b), and an increase in the frequency of segmental 
duplications (c).
Segmental duplications are a class of low-copy repeats in the human 
genome. They range in size from l-400kb in length and have a very high 
sequence identity (>90%) between repeats. Unlike other classes of repeating 
sequences, such as LINEs and SINEs (Long and Short Interspersed Nuclear 
Elements, eg Alu repeats), LTRs (Long Terminal Repeat elements), and 
satellite repeats; segmental duplications are not blocked by C0t-1 DNA, due to 
their low copy number (Strachan and Read 2004). Recently, segmental 
duplications have been observed to be associated with copy numberChapter 7 Construction and validation of a chromosome 7a tiling path genomic microarrav
polymorphisms between individuals, and so differences between samples may 
reflect copy number variation between two individuals (Sharp et al. 2005). A 
study by Locke et al examined the effects of segmental duplications on the 
hybridisation characteristics of BAC microarrays. They found that increased 
proportions of segmental duplications in a BAC increased the spread of data in 
hybridisations of normal DNA, compared to BACs with no segmental 
duplications (Locke et al. 2004).
Regions of increased GC content associate with the regions of greater 
spread of data. This effect may be due to the effects of increased GC content 
on the hybridisation dynamics of the DNA. Since G-C pairing in DNA 
involves 3 hydrogen bonds, compared to the 2 in A-T pairing (Watson and 
Crick 1953), GC-rich regions have a higher melting temperature (Tm ) than 
AT-rich regions (Strachan and Read 2004).
Since the test and reference DNA samples were identical in this 
particular experiment, copy number variation was unlikely to be a cause of the 
broader spread of data, although it was considered an important factor in 
analysis of results of hybridisations between samples from different 
individuals. The difference more likely arises from the chemical properties of 
the Cy3 and Cy5 fluorochromes. An effect has been previously observed (Cox 
et al. 2004) and it is thought that dye-dye interactions occur between Cy3 and 
Cy5 result in fluorescence quenching and increased signal variance, 
particularly for Cy5. In GC-rich regions, a greater concentration of dye would 
be present, since it is conjugated to dCTP, and so fluorescence quenching is 
more likely to be observed. Since this quenching affects Cy5 more than Cy3,
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the Cy5/Cy3 fluorescence ratio will be skewed to imply reduced copy number 
of tumour DNA.
It was important to take these regions into account when analysing data 
from tumours, in order to prevent false calls of copy number change. Since 
these differences occur infrequently, no permanent alteration to the analysis 
procedure was deemed necessary. Instead, great care was taken to standardise 
the experimental technique to minimise variation between arrays. Upon 
analysis of tumour samples, these regions were treated with care, and any 
potential changes involving these regions were validated by other 
experimental techniques, such as LOH analysis using local microsatellites and 
SNPs.
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7.3.3  Known deletion hybridisation
To test the ability of the array to detect copy number polymorphisms, 
hybridisations were carried out using two leiomyoma cell line samples with 
known deletions detected on the 1Mb resolution array. The first, F9CR, has a 
deletion of all of chromosome 7, while the second, Awaki, has an interstitial 
single-copy deletion of chromosome 7q, and a single copy deletion of 
chromosome 2 2.
In both samples, the changes observed on the 1Mb array were also 
detected on the 7q array. For the Awaki sample, the limits of the interstitial 
deletion of 7q occurred in the same region to those observed on the 1Mb array. 
However, the increased resolution of the 7q array gave a more accurate 
representation of the location of the breakpoints (Figure 7.10a). Detection of 
changes was not perfect, several outlying clones were called as losses, and 
several clones within the region of deletion were not called deleted. This is an 
artefact of the higher resolution of the array since many clones will have 
homology to other chromosomes without copy number changes. In these 
cases, as for the 1Mb array, such regions were called by eye.
The whole chromosome deletion in F9CR was also identified using the 
7q array (Figure 7.10b). Again, a number of clones failed to reach a 
significant level of loss. The distinctive pattern likely resulting from high GC 
content and dye interaction was also observed in this sample, particularly 
around 100Mb.
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a) Chromosome 7 - Awaki
b)
1.0e*08  126*08
Position (bp)
Chromosome 7 - F9CR
-
1.0e+08  1.2e+08
Posilion (bp)
Figure 7.10 Results from hybridisations of known samples. The interstitial 
deletion detected in the Awaki sample (a -  red line) exactly matches the 
observed deletion using the 1Mb resolution arrays (blue line). Whole 
chromosome deletion of 7q was detected in F9CR (b).
3097.4 Discussion
The aim of the work in this chapter was to construct and validate a 
tiling-path resolution BAC CGH microarray for the further analysis and 
refinement of deletions of chromosome 7q in sporadic uterine leiomyomas. 
Validation results demonstrated the array was able to detect copy number 
changes of chromosome 7q.
While validating the array a number of features of the array were 
identified that were important to consider for data analysis. Chief among these 
was the apparent effects of increased dye concentrations in GC-rich regions 
leading to fluouresence quenching. For reasons of economy the Cy3 and Cy5 
labelling dyes used, but special care was taken in interpreting the results of the 
GC rich regions. In addition, variation of single clone log2 ratios was also 
observed. This variation may be due to local clone GC content, or homology 
to other regions of the genome. Again, single clone changes were carefully 
treated when interpreting results.
Overall, the array was considered suitable for the detection of copy 
number changes of chromosome 7q, but with the difficulties described above 
taken into account when analysing the data, and it was decided to proceed 
with a further study of 7q deletions in uterine leiomyomas.
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8.1  Introduction
Having successfully constructed a tiling-path resolution genomic 
microarray to examine chromosome 7q deletions in sporadic uterine 
leiomyomas, a larger study was undertaken to examine sporadic leiomyoma 
samples using this array in order to minimise the critical region of deletion, 
and thus identify the most likely candidates. Furthermore, the increased 
resolution would allow the identification of potential homozygous deletions. 
Potential candidate genes could be further analysed in an attempt to identify 
the gene.
In addition to identifying the minimal region of deletion, a study was 
also undertaken to examine the frequency of 7q deletions in uterine 
leiomyomas in patients of African and Afro-Caribbean ethnicity compared to 
patients of Caucasian and other ethnicities in order to identify whether there is 
a different pattern of occurrence of this particular chromosomal aberration.
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8.2  Materials and Methods
8.2.1 Selection of samples
DNA samples from all frozen sporadic uterine leiomyomas were used 
for initial LOH analysis. This included the sample cohorts from: 
Addenbrookes hospital in Cambridge; the Hammersmith and North Middlesex 
hospitals in London; and Groote Schuur Hospital in Cape Town, South Africa. 
In addition, the Finnish samples provided by Lauri Aaltonen with known 7q 
LOH and used in chapter 6 were also analysed using the arrays. Samples were 
grouped into four categories of ethnicity: African/Afro-Caribbean; Caucasian; 
Other, for all other ethnicities where defined; and unknown.
All samples were confirmed as uterine leiomyomas by pathologists at 
each location and DNA from each of these samples was prepared as described 
in Chapter 2 (2.2)
8.2.2 Loss of heterozygosity analysis of sporadic uterine leiomyomas
An initial screen of all the leiomyoma samples bar those from Finland, 
was carried out by loss of heterozygosity (LOH) on 7q as described in Chapter 
2 (2.7). Details of the markers used are shown in Table 8.1. Markers were 
chosen to be of greater density in the two regions of 7q deletion observed in 
Chapter 6. Samples showing LOH were used for subsequent 7q microarray 
CGH analysis. Where no matched normal DNA was available, samples with a 
stretch of apparent homozygosity covering at least three consecutive markers 
were used.
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8.2.3 Tiling path microarray CGH analysis
Samples fulfilling the above criteria were used for microarray CGH 
analysis using the 7q tiling-path microarray. Hybridisation and data analysis 
were carried out as described in Chapter 2 (2.13.22.11.1) with the adaptations 
specific for the 7q array described in Chapter 7 (7.3.2.1).
8.2.4 Gene screening
Screening of the 2 genes in the minimal region, MLL5 and SRPK2, was 
carried out by an initial high resolution melting screen comparing tumour 
DNA to normal DNA, as described in Chapter 2 (2.5.2). Samples showing 
differences between the tumour and normal were then sequenced as previously 
described (2.6). Primer sequences and conditions are shown in Table 8.2.
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Table 8.1 Markers used for LOH analysis of uterine leiomyomas.
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Table 8.2 Primer sequence and conditions for DNA primers for screening 
MLL5 and SRPK2. All PCR reactions were carried out with 1.5mM MgCh, 
5% DMSO, and lx LC-Green reagent. Details of the PCR programs can be 
found in Chapter 2 (2.3.2.1).
Primer Name Primer Sequence Product
Length
PCR
program
MLL5xlF CTTCATCCCCTCCCCCTCT 468bp AR55
MLL5xlR AACT  CCC  ATGG  AGACG  AC AG
MLL5x2F TTGGCTGCTTTGTGTGAGTC 223bp AR55
MLL5x2R T  GGC  AGCC  ATT  A  A  AG A  AAT  A  A
MLL5x3F TGCCCCAGTGTTTTGGATAC 210bp AR55
MLL5x3R CTTCTTCCTACTTTCTAGCTCCAG
MLL5x4F TTTGTATAGCCATTATTTTGCTGTAAG 314bp AR55
MLL5X4R TTCAAACATGCCGTTTCAAG
MLL5X5F TTTAAGTTGCTTGGTTTATATCATTG 362bp EJ55
MLL5X5R C  A  AC  ATTACC  A  A  AGGTT  AT  C  AG C
MLL5X6F GGAGTACTAAGCTCAAAGTAGGTGCT 233bp AR55
MLL5x6R AAAATTACTGGCAATGTTATCAGA
MLL5x7F A  AACT GT  ATTGC AAGGG  ATTTTG 329bp AR55
MLL5x7R CAATCAACATTCATCAACAAGG
MLL5x8F AAAGATGGAGACGACAATACTTTG 331 bp EJ55
MLL5x8R AAATTCAGTTCCCTATCCGC
MLL5x9F TCTCCTAGTGTCAGCTTTCTTGG 325bp EJ55
MLL5x9R GAACTAAGGTCCCACTCCTGG
MLL5xlOF CCGT  A  AGT  CC  AG  AT  A CTA A  AGCT C  A 297bp EJ55
MLL5xlOR CAATTTTTGGACAAATGATGTATT
MLL5xl IF TCCTGTAGAGGTAAATACATCATTTG 328bp EJ55
MLL5xllR TCACAACATCTAGGTAAAACAGCC
MLL5xl2F GCCCGGCCTAAAATGTTAAT 225bp EJ55
MLL5xl2R TGCTCAGATTCCAACACACC
MLL5xl3F TTTTCCAGGTTGTGTTTGTG 303bp EJ55
MLL5xl3R TGACAATACCTAAATTATTACAGGGAC
MLL5xl4F TGGAGTTGCAGCTTAAAATGG 578bp EJ55
MLL5xl4R TTGTCTGCAATTCTGCAAGG
MLL5xl5F GGCTGTGTACATGTTGAATTTG 292bp EJ55
MLL5xl5R AAAAGCCCATGTAAAGGCAG
316Chapter 8 Analysis of Chromosome 7a deletions in sporadic uterine leiomyomata
MLL5xl6F TTTTCTCCCCATATCCACC 451 bp EJ55
MLL5xl6R GCTGAAACTCCCATAGGATCTG
MLL5xl7F TTCCATTCGCTTGTATTTTGA 374bp EJ55
MLL5xl7R CTGTTAGAAAAACAGTTCTTACATTCA
MLL5xl8F TTCAAGGGAGAATTTGGAATTA 368bp AR55
MLL5xl8R AGGAATGAGTTGGCATTTGG
MLL5xl9F AAATGCTTTTGGAATCGGC 304bp EJ55
MLL5xl9R TGCCTGTTATAAAGCTGTATGTATG
MLL5x20F TGGGGTAAAAGTCATAACTGCC 451 bp EJ55
MLL5x20R TGTTAAAGGAGGGGAAAGAGC
MLL5x21F CAGTCTTATTTGGGGAATGG 308bp EJ55
MLL5x21R TCACATCTTGGGACTGTTTATTTC
. MLL5x22aF AATTTTGAAATAAACAGTCCCAAG 426bp AR55
MLL5x22aR TGTCAGGTCCCTCAAGTTGG
MLL5x22bF CTGAGCCCAACAGCCAAC 413bp EJ55
MLL5x22bR A  AT  AC AT  CTA  AC  AATTCCCCTC  AG
MLL5x23F AAAAGAATGCATTGGTTCTGAC 440bp EJ55
MLL5x23R CCTTGGGAGAACAACAAATAGG
MLL5x24-25F TTTTCCCAGTAGATCAAAAGCC 558bp AR55
MLL5x24-25R AACACTGTTTTAACACCACAAAGC
MLL5x26F GAATGTATGTTGCTTTGTGGTG 238bp EJ55
MLL5x26R CAGCTTTTCTGCACTCAACC
MLL5x27aF AGGATGTTATTTCCTGCCCC 581 bp EJ55
MLL5x27aR ATTGGCTGGAAGGTTCTGTG
MLL5x27bF CACCAAAGCCTCCTTCACAG 481 bp AR55
MLL5x27bR ACTACGGCAGCAGCAGTTTG
MLL5x27cF ACCACAAGCCAGCAAACAG 470bp EJ55
MLL5x27cR AGTGGAGGTCCTTGATGAGG
MLL5x27dF ATCCACAGGACTCCAAGGTC 625bp EJ55
MLL5x27dR AAAATACAACGAAAGAGCACTGG
SRPK2xlF GCAGGCAATCTTGGTTGTG 165bp EJ55
SRPK2xlR CCTGGTTTGTTTCTTAGCAATG
SRPK2x2F C  AA  AT  GC  ATCC AT  AATGC  AAG  A 296bp EJ55
SRPK2x2R TCCATTCCCCCAACAAATTA
SRPK2x3F TGACATCAAGAATGACAAAAGAGA 234bp EJ55
SRPK2x3R TCCAGGAAACAAATGCACAA
SRPK2x4F CCCAGCCAAACTTGACTTTA 279bp AR55
SRPK2x4R CCAATTAGGGATGCTCAACCT
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SRPK2x5F TTTAAACAGTATTGGTGTTATAATGGG 274bp EJ55
SRPK2x5R TTTATGTTGAAGGTGATACAGCAG
SRPK2x6F AACTGCCTCACTCCAGGC 371bp AR55
SRPK2x6R ATGTTGTTCCCTTCACAACAC
SRPK2x7F A  ACTTTGTACCCTGGC  ATTG 327bp EJ55
SRPK2x7R GCAACTTTGCAAGCTCCC
SRPK2x8F CCTACATGAAGGCATGTGTCTG 156bp EJ55
SRPK2x8R TTGAACAACTCAATAATAAACGGTC
SRPK2x9F ATTGCTATTTGCCATGCTGC 403bp EJ55
SRPK2x9R TTGACCTGGCAGAACCCTAC
SRPK2xl0aF ACAGGGCTTGGCCACTTC 499bp EJ55
SRPK2xl0aR CGAACATAGACCCTACGTGGA
SRPK2xl0bF CACTTTCTGCATTTGGCTCA 385bp AR55
SRPK2xl0bR TTTTACCCCAAAAGCCAAGA
SRPK2xl 1-12F CACATGCAAACCACCTATCC 452bp AR55
SRPK2xl 1-12R GAGTGTGAAAGGAACGAGCC
SRPK2xl3F AAAAGCTGTTGACTTGGGG 194bp AR55
SRPK2xl3R TACAGAAGTTCAGGGCTGGC
SRPK2xl4F TTTATCCCATCCTTCCCTTTG 213bp AR55
SRPK2xl4R GCAGCTGCTCTTCAGTTTCTG
SRPK2xl5F CACCGTTTAGGTCCAATGTACT 300bp AR55
SRPK2xl5R GGAATGCAGATTTGGAGCTT
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8.3  Results
8.3.1  LOH analysis of samples
LOH analysis was carried out on a total of 227 leiomyoma samples 
from 178 patients. Of these samples, there were 22 leiomyomas from 21 
Caucasian patients; 56 leiomyomas from 32 African or Afro-Caribbean 
patients; 75 leiomyomas from 52 patients of other ethnicity; and 74 
leiomyomas from 73 patients of unknown ethnicity.
An example of LOH at one marker is shown in Figure 8.1. In total, 14 
samples showed LOH of at least one marker, where matched germline DNA 
was available (Figure 8.2). The minimum region of LOH was defined by 
samples FG103 and FG121, between markers D7S2545 and D7S501, a region 
of 1.72Mbp. These markers were consecutive in the marker set used, and so 
no single marker showed LOH in all samples. In addition, 2 samples without 
matched normal DNA (200173E and 200050A) showed stretches of apparent 
homozygosity greater than 3 markers long. No evidence of contaminating 
normal was observed in these samples. One final sample (200062B) showed 
LOH compared to another leiomyoma sample from the same patient. 
Therefore, 17/227 (7.5%) of all samples had 7q LOH or indications of LOH. 
This matched the frequency of LOH observed in the Finnish samples (12/165 
(7.3%) of samples). These samples were subsequently analysed by microarray 
CGH using the 7q tiling-path array.
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Figure 8.1 Example of LOH at marker D7S1799 in sample FG145 F2. The 
tumour sample has lost almost all of allele 161. However, a residual peak 
remains indicating some contamination of normal material.
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Figure 8.2 Summary of sporadic uterine leiomyomas with LOH on chromosome 7q. (LOH) - loss-of-heterozygosity at this 
marker, (NI) - marker was non-informative; (-) - no LOH was seen at this marker; () - marker not done for this sample. 
Samples without a normal tissue reference, but with more than 3 consecutive homozygous markers were considered as 
having LOH. A minimum region of loss was defined by samples FG121 and FG103, between markers D7S2545 and 
D7S501, a region of 1.73Mbp.
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8.3.2  Tiling path resolution microarray CGH
The 17 samples with LOH of 7q and 9 of the 12 Finnish samples with 
known 7q LOH provided by Lauri Aaltonen were analysed by tiling-path 
microarray CGH. In addition, the results of the hybridisations of the Awaki 
and F9CR cell lines used to test the array in the previous chapter were added 
to the results of the other hybridisations. A further 22 samples with no 7q 
LOH or regions of homozygosity were analysed to identify small deletions 
that may occur below the resolution of the microsatellite markers.
Of the samples with 7q LOH, 27/28 showed detectable copy number 
changes of chromosome 7q (Figure 8.2, Table 8.3). One experiment, on 
tumour FG129 F2, failed to produce an adequate hybridisation. Of the 22 
samples without 7q LOH that were analysed, only one sample, TB03 0356, 
showed a discrete deletion of 7q. This deletion occurred in a region that was 
covered by the markers, although there was no evidence of LOH. The 
remaining 21 samples with no 7q LOH showed no copy number changes.
A majority of the observed copy number changes were deletions. 
However one sample, FG103, showed a copy number gain of part of the 
chromosome arm, followed by deletion of the end of the chromosome arm 
(Figure 8.3). In addition to this sample, 3 further samples, 29M2, 14M4 and 
FG30, also had multiple copy number changes, all deletions (Table 8.3, 
Figure 8.5). No samples demonstrated changes indicative of homozygous 
deletion, which was considered if the log2 ratio was less than -1.
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Figure 8.2 Ideogram of copy number changes identified on chromosome 7q in 
sporadic uterine leiomyomas. Red bars indicate regions of copy number loss, 
and green bars represent regions of copy number gain.
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Table 8.3 Results of chromosome 7q tiling path array CGH. All changes are 
deletions unless otherwise specified.
Proximal Breakpoint1 Distal Breakpoint1
Sample Clone Position2
(Mbp)
Clone Position2
(Mbp)
Size (Mbp)
F9CR Pcen 60 pter 158.82 Whole arm
TB02 0473 RP11-32N3 71.70 pter 158.82 87.11
TB03 0413 RP11-390C15 78.80 RP11-618G22 123.74 44.95
14M4 (1st 
deletion)
RP11-448A3 81.35 RP11-135K23 115.31 33.97
14M4 (2nd 
deletion)
RP11-561D8 139.33 RP11-177L17 144.29 4.96
200050A RP11-575G1 81.56 RP11-443110 107.29 25.73
TB02 0339 RP11-24013 82.32 RP11-488K2 114.48 32.17
44M1 RP11-142G6 82.64 pter 158.82 76.18
Awaki RP11-313H6 83.64 RP11-259H24 112.28 28.64
FG48 RP11-493G7 88.06 RP11-398D9 118.63 30.57
14M8 RP11-467N23 92.45 RP11-544C1 110.58 18.13
TB03 0356 RP11-78F12 93.37 RP11-746L19 123.04 29.68
11M1 RP11-78F12 93.37 RP13-75016 129.75 36.38
200173E RP11-82B2 94.46 RP11-760110 115.54 21.08
9M5 RP11-802H13 98.47 RP11-139J13 107.88 9.41
TB03 0358 RP11-694E14 98.66 RP11-786A20 112.88 14.21
34M1 RP11-487B17 99.56 RP11-649H20 107.47 7.91
200062B RP11-487B17 99.56 RP 11-64302 129.12 29.56
9M1 RP11-443E21 99.80 RP11-18H15 107.98 8.18
FG21 RP11-484K16 100.70 RP11-649H20 107.47 6.77
FG103 F2 
(Gain)
RP11-753M2 104.54 RP11-416H18 140.10 35.56
FG103 F2 RP11-661B8** 140.10** qter 158.82 18.73
FG121  F2 RP11-467N23 92.45 RP11-708P17* 104.78* 12.33
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Proximal Breakpoint1 Distal Breakpoint1
Sample Clone Position2
(Mb)
Clone Position2
(Mb)
Size (Mb)
FG156F1 RP11-39H7 82.01 RP11-417K19 117.94 35.93
FG30 (1st 
deletion)
RP11-115M02 83.60 RP11-750F10 84.08 0.48
FG30 (2nd 
deletion)
RP11-82B2 94.46 RP11  -321 El 8 96.92 2.47
FG30 (3rd  
deletion)
RP11-382F18 111.48 RP11-274E22 113.85 2.37
FG30 (4th  
deletion)
RJP11-661B8** 140.10" RP11-318D10 149.20 9.11
FG145 F2 RP11-163E9 101.86 RP11-651N9 120.83 18.97
FG153 F2 RP11-610J1 95.93 RP11-206A4 108.24 12.30
FG156F2 RP11-555E22 86.02 RP11-568111 126.93 40.92
38M1 RP11-434M1* 104.51* RP11-746L19 123.04 18.66
29M2 (1st 
deletion)
RP11-487B17 99.22 RP11-617P22 102.07 2.85
29M2 (2nd 
deletion)
RP11-519011 124.95 RP11-203113** 141.61** 16..66
Indicates clones delimiting the minimal region of deletion of 7q22.2 
"indicates clones delimiting the minimal region of deletion of 7q34 
'Breakpoint clones are the first clones not considered deleted, flanking the region of
deletion
Positions are defined as the position of the end of the breakpoint clone closest to the 
deletion. Positions were obtained using the Ensembl and UCSC genome browsers and 
data from the NCBI clone registry.
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Chromosome 7 - FG103 F2
O
!
Figure 8.3 Result from sample FG103 showing copy number gain of 7q, 
followed by a terminal deletion. The red line indicates the call from the R- 
based analysis program, and the blue line is the called change smoothed by 
eye. The proximal breakpoint of the amplification is identical to the proximal 
breakpoint of the minimal region of deletion of 7q22.2, and the distal 
breakpoint of the amplification is identical to the proximal breakpoint of the 
minimal region of deletion at 7q34.
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8.3.3  Minimum regions of copy number change
The results from the microarray CGH demonstrated a number of 
minimal regions of deletion in sporadic uterine leiomyomas. In particular, 2 
minimal regions of deletion of chromosome 7q were identified. Deletion of 
the first region occurred in 26/28 samples with detected deletions (Figure 
8.4). This is the frequently reported region of 7q22. The breakpoints of the 
minimum deleted region were defined by two samples: proximally by sample 
38M1, flanked by the clone RP11-434M1 (104.51 kb); and distally by sample 
FG121, flanked by clone RP11-708P17 (104.78kb). This deletion spans a 
single clone (RP11-753M2) on the array, a distance of approximately 271 kb, 
and contains only 2 genes: the 3’ end of Mixed Lineage Leukaemia gene 5 
(MLL5); and serine/arginine-specific Protein Kinase 2 (SRPK2) (Figure 8.4b).
In addition to the observed minimal region of deletion, one final 
sample gave a further clue to the identity of the involved gene. Sample FG103 
was unusual in that it contained an amplification of 7q (Figure 8.3). The 
breakpoint of this amplification at 7q22 occurred at clone RP11-753M2, the 
one commonly deleted clone in the minimal region. The proximal end of this 
clone occurs within the final intron of the MLL5 gene (Figure 8.4b). The 
potential disruption of a single copy of MLL5 by this amplification could 
implicate it as the gene of interest. This assumes that the amplification disrupts 
the gene in the first place.
The second minimal region of deletion, at 7q34, was detected in 7/28 
samples, but was observed discreetly in only 4 samples, and only where more 
than one copy number change occurred on 7q (Figure 8.5). This region was 
flanked proximally in sample FG30 by clone RP11-661B8 (140.10Mb); and
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distally in sample 29M2 by clone RP11-203113 (141.61Mb), a region of 
1.51Mb.
Four other small discrete regions of deletion were observed, all in 
samples with a deletion involving 7q34 (Figure 8.2, Figure 8.5a): three 
deletions, of 0.48, 2.47 and 2.37Mb, in sample FG30; and a 2.85Mb deletion 
in sample 29M2. These regions are shown in Figure 8 .6 . The deletion in 
29M2 was also observed as a single clone deletion by 1Mb resolution CGH in 
Chapter 6 .
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Figure 8.4 a) The minimum region of deletion in 7q22 is defined by samples 
38M1 and FG121, occurs in 26/28 samples with 7q deletions, b) This region 
of deletion spans a single clone (RP11-753M2) and contains one whole gene 
(SRPK2) and the 5’ end of another (MLL5).
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Figure 8.5 a) The minimal region of deletion of 7q34 as defined by samples 
29M2 and FG30 spans a region of 1.51Mb. This region (b) contains 16 genes. 
These two samples demonstrate four further unique regions of deletion (i - iv), 
more detail of which can be found in (Figure 8 .6).
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Figure 8 .6 Genes in the small regions of deletion in samples 29M2 (i) and 
FG30 (ii, iii and iv).
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8.3.4  Analysis of potential candidate genes
The two genes in the observed minimum region of 7q22.2, MLL5 and 
SRPK2, were both screened for mutations in 10 of the samples with 7q 
deletions. Normal and tumour DNAs were amplified in duplicate for each 
exon using the primers and conditions described in Table 8.2. The resulting 
PCR products were analysed by high resolution melting using a Lightscanner 
instrument (Idaho Technology, USA) as described in Chapter 2 (2.5.2).
Results for tumour samples were compared with results for matched normal 
DNA. Samples showing a change in melting profile between tumour and 
normal were sequenced. Results of the sequencing analysis failed to show any 
pathogenic changes in either MLL5 or SRPK2.
In addition to the sequencing analysis, Sakari Vanharanta at the 
University of Helsinki carried out a series of expression analysis experiments 
on the Finnish leiomyoma samples. The analysis compared myometrium with 
uterine leiomyomas with and without 7q deletions. The analysis was carried 
out on Asymetrix HG-U133A arrays by the manufacturer’s protocol and the 
data analysed using Affymetrix MAS 5.0 software and dChip 1.3. Analysis of 
the results showed neither a change in the expression of SRPK2 between 
leiomyomas with 7q deletions and those without, nor any change in expression 
between myometrium and leiomyomas. MLL5 is not represented on the HG- 
U133A arrays.
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8.3.5 Ethnic distribution of del7q deletions
Disregarding the Finnish and cell line samples, 227 samples were 
screened for LOH of 7q, and 18 samples were found to have deletions of 7q. 
Of these, 5 were from patients of African and Afro-Caribbean ethnicity, 2 
were from Caucasian patients, 6 were from patients of other (neither 
African/Afro-Caribbean or Caucasian) ethnicity, and 5 were from patients of 
unknown ethnicity. Fisher’s exact test was used to compare the frequency of 
7q deletions in African and Afro-Caribbean patients with that of Caucasian 
patients, and with that of non-African/Afro-Caribbean patients. Both 
comparisons showed no significant difference in the frequency of del(7q) 
between Caucasian and African/Afro-Caribbean patients (p=l, two-tailed 
Fisher’s exact test), or between African/Afro-Caribbean patients and all other 
patients (p=0.770, two-tailed Fisher’s exact test) (Table 8.4).
Table 8.4 Distribution of observed LOH by ethnicity
Ethnicity3 Total
Samples
Samples 
with del(7q)
Proportion 
with del(7q)
Median age 
of patients 
with del(7q)
African/Afro-
Caribbean
56 5 8.9% 31
Caucasian 2 2 2 9.1% 50.5
Otherb 75 6 8% 47
Unknown 74 5 6 .8% 51
aEthnicity self-reported by questionnaire
includes samples from Asian and mixed-race patients.
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8.4  Discussion
Deletions of chromosome 7q are a relatively frequent event in sporadic 
uterine leiomyomas. They are estimated to occur in approximately 17% of 
karyotypically abnormal uterine leiomyomas, or 7% of all leiomyomas (Xing 
et al. 1997). The data in this chapter have demonstrated a frequency by LOH 
of 7.5%, a result corroborated by the LOH results for the Finnish samples. For 
most of the samples in this study, LOH was caused by deletion, however, in 
one case it resulted from copy number gain. Furthermore, one sample with no 
LOH demonstrated a deletion when analysed by microarray CGH. This may 
have been indicative of loss of 2 copies from a triploid genome. It may also 
support the proposal in Chapter 6 , questioning the reliability of LOH studies 
as a reliable means of identifying deleted regions of 7q in leiomyomas, or any 
tumour. Given that one sample without 7q LOH still showed a deletion, it was 
possible that other samples with 7q deletions were excluded from CGH 
analysis because LOH was not observed in these tumours.
The increased resolution of the CGH array used in this study allowed a 
detailed study of 7q deletions, ultimately demonstrating a minimal region of 
deletion of ~273kb in 7q22.2. To date, this is the smallest common region of 
deletion identified, and the two genes in this region are the strongest 
candidates for the elusive tumour suppressor. Furthermore, several alternative 
regions of deletion of 7q have been identified, most notably at 7q34, which 
may provide interesting clues to other pathways involved in leiomyoma 
tumorigenesis.
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8.4.1 MLL5 or SRPK2 as the gene associated with uterine 
leiomyomas on 7q22.2
The minimum region of deletion of 7q22.2 consisted of a single clone 
deletion, which occurred in 26/28 samples demonstrating 7q deletions. This 
region contains one complete gene (SRPK2) and the 3’ end of a second gene 
(MLL5). To date, neither of these genes have been proposed as candidates for 
the 7q tumour suppressor gene. Unfortunately, sequence analysis of these 
genes failed to identify any pathogenic changes in the exons of either gene. 
Therefore, either gene is potentially involved.
Since no coding mutations were identified in either of these two genes, 
it remains plausible that haploinsufficiency could be an important factor in 
leiomyoma pathogenesis. With SRPK2, the information from expression 
microarray experiments does not suggest that this is the case. However, no 
such work has been carried out on MLL5 and it would be important to 
examine the expression of this gene with respect to both normal myometrium 
and uterine leiomyomas without 7q deletions. In order to greater assess the 
potential role of these two genes, a study of published literature was carried 
out. In particular, the potential for each gene to act as a tumour suppressor, as 
has been previously proposed by some groups (Ishwad et al.  1995), or to 
negatively affect cell growth, as proposed by others (Xing et al. 1997), was 
assessed.
8.4.1.1 Mixed-lineage leukaemia 5 (MLL5)
To date, little work has been carried out on MLL5, and only two papers 
exist devoted exclusively to this protein (Emerling et al. 2002; Deng et al.
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2004). However, the work in these papers, and studies of related proteins 
make this a particularly strong candidate tumour suppressor. MLL5 is a 
homolog of the Drosophila trihorax gene. Trithorax-family genes modulate 
transcriptional programs through protein-protein interactions involving PHD 
and SET domains (Emerling et al. 2002). It was originally identified as a novel 
gene in a 2.5Mb commonly deleted region of 7q22 in myeloid leukaemia with 
a high homology to other MLL-family genes (Emerling et al. 2002), the 
founder member of which, MLL, is involved in recurring translocations with 
more than 30 partner genes in acute myeloid leukaemia (Armstrong et al.
2002; Emerling et al. 2002).
A functional study carried out by Deng et al found that MLL5 is a 
nuclear protein that forms intranuclear foci. Since MLL5 contains no DNA 
binding domain, these foci were the result of protein-protein interactions. 
These foci did not co-localise with other proteins that form intranuclear foci, 
such as BRCA1, Rad51, Bmi-1 and PCNA. In addition, cells transfected with 
MLL5 resulted in cell cycle arrest at the G1 phase, implying a role as a 
potential tumour suppressor (Deng et al. 2004). The related protein MLL-1 has 
also been shown to form nuclear foci and, interestingly, has been shown to 
interact with the protein Menin, encoded by the Multiple-endocrine neoplasia 
1  gene (MEN1) (Yokoyama et al. 2005).
8.4.1.2  Serine/Arginine-specific protein kinase 2
The SRPK2 gene encodes a serine protein kinase responsible for the 
phosphorylation of SR proteins, which are involved in spliceosome formation 
(Wang et al. 1998). Like MLL5, little has been specifically published on the 
function of this protein, but more has been published on the homologous
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SRPK1. Both kinases appear to have an important role in spliceosome 
assembly and disassembly, and overexpression of SRPK2 has been shown to 
disassemble nuclear speckles, thought to be locations of spliceosomes, 
containing the SR proteins SF2/ASF and SC35 (Kuroyanagi et al. 1998; Wang 
et al. 1998).
Both SRPK1 and SRPK2 are localised to the cytoplasm, despite both 
containing nuclear localisation sequences (Ding et al. 2006). It is thought that 
they are responsible for the import of SR proteins into the nucleus, since they 
are imported in a phosphorylation dependent manner (Yun et al. 2003). It has 
also been shown that SRPK1 and SRPK2 are transported to the nucleus at the 
G2/M boundary (Ding et al. 2006). The function of this transition is unclear 
but given that SRPK proteins appear to disassemble spliceosomes when 
overexpressed (Kuroyanagi et al. 1998; Wang et al. 1998), this transition 
could allow the disassembly of the spliceosomes prior to chromatin 
condensation at metaphase. Therefore, loss or reduction of expression or 
function may lead to a reduction in cell growth.
SRPK2 has also been implicated in viral pathogenesis. Both DNA and 
RNA viruses have been shown to hijack the cells alternative splicing 
machinery in order to produce the necessary proteins required for viral 
replication and packaging (Daub et al. 2002). A recent report demonstrated 
that increased expression of SRPK2 up-regulated expression of HIV in 293 
cells. Pharmacological inhibition of SRPK2 had some effect on reducing HIV 
expression, but had a more potent effect on Sindbis virus (Fukuhara et al. 
2006).
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8.4.1.3  Conclusions from the literature
Uterine leiomyomas with deletions of 7q have been shown to be of a 
similar size, or slightly smaller than leiomyomas with no karyotypic 
abnormalities (Rein et al.  1991). Furthermore, they have been shown to be as 
susceptible to GnRH analogue treatment as karyotypically normal tumours 
(Takahashi et al. 2002). Finally, culture of leiomyoma cells with 7q deletions 
in vitro has shown that these cells grow more slowly than karyotypically 
normal cells, and are eventually selected out in culture (Xing et al. 1997). 
Therefore, the significance of 7q deletions in uterine leiomyomas remains 
unclear. If the involved gene is a tumour suppressor, perhaps loss of function 
protects the tumour not by conferring sex hormone independence or increasing 
proliferation, but maybe through immune evasion. From the literature, MLL5 
appears to have a clearer tumour suppressor function (Deng et al. 2004). 
However, the apparent growth disadvantage in vitro would suggest that 7q 
deletions are detrimental to cell growth, a role that suggest SRPK2 as a better 
candidate due to its apparent role in allowing the cell cycle to progress into 
mitosis (Ding et al. 2006). Therefore, no clear candidate as yet emerges. 
Unfortunately, time failed to allow studies on the expression of MLL5 or 
SRPK2 using a more sensitive real-time PCR approach. These studies, and 
other in vitro studies of leiomyoma cell lines may help to identify the gene on 
7 q involved in uterine leiomyoma pathogenesis.
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8.4.2  Novel regions of copy number change in 7q imply a distinct 
cytogenetic group of leiomyomas.
In addition to the frequently reported region of deletion of 7q22.2, 
further novel deletions of 7q were also observed. The most frequent of these 
was a deletion of 7q34, observed discretely in 4 samples. Interestingly, these 
deletions only occurred when at least one other copy number change of 7q was 
present. One of the limitations of array CGH is its inability to distinguish 
between individual chromosomes. Thus, it is uncertain whether the observed 
copy number changes occur on the same chromosome, or on one copy of each 
chromosome.
A search of the Mitelman database of chromosomal aberrations 
revealed that deletions of 7q34 have been reported infrequently in sporadic 
uterine leiomyomas (Mitelman et al. 2006). However, in several cases, 
inversions of chromosome 7 with a breakpoint in 7q34 have been reported, 
implying that this region may be a novel region involved in leiomyoma 
pathogenesis (Pandis et al. 1991). Interestingly, in 2 samples, the proximal 
breakpoints in the 7q34 deletion were identical, while the proximal breakpoint 
in a third sample was also very close to this region.
The four other small regions of deletion are found in samples with 
7q34 deletions. One of these regions, in sample 29M2, was previously 
identified as a single clone deletion in the 1Mb resolution CGH array (See 
Chapter 6 ). This region (Figure 8 .6 i) contains 2 of the genes previously 
proposed as candidates for the 7q22 tumour suppressor gene, PCOLCE (Ligon 
et al. 2002), and CUTLl (Zeng et al.  1997).
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One of the three remaining small novel regions, all observed in sample 
FG30, contains part of a single gene, SEMA3A (Figure 8 .6 ii). This gene 
encodes the Semaphorin 3A protein, which is responsible for axon guidance in 
embryonic development (Polleux et al. 2000). It is also involved in vascular 
morphogenesis. Nonendothelial cells secrete Semaphorin to guide developing 
blood vessels through tissues by exhibiting a repulsive effect (Serini et al. 
2003). Thus loss of expression would allow infiltration of microvessels, 
increasing tumour vascularity. It would be interesting to see if the original 
tumour sample from this patient was more vascular than other uterine 
leiomyomas, which are typically less vascular than the host myometrium 
(Poncelet et al. 2002; Pollard et al. 2005a).
The remaining two regions contain a number of genes, with a number 
of interesting candidates (Figure 8 .6 iii and iv). Interesting genes in the 7q21.3 
deletion include: PDK4 (Pyruvate dehydrogenase kinase 4), which modulates 
glucose metabolism by inhibiton of pyruvate dehydrogenase (Sugden and 
Holness 2003); and ASB4, which is thought to be involved in the degradation 
of the suppressor of cytokine signalling (SOCS) proteins (Kile et al. 2000). 
Genes in the 7q31.1 region include: PPP1R3A (Protein phosphatase 1  
regulatory subunit 3A), polymorphisms of which are associated with diabetes 
mellitus (Chen et al.  1994); and IFRD1 (Interferon-related developmental 
regulator  1), which is thought to be involved in regulating gene activity in 
response to NGF (Tirone and Shooter 1989).
The high frequency of copy number changes reported in uterine 
leiomyomas suggests that it is possible that the del(7q34) group of 
leiomyomas are a distinct cytogenetic group from those with deletions of
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7q22.2. Whereas the del(7q22.2) group contain single deletions with the 
common deleted region at 7q22.2 containing SRPK2 and MLL5, the del(7q34) 
group contain two deletions, a deletion around 7q34, and a further deletion 
elsewhere on 7q.
8.4.3  Ethnicity and deletions of chromosome 7q
One part of this study involved studying the ethnic distribution of 
samples with 7q LOH. Of the 227 leiomyoma samples used in this study, 153 
were from patients who had reported their ethnicity. Stratification of the 
samples revealed a near identical frequency of 7q LOH in Caucasian and 
African/Afro-Caribbean patients. A comparison of non-African/Afro- 
Caribbean with African/Afro-Caribbean patients also revealed no change in 
the frequency of 7q LOH.
The higher frequency and lower age of onset of symptoms of African 
and Afro-Caribbean women with multiple uterine leiomyomas (Marshall et al. 
1997) would seem suggestive of an alternative pathological mechanism of 
tumour growth and development in these patients. It was expected that this 
might be reflected by African and Afro-Caribbean women having a different 
frequency of 7q deletions than women of other ethnicities. However, this was 
found not to be the case. It was also possible that those African/Afro- 
Caribbean women with 7q deletions would be of a comparable age to women 
of other ethnicities with 7q deletions, while those women with the more severe 
multiple leiomyoma phenotype would be of a younger age and exhibit a 
distinct pathogenic mechanism. Again, however, this was not the case; the 
median age of the African/Afro-Caribbean women with leiomyomas with 7q
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deletions was 34.5yrs (Range: 31-44), whereas the median age of women of 
other ethnicities with leiomyomas with 7q deletions was 49yrs (Range: 39-62).
Therefore, this suggests some form of common pathogenic mechanism 
even in uterine leiomyomas resulting from ethnicity. The mechanism of 
leiomyoma formation is thought to be an initial transformation of normal 
myometrial cells into abnormal cells, followed by growth into tumours. 
Studies of cytogenetic aberrations, particularly of del(7q), has identified 
karyotypic mosaicism, suggestive of these changes being secondary events in 
leiomyoma pathogenesis. The identical frequencies of 7q deletions in patients 
of different ethnicities are perhaps further suggestive of them being secondary 
aberrations in leiomyomas.
From these results, it can be hypothesised that the differences in the 
age of onset and frequency of uterine leiomyomas between African/Afro- 
Caribbean women and women of other ethnicities may be due to the initial 
event resulting in the transformation of normal myometrial cells into 
leiomyoma cells. Following this initial event, the tumours follow common 
paths of leiomyoma pathogenesis, including deletions of chromosome 7q.
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8.4.4  Conclusions
The work in this chapter has provided a number of interesting 
conclusions regarding the pathogenesis of uterine leiomyomas.
i)  A 273kb region of 7q22.2 harbours a locus implicated in the 
pathogenesis of uterine leiomyomas.
ii)  MLL5 and SRPK2 are equally strong candidates for this gene, 
given the effects of 7q deletions on uterine leiomyomas 
observed in vivo and in vitro.
iii)  A cytogenetic subgroup of uterine leiomyomas exists with 
deletions at 7q34. Leiomyomas with this deletion also 
contain further deletions of chromosome 7q.
iv)  Deletions of 7q occur with an equal frequency in 
African/Afro-Caribbean women and women of other 
ethnicities. This could imply that uterine leiomyomas from 
patients of different ethnicities are initiated through separate 
mechanisms, resulting in different frequencies of occurrence 
and age of onset, but ultimately follow converging 
tumorigenic paths.
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9.1 Introduction
Despite their frequency and the huge number of studies that have been 
carried, the mechanisms by which uterine leiomyomas arise and develop 
remain poorly understood. The work in this thesis examined several aspects of 
leiomyoma pathogenesis in inherited, sporadic, and ethnically prevalent 
tumoura, both at a functional and genetic level. The results from this work 
have provided further clues to the pathogenic mechanisms involved in uterine 
leiomyomas and have identified important functional differences between, in 
particular, sporadic and HLRCC uterine leiomyomas.
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9.2  Pathobiology of uterine leiomyomas
9.2.1  HLRCC and sporadic uterine leiomyomas appear to have 
distinct pathogenesis
The earlier chapters of this thesis compared several features of 
HLRCC and sporadic uterine leiomyomas. In particular, the frequency of 
pathogenic FH mutations, the occurrence of mtDNA mutations, the potential 
role of apoptosis, and ultrastructural features of each of these tumour types 
were examined. The results of each of these studies demonstrated significant 
differences between the pathogenicity of HLRCC and sporadic uterine 
leiomyomas.
It appears that the initiating event in HLRCC uterine leiomyoma 
pathogenesis is loss of the wild-type FH allele, either through a second 
mutation, or through loss of heterozygosity (Alam et al. 2003). This results in 
loss of FH protein function, which then initiates tumorigenesis through a 
pseudo-hypoxic pathway (Pollard et al. 2005b). The study of the frequency of 
FH mutations in the sporadic uterine leiomyoma patients (Chapter 3) 
demonstrated that only 2.8% of these patients had germline FH mutations. 
When the samples were split on the basis of ethnicity, African/Afro-Caribbean 
patients, despite having a younger age of onset in the study cohort, were found 
to have no FH mutations, although the difference in frequency of FH 
mutations between African/Afro-Caribbean patients and those of other 
ethnicities, including Caucasian, failed to reach statistical significance.
The lack of FH mutations in the germline of sporadic uterine 
leiomyoma patients, and in their tumours (Barker et al. 2002) implies that a
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separate mechanism of initiation occurs in sporadic leiomyomas compared to 
HLRCC leiomyomas. This finding also has significance for the downstream 
pathobiology of the two tumour types.
In addition to the initiation of tumorigenesis, other distinctions 
between the two tumour types have been observed. Pollard et al compared the 
microvessel density of sporadic and HLRCC uterine leiomyomas, and found 
the latter to be far more vascular, and also noted the expression of VEGF and 
BNIP3, which are indicative of hypoxic activation. The reduction in 
vascularity in sporadic leiomyomas, and the lack of VEGF expression implies 
that hypoxia is not an important pathogenic mechanism of sporadic tumours 
(Pollard et al. 2005a).
Work in this thesis identified differences in the expression of apoptotic 
factors, and proliferative markers between HLRCC and sporadic leiomyomas. 
The results demonstrated increased expression of Bcl-2 and PCNA in both 
types of tumour compared to myometrium, indicative of increased 
proliferation and resistance to apoptosis, a result that has described previously 
(Dixon et al. 2002; Wu et al. 2002). However, HLRCC leiomyomas also 
demonstrated increased expression of anti-apoptotic Bcl-x and decreased pro- 
apoptotic Bak, implying that further pathways protecting these cells from 
apoptosis were involved. In addition, PCNA was significantly more highly 
expressed in HLRCC leiomyomas than sporadic leiomyomas, indicating a 
greater level of cell proliferation. These differences are likely to be a result of 
the involvement of hypoxia in HLRCC pathogenesis, and will be further 
discussed later.
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Ultrastructural studies also revealed differences between HLRCC and 
sporadic leiomyomas. HLRCC leiomyomas differed in particular in their 
cellularity and extracellular matrix. Sporadic leiomyomas have an increased 
extracellular matrix compared to the myometrium, thought to be a result of 
dysregulated TGFp-3 signalling (Lee and Nowak 2001). However, HLRCC 
leiomyomas demonstrated no increase in ECM content compared to the 
myometrium. This implies that TGF|3-3 signalling does not play a part in the 
pathogenesis of HLRCC leiomyomas. In addition, the HLRCC leiomyomas 
were found to be more cellular than their sporadic counterparts, this could be a 
result of a lack of ECM, allowing the cells to pack more closely together.
Other differences in the ultrastructures of HLRCC and sporadic 
leiomyomas were observed, including  difference in aggregation of 
intermediate filaments in the cytoplasm, but the significance of these 
differences were not identified.
The results from Chapters 3 and 4 suggest that HLRCC and sporadic 
uterine leiomyomas have different pathogenic mechanisms, both in the initial 
onset of tumorigenesis, and in the pathways that allow tumorigenesis to 
continue.
9.2.2  Hypoxia and apoptosis resistance in HLRCC uterine 
leiomyomas
The results from Chapters 4 and 5 gave further clues as to the 
mechanism of pathogenesis of HLRCC leiomyomas. When FH was initially 
identified as the HLRCC tumour suppressor, several theories of pathogenesis 
were proposed, including pseudo-hypoxia, apoptosis resistance, anabolic
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drive, stress pathway activation, and increased reactive oxygen species, 
discussd in detail in 1.2.1.1.1.1. The work in this thesis examined two more of 
these hypotheses. The role of apoptosis was studied by 
immunohistochemistry, and the production of reactive oxygen species was 
studied indirectly by examining mtDNA mutations in HLRCC and sporadic 
leiomyomas.
Constitutive activation of HIFla in HLRCC tumours leads to a 
pseudo-hypoxic state, leading to the production of angiogenic factors such as 
VEGF. A cell exposed to chronic hypoxia will eventually die (Graham et al. 
2004). However, in a pseudo-hypoxic state, the cell is still exposed to oxygen, 
and the highly vascular nature of HLRCC tumours further suggests that a 
ready supply of oxygen is available (Pollard et al. 2005a). Therefore, 
alternative mechanisms of oxygen sensing within the cell must override the 
pro-apoptotic effects of chronic hypoxia. As discussed in Chapter 4, this effect 
has already been observed in cells expressing constitutively active HIFla, 
which demonstrated increased resistance to apoptosis by increased expression 
of Bcl-x and Bcl-2, and decreased Bak and Bax, when cultured under 
normoxia (Sasabe et al. 2005). This mimics the results observed in vivo in 
Chapter 4, which demonstrated an increase in Bcl-2 and Bcl-x expression, and 
decreased Bak expression.
The focus, therefore, is on the alternative mechanism of oxygen 
sensing that provides a protection from chronic hypoxia-induced apoptosis. 
One obvious target would be the mitochondrial electron transport chain, which 
requires oxygen at the last enzyme to mop up electrons used to generate a 
proton gradient required for ATP synthesis. HIFla stabilisation has been
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shown to require a functioning electron transport chain in some instances 
(Agani et al. 2000). However, blockage of the Krebs cycle, occurring due to 
loss of FH function, could lead to reduction, or loss of electron transport chain 
activity.
Electron transport chain function was indirectly measure in HLRCC 
leiomyomas by the frequency of mitochondrial DNA mutations, which are 
indicative of increased ROS (Czamecka et al. 2006). It was found that the 
frequency of HLRCC mtDNA mutations was no greater than that observed in 
sporadic leiomyomas, and only 1/3 tumours showed any mtDNA mutations. 
Thus it was predicted that the lack of mtDNA mutations implied no increase in 
ROS, and so a functioning electron transport chain. Therefore, it appears that 
HLRCC tumours retain electron transport chain activity, possibly through the 
generation of NADH through other metabolic pathways, such as the pentose 
phosphate pathway, which produces NADPH (which is readily converted to 
NADH) without requiring Krebs cycle function (Berg et al. 2002).
This apparently retained function has great significance for HLRCC 
leiomyoma pathogenesis. Firstly, as mentioned above, HIFla requires a 
functioning electron transport chain for stabilisation (Agani et al. 2000). 
Secondly, the functioning chain could act as a signal to the cell that some 
molecular oxygen is present, and so promote survival through a hitherto 
unknown pathway, possibly involving mitochondrial membrane potential.
9.2.3  Pathobiology of sporadic uterine leiomyomas
The major focus on the pathobiology of sporadic uterine leiomyomas 
looked at genetic changes in these tumours. The functional results examining
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apoptosis-related proteins in these tumours concurred with the literature 
(Dixon et al. 2002; Wu et al. 2002; Kovacs et al. 2003), but did not provide 
any new insights into apoptosis resistance in leiomyomas.
As discussed above, FH mutations do not play a significant role in the 
pathogenesis of sporadic uterine leiomyomas. Therefore, it was decided to 
investigate two other types of genetic change in these tumours: copy number 
changes, with an eventual focus on the frequently deleted region of 
chromosome 7q; and mutations of the mitochondrial genome.
Results from the mtDNA screen, despite the limitations of the method 
used, revealed several tumours containing a number of heteroplasmic 
mutations. Some of these mutations affected the coding region of mtDNA, 
resulting in missense changes, some of which were predicted to be 
pathological by Polyphen (Ramensky et al. 2002). The effect of these 
mutations on leiomyoma pathogenesis was unknown, and further work needs 
to be done on the physiological effects of these mutations, particularly on 
mitochondrial metabolism, and subsequently on cell growth.
The high frequency of copy number changes in sporadic uterine 
leiomyomas is suggestive of an important role in leiomyoma pathobiology 
(Ligon and Morton 2001). The work in this thesis used microarray CGH to 
identify copy number changes in sporadic uterine leiomyomas at a higher 
resolution than previous studies. A large number of copy number changes 
were observed in these tumours, however, a low number of samples, resulting 
from limited availability of the microarrays, meant that few recurring copy 
number changes were observed. As expected, the most frequent of these 
changes was deletion of 7q22, the minimal region for which was minimised by
351Chapter 9 Discussion
these arrays to ~3.8Mb. While this was a larger region than previous LOH- 
based reports (Ishwad et al. 1997; Sell et al. 2005), it was the smallest minimal 
region identified by actual demonstration of deletion, rather than implied 
deletion by LOH.
The frequency of copy number changes identified by microarray CGH 
was higher than the frequency of reported karyotypic changes in leiomyomas 
(Ligon and Morton 2001). Therefore, it is likely that the increased resolution 
of techniques such as array CGH, and more recently copy number analysis 
using SNP microarrays (LaFramboise et al. 2005), will lead to the 
identification of novel smaller regions of copy number change in leiomyomas 
that may be important for leiomyoma pathogenesis. It may also increase the 
reported frequency of leiomyomas with karyotypic aberrations.
The success of the microarray in minimising the region of deletion lead 
to the construction of a tiling-path resolution array, which eventually lead to a 
minimal region of ~273kb at 7q22.2. The actual effect of the 7q22.2 deletion 
on leiomyoma pathogenesis is still being debated. The frequency of deletion 
has lead some to suggest that a tumour suppressor is present within the 
deletion (Ishwad et al. 1995). However, the behaviour of leiomyoma cells with 
7 q deletions in vitro has lead some to propose that deletion of the involved 
gene may be detrimental to leiomyoma cell growth (Xing et al. 1997). The 
functions of the two genes within this minimal region, MLL5 and SRPK2, 
support either of these hypotheses, and so no clear candidate, or mechanism, 
has yet emerged. It is possible that some, as yet unidentified, genomic feature 
in this region is responsible for the importance of 7q deletions in uterine 
leiomyomas.
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9.2.4  Factors affecting ethnic prevalence of uterine leiomyomas
As a part of a number of the studies in this thesis, ethnicity was 
considered, particularly within genetic studies, in order to identify differences 
or similarities in the tumorigenic pathways of leiomyomas from Affican/Affo- 
Caribbean patients, and those of other ethnicities. It was found that FH 
mutations do not appear to play a significant role in this altered prevalence. In 
addition, the frequency of 7q deletions in leiomyomas of different ethnicities 
was studied. It was found that deletions of 7q occur with an equal frequency in 
uterine leiomyomas from African/Afro-Caribbean patients and Caucasian 
patients. The hypothesis that emerges from this result is that uterine 
leiomyomas from Caucasian and African/Afro-Caribbean patients follow 
similar paths of tumorigenesis with regard to karyotypic changes, but the 
difference in prevalence occurs due to the initial lesion resulting in leiomyoma 
growth. It would be very interesting to test this hypothesis using other 
common cytogenetic aberrations that occur in leiomyomas, including t(12; 14) 
and rearrangements of 6 p.
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9.3 Further work
The results of the studies in this thesis have brought about a number of 
further questions that could be addressed. Consideration of this further work is 
presented below.
9.3.1  Chapter 3 -  FH mutations in HLRCC
The lack of tumour and cell line material for each patient made testing 
the effects of each mutation more speculative, and the effects of the novel 
observed mutations remain unclear. In order to test their effects, in vitro 
studies, involving the generation of the mutant cDNA by cloning, and in vitro 
transcription and translation, followed by a functional FH assay, would give a 
definitive answer to the effects of the novel missense mutants. In addition, 
fusion of the mutant mitochondrial leader sequences to a reporter protein, such 
as GFP, would give an answer to the effects of these mutations.
One of the biggest flaws of this study was the lack of ‘normal’ controls 
sequenced. Therefore, screening of a panel of normal patients for the novel 
changes observed would give a better idea of their pathogenicity.
Finally, further screening techniques could be used to get the fullest 
picture of FH mutations in HLRCC. In particular, looking for exon deletions 
within the gene using techniques such as MAPH and MLPA (Sellner and 
Taylor 2004) may reveal hitherto missed exon copy number polymorphisms in 
HLRCC patients.
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9.3.2 Chapter 4 -  Apoptosis and ultrastructure in sporadic and 
HLRCC leiomyomas
The results of this study threw up a number of interesting hypotheses 
regarding the mechanisms of apoptosis resistance in HLRCC uterine 
leiomyomas, which may extend to HLRCC tumours in general. In particular, 
the pathways by which HLRCC tumour cells stay alive despite a chronic 
hypoxia signal, and investigation of alternative pathways of oxygen sensing. 
The development of an in vitro model for HLRCC would be an important first 
step for these studies. Following this, the role of the electron transport chain in 
keeping HLRCC cells alive, despite chronic HIFla stabilisation could be 
investigated, for example by measuring electron transport chain function, or 
by assessing the effects of inhibition using specific inhibitors such as rotenone 
or oligomycin. The results of such a study could have important implications 
for other tumour types, and could possibly reveal new drug targets.
9.3.3 Chapter 5 -  mtDNA mutations in uterine leiomyomas
As for a number of the novel FH mutations, the functional effects of 
mtDNA mutations in uterine leiomyomas were unclear. Therefore, more work 
would be required to assess their role in tumorigenesis. The difficulties in 
interpreting the data from the Mitochip array probably means that a number of 
mutations were missed. Therefore, a more thorough method of mtDNA 
screening, such as traditional sequencing, would probably be a better option 
until such time as resequencing array technology can overcome the inherent
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difficulties in the technology. This would also allow the mutations observed in 
Chapter 5 to be confirmed.
9.3.4 Chapter 6 -  1Mb array CGH of uterine leiomyomas
The microarray CGH experiments revealed a number of novel regions 
of copy number change that could harbour important genes in uterine 
leiomyoma pathology. There are two chief ways in which this study could be 
continued: Firstly, through analysis of more tumours by 1Mb CGH to identify 
more novel regions of interest, and to refine these copy number changes; and 
secondly, through expression studies to try to correlate changes in expression 
with regions of copy number change, and so to identify further key players in 
leiomyoma pathogenesis. The size of the study in this chapter was, 
unfortunately, limited due to a finite supply of 1Mb arrays.
9.3.5 Chapter 8 - 7q deletions in uterine leiomyomas
The identification of a minimal region of deletion of 7q22.2 in uterine 
leiomyomas is an important finding. Unfortunately, time limitations prevented 
further analysis of this region. Therefore, the next step in this study would be 
to examine both candidates in depth. Quantitative real-time PCR expression 
studies, which are more sensitive than microarray expression studies, would 
be an important experiment to carry out initially, followed by protein 
expression analysis using western blot and immunohistochemistry. In 
addition, the breakpoints could be properly defined by the use of FISH, or 
real-time PCR to ensure the minimum region is accurately mapped.
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The results from the literature suggested that both genes are potential 
candidates. However, their suitability as candidates is determined by the role 
that 7q deletions have in vivo. If, as some suggest, deletions of 7q are 
indicative of a tumour suppressor gene (Ishwad et al. 1995), then MLL5 is a 
more suitable candidate. However, if deletions actually inhibit cell growth in 
some way (Xing et al. 1997), then SRPK2 emerges as the stronger candidate. 
Therefore, in order to identify the involved gene on 7q, the role of these 
deletions on leiomyoma pathogenesis needs to be more thoroughly defined. 
Additionally, the non-coding DNA of the minimal region may yet harbour a 
hitherto unknown genetic variant, separate from MLL5 and SRPK2 that is 
actually the important variant.
In addition to the deletion of 7q22.2, a number of other smaller 
deletions were also observed, particularly at 7q34, and the role of these 
deletions in leiomyoma pathogenesis requires investigation. Further 
investigation of the multiple changes observed on 7q in combination with 
7q34 deletions would also be required. In particular, identifying whether the 
changes occur on the same or different copies of chromosome 7.
The role of these novel deletions would be interesting to study. For 
example, in sample FG30, one of the small deletions contained a single gene, 
SEMA3A, which has a role in guiding vessel formation. To assess the effects 
of this deletion on the tumour, the vascularity of the original tumour could be 
studied and quantified. The roles of other novel copy number changes could 
be assessed in similar ways.
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9.4  Future perspectives
The next step in the investigation of uterine leiomyoma pathogenesis is 
likely to be the implementation of large association studies looking for 
variants that increase a patient’s risk of developing uterine leiomyomas. At 
least one study is in the process of recruiting patients, the ‘finding genes for 
fibroids’ study at Harvard Medical School (http://www.fibroids.net). Recent 
developments in array-based SNP-typing, plus the publication of the human 
HapMap have made this a far more viable possibility (2005), allowing 
simultaneous screening of 500,000+ SNPs on a single array. There are a 
number of different factors that could be investigated by such a study:
i)  Variants increasing the risk of developing uterine leiomyomas.
ii)  Variants determining differences in leiomyoma prevalence with 
ethnicity.
iii)  Variants influencing leiomyoma size or location.
One of the biggest difficulties facing such a study would be the 
recruitment of adequate controls. Cramer and Patel’s serial sectioning study of 
hysterectomy specimens revealed a far higher prevalence of uterine 
leiomyomas than was originally thought, reporting leiomyomas in 77% of 
specimens. These were often very small, asymptomatic tumours (Cramer and 
Patel 1990). If such a high prevalence is representative of the whole 
population, obtaining true controls whose uteri are free from leiomyomas 
would require meticulous work and careful selection. Perhaps the best controls 
for such a study would be post-menopausal patients having hysterectomies for 
other disorders whose uteri show no evidence of tumours following serial 
sectioning. However, there may be genetic variants that determine whether
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leiomyomas grow to a size that results in morbidity, rather than remain small 
and asymptomatic. Obtaining controls for that study would be easier.
An association study examining the genetic factors that affect 
prevalence of leiomyomas in women of different ethnicities would also be a 
useful study. Again, the high prevalence of leiomyomas in African/Afro- 
Caribbean women would make the identification of controls very difficult. 
Again, stratification based on a patients phenotype may be required, 
comparing patients with few leiomyomas at an older age of onset, with 
younger patients with more leiomyomas.
However, the results of a carefully designed study should give further 
insights into leiomyoma pathogenesis that would allow a more complete 
insight into their pathobiology.
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9.5 Conclusions
The pathobiology of uterine leiomyomas is complex for such an 
apparently basic tumour. The work in this thesis has made an important 
contribution to the knowledge of uterine leiomyoma pathobiology, particularly 
in regard to mechanisms of apoptosis resistance in HLRCC leiomyomas, and 
also copy number changes of chromosome 7q, which could provide a stepping 
stone to further understanding of a question that is simple to ask, yet difficult 
to answer: “What causes fibroids?”
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397Appendix 1
BAC clones used in the 
chromosome 7q genomic 
microarray
398A 1.1 Control Clones
554 BAC clones were selected at approximately 5 megabase intervals 
from the set of clones selected by Fiegler et al for the 1Mb resolution genomic 
microaray (Fiegler et al. 2003). Clones were selected on the basis of previous 
experiments using the 1Mb genomic microarray. Clones consistently producing 
unexpected results were removed and adjacent alternatives selected. These clones 
were selected to act as a whole genome normalisation control. DNA for these 
clones was extracted by Regina Regan at the Wellcome Trust centre for Human 
Genetics in Oxford. Clones producing unexpected hybridisations in the final array 
are highlighted in yellow.
Clone Name Chromosome Start End Midpoint
Position
Clone Size
RP3-438L4 1 6734038 6860851 6797444.5 126813
RP4-575L21 1 9762410 9856831 9809620.5 94421
RP4-560M15 1 14820829 14955897 14888363 135068
RP1-184J9 1 22483929 22584879 22534404 100950
RP4-669K10 1 28332168 28467987 28400077.5 135819
RP11-114B7 1 32528048 32700923 32614485.5 172875
RP4-731G4 1 36258282 36397220 36327751 138938
RP1-118J21 1 40071667 40238162 40154914.5 166495
RP11-428D12 1 48503255 48688954 48596104.5 185699
RP11-117D22 1 53095140 53274113 53184626.5 178973
RP11-5P4 1 62780646 62959676 62870161 179030
399RP4-547N15 1 66824623 66955867 66890245 131244
RP11-175G14 1 71539699 71706962 71623330.5 167263
RP11-297N6 1 75462153 75643352 75552752.5 181199
RP11-398N17 1 81943890 82121042 82032466 177152
RP4-722L13 1 85384438 85479558 85431998 95120
RP11-298P9 1 89861338 90022603 89941970.5 161265
RP11-14019 1 95126453 95304425 95215439 177972
RP11-260K3 1 99189373 99354410 99271891.5 165037
RP11-202K23 1 101884899 102025519 101955209 140620
RP5-916A15 1 106115383 106239985 106177684 124602
RP11-20F20 1 108740654 108905960 108823307 165306
RP5-831G13 1 109116674 109232785 109174729.5 116111
RP4-663N10 1 114959020 115136085 115047552.5 177065
RP4-610L12 1 118706067 118826176 118766121.5 120109
RP4-706A17 1 143505085 143626363 143565724 121278
RP11-216N14 1 150463354 150613519 150538436.5 150165
RP11-17216 1 152857449 152909842 152883645.5 52393
RP11-430G6 1 159642370 159818401 159730385.5 176031
RP4-702J19 1 164681223 164781866 164731544.5 100643
RP3-433G19 1 171402964 171464845 171433904.5 61881
RP11-163L4 1 174289185 174469501 174379343 180316
RP11-71D4 1 179149277 179299768 179224522.5 150491
RP11-108M21 1 183696640 183867278 183781959 170638
RP11-3B17 1 187174084 187325974 187250029 151890
RP11-552K17 1 192685962 192837310 192761636 151348
RP11-469A15 1 196748763 196914264 196831513.5 165501
RP11-383G10 1 201436746 201617779 201527262.5 181033
400RP5-879K22 1 207161851 207299528 207230689.5 137677
RP11-438G15 1 212236238 212440909 212338573.5 204671
RP11-492K2 1 216023276 216223712 216123494 200436
RP11-105112 1 220324315 220505567 220414941 181252
RP11-99J16 1 227364296 227563459 227463877.5 199163
RP5-940F7 1 232351444 232515453 232433448.5 164009
RP11-553N16 1 238232307 238376273 238304290 143966
RP11-438H8 1 243994883 244162295 244078589 167412
RP11-292A20 2 4443265 4601782 4522523.5 158517
RP11-413M20 2 27530765 27726644 27628704.5 195879
RP11-288C18 2 36948031 37131949 37039990 183918
RP11-299C5 2 42438000 42622949 42530474.5 184949
RP11-27C22 2 45998023 46189235 46093629 191212
RP11-335022 2 52297470 52477417 52387443.5 179947
RP11-152018 2 55771556 55938781 55855168.5 167225
RP11-422B1 2 58197781 58322040 58259910.5 124259
RP11-52F10 2 62699704 62846957 62773330.5 147253
RP11-304A15 2 68964455 69128448 69046451.5 163993
RP11-343N14 2 72351544 72532758 72442151 181214
RP11-9010 2 78038303 78192922 78115612.5 154619
RP11-294120 2 89043591 89209246 89126418.5 165655
RP11-542D13 2 97710653 97941078 97825865.5 230425
RP11-30G7 2 100355304 100530412 100442858 175108
RP11-350B7 2 105105221 105287572 105196396.5 182351
RP11-528G9 2 110363698 110539320 110451509 175622
RP11-412A2 2 115983908 116126580 116055244 142672
RP11-19E11 2 119472589 119622682 119547635.5 150093
401RP11-207G14 2 129826704 129989789 129908246.5 163085
RP11-1L22 2 133192012 133371737 133281874.5 179725
RP11-279M2 2 141694696 141869885 141782290.5 175189
RP11-207014 2 146897423 147081828 146989625.5 184405
RP11-329H24 2 150455875 150656782 150556328.5 200907
RP11-266L10 2 155783329 155962516 155872922.5 179187
RP11-440P12 2 161852242 162042452 161947347 190210
RP11-5J4 2 164341415 164503712 164422563.5 162297
RP11-55102 2 170052584 170193044 170122814 140460
RP11-176L20 2 172373348 172540036 172456692 166688
RP4-745K6 2 177126136 177217628 177171882 91492
RP11-391P1 2 180577822 180756826 180667324 179004
RP11-29E4 2 186051834 186257023 186154428.5 205189
RP11-172N20 2 189111537 189281464 189196500.5 169927
RP11-363G3 2 194026091 194196561 194111326 170470
RP11-347P5 2 196794111 197009289 196901700 215178
RP11-329010 2 203573149 203736110 203654629.5 162961
RP11-470J24 2 207080568 207279068 207179818 198500
RP11-560C24 2 213416750 213602967 213509858.5 186217
RP11-307A11 2 217317794 217482271 217400032.5 164477
RP11-444B5 2 221590943 221767798 221679370.5 176855
RP11-551D18 2 224273832 224403384 224338608 129552
RP11-95E11 3 3151017 3321810 3236413.5 170793
RP11-129J10 3 5044648 5197799 5121223.5 153151
RP11-163D23 3 12607628 12752839 12680233.5 145211
RP11-80D24 3 17198216 17362120 17280168 163904
RP11-16E8 3 21449056 21617033 21533044.5 167977
402RP11-421F9 3 25322783 25426788 25374785.5 104005
RP11-69K20 3 30150307 30322389 30236348 172082
RP11-524015 3 32325331 32522440 32423885.5 197109
RP11-129K12 3 36705146 36874417 36789781.5 169271
RP4-613B23 3 42444041 42629201 42536621 185160
RP11-88B8 3 47702308 47891600 47796954 189292
RP11-89F17 3 51272113 51440611 51356362 168498
RP11-58015 3 55485886 55677395 55581640.5 191509
RP11-170K19 3 59581144 59755752 59668448 174608
RP11-108A8 3 63134788 63276188 63205488 141400
RP11-152N21 3 69124542 69282193 69203367.5 157651
RP11-252010 3 73186876 73335038 73260957 148162
RP11-442C9 3 81370437 81532918 81451677.5 162481
RP11-474M18 3 84346772 84524804 84435788 178032
RP11-12A13 3 95891701 96049008 95970354.5 157307
RP11-121C1 3 100289280 100344133 100316706.5 54853
RP11-115B22 3 105613784 105769982 105691883 156198
RP11-56104 3 108071506 108263827 108167666.5 192321
RP11-402J7 3 112541586 112738134 112639860 196548
RP11-58D2 3 116078196 116228489 116153342.5 150293
RP11-295B8 3 119474842 119621371 119548106.5 146529
RP11-299J3 3 123285258 123456636 123370947 171378
RP11-71H17 3 125709391 125875461 125792426 166070
RP11-129J11 3 131256145 131415278 131335711.5 159133
RP11-91K8 3 134417031 134570680 134493855.5 153649
RP11-197K1 3 137505672 137686933 137596302.5 181261
RP11-397E9 3 140070644 140250349 140160496.5 179705
403RP11-165M11 3 144645061 144830491 144737776 185430
RP11-21M4 3 147509084 147650355 147579719.5 141271
RP11-251C9 3 151899193 152078689 151988941 179496
RP11-117L15 3 156440983 156608976 156524979.5 167993
CTD-2049J23 3 160880530 161037608 160959069 157078
RP11-491K7 3 166828293 166999550 166913921.5 171257
RP11-3K16 3 170648661 170851376 170750018.5 202715
RP11-163H6 3 173100478 173267359 173183918.5 166881
RP11-71G7 3 177604260 177768984 177686622 164724
RP11-682A21 3 180212677 180368586 180290631.5 155909
RP11-445C21 3 182217326 182390040 182303683 172714
RP11-252K11 3 197315053 197479187 197397120 164134
RP3-323A24 4 2644489 2700384 2672436.5 55895
RP11-168E17 4 11509028 11670803 11589915.5 161775
RP 11 -441012 4 18107264 18293016 18200140 185752
RP11-406E22 4 22991214 23141025 23066119.5 149811
RP11-390C19 4 29460286 29637752 29549019 177466
RP11-135M12 4 35365058 35558567 35461812.5 193509
RP11-213G21 4 38333901 38515731 38424816 181830
RP11-354H17 4 41201012 41383758 41292385 182746
RP11-100N21 4 47419175 47587351 47503263 168176
RP11-18M17 4 54201059 54359963 54280511 158904
RP11-738E22 4 57589610 57805706 57697658 216096
RP11-340A13 4 59788461 59961559 59875010 173098
RP11-204H9 4 65123062 65288065 65205563.5 165003
RP11-1J11 4 72420936 72587412 72504174 166476
RP11-224D4 4 77956327 78117137 78036732 160810
404RP11-377G16 4 81489983 81684140 81587061.5 194157
RP11-107G7 4 88905288 89077149 88991218.5 171861
RP11-115D19 4 90928929 91098412 91013670.5 169483
RP11-16117 4 94836626 95012134 94924380 175508
RP11-242D9 4 98796646 99007208 98901927 210562
RP11-13F20 4 101684333 101845851 101765092 161518
RP11-122B24 4 105462123 105623074 105542598.5 160951
RP11-109F18 4 108812660 108970859 108891759.5 158199
RP11-402J6 4 113751654 113953271 113852462.5 201617
RP11-100C9 4 120062268 120241680 120151974 179412
RP11-15017 4 126528468 126693514 126610991 165046
RP11-209D20 4 130174860 130369188 130272024 194328
RP11-335K21 4 134545830 134725170 134635500 179340
RP11-425J20 4 138619496 138796522 138708009 177026
RP11-14111 4 144001065 144155358 144078211.5 154293
RP11-425A23 4 149001370 149198594 149099982 197224
RP 11-64M20 4 151778069 151965491 151871780 187422
RP11-27G13 4 156620582 156798785 156709683.5 178203
RP11-171N4 4 157912091 158086952 157999521.5 174861
RP11-440L13 4 168193229 168367049 168280139 173820
RP11-119J20 4 173588498 173758054 173673276 169556
RP11-287F9 4 176695234 176916111 176805672.5 220877
RP 11-396122 4 181563401 181770189 181666795 206788
RP11-228F3 4 186219769 186387681 186303725 167912
RP11-121L11 5 3405732 3576991 3491361.5 171259
RP11-114M17 5 6495614 6688370 6591992 192756
RP11-215G15 5 10624443 10804444 10714443.5 180001
405RP11-269G2 5 13197866 13354720 13276293 156854
RP11-1902 5 16173373 16338191 16255782 164818
RP11-46C20 5 27450982 27605795 27528388.5 154813
RP11-53L13 5 32706750 32880188 32793469 173438
RP11-7M4 5 36952938 37141434 37047186 188496
RP11-274J22 5 41626760 41793769 41710264.5 167009
RP4-592P18 5 51018605 51167212 51092908.5 148607
RP11-506H20 5 54497449 54698853 54598151 201404
RP11-16B11 5 59275673 59425673 59350673 150000
RP11-18K15 5 63260284 63433944 63347114 173660
RP11-421A17 5 67432932 67611836 67522384 178904
RP11-399M5 5 73128988 73317911 73223449.5 188923
CTC-1347N9 5 73875863 74044548 73960205.5 168685
RP11-538B23 5 79939288 80085749 80012518.5 146461
RP11-463C5 5 82573059 82745846 82659452.5 172787
RP11-302L17 5 89567617 89731589 89649603 163972
CTC-1366N20 5 94530747 94666121 94598434 135374
RP11-195 A20 5 98957041 99114398 99035719.5 157357
RP11-528K12 5 102995361 103193051 103094206 197690
RP11-276018 5 109352836 109509336 109431086 156500
RP11-467F22 5 112491785 112698521 112595153 206736
RP11  -321G16 5 118274416 118447293 118360854.5 172877
RP11-48C14 5 124182286 124353907 124268096.5 171621
CTC-1352M6 5 127600154 127762073 127681113.5 161919
RP1-241C15 5 131368738 131580952 131474845 212214
RP11-114H21 5 135742954 135919021 135830987.5 176067
RP 1-98022 5 137715529 137836260 137775894.5 120731
406CTD-2185H17 5 142508071 142745792 142626931.5 237721
CTB-1176115 5 147872964 147929136 147901050 56172
CTB-1013H5 5 149410404 149497218 149453811 86814
CTC-1263A14 5 154420715 154524576 154472645.5 103861
CTC-1279E3 5 159198172 159281832 159240002 83660
RP11-170P5 5 165680688 165844015 165762351.5 163327
RP11-420L4 5 168985026 169142475 169063750.5 157449
RP11-15N12 6 3337049 3516147 3426598 179098
RP11-320C15 6 6692138 6850876 6771507 158738
RP3-365E2 6 14490663 14628392 14559527.5 137729
RP11-408C8 6 18892364 19085810 18989087 193446
RP11-204E9 6 21466595 21653117 21559856 186522
RP11-289G11 6 25437140 25631948 25534544 194808
RP11-150A6 6 29275623 29450291 29362957 174668
RP3-468B3 6 33769697 33906582 33838139.5 136885
RP3-350J21 6 38883787 39022618 38953202.5 138831
RP11-501118 6 42709208 42849343 42779275.5 140135
RP11-334H12 6 48718029 48886789 48802409 168760
RP3-341E18 6 52889365 52981922 52935643.5 92557
RP11-199A24 6 58503657 58682040 58592848.5 178383
RP3-324B8 6 66770251 66915033 66842642 144782
RP11-111D8 6 72050748 72235703 72143225.5 184955
RP11-343P23 6 77517433 77681806 77599619.5 164373
RP11-379B8 6 82396598 82583994 82490296 187396
RP11-106G15 6 88179481 88349676 88264578.5 170195
RP1-154G14 6 91144723 91245716 91195219.5 100993
RP11-572N15 6 96215454 96396616 96306035 181162
407RP1-167P23 6 101293237 101434643 101363940 141406
RP3-454N4 6 105931842 106046929 105989385.5 115087
RP1-71D21 6 110558902 110677884 110618393 118982
RP1-230I3 6 118569617 118681380 118625498.5 111763
RP1-84N20 6 125282636 125434684 125358660 152048
RP11-593A16 6 130125822 130298637 130212229.5 172815
RP11-323N12 6 135426583 135611804 135519193.5 185221
RP11-368P1 6 142115804 142254889 142185346.5 139085
RP11-54515 6 145958830 146159631 146059230.5 200801
RP3-443C4 6 152007969 152101913 152054941 93944
RP11-266C7 6 158158294 158354215 158256254.5 195921
RP11-300M24 6 164974796 165158137 165066466.5 183341
CTB-57H24 6 170456322 170561549 170508935.5 105227
RP11-172013 7 5448528 5590890 5519709 142362
RP11-505D17 7 7691571 7869931 7780751 178360
RP5-855F16 7 10648774 10744118 10696446 95344
RP11-512E16 7 13852390 14023199 13937794.5 170809
RP11-486P11 7 19740880 19929817 19835348.5 188937
RP11-343P21 7 24231396 24400925 24316160.5 169529
RP4-59609 7 28201516 28345393 28273454.5 143877
RP11-179B11 7 33885182 34034436 33959809 149254
RP11-571N3 7 45697110 45864440 45780775 167330
RP4-756H11 7 65407869 65542912 65475390.5 135043
RP11-156A14 7 67306381 67464348 67385364.5 157967
RP11-45003 7 71834041 72029592 71931816.5 195551
RP4-79908 7 75950356 76121892 76036124 171536
RP5-1136A10 7 80148213 80288468 80218340.5 140255
408RP11-313H6 7 83231894 83395664 83313779 163770
RP11-212B1 7 86666503 86814646 86740574.5 148143
RP5-998H4 7 88431567 88556269 88493918 124702
RP5-1099C19 7 91733496 91850768 91792132 117272
RP4-550A13 7 98465321 98544836 98505078.5 79515
RP5-1059M17 7 100735998 100909966 100822982 173968
RP11-374M7 7 116081375 116235248 116158311.5 153873
RP11-88K4 7 136015635 136168619 136092127 152984
RP5-1173P7 7 140076153 140242117 140159135 165964
RP4-721B17 7 143536315 143643109 143589712 106794
RP11-302C22 7 146768222 146943332 146855777 175110
RP11-19N21 8 16209078 16383596 16296337 174518
RP11-667P13 8 19608613 19660956 19634784.5 52343
RP11-177H13 8 22871911 23051255 22961583 179344
RP11-473A17 8 30682363 30862460 30772411.5 180097
RP11-51K12 8 40122856 40271044 40196950 148188
RP11-567J20 8 49071182 49246550 49158866 175368
RP11-11C20 8 52337416 52481168 52409292 143752
RP11-342K10 8 57478832 57662499 57570665.5 183667
RP3-491L6 8 61479259 61554406 61516832.5 75147
RP11-366K18 8 66739606 66904686 66822146 165080
RP11-351E7 8 73059447 73238151 73148799 178704
RP11-48D4 8 77430450 77594059 77512254.5 163609
RP11-62E9 8 81464963 81656320 81560641.5 191357
RP5-1098020 8 90547005 90666572 90606788.5 119567
RP11-320N21 8 95578454 95777663 95678058.5 199209
RP11-21E8 8 101895464 102075830 101985647 180366
409RP11-132E3 8 104817649 105002116 104909882.5 184467
RP11-115M13 8 108579701 108736971 108658336 157270
RP11-11A18 8 113091472 113259535 113175503.5 168063
RP11-45519 8 118789437 118973003 118881220 183566
RP11-96B2 8 123125490 123297613 123211551.5 172123
RP11-17E16 8 130164147 130303786 130233966.5 139639
RP11-45B19 8 135192573 135355179 135273876 162606
RP11-172M18 8 138922576 139068480 138995528 145904
CTC-489D14 8 145662838 145767796 145715317 104958
'  RP11-19G1 9 9932073 10130653 10031363 198580
RP11-413D24 9 13729563 13912972 13821267.5 183409
RP11-503K16 9 18579957 18743122 18661539.5 163165
RP11-33K8 9 24090707 24243454 24167080.5 152747
RP11-264J11 9 28670843 28840515 28755679 169672
RP11-265B8 9 65119518 65307680 65213599 188162
RP11-71A24 9 69188839 69357940 69273389.5 169101
RP11-174K23 9 74875373 75056851 74966112 181478
RP11-384P5 9 76523026 76704628 76613827 181602
RP11-40C6 9 83573764 83740617 83657190.5 166853
RP11-8B23 9 85977930 86146744 86062337 168814
RP11-33317 9 90635179 90810468 90722823.5 175289
RP11-23J9 9 93498478 93663909 93581193.5 165431
RP11-96L7 9 95300677 95476573 95388625 175896
RP11-75J9 9 97899288 98058418 97978853 159130
RP11-287A8 9 101601630 101774553 101688091.5 172923
RP11-470J20 9 106331849 106509763 106420806 177914
RP11-78H18 9 111021219 111179918 111100568.5 158699
410RP11-58C3 9 112325822 112495168 112410495 169346
RP11-360A18 9 116149987 116332280 116241133.5 182293
RP11-101K10 9 120541770 120704608 120623189 162838
RP11-545E17 9 124915364 125082027 124998695.5 166663
RP11-295G24 9 128975111 129184321 129079716 209210
RP11-298K24 10 6387907 6586872 6487389.5 198965
RP11-730A19 10 13168712 13364914 13266813 196202
RP11-37P5 10 16149169 16307032 16228100.5 157863
RP11-12907 10 25251193 25417053 25334123 165860
'  RP11-207K8 10 29951571 30125165 30038368 173594
RP11-22G4 10 34581983 34749229 34665606 167246
RP11-38B21 10 44319977 44479480 44399728.5 159503
RP11-534N5 10 45880691 46088516 45984603.5 207825
RP11-47013 10 53120747 53291835 53206291 171088
RP11-430K23 10 56932219 57104585 57018402 172366
RP11-166B18 10 62124592 62291417 62208004.5 166825
RP11-161L14 10 67034063 67184024 67109043.5 149961
RP11-816P15 10 70892063 71090978 70991520.5 198915
RP11-506B4 10 75947886 76118719 76033302.5 170833
RP11-90J7 10 79910369 80067437 79988903 157068
RP11-20E23 10 82620395 82789946 82705170.5 169551
RP11-165M8 10 89673152 89836182 89754667 163030
RP11-80H5 10 91456500 91604895 91530697.5 148395
RP11-162K11 10 95915414 96065358 95990386 149944
RP11-19C6 10 99761532 99922766 99842149 161234
RP11-724N1 10 104793687 104954739 104874213 161052
RP11-478K18 10 109431987 109629942 109530964.5 197955
411RP11-426E5 10 114001336 114197992 114099664 196656
RP11-264E18 10 129972701 130134744 130053722.5 162043
RP11-206L19 11 11764177 11910857 11837517 146680
RP11-4B7 11 16709495 16884205 16796850 174710
RP11-121C18 11 21648954 21829680 21739317 180726
RP11-406D1 11 27967439 28140995 28054217 173556
RP11-163K24 11 62765180 62915180 62840180 150000
RP5-1083G3 11 31858329 31983998 31921163.5 125669
RP11-31123 11 34842421 35018652 34930536.5 176231
RP11-194C13 11 36752876 36935109 36843992.5 182233
RP11-220C23 11 41011253 41172121 41091687 160868
RP11-12C11 11 44954201 45121167 45037684 166966
RP11-131J4 11 55331941 55500242 55416091.5 168301
RP11-399J13 11 65057551 65245484 65151517.5 187933
RP11-569N5 11 68565746 68772008 68668877 206262
RP11-598K3 11 70851736 71024499 70938117.5 172763
RP11-512124 11 71141644 71334855 71238249.5 193211
RP11-179A16 11 81847029 81988303 81917666 141274
RP11-291N1 11 91502319 91708399 91605359 206080
RP11-349116 11 94545261 94706664 94625962.5 161403
RP11-45C5 11 100674260 100828417 100751338.5 154157
RP11-725J15 11 102782437 102849564 102816000.5 67127
RP11-569A20 11 106612629 106780908 106696768.5 168279
RP11-241D13 11 108069316 108250858 108160087 181542
RP11-10N17 11 125016509 125174951 125095730 158442
RP11-264F23 12 4183840 4350675 4267257.5 166835
RP11-277E18 12 7927138 7998956 7963047 71818
412RP11-144023 12 10853956 11027690 10940823 173734
RP11-328P13 12 19289723 19425674 19357698.5 135951
RP11-230B21 12 28632872 28783457 28708164.5 150585
RP11-333D23 12 38630437 38800069 38715253 169632
RP11-510P12 12 42925574 43054923 42990248.5 129349
RP11-493L12 12 47292778 47484823 47388800.5 192045
RP11-152A18 12 49510213 49689943 49600078 179730
RP11-112N23 12 50448120 50629221 50538670.5 181101
RP11-183H16 12 56269874 56438367 56354120.5 168493
RP 11-290121 12 64284724 64436391 64360557.5 151667
RP11-444B24 12 68171312 68362272 68266792 190960
RP11-566J10 12 76518277 76702092 76610184.5 183815
RP11-202G24 12 77933796 78069040 78001418 135244
RP11-362A1 12 82235777 82382759 82309268 146982
RP11-202H2 12 86931689 87094934 87013311.5 163245
RP11-239F20 12 91781777 91959053 91870415 177276
RP 11 -410  A13 12 95890010 96038191 95964100.5 148181
RP1-261P5 12 112399736 112537419 112468577.5 137683
RP11-497G19 12 116785783 116936893 116861338 151110
RP11-18C24 12 120696111 120833352 120764731.5 137241
RP11-178A2 12 128823421 129014458 128918939.5 191037
RP11-110K8 13 21014693 21193824 21104258.5 179131
RP11-570F6 13 25930592 26097378 26013985 166786
RP11-218E6 13 28869843 29040462 28955152.5 170619
RP11-87G1 13 32881076 33063992 32972534 182916
RP11-131P10 13 37835914 37989889 37912901.5 153975
RP11-117113 13 42194047 42339827 42266937 145780
413RP11-264F20 13 46587555 46737915 46662735 150360
RP11-40A8 13 50367155 50510478 50438816.5 143323
RP11-478B20 13 55410925 55582814 55496869.5 171889
RP11-310K10 13 60757818 60921048 60839433 163230
RP11-424E21 13 65332707 65500164 65416435.5 167457
RP11-370A2 13 68219446 68373244 68296345 153798
RP11-309H15 13 72645530 72815984 72730757 170454
RP11-52L5 13 77993552 78150853 78072202.5 157301
RP11-120L14 13 83805114 83963196 83884155 158082
RP11-275J18 13 88514869 88681377 88598123 166508
RP11-632L2 13 92538397 92719963 92629180 181566
RP11-383H17 13 97306800 97505793 97406296.5 198993
RP11-564N10 13 101357326 101546021 101451673.5 188695
RP11-232K22 13 106566054 106746872 106656463 180818
RP11-480K16 13 112064534 112246895 112155714.5 182361
RP11-84C10 14 19303764 19461742 19382753 157978
RP11-144C18 14 25481639 25665288 25573463.5 183649
RP11-159L20 14 29078484 29245614 29162049 167130
RP11-259K15 14 34533893 34699018 34616455.5 165125
RP11-34018 14 38289308 38458298 38373803 168990
RP11-134J10 14 42208900 42373413 42291156.5 164513
RP11-346L24 14 47799905 47971249 47885577 171344
RP11-262M8 14 50687246 50885062 50786154 197816
RP11-108M12 14 55377186 55543671 55460428.5 166485
RP11-62H20 14 58256276 58421210 58338743 164934
RP 11-544120 14 62262466 62420889 62341677.5 158423
RP11-226F19 14 67330230 67496508 67413369 166278
414RP4-816G1 14 70097161 70228291 70162726 131130
RP11-316E14 14 73306343 73509352 73407847.5 203009
RP11-463C8 14 75573588 75753918 75663753 180330
RP11-114N19 14 79418008 79578366 79498187 160358
RP11-203D9 14 82773865 82921435 82847650 147570
RP11-2E15 14 85754128 85906871 85830499.5 152743
RP11-79J20 14 87739152 87907321 87823236.5 168169
RP 11-298123 14 93822042 93987822 93904932 165780
RP11-6818 14 96755903 96931901 96843902 175998
RP11-73M18 14 102137566 102303182 102220374 165616
RP11-289D12 15 20230681 20409344 20320012.5 178663
RP11-142M24 15 24237601 24416992 24327296.5 179391
RP11-164K24 15 29000750 29159519 29080134.5 158769
RP11-70A1 15 34492228 34652252 34572240 160024
RP11-164J13 15 40191009 40336241 40263625 145232
RP11-519G16 15 43204847 43405649 43305248 200802
RP11-232J12 15 51370999 51528040 51449519.5 157041
RP11-178D12 15 53203690 53354822 53279256 151132
RP11-169M2 15 60509763 60687245 60598504 177482
RP11-321F6 15 64420512 64630680 64525596 210168
RP 11 -2117 15 69931377 70102499 70016938 171122
RP11-78M2 15 74288711 74436014 74362362.5 147303
RP11-127F21 15 80974294 81145086 81059690 170792
RP11-133L19 15 84972397 85149035 85060716 176638
RP3-443N8 15 88547365 88627956 88587660.5 80591
RP11-34L4 15 92789758 92955983 92872870.5 166225
RP11-262P8 15 96822948 97001148 96912048 178200
415RPl 1-14C10 15 99606717 99811390 99709053.5 204673
RP11-433P17 16 3352717 3532227 3442472 179510
RP11-518I8 16 5501064 5704568 5602816 203504
RP11-148F10 16 7992941 8180436 8086688.5 187495
RPl 1-48901 16 15431773 15593312 15512542.5 161539
RP5-973M2 16 21924160 22037720 21980940 113560
CTD-2515A14 16 24657417 24876429 24766923 219012
RPl 1-74E23 16 29641806 29821555 29731680.5 179749
RP11-523L20 16 47637620 47785040 47711330 147420
RPl 1-424K7 16 50797985 50973961 50885973 175976
RPl 1-357N13 16 53608406 53806822 53707614 198416
RPl 1-405F3 16 57356486 57508641 57432563.5 152155
RPl 1-157H19 16 61536303 61704456 61620379.5 168153
RPl 1-22903 16 64639732 64793319 64716525.5 153587
RPl 1-76H6 16 68130660 68312309 68221484.5 181649
RPl 1-311C24 16 69342826 69509651 69426238.5 166825
RP5-991G20 16 72494571 72635883 72565227 141312
RPl 1-281J9 16 77615449 77787782 77701615.5 172333
RP11-2L4 16 82302795 82461010 82381902.5 158215
RPl 1-478M13 16 85563108 85723221 85643164.5 160113
RPl 1-4F24 17 1568827 1779994 1674410.5 211167
RPl 1-104019 17 4005140 4173973 4089556.5 168833
RPl 1-144K9 17 6898009 7008780 6953394.5 110771
RPl 1-12H18 17 8411033 8576675 8493854 165642
RPl 1-388F14 17 13213933 13419102 13316517.5 205169
RPl 1-385D13 17 15323659 15512500 15418079.5 188841
RP5-836L9 17 19977261 20098081 20037671 120820
416RPl 1-104120 17 27899018 28089346 27994182 190328
RP1-29G21 17 31107106 31248368 31177737 141262
RP11-115K3 17 35797540 35979164 35888352 181624
RPl 1-390P24 17 37460666 37635985 37548325.5 175319
RP5-1110E20 17 38891937 39028958 38960447.5 137021
RP5-905N1 17 41837623 41932374 41884998.5 94751
RPl 1-374N3 17 43716793 43751400 43734096.5 34607
RPl 1-81K2 17 47741447 47929515 47835481 188068
RPl 1-42901 17 50831753 51016056 50923904.5 184303
RPl 1-372K20 17 53099732 53255181 53177456.5 155449
RPl 1-19F16 17 55603555 55747849 55675702 144294
RPl 1-332H18 17 59644799 59834154 59739476.5 189355
RPl 1-89H15 17 62459662 62614325 62536993.5 154663
RPl 1-238F2 17 69147559 69296184 69221871.5 148625
RPl 1-155C2 17 72409645 72586956 72498300.5 177311
RPl 1-313F15 17 79131187 79302492 79216839.5 171305
RPl 1-324G2 18 168428 340445 254436.5 172017
RPl 1-502P1 18 3863228 4046694 3954961 183466
RPl 1-146G7 18 6752911 6933647 6843279 180736
RPl 1-99M10 18 10436606 10587118 10511862 150512
RPl 1-17J14 18 20658424 20815606 20737015 157182
RPl 1-52618 18 24374624 24565006 24469815 190382
RPl 1-41319 18 29891111 30049089 29970100 157978
RPl 1-383C19 18 33969157 34136044 34052600.5 166887
RPl 1-25C13 18 37123788 37291079 37207433.5 167291
RP11-463D17 18 42850560 43042716 42946638 192156
RPl 1-141E12 18 46659813 46821973 46740893 162160
417RPl 1-1E21 18 48908822 49077297 48993059.5 168475
RPl 1-397A16 18 53079547 53282112 53180829.5 202565
RPl 1-350K6 18 56501246 56683540 56592393 182294
RPl 1-28F1 18 60692611 60849700 60771155.5 157089
RPl 1-430H7 18 68387071 68563596 68475333.5 176525
RPl 1-11812 18 75238962 75410506 75324734 171544
RPl 1-16L7 18 75542665 75651403 75597034 108738
RPl 1-269124 18 131243135 131396939 131320037 153804
CTC-546C11 19 295393 475000 385196.5 179607
CTB-1025J19 19 7064590 7214590 7139590 150000
CTB-1187L3 19 15400042 15553105 15476573.5 153063
RPl 1-26D24 19 21329374 21488498 21408936 159124
RPl 1-359H18 19 23539218 23716516 23627867 177298
CTD-2043I16 19 33277317 33383462 33330389.5 106145
CTD-2525J15 19 41994480 42183965 42089222.5 189485
RPl 1-15A1 19 49030102 49190855 49110478.5 160753
RPl 1-2J15 19 51650034 51819357 51734695.5 169323
RP11-423F16 19 56300117 56487777 56393947 187660
RP5-1060P11 19 59906569 59990304 59948436.5 83735
RPl 1-394L10 19 60898594 61072653 60985623.5 174059
CTD-3138B18 19 63340054 63500905 63420479.5 160851
RP4-686C3 20 2441323 2600594 2520958.5 159271
RP4-811H13 20 9197701 9340955 9269328 143254
RPl 1-526K24 20 13564713 13774030 13669371.5 209317
RP5-1096J16 20 20143748 20240131 20191939.5 96383
RP5-1025A1 20 24936530 25109994 25023262 173464
RP1-310O13 20 31173458 31336433 31254945.5 162975
418RP5-1161H23 20 34112722 34254763 34183742.5 142041
RP4-633O20 20 37039719 37136178 37087948.5 96459
RP1-232N11 20 41885784 41997424 41941604 111640
RP3-337018 20 45094666 45180745 45137705.5 86079
RP4-791K14 20 48587999 48743316 48665657.5 155317
RP4-724E16 20 52766526 52895396 52830961 128870
RP5-1167H4 20 55541473 55677165 55609319 135692
RP4-719C8 20 58788624 58939608 58864116 150984
RP5-1107C24 20 61099667 61221648 61160657.5 121981
RP1-270M7 21 15134622 15379650 15257136 245028
RPl 1-258A5 21 22151924 22333706 22242815 181782
RPl 1-15H6 21 26643245 26798260 26720752.5 155015
RP1-245P17 21 34482485 34601463 34541974 118978
RPl 1-164E1 21 38599546 38738905 38669225.5 139359
RPl 1-113F1 21 42528815 42710796 42619805.5 181981
CTA-221G9 22 23874371 23991534 23932952.5 117163
RP3-353E16 22 26491834 26717291 26604562.5 225457
RP1-127L4 22 30829975 30927214 30878594.5 97239
CTA-221H1 22 32879027 32927801 32903414 48774
CTA-445C9 22 36033386 36125793 36079589.5 92407
RPl 1-12M9 22 39614662 39790948 39702805 176286
RP3-437M21 22 41430046 41517447 41473746.5 87401
RP3-398C22 22 44312892 44441800 44377346 128908
RP5-925J7 22 47573681 47672127 47622904 98446
RP1-122K4 23 13107070 13307215 13207142.5 200145
RP 11 -421K1 23 18257078 18448395 18352736.5 191317
RPl 1-37E19 23 28220640 28306944 28263792 86304
419RP5-1147016 23 31639277 31771566 31705421.5 132289
RPl 1-469E19 23 39714763 39904047 39809405 189284
RP5-1158E12 23 44467859 44631729 44549794 163870
RPl 1-576P23 23 48815725 48982820 48899272.5 167095
RP13-34C21 23 60584706 60779286 60681996 194580
RPl 1-284B18 23 61667590 61836491 61752040.5 168901
RPl 1-523P2 23 69685582 69880502 69783042 194920
RPl 1-159L8 23 76407107 76573916 76490511.5 166809
RP5-1156N12 23 79543649 79690008 79616828.5 146359
RP5-1109K10 23 81885385 81995148 81940266.5 109763
RP13-166C10 23 88331157 88482056 88406606.5 150899
RPl 1-274M8 23 94499022 94658413 94578717.5 159391
RPl 1-230E14 23 101644461 101803008 101723734.5 158547
RP5-820B18 23 105067893 105195945 105131919 128052
RP5-914P14 23 108481901 108637275 108559588 155374
RP6-155F9 23 115573778 115696451 115635114.5 122673
RP1-181N1 23 120342878 120469351 120406114.5 126473
RP6-109P7 23 125880539 126039266 125959902.5 158727
RP5-965E19 23 129301158 129460507 129380832.5 159349
RP1-20J23 23 134389225 134526335 134457780 137110
RPl 1-518F7 23 138317108 138482486 138399797 165378
RPl 1-390024 23 142033283 142211890 142122586.5 178607
RP5-937E21 23 146524468 146636027 146580247.5 111559
RPl 1-54120 23 150291840 150471039 150381439.5 179199
420A.2 7q BAC clones
1082 BAC clones for chromosome 7q were selected from the BAC 32k 
rearray produced by BACPAC resources at the Oakland Children’s Hospital, 
Oakland, CA, USA. The whole genome set was purchased as a series of prepared 
BAC DNA, and 7q clones were selected and amplified by DOP-PCR. Clones 
producing unexpected hybridisation on the final array are highlighted in yellow.
Clone Name Chromosome Start End Mid point Length
RPl 1-764P14 1 21980519 22120000 22050259.5 139481
RPl 1-15K14 1 57593750 57638814 57616282 45064
RPl 1-104  J19 1 83571016 83648391 83609703.5 77375
RPl 1-34016 1 234896179 234971851 234934015 75672
CTD-2017N4 2 41341791 41399901 41370846 58110
RPl 1-454E16 2 119825056 119892019 119858537.5 66963
RPl 1-612G11 3 4525274 4659725 4592499.5 134451
RP13-866K15 3 106807531 106871559 106839545 64028
RPl 1-767K21 4 118488401 118600000 118544200.5 111599
RPl 1-69216 4 135439967 135517137 135478552 77170
RPl 1-637124 4 164311751 164344833 164328292 33082
RPl 1-659F13 6 88922418 88986995 88954706.5 64577
RPl 1-172013 7 5499542 5668701 5584121.5 169159
RPl 1-505D17 7 7741405 7930339 7835872 188934
RPl 1-172C5 7 19278897 19354440 19316668.5 75543
RPl 1-486P11 7 19813021 19987132 19900076.5 174111
RP11-343P21 7 24296329 24465905 24381117 169576
421RPl 1-818A14 7 25880205 25942006 25911105.5 61801
CTD-2004J10 7 56624162 56759445 56691803.5 135283
RPl 1-1298L14 7 56629051 56839676 56734363.5 210625
RP11-410M8 7 60902367 61068300 60985333.5 165933
RP11-533E18 7 60900893 61085935 60993414 185042
RP13-621P11 7 61053523 61082414 61067968.5 28891
RPl 1-34122 7 61420370 61604430 61512400 184060
CTD-2420F24 7 61537065 61566295 61551680 29230
RPl 1-112015 7 61604424 61762853 61683638.5 158429
CTD-2229D8 7 61747424 61884692 61816058 137268
RP11-288C22 7 61941236 62121831 62031533.5 180595
RPl 1-373D7 7 62042085 62168633 62105359 126548
RPl 1-44505 7 62099056 62346012 62222534 246956
RPl 1-560L17 7 62176597 62328847 62252722 152250
CTD-2005N23 7 62196113 62316194 62256153.5 120081
RPl 1-73B2 7 62196113 62316194 62256153.5 120081
RP11-1162A20 7 62176597 62346012 62261304.5 169415
RPl 1-1268A5 7 62176597 62346012 62261304.5 169415
RPl 1-555G16 7 62415501 62581198 62498349.5 165697
RPl 1-618G11 7 62406872 62591309 62499090.5 184437
RPl 1-331L17 7 62441180 62623260 62532220 182080
RPl 1-802G15 7 62547503 62724726 62636114.5 177223
RPl 1-500H11 7 62623261 62781464 62702362.5 158203
CTD-2143G24 7 62848012 62981658 62914835 133646
RPl 1-726L22 7 62920373 63118752 63019562.5 198379
RPl 1-585N1 7 62993350 63165317 63079333.5 171967
RPl 1-584F18 7 63068804 63235110 63151957 166306
422RP11-725P15 7 63104011 63302395 63203203 198384
RP11-561012 7 63247581 63440908 63344244.5 193327
RP11-149J7 7 63392493 63565761 63479127 173268
RP11-417K4 7 63426208 63611584 63518896 185376
RP11-416N13 7 63488050 63693966 63591008 205916
RP11-263F16 7 63564798 63693966 63629382 129168
RP11-493114 7 63598125 63815665 63706895 217540
RP11-637E4 7 63687614 63863547 63775580.5 175933
RP11-808P5 7 63780000 63970285 63875142.5 190285
,  RP11-466B18 7 63863813 64024115 63943964 160302
RP11-225E12 7 63874986 64036736 63955861 161750
RP11-12L22 7 63912609 64073410 63993009.5 160801
CTD-2090P17 7 64015538 64115462 64065500 99924
RP13-650L9 7 64014519 64157106 64085812.5 142587
RP13-887C2 7 64097646 64225895 64161770.5 128249
RP11-350C17 7 64099891 64274606 64187248.5 174715
RP11-328P23 7 64150188 64225895 64188041.5 75707
RP13-244017 7 64107525 64294312 64200918.5 186787
CTD-2288I20 7 64149128 64292262 64220695 143134
RP11-521010 7 64150188 64300275 64225231.5 150087
RP11-746P2 7 64150188 64321567 64235877.5 171379
RP13-929L15 7 64199976 64321567 64260771.5 121591
RP13-680C23 7 64210249 64393129 64301689 182880
RP11-667F9 7 64291470 64343664 64317567 52194
RP13-626B11 7 64384198 64495088 64439643 110890
RP11-124K5 7 64424689 64515187 64469938 90498
RP11-551F1 7 64429612 64556370 64492991 126758
423RP11-445F7 7 64429612 64595091 64512351.5 165479
RP11-146A10 7 64465603 64565479 64515541 99876
RP13-171N4 7 64429612 64625953 64527782.5 196341
RP13-157F18 7 64419123 64648950 64534036.5 229827
RP11-96H22 7 64454792 64623450 64539121 168658
RP11-465L14 7 64427093 64665343 64546218 238250
RP11-522D19 7 64429612 64665343 64547477.5 235731
RP11-47909 7 64535967 64728195 64632081 192228
RP11-265G24 7 64610556 64821321 64715938.5 210765
,  RP11-567L18 7 64610556 64821321 64715938.5 210765
RP11-376L15 7 64779110 64942870 64860990 163760
RP11-636K11 7 64855188 65025393 64940290.5 170205
RP11-732N17 7 64855188 65035288 64945238 180100
RP11-763P10 7 64985190 65200253 65092721.5 215063
RP11-318B19 7 65150900 65353464 65252182 202564
RP11-618F10 7 65335959 65504079 65420019 168120
RP11-350A24 7 65484475 65663813 65574144 179338
RP11-217F24 7 65541083 65647129 65594106 106046
RP11-701N9 7 65614342 65726526 65670434 112184
RP11-605M5 7 65598163 65801440 65699801.5 203277
CTD-2140O19 7 65720032 65896612 65808322 176580
RP11-6C21 7 65798928 65980537 65889732.5 181609
RP11-325K1 7 65843310 66015941 65929625.5 172631
RP11-368E23 7 65960958 66164635 66062796.5 203677
RP13-500P23 7 66032848 66189383 66111115.5 156535
RP11-243C20 7 66140699 66322463 66231581 181764
CTD-2011 LI 5 7 66151160 66335601 66243380.5 184441
424RP13-936H15 7 66310518 66465758 66388138 155240
RP13-628N2 7 66413722 66554741 66484231.5 141019
RP13-827M24 7 66461278 66583218 66522248 121940
RP13-829H10 7 66507264 66552207 66529735.5 44943
RP13-525L9 7 66507264 66621396 66564330 114132
RP11-522A22 7 66459386 66704367 66581876.5 244981
RP11-446P8 7 66682329 66883765 66783047 201436
CTD-2337G16 7 66806739 66907490 66857114.5 100751
RP11-752D15 7 66878330 67028660 66953495 150330
RP11-793E12 7 66951340 67179746 67065543 228406
RP11-339E23 7 67159505 67350483 67254994 190978
RP11-754N7 7 67205052 67392557 67298804.5 187505
RP11-156A14 7 67357045 67519496 67438270.5 162451
RP11-156A14 7 67357045 67519496 67438270.5 162451
RP11-151E8 7 67483110 67618584 67550847 135474
RP11-521N10 7 67618585 67782919 67700752 164334
RP11-535N23 7 67749005 67918785 67833895 169780
RP11-594G14 7 67748165 67957400 67852782.5 209235
RP11-547J3 7 68017401 68190260 68103830.5 172859
RP11-752M2 7 68110519 68224668 68167593.5 114149
RP11-790K18 7 68250971 68447376 68349173.5 196405
RP11-561G6 7 68383831 68540830 68462330.5 156999
RP11-617P15 7 68407458 68591111 68499284.5 183653
RP11-818D5 7 68443565 68658171 68550868 214606
RP11-358I11 7 68566820 68809142 68687981 242322
RP11-170H15 7 68659462 68813002 68736232 153540
RP11-232F14 7 68767880 68924046 68845963 156166
425RP11-309P19 7 68920563 69060225 68990394 139662
RP11-138M21 7 69006585 69147184 69076884.5 140599
RP11-801B4 7 69087377 69273898 69180637.5 186521
RP11-180J15 7 69219215 69423175 69321195 203960
RP11-689B18 7 69439915 69661929 69550922 222014
RP11-366L17 7 69634002 69682830 69658416 48828
RP11-575M4 7 69630435 69817986 69724210.5 187551
RP11-80305 7 69752965 69958239 69855602 205274
RP11-49203 7 69938062 70140768 70039415 202706
RP11-330E10 7 70072482 70284888 70178685 212406
RP11-786A1 7 70193724 70322667 70258195.5 128943
RP11-237L22 7 70280835 70454588 70367711.5 173753
RP11-332E12 7 70444428 70616535 70530481.5 172107
RP11-421B22 7 70568140 70756211 70662175.5 188071
RP11-395G21 7 70678115 70881857 70779986 203742
RP11-460F3 7 70816056 71008669 70912362.5 192613
RP11-90B1 7 70888200 71032684 70960442 144484
RP11-694L3 7 70940726 71116177 71028451.5 175451
RP11-53M13 7 71011779 71177768 71094773.5 165989
RP11-746H3 7 71014000 71179901 71096950.5 165901
RP11-751G4 7 71039330 71177768 71108549 138438
RP11-642F10 7 71011779 71258401 71135090 246622
RP11-542011 7 71171643 71321909 71246776 150266
CTD-2018O17 7 71225446 71351669 71288557.5 126223
RP11-359E24 7 71302680 71489145 71395912.5 186465
RP11-32N3 7 71351670 71506334 71429002 154664
RP11-576G4 7 71403999 71559889 71481944 155890
426RP11-35P20 7 71464807 71637730 71551268.5 172923
RP11-213A22 7 71489180 71640842 71565011 151662
RP11-519I5 7 71528854 71684059 71606456.5 155205
RP11-795J4 7 71590803 71782008 71686405.5 191205
RP11-78P11 7 71673466 71832562 71753014 159096
RP11-762B10 7 71778705 71969666 71874185.5 190961
RP11-313P13 7 71778705 71971622 71875163.5 192917
RP11-1328G23 7 71766538 71996821 71881679.5 230283
CTD-2143B9 7 71821081 71971622 71896351.5 150541
RP11-780K20 7 71843425 72034679 71939052 191254
RP11-548E9 7 71881953 72060659 71971306 178706
RP11-728E18 7 71963625 72133505 72048565 169880
RP11-367N11 7 71963826 72164463 72064144.5 200637
RP11-334D20 7 72032613 72301047 72166830 268434
RP11-28812 7 72141187 72319733 72230460 178546
RP11-101D2 7 72259198 72436625 72347911.5 177427
RP11-667P12 7 72242381 72480257 72361319 237876
RP11-552B12 7 72329400 72504915 72417157.5 175515
RP11-590H3 7 72415294 72585074 72500184 169780
RP11-737E18 7 72415294 72675576 72545435 260282
RP11-100D10 7 72519572 72682330 72600951 162758
RP11-307G22 7 72570957 72789866 72680411.5 218909
RP11-11122 7 72611015 72811598 72711306.5 200583
RP13-56808 7 72771565 72927656 72849610.5 156091
RP11-644H24 7 72839800 73004869 72922334.5 165069
RP11-356N2 7 72874739 73045496 72960117.5 170757
RP11-100C23 7 72929705 73136892 73033298.5 207187
427RP11-41F22 7 72970758 73109172 73039965 138414
RP11-331N10 7 72981346 73134408 73057877 153062
RP11-42201 7 73141937 73264896 73203416.5 122959
RP11-329B5 7 73174290 73340724 73257507 166434
RP11-189A5 7 73233795 73429688 73331741.5 195893
RP11-196F10 7 73317260 73482782 73400021 165522
RP11-137E8 7 73389370 73574238 73481804 184868
RP11-583G15 7 73411006 73559231 73485118.5 148225
RP11-659G13 7 73411006 73588349 73499677.5 177343
RP11-180C6 7 73413479 73588349 73500914 174870
RP11-91L7 7 73413479 73588349 73500914 174870
RP11-1328E4 7 73487707 73707365 73597536 219658
RP11-813J7 7 73530488 73707365 73618926.5 176877
RP11-259J2 7 73597589 73763640 73680614.5 166051
RP11-681A16 7 73645740 73812663 73729201.5 166923
CTD-2285H13 7 73708037 73829266 73768651.5 121229
RP11-774J17 7 73774411 73946646 73860528.5 172235
RP11-1254M14 7 73825432 74015866 73920649 190434
RP11-219M8 7 73861902 74050724 73956313 188822
RP 11-502124 7 73946647 74100113 74023380 153466
RP11-567F24 7 73958192 74100113 74029152.5 141921
CTD-210414 7 74108701 74157258 74132979.5 48557
RP11-119P19 7 74596259 74710216 74653237.5 113957
RP11-613J9 7 74620669 74847736 74734202.5 227067
RP11-279K6 7 74689304 74870225 74779764.5 180921
RP11-99J9 7 74771608 74952654 74862131 181046
RP11-429B10 7 74900077 75062475 74981276 162398
428RP 11-812L15 7 74966957 75152692 75059824.5 185735
CTD-2032H20 7 75072873 75254057 75163465 181184
RP11-379D10 7 75164883 75317803 75241343 152920
RP11-229D13 7 75221960 75388533 75305246.5 166573
RP11-7A21 7 75330292 75498794 75414543 168502
RP11-351A5 7 75695279 75770021 75732650 74742
RP11-122A5 7 75767576 75949027 75858301.5 181451
RP11-398010 7 75919802 76088478 76004140 168676
RP11-683119 7 75954043 76144650 76049346.5 190607
RP11-85K14 7 76026292 76203167 76114729.5 176875
RP11-409L7 7 76048273 76183097 76115685 134824
RP11-506L7 7 76117750 76319174 76218462 201424
RP11-672F22 7 76242931 76418754 76330842.5 175823
RP11-467H10 7 76297379 76493929 76395654 196550
RP11-275G11 7 76491236 76674207 76582721.5 182971
RP11-764116 7 76517399 76680579 76598989 163180
RP11-533K2 7 76587420 76774091 76680755.5 186671
RP11-176J13 7 76758870 76923102 76840986 164232
RP11-229J1 7 76838579 76996855 76917717 158276
RP11-98012 7 76946486 77120129 77033307.5 173643
RP 11-60416 7 77039517 77218346 77128931.5 178829
RP11-86C23 7 77081758 77213123 77147440.5 131365
RP11-44608 7 77122663 77364719 77243691 242056
RP11-157F12 7 77326058 77508779 77417418.5 182721
RP 11-29417 7 77399856 77591743 77495799.5 191887
CTD-2242M21 7 77524430 77631633 77578031.5 107203
RP11-567K8 7 77505194 77686751 77595972.5 181557
429RP11-538D15 7 77505194 77705500 77605347 200306
RP11-634B10 7 77574029 77772382 77673205.5 198353
RP11-788P16 7 77614347 77783217 77698782 168870
RP11-144P23 7 77652773 77789143 77720958 136370
RP11-290P2 7 77721708 77939218 77830463 217510
RP11-130120 7 77862948 78029856 77946402 166908
RP11-210G8 7 77993295 78153755 78073525 160460
RP11-758019 7 78187961 78375276 78281618.5 187315
RP13-486L4 7 78267846 78476649 78372247.5 208803
RP11-718N3 7 78348835 78520898 78434866.5 172063
RP11-390C15 7 78439299 78597845 78518572 158546
RP11-561D14 7 78464150 78617873 78541011.5 153723
RP11-638G10 7 78597846 78762614 78680230 164768
RP 11-47212 7 78727275 78907495 78817385 180220
RP11-757A2 7 78844612 79035883 78940247.5 191271
RP11-327P19 7 78917558 79094083 79005820.5 176525
RP11-566B4 7 79027204 79206634 79116919 179430
RP11-500G1 7 79098073 79275458 79186765.5 177385
RP11-317H18 7 79173130 79335517 79254323.5 162387
RP11-176M5 7 79315596 79449943 79382769.5 134347
RP 11-46913 7 79370782 79514484 79442633 143702
RP11-421P24 7 79405990 79589008 79497499 183018
RP11-512J17 7 79477517 79628729 79553123 151212
RP11-284B4 7 79628730 79766963 79697846.5 138233
RP11-331E13 7 79663018 79824856 79743937 161838
RP11-764E4 7 79764065 79966743 79865404 202678
RP11-563A3 7 79924739 80139245 80031992 214506
430RP11-501A18 7 80102558 80259014 80180786 156456
RP11-520A8 7 80254235 80411748 80332991.5 157513
RP11-633A20 7 80366424 80563242 80464833 196818
RP11-223F3 7 80486344 80657055 80571699.5 170711
RP11-665G16 7 80525983 80724425 80625204 198442
RP11-211K16 7 80568191 80718612 80643401.5 150421
RP 11-284124 7 80716396 80893900 80805148 177504
RP11-295A1 7 80827692 81001334 80914513 173642
RP11-24F4 7 80961854 81140390 81051122 178536
RP11-448A3 7 80965735 81157984 81061859.5 192249
RP11-522D24 7 81047718 81223527 81135622.5 175809
RP11-575G1 7 81230368 81424378 81327373 194010
RP11-459E23 7 81390339 81547805 81469072 157466
RP11-556B13 7 81515961 81670637 81593299 154676
RP11-560N24 7 81626840 81804831 81715835.5 177991
RP11-39H7 7 81794174 82009417 81901795.5 215243
RP 11-78914 7 81940351 82140185 82040268 199834
RP11-56M7 7 82010714 82169871 82090292.5 159157
RP11-56203 7 82011240 82219036 82115138 207796
RP 11-24013 7 82140186 82315457 82227821.5 175271
CTD-2085L13 7 82246720 82355800 82301260 109080
RP11-261H1 7 82264155 82423339 82343747 159184
RP11-785F16 7 82293334 82472163 82382748.5 178829
RP11-796P2 7 82387322 82578005 82482663.5 190683
RP11-142G6 7 82471135 82637070 82554102.5 165935
RP11-772C17 7 82588795 82767188 82677991.5 178393
RP11-592A12 7 82726787 82905118 82815952.5 178331
431RP11-750H24 7 82840903 83012166 82926534.5 171263
RP11-514G1 7 82923829 83111542 83017685.5 187713
RP11-456A9 7 83020089 83204224 83112156.5 184135
RP11-398N16 7 83133933 83293271 83213602 159338
RP11-794C5 7 83218908 83433600 83326254 214692
RP11-115M2 7 83253404 83404554 83328979 151150
RP 11-488020 7 83265657 83467392 83366524.5 201735
RP11-166121 7 83312072 83467392 83389732 155320
RP11-663J4 7 83348114 83550882 83449498 202768
CTD-201004 7 83377432 83524652 83451042 147220
RP11-98M4 7 83460861 83610655 83535758 149794
RP11-343P19 7 83451737 83630396 83541066.5 178659
RP11-572C2 7 83536658 83693553 83615105.5 156895
RP11-674G6 7 83692641 83847856 83770248.5 155215
RP11-600K18 7 83774675 83978080 83876377.5 203405
RP13-959M22 7 83805221 83971740 83888480.5 166519
RP11-750F10 7 83876589 84052732 83964660.5 176143
RP11-746J12 7 83922250 84120361 84021305.5 198111
RP11-29909 7 84000647 84171912 84086279.5 171265
RP11-765N7 7 84179139 84344811 84261975 165672
RP11-617F3 7 84237140 84424961 84331050.5 187821
RP11-343D5 7 84250600 84448204 84349402 197604
RP11-270A23 7 84319911 84498431 84409171 178520
RP11-269B15 7 84376350 84536300 84456325 159950
RP11-683E23 7 84389905 84573523 84481714 183618
RP11-34905 7 84406854 84587182 84497018 180328
RP11-533L22 7 84537359 84707351 84622355 169992
432RP11-706L16 7 84649308 84780969 84715138.5 131661
RP11-278A21 7 84799599 84966567 84883083 166968
RP11-695L4 7 84870411 85035793 84953102 165382
CTD-2023H7 7 84953468 85053534 85003501 100066
CTD-2083K15 7 84975040 85084144 85029592 109104
RP13-535J21 7 85011183 85151554 85081368.5 140371
CTD-2265E6 7 85032482 85136294 85084388 103812
RP13-483024 7 85070497 85245896 85158196.5 175399
CTD-2651D18 7 85092011 85291211 85191611 199200
RP11-729A18 7 85222295 85384466 85303380.5 162171
RP11-561F17 7 85339868 85495476 85417672 155608
RP11-43507 7 85441441 85605530 85523485.5 164089
RP11-555E22 7 85639303 85833284 85736293.5 193981
RP11-28704 7 85757083 85922055 85839569 164972
RP11-669A8 7 85912822 86085650 85999236 172828
RP11-449H8 7 86021997 86206087 86114042 184090
RP11-811P13 7 86054671 86277736 86166203.5 223065
RP11-543E17 7 86284097 86475852 86379974.5 191755
RP11-69L24 7 86363255 86527064 86445159.5 163809
RP11-488M3 7 86380556 86563553 86472054.5 182997
RP11-310P19 7 86389443 86563553 86476498 174110
RP11-575C11 7 86499469 86666561 86583015 167092
RP11-127F1 7 86659102 86811423 86735262.5 152321
RP11-537J16 7 86702498 86857403 86779950.5 154905
RP11-103N4 7 86822603 86990346 86906474.5 167743
RP11-784B3 7 86855425 87078303 86966864 222878
RP11-513N8 7 86954450
.
87124028 87039239 169578
433RP11-542G18 7 87051502 87252322 87151912 200820
RP11-803P20 7 87240760 87430447 87335603.5 189687
RP11-315D17 7 87378607 87564718 87471662.5 186111
RP11-815D20 7 87509173 87695944 87602558.5 186771
RP11-462N5 7 87558480 87714977 87636728.5 156497
RP11-470G18 7 87731845 87945648 87838746.5 213803
RP11-174114 7 87804935 87968364 87886649.5 163429
RP11-493G7 7 87866824 88062333 87964578.5 195509
RP11-766E9 7 87891721 88084221 87987971 192500
RP13-577C5 7 87965641 88142802 88054221.5 177161
RP11-772C5 7 88044311 88193159 88118735 148848
RP13-220C18 7 88044311 88222389 88133350 178078
RP13-359015 7 88072176 88246113 88159144.5 173937
RP11-209B4 7 88127207 88264152 88195679.5 136945
RP11-1279M16 7 88127207 88305425 88216316 178218
RP11-756A17 7 88257143 88441998 88349570.5 184855
RP11-82D15 7 88328564 88515266 88421915 186702
RP11-693A17 7 88352275 88564392 88458333.5 212117
CTD-2326K17 7 88444568 88547502 88496035 102934
RP11-702P9 7 88497523 88650479 88574001 152956
RP11-279D8 7 88514554 88670815 88592684.5 156261
RP11-732C21 7 88505913 88700714 88603313.5 194801
RP11-19209 7 88589450 88741028 88665239 151578
RP11-360F3 7 88650481 88804737 88727609 154256
RP 11-62413 7 88766086 88945296 88855691 179210
RP11-734C11 7 88797827 88974504 88886165.5 176677
RP11-404B16 7 88947165 89104685 89025925 157520
434RP11-12D1 7 89068064 89257523 89162793.5 189459
RP11-584M11 7 89143108 89317970 89230539 174862
RP11-45105 7 89241989 89425049 89333519 183060
RP13-560A13 7 89275939 89432393 89354166 156454
RP11-454K3 7 89297229 89468333 89382781 171104
RP11-660C12 7 89297622 89473971 89385796.5 176349
CTD-2038A8 7 89364926 89511319 89438122.5 146393
RP11-248A17 7 89380390 89509445 89444917.5 129055
RP11-544P11 7 89476556 89655603 89566079.5 179047
RP11-594G22 7 89578340 89731552 89654946 153212
RP11-57306 7 89647357 89850441 89748899 203084
RP11-717E22 7 89764787 89985650 89875218.5 220863
RP13-508F18 7 89899361 90068993 89984177 169632
RP11-298J7 7 90006176 90144413 90075294.5 138237
RP11-553F2 7 90006176 90176583 90091379.5 170407
RP11-98J8 7 90083990 90269903 90176946.5 185913
RP11-215P16 7 90123930 90278380 90201155 154450
RP11-342C19 7 90234101 90383349 90308725 149248
RP11-291D21 7 90278381 90416651 90347516 138270
RP11-337D7 7 90496685 90694000 90595342.5 197315
RP11-646C11 7 90563861 90757345 90660603 193484
RP11-658E10 7 90598652 90816097 90707374.5 217445
RP11-332H6 7 90745616 90928607 90837111.5 182991
CTD-2333B13 7 90776867 90900353 90838610 123486
RP11-568M21 7 90772084 90975471 90873777.5 203387
RP11-225G3 7 90913043 91109788 91011415.5 196745
RP11-62D6 7 90964659 91126591 91045625 161932
435RP11-806014 7 91040071 91237927 91138999 197856
RP11-623E20 7 91226541 91352826 91289683.5 126285
RP11-371H19 7 91245408 91406462 91325935 161054
RP11-291G20 7 91388974 91592980 91490977 204006
RP11-339M3 7 91514274 91724132 91619203 209858
RP 11-73601 7 91608735 91777185 91692960 168450
RP11-606J5 7 91681581 91860158 91770869.5 178577
RP11-82E23 7 91781912 91951988 91866950 170076
RP11-514K1 7 91885885 92105262 91995573.5 219377
RP11-332M5 7 91975364 92160167 92067765.5 184803
RP11-467N23 7 92075268 92260660 92167964 185392
CTD-2260H18 7 92197467 92346033 92271750 148566
RP11-335L6 7 92283061 92490798 92386929.5 207737
RP11-773N18 7 92450337 92659473 92554905 209136
RP11-269A13 7 92648735 92786012 92717373.5 137277
RP11-309L13 7 92672117 92853228 92762672.5 181111
RP11-471H1 7 92784568 92947529 92866048.5 162961
RP11-78F12 7 92983772 93174165 93078968.5 190393
RP11-461H15 7 93150129 93326095 93238112 175966
RP11-470G15 7 93492602 93648187 93570394.5 155585
RP11-57C4 7 93647739 93812420 93730079.5 164681
CTD-2130O12 7 93794436 93909780 93852108 115344
RP11-648L18 7 93852006 94002009 93927007.5 150003
RP11-367L3 7 93845994 94038039 93942016.5 192045
RP11-564F14 7 94016109 94188079 94102094 171970
RP11-619A2 7 94149723 94338293 94244008 188570
RP11-82B2 7 94282577 94456401 94369489 173824
436RP11-601D18 7 94463006 94606231 94534618.5 143225
RP11-48F16 7 94548068 94709169 94628618.5 161101
RP11-674B12 7 94665835 94887039 94776437 221204
RP11-84F19 7 94820970 94990548 94905759 169578
RP11-95A10 7 94927842 95117170 95022506 189328
RP11-295J1 7 94990549 95170265 95080407 179716
RP11-574B19 7 95033117 95233192 95133154.5 200075
RP11-769F19 7 95189210 95370254 95279732 181044
RP11-94N6 7 95370026 95523366 95446696 153340
RP11-814L20 7 95463854 95630339 95547096.5 166485
RP11-413E12 7 95589287 95787884 95688585.5 198597
RP11-610J1 7 95752181 95933693 95842937 181512
RP11-418K11 7 95920483 96080682 96000582.5 160199
RP11-94N7 7 96020619 96192101 96106360 171482
RP11-2N22 7 96190805 96367434 96279119.5 176629
RP11-63H9 7 96347104 96519179 96433141.5 172075
RP11-800014 7 96410124 96616120 96513122 205996
RP11-184F2 7 96596782 96746120 96671451 149338
RP11-321E18 7 96721430 96934470 96827950 213040
RP11-312C19 7 96833385 96981453 96907419 148068
RP11-743C24 7 96960514 97146716 97053615 186202
RP11-380G21 7 97120935 97292680 97206807.5 171745
RP 11-52614 7 97259838 97409099 97334468.5 149261
RP11-212K3 7 97371530 97535201 97453365.5 163671
RP11-52E8 7 97477080 97644254 97560667 167174
RP11-65E17 7 97504820 97710179 97607499.5 205359
RP11-723A10 7 97563681 97676851 97620266 113170
437RP11-473H4 7 97726720 97900477 97813598.5 173757
RP11-470P14 7 97838856 98018471 97928663.5 179615
RP11-112P23 7 97974638 98128898 98051768 154260
RP11-802H13 7 98094101 98277304 98185702.5 183203
RP11-412N23 7 98181856 98313174 98247515 131318
RP11-1358J4 7 98265318 98454943 98360130.5 189625
RP11-694E14 7 98277414 98460689 98369051.5 183275
RP13-1013E23 7 98469549 98615253 98542401 145704
RP11-140D10 7 98464223 98651132 98557677.5 186909
RP11-112113 7 98592779 98772235 98682507 179456
RP11-717M24 7 98778305 98979264 98878784.5 200959
RP11-757A13 7 98913558 99107604 99010581 194046
RP11-543L21 7 99079251 99262630 99170940.5 183379
RP11-487B17 7 99216953 99367271 99292112 150318
RP11-494B20 7 99318239 99367271 99342755 49032
RP11-443E21 7 99375909 99604363 99490136 228454
RP11-758P17 7 99562676 99758064 99660370 195388
RP11-44M6 7 99680294 99845417 99762855.5 165123
RP11-344K24 7 99807154 100007486 99907320 200332
RP11-336D7 7 99861727 100040000 99950863.5 178273
RP11-126L15 7 100007608 100172069 100089838.5 164461
RP13-650G11 7 100070310 100189539 100129924.5 119229
RP11-395B7 7 100199486 100338967 100269226.5 139481
RP11-279E13 7 100246271 100411890 100329080.5 165619
RP11-484K16 7 100285732 100510453 100398092.5 224721
RP11-55407 7 100397851 100560929 100479390 163078
RP11-151L12 7 100422282 100605109 100513695.5 182827
438RP11-132A1 7 100467644 100677365 100572504.5 209721
RP11-596H8 7 100688380 100850921 100769650.5 162541
RP11-277D15 7 100803715 100970467 100887091 166752
RP11-692F19 7 100866930 101060211 100963570.5 193281
RP11-962B9 7 101011690 101197426 101104558 185736
RP11-177B2 7 101057565 101228116 101142840.5 170551
RP11-703F10 7 101222556 101402062 101312309 179506
RP11-396D9 7 101286517 101478869 101382693 192352
RP11-765M9 7 101399535 101581563 101490549 182028
RP11-163E9 7 101494175 101666161 101580168 171986
RP11-342G18 7 101574440 101889820 101732130 315380
RJP13-771B7 7 101730411 101830616 101780513.5 100205
RP13-944M22 7 101730411 101908605 101819508 178194
RP13-874J16 7 101749448 101908605 101829026.5 159157
RP11-1385F10 7 101730411 101928015 101829213 197604
RP11-676J21 7 101808025 101908605 101858315 100580
RP11-792E22 7 101776746 101969901 101873323.5 193155
RP11-694M1 7 101900000 102081147 101990573.5 181147
RP11-617P22 7 102057995 102281705 102169850 223710
RP11-226H9 7 102285195 102447467 102366331 162272
RP11-203D11 7 102372859 102558921 102465890 186062
RP11-779F24 7 102501181 102707747 102604464 206566
RP11-186B5 7 102633570 102813087 102723328.5 179517
RP 11-424G13 7 102734623 102936339 102835481 201716
RP11-510M19 7 102844684 103048153 102946418.5 203469
RP11-574B15 7 102969618 103162771 103066194.5 193153
RP11-689F3 7 103096409 103268595 103182502 172186
439RP11-815A11 7 103212352 103366689 103289520.5 154337
RP11-36J11 7 103305533 103460117 103382825 154584
RP11-451J3 7 103333988 103527366 103430677 193378
RP11-172N10 7 103509244 103679659 103594451.5 170415
RP11-150H24 7 103587014 103779432 103683223 192418
RP11-148A10 7 103737568 103889393 103813480.5 151825
RP11-640M20 7 103826865 104029888 103928376.5 203023
RP11-612L3 7 103867654 104055303 103961478.5 187649
RP11-203P23 7 104016454 104190717 104103585.5 174263
RP11-437M1 7 104113486 104314735 104214110.5 201249
RP11-753M2 7 104347813 104543037 104445425 195224
RP11-764M5 7 104462730 104611313 104537021.5 148583
RP11-708P17 7 104553819 104706452 104630135.5 152633
CTD-2305F9 7 104694931 104808189 104751560 113258
RP11-96B13 7 104762663 104914797 104838730 152134
RP11-752M11 7 104876692 105080591 104978641.5 203899
RP11-735J9 7 105040118 105181650 105110884 141532
CTD-2060N15 7 105147091 105299944 105223517.5 152853
RP11-193P5 7 105214647 105360515 105287581 145868
RP11-532G4 7 105239746 105409310 105324528 169564
CTD-2014M11 7 105360514 105490493 105425503.5 129979
RP11-22N19 7 105395309 105566071 105480690 170762
CTD-2026C17 7 105443947 105649531 105546739 205584
RP11-620K1 7 105476052 105669998 105573025 193946
RP11-621C24 7 105561634 105756778 105659206 195144
RP11-17110 7 105597335 105756723 105677029 159388
RP11-610G5 7 105627919 105822108 105725013.5 194189
440RP11-768J5 7 105707392 105893141 105800266.5 185749
RP11-687D7 7 105856379 106011089 105933734 154710
RP11-375A10 7 105908031 106085619 105996825 177588
RP11-523G16 7 106082845 106267131 106174988 184286
RP11-258L19 7 106182920 106346360 106264640 163440
RP11-262G16 7 106267416 106466411 106366913.5 198995
RP11-762B6 7 106403391 106572650 106488020.5 169259
RP 11-454121 7 106529757 106716110 106622933.5 186353
RP11-158F24 7 106558882 106701295 106630088.5 142413
RP11-764B12 7 106655311 106830949 106743130 175638
RP11-1N16 7 106706672 106862550 106784611 155878
CTD-2315016 7 106790439 106928106 106859272.5 137667
RP11-467F9 7 106843265 107018037 106930651 174772
RP11-516H16 7 106883096 107044176 106963636 161080
RP11-149B12 7 106977329 107168961 107073145 191632
RP11-443110 7 107091051 107287631 107189341 196580
RP11-698M9 7 107153601 107347972 107250786.5 194371
RP 11-70819 7 107269200 107432552 107350876 163352
RP11-649H20 7 107281569 107471191 107376380 189622
RP11-590J14 7 107380601 107605147 107492874 224546
CTD-2182E11 7 107634902 107720250 107677576 85348
RP11-139J13 7 107706571 107838229 107772400 131658
RP11-18H15 7 107779927 107931476 107855701.5 151549
RP11-152F20 7 107846683 108007125 107926904 160442
RP11-206A4 7 107931477 108068358 107999917.5 136881
RP11-372G6 7 108060421 108240355 108150388 179934
RP11-393L14 7 108161412 108338244 108249828 176832
441RP11-461P5 7 108189573 108370997 108280285 181424
RP11-698J23 7 108350169 108517595 108433882 167426
RP11-21G9 7 108400570 108575544 108488057 174974
RP11-90N13 7 108530568 108684654 108607611 154086
RP11-32519 7 108643780 108831936 108737858 188156
RP11-328M14 7 108820205 109013485 108916845 193280
RP11-718D16 7 108955016 109121654 109038335 166638
RP11-515113 7 109112115 109306191 109209153 194076
RP11-347P13 7 109179037 109385816 109282426.5 206779
RP11-110B16 7 109277103 109446394 109361748.5 169291
RP11-331K20 7 109393071 109581136 109487103.5 188065
RP11-64F12 7 109447938 109609486 109528712 161548
RP11-762D9 7 109546885 109700091 109623488 153206
RP11-639F12 7 109697013 109844116 109770564.5 147103
RP11-647L12 7 109813087 109961656 109887371.5 148569
RP11-312H11 7 109972971 110126699 110049835 153728
RP11-49508 7 110057541 110233163 110145352 175622
RP11-452K21 7 110202859 110381728 110292293.5 178869
CTD-2105K8 7 110286481 110450495 110368488 164014
RP11-645L13 7 110438906 110612834 110525870 173928
RP11-544C1 7 110584343 110770763 110677553 186420
RP11-86H8 7 110743496 110904224 110823860 160728
RP11-80H21 7 110818942 110975163 110897052.5 156221
RP11-124K17 7 110911401 111107805 111009603 196404
RP11-260P7 7 110992649 111176054 111084351.5 183405
RP11-382F18 7 111103847 111282168 111193007.5 178321
RP11-92J13 7 111233618 111401092 111317355 167474
442RP11-153L5 7 111381724 111555750 111468737 174026
RP11-315F18 7 111477314 111657880 111567597 180566
CTD-2252G20 7 111594788 111707124 111650956 112336
RP 11-397020 7 111662670 111826800 111744735 164130
RP11-674F20 7 111753987 111945379 111849683 191392
RP11-184K23 7 111823857 111982641 111903249 158784
RP11-259H24 7 112084438 112269456 112176947 185018
RP11-467K21 7 112178105 112362579 112270342 184474
RP11-638L12 7 112276571 112444564 112360567.5 167993
RP11-335D17 7 112316394 112538487 112427440.5 222093
RP11-698G17 7 112415340 112602267 112508803.5 186927
RP11-703P11 7 112530662 112684795 112607728.5 154133
RP11-786A20 7 112652900 112835444 112744172 182544
RP11-697C1 7 112782654 112948201 112865427.5 165547
RP11-158E8 7 112849253 113037563 112943408 188310
RP11-687A7 7 113037268 113224986 113131127 187718
RP11-43J7 7 113055027 113211379 113133203 156352
RP11-658L17 7 113290825 113405020 113347922.5 114195
RP11-433L10 7 113296351 113457471 113376911 161120
CTD-2023N18 7 113377670 113525513 113451591.5 147843
RP11-160G23 7 113445564 113619447 113532505.5 173883
RP11-5312 7 113525514 113725786 113625650 200272
RP11-274E22 7 113661493 113812671 113737082 151178
RP11-664F19 7 113813391 114004005 113908698 190614
RP11-663118 7 113925921 114091366 114008643.5 165445
CTD-2340L2 7 114002799 114106349 114054574 103550
RP11-78C11 7 114102146 114261695 114181920.5 159549
443RP11-695F7 7 114157882 114340254 114249068 182372
RP11-488K2 7 114301749 114505070 114403409.5 203321
RP11-103A1 7 114409017 114573150 114491083.5 164133
RP11-17G24 7 114564920 114729171 114647045.5 164251
RP11-192B3 7 114680458 114834129 114757293.5 153671
RP11-164A15 7 114782264 114945318 114863791 163054
RP11-458K10 7 114911858 115128416 115020137 216558
RP11-22K23 7 115048848 115198394 115123621 149546
RP11-135K23 7 115121645 115268164 115194904.5 146519
RP11-242J21 7 115209498 115393576 115301537 184078
RP11-760110 7 115347661 115546310 115446985.5 198649
RP11-299N2 7 115491977 115652311 115572144 160334
RP11-413C23 7 115527476 115699897 115613686.5 172421
RP11-146P12 7 115573634 115751056 115662345 177422
RP11-691L23 7 115573634 115795471 115684552.5 221837
RP11-367L24 7 115650414 115795471 115722942.5 145057
RP11-730H9 7 115738660 115915208 115826934 176548
RP11-153D24 7 115833131 115996125 115914628 162994
RP 11-95120 7 115892918 116062671 115977794.5 169753
RP11-564A14 7 116008685 116243417 116126051 234732
RP11-706D4 7 116202831 116372147 116287489 169316
CTD-2163N8 7 116270185 116392319 116331252 122134
RP11-326M1 7 116343485 116545962 116444723.5 202477
CTD-2125N8 7 116435263 116567597 116501430 132334
RP 11-644B4 7 116551115 116741704 116646409.5 190589
RP11-182C8 7 116723712 116877465 116800588.5 153753
RP11-514N9 7 116773499 116967352 116870425.5 193853
444RP11-702P18 7 116934463 117153925 117044194 219462
RP11-69A8 7 117035127 117189569 117112348 154442
RP11-99N14 7 117175814 117334302 117255058 158488
RP11-79717 7 117287504 117459764 117373634 172260
RP11-31805 7 117449808 117606964 117528386 157156
RP11-110G3 7 117487407 117635500 117561453.5 148093
CTD-2002E16 7 117603751 117737780 117670765.5 134029
RP11-417K19 7 117716364 117894543 117805453.5 178179
RP11-808J6 7 117894544 118095729 117995136.5 201185
RP11-631C5 7 117946858 118117624 118032241 170766
RP11-747E15 7 117999639 118205979 118102809 206340
RP11-533K11 7 118137291 118333313 118235302 196022
RP11-304F13 7 118351102 118507350 118429226 156248
RP11-105B19 7 118436021 118613318 118524669.5 177297
RP11-418E22 7 118478492 118660097 118569294.5 181605
RP11-398D9 7 118633456 118794921 118714188.5 161465
RP11-447A2 7 118660098 118876217 118768157.5 216119
CTD-2009D17 7 118807484 118960176 118883830 152692
RP 11-722121 7 118834912 119022260 118928586 187348
RP11-642D23 7 118876218 119078218 118977218 202000
RP11-328J2 7 118950995 119115211 119033103 164216
RP11-542G3 7 119045589 119250062 119147825.5 204473
RP11-227H8 7 119179120 119370570 119274845 191450
RP11-317F8 7 119277466 119480228 119378847 202762
RP11-2C10 7 119508230 119671077 119589653.5 162847
RP11-683J21 7 119670108 119853467 119761787.5 183359
CTD-2006F7 7 119728155 119850608 119789381.5 122453
445RP11-367A17 7 119738869 119911447 119825158 172578
RP11-693C16 7 119876610 120089138 119982874 212528
RP11-291E13 7 120020363 120180087 120100225 159724
RP11-506L11 7 120189575 120398461 120294018 208886
RP11-69L14 7 120343110 120529807 120436458.5 186697
RP11-23L15 7 120428649 120571228 120499938.5 142579
RP11-583P4 7 120503933 120659306 120581619.5 155373
RP11-636H22 7 120645216 120849013 120747114.5 203797
RP11-651N9 7 120834002 120991323 120912662.5 157321
RP11-716D15 7 120902171 121089051 120995611 186880
RP11-217B9 7 120951567 121119054 121035310.5 167487
RP11-269L1 7 121005972 121176604 121091288 170632
RP11-407M2 7 121044165 121238797 121141481 194632
RP11-384A20 7 121121491 121279437 121200464 157946
RP11-367M11 7 121097893 121337847 121217870 239954
RP11-179C1 7 121295532 121470253 121382892.5 174721
RP11-95F4 7 121397679 121554961 121476320 157282
RP11-12H16 7 121483708 121654613 121569160.5 170905
RP11-197A20 7 121604983 121787109 121696046 182126
RP11-350G10 7 121738662 121919382 121829022 180720
RP11-770113 7 121790162 121971603 121880882.5 181441
RP11-805P19 7 121895552 122088724 121992138 193172
RP11-633J6 7 122023294 122212582 122117938 189288
RP11-61D3 7 122192244 122345539 122268891.5 153295
RP11-605K13 7 122297358 122480789 122389073.5 183431
RP11-58819 7 122473376 122666511 122569943.5 193135
RP11-15L19 7 122509495 122694782 122602138.5 185287
446RP11-674K13 7 122540790 122704085 122622437.5 163295
RP11-598C13 7 122681563 122853927 122767745 172364
RP11-746L19 7 122849569 123052370 122950969.5 202801
RP11-143J10 7 122924300 123080213 123002256.5 155913
RP11-601G11 7 123057049 123202774 123129911.5 145725
RP11-592J18 7 123138761 123318372 123228566.5 179611
RP11-345L15 7 123169643 123384384 123277013.5 214741
RP11-805E14 7 123397083 123591888 123494485.5 194805
RP11-618G22 7 123551327 123683137 123617232 131810
RP11-726A19 7 123647606 123855205 123751405.5 207599
RP11-379L24 7 123766218 123941478 123853848 175260
RP11-324E14 7 123865174 124025089 123945131.5 159915
RP11-661D8 7 123984966 124164118 124074542 179152
RP11-550C15 7 124069636 124227519 124148577.5 157883
RP11-415010 7 124203910 124357946 124280928 154036
RP11-3B12 7 124307960 124484070 124396015 176110
RP11-272G19 7 124407397 124583300 124495348.5 175903
RP11-420H19 7 124485201 124668576 124576888.5 183375
RP11-119C8 7 124568858 124707041 124637949.5 138183
RP11-818112 7 124562285 124750079 124656182 187794
RP11-807H17 7 124638725 124801647 124720186 162922
RP11-732N22 7 124640207 124847850 124744028.5 207643
RP11-210B22 7 124793577 124938633 124866105 145056
RP11-519011 7 124948922 125127005 125037963.5 178083
RP11-610F5 7 125047576 125192091 125119833.5 144515
RP11-398N23 7 125150998 125351170 125251084 200172
RP11-791P8 7 125369486 125529388 125449437 159902
447RP11-346L18 7 125465104 125629770 125547437 164666
RP11-510020 7 125577084 125770941 125674012.5 193857
RP11-105E3 7 125666080 125834115 125750097.5 168035
RP11-432H11 7 125775702 125957492 125866597 181790
RP11-475H14 7 125937229 126119121 126028175 181892
CTD-2100M22 7 126070577 126201513 126136045 130936
RP11-16K22 7 126120350 126265569 126192959.5 145219
RP11-309K22 7 126120350 126265569 126192959.5 145219
RP11-290P11 7 126129088 126292020 126210554 162932
RP11-641M11 7 126187314 126368364 126277839 181050
RP11-715K19 7 126238527 126419176 126328851.5 180649
RP11-32905 7 126388390 126541276 126464833 152886
RP11-562D24 7 126512334 126701134 126606734 188800
RP11-619D12 7 126600073 126797107 126698590 197034
RP11-568111 7 126737158 126951836 126844497 214678
RP11-531B18 7 126883462 127104347 126993904.5 220885
RP11-348K6 7 127054946 127264956 127159951 210010
RP11-809F9 7 127205070 127371393 127288231.5 166323
RP11-475K8 7 127285757 127458115 127371936 172358
RP11-640G20 7 127416566 127619167 127517866.5 202601
RP11-282F23 7 127455621 127619168 127537394.5 163547
RP11-155G14 7 127564262 127729340 127646801 165078
RP11-636E12 7 127564296 127741861 127653078.5 177565
RP11-79D5 7 127655629 127814781 127735205 159152
RP11-683N8 7 127701088 127904595 127802841.5 203507
RP11-338L6 7 127774677 127950852 127862764.5 176175
RP11-526K5 7 127830025 128033552 127931788.5 203527
448RP11-66F23 7 127950853 128145770 128048311.5 194917
RP11-638M14 7 128006656 128189702 128098179 183046
CTD-2036B8 7 128187799 128349949 128268874 162150
RP11-198N5 7 128310207 128468642 128389424.5 158435
RP11-396H10 7 128339444 128562653 128451048.5 223209
RP11-69C1 7 128511843 128667708 128589775.5 155865
RP11-126N23 7 128656991 128834751 128745871 177760
RP11-448A19 7 128787761 128997928 128892844.5 210167
CTD-2107H2 7 128979960 129157258 129068609 177298
CTD-235302 7 129085218 129216171 129150694.5 130953
RP11-64302 7 129119357 129296428 129207892.5 177071
RP11-306G20 7 129167640 129352442 129260041 184802
RP11-710121 7 129338473 129518049 129428261 179576
RP11-190G13 7 129413444 129583846 129498645 170402
RP11-2E11 7 129578386 129745580 129661983 167194
RP13-554J11 7 129652384 129744784 129698584 92400
RP11-584H16 7 129702778 129798422 129750600 95644
RP11-537A1 7 129745642 129869408 129807525 123766
RP13-750I6 7 129746887 129889663 129818275 142776
CTD-2214L23 7 129860793 130003621 129932207 142828
RP11-36B6 7 129882101 130056512 129969306.5 174411
RP11-161B24 7 130010308 130168946 130089627 158638
RP 11-44917 7 130045387 130217438 130131412.5 172051
RP11-288L5 7 130145565 130336488 130241026.5 190923
RP11-375L14 7 130266296 130434915 130350605.5 168619
RP11-420J2 7 130388405 130564845 130476625 176440
RP11-692A14 7 130496055 130632752 130564403.5 136697
449RP11-14M12 7 130488687 130643566 130566126.5 154879
RP11-145E16 7 130597244 130756297 130676770.5 159053
RP11-180C16 7 130632753 130787253 130710003 154500
RP13-668E23 7 130680558 130841957 130761257.5 161399
CTD-2063A19 7 130841956 130898507 130870231.5 56551
CTD-2007A16 7 130841962 130973584 130907773 131622
RP11-193117 7 130931500 131118684 131025092 187184
RP11-19B3 7 131030855 131194206 131112530.5 163351
RP11-805M23 7 131166329 131379118 131272723.5 212789
RP11-195M5 7 131252256 131439080 131345668 186824
RP11-348A15 7 131374719 131525870 131450294.5 151151
RP11-24E10 7 131484326 131662166 131573246 177840
RP11-44F19 7 131566704 131737474 131652089 170770
RP11-540B11 7 131603386 131788183 131695784.5 184797
CTD-2234G19 7 131697489 131800637 131749063 103148
RP11-29A12 7 131702292 131861777 131782034.5 159485
RP11-545C1 7 131861778 132061711 131961744.5 199933
CTD-2225B7 7 131967961 132072125 132020043 104164
RP11-734G16 7 132041731 132216707 132129219 174976
RP 11-6706 7 132155853 132328525 132242189 172672
RP11-105M19 7 132274731 132439011 132356871 164280
RP11-435P4 7 132307829 132496405 132402117 188576
CTD-2265P2 7 132430629 132544364 132487496.5 113735
RP11-104L14 7 132499530 132687690 132593610 188160
RP11-25J16 7 132607054 132795898 132701476 188844
RP11-108H23 7 132752166 132919188 132835677 167022
RP11-118J20 7 132856117 133077899 132967008 221782
450RP11-237E23 7 132901984 133053289 132977636.5 151305
CTD-2019H7 7 133001258 133174930 133088094 173672
RP11-641M23 7 133110274 133314244 133212259 203970
RP11-4G15 7 133213460 133359005 133286232.5 145545
RP11-16K7 7 133328686 133493650 133411168 164964
RP11-98D12 7 133357500 133529727 133443613.5 172227
RP11-651P9 7 133533353 133701682 133617517.5 168329
RP11-599C9 7 133567032 133761936 133664484 194904
RP11-69H23 7 133632921 133791741 133712331 158820
RP11-73K10 7 133719760 133885847 133802803.5 166087
RP11-792L21 7 133734311 133920574 133827442.5 186263
RP13-728L15 7 133847795 133993959 133920877 146164
RP11-221G19 7 133893049 134036379 133964714 143330
RP11-615F13 7 133922665 134127976 134025320.5 205311
RP11-248K17 7 133965367 134136822 134051094.5 171455
RP11-597L4 7 134074495 134248828 134161661.5 174333
RP11-814N17 7 134235619 134446899 134341259 211280
RP11-260N14 7 134295876 134456240 134376058 160364
RP11-161C4 7 134364499 134546349 134455424 181850
RP11-166D1 7 134511355 134680583 134595969 169228
RP11-140114 7 134546627 134697486 134622056.5 150859
RP11-706J21 7 134622360 134783209 134702784.5 160849
RP11-649J7 7 134640000 134799096 134719548 159096
RP11-1411 7 134733289 134896863 134815076 163574
RP11-577P14 7 134826046 134999449 134912747.5 173403
RP11-663H22 7 134931508 135119715 135025611.5 188207
RP 11-24123 7 135046341 135198644 135122492.5 152303
451RP11-473G8 7 135125392 135308607 135216999.5 183215
RP11-277F10 7 135295894 135461727 135378810.5 165833
RP11-116N1 7 135314168 135484458 135399313 170290
RP11-607B22 7 135442680 135637665 135540172.5 194985
RP11-811K22 7 135589552 135786273 135687912.5 196721
RP11-733N14 7 135631263 135806424 135718843.5 175161
RP11-324017 7 135676027 135895729 135785878 219702
RP11-798E5 7 135822074 136037994 135930034 215920
RP11-66116 7 135887746 136074343 135981044.5 186597
RP11-48601 7 135907641 136099418 136003529.5 191777
RP11-346J1 7 136040699 136212996 136126847.5 172297
RP11-322H10 7 136075865 136244939 136160402 169074
RP11-708B14 7 136087221 136265690 136176455.5 178469
RP11-294C9 7 136205587 136373210 136289398.5 167623
RP11-107J16 7 136288920 136463723 136376321.5 174803
RP11-777L18 7 136439969 136612770 136526369.5 172801
RP11-805B10 7 136515507 136711418 136613462.5 195911
RP11-19L13 7 136667159 136821404 136744281.5 154245
RP11-115N3 7 136761627 136914342 136837984.5 152715
RP11-360115 7 136770095 136973982 136872038.5 203887
RP11-390H20 7 136833582 137011020 136922301 177438
RP11-29B3 7 136957814 137110063 137033938.5 152249
CTD-2002C18 7 137093304 137207181 137150242.5 113877
RP11-83111 7 137074710 137281029 137177869.5 206319
RP11-20M11 7 137168702 137322726 137245714 154024
RP11-183120 7 137253723 137392056 137322889.5 138333
RP11-175F11 7 137341566 137490372 137415969 148806
452RP11-289F17 7 137365966 137542971 137454468.5 177005
RP11-512K22 7 137419716 137631607 137525661.5 211891
RP11-663A4 7 137535434 137722903 137629168.5 187469
RP11-559C14 7 137708060 137885149 137796604.5 177089
RP11-355D18 7 137927743 138131368 138029555.5 203625
RP11-737E2 7 138095648 138286187 138190917.5 190539
RP11-600E3 7 138153618 138329432 138241525 175814
RP11-787G19 7 138332910 138507966 138420438 175056
RP11-373E1 7 138318449 138533002 138425725.5 214553
RP11-634H22 7 138436289 138614761 138525525 178472
RP11-413B4 7 138537272 138713176 138625224 175904
RP11-1172G19 7 138533003 138728029 138630516 195026
RP13-912P9 7 138634783 138782279 138708531 147496
RP11-202L12 7 138640547 138803809 138722178 163262
RP11-693A14 7 138651930 138803809 138727869.5 151879
RP13-820B19 7 138886360 139026544 138956452 140184
RP11-236H5 7 138936589 139090239 139013414 153650
RP11-265A15 7 138937718 139105508 139021613 167790
CTD-2105E24 7 138967429 139126997 139047213 159568
RP11-65A18 7 138985502 139147510 139066506 162008
RP11-758F21 7 139020010 139213908 139116959 193898
RP11-101M4 7 139093460 139263870 139178665 170410
RP11-812N19 7 139245520 139415953 139330736.5 170433
RP11-561D8 7 139331785 139521722 139426753.5 189937
RP11-795E24 7 139479689 139617245 139548467 137556
RP11-723C11 7 139589728 139760648 139675188 170920
RP11-78806 7 139694523 139880060 139787291.5 185537
453RP11-661B8 7 139703996 139872708 139788352 168712
RP11-304K20 7 139845406 140055499 139950452.5 210093
RP11-416H18 7 139900744 140090590 139995667 189846
RP11-447A24 7 140066850 140232631 140149740.5 165781
RP11-793D16 7 140054475 140251563 140153019 197088
RP11-186024 7 140205233 140367684 140286458.5 162451
RP11-657G24 7 140255824 140451548 140353686 195724
RP11-313020 7 140360091 140527038 140443564.5 166947
RP11-471G1 7 140462195 140641230 140551712.5 179035
RP11-118A19 7 140511823 140653667 140582745 141844
RP11-717H20 7 140617638 140774510 140696074 156872
RP11-155M10 7 140700133 140863676 140781904.5 163543
RP11-120E14 7 140812955 140961603 140887279 148648
RP11-693F16 7 140851580 141019431 140935505.5 167851
RP11-64M15 7 140983746 141135677 141059711.5 151931
RP11-17D6 7 141000038 141163390 141081714 163352
RP11-1353A4 7 141000038 141194658 141097348 194620
RP13-581E15 7 141085851 141248158 141167004.5 162307
RP11-10L5 7 141289326 141430453 141359889.5 141127
RP11-786A19 7 141367324 141547420 141457372 180096
RP11-714J22 7 141429528 141610636 141520082 181108
RP11-143G2 7 141536842 141691318 141614080 154476
RP11-203113 7 141610138 141782205 141696171.5 172067
RP11-32504 7 141638863 141840748 141739805.5 201885
RP11-453N21 7 141750162 141919082 141834622 168920
RP11-114B6 7 141813913 141973680 141893796.5 159767
CTD-2087C12 7 141887557 142030287 141958922 142730
454RP11-114L10 7 141931613 142123518 142027565.5 191905
RP11-368115 7 142045199 142239842 142142520.5 194643
RP11-78G15 7 142067625 142240972 142154298.5 173347
RP11-18B22 7 142252023 142432885 142342454 180862
RP11-556113 7 142402113 142561955 142482034 159842
RP11-202L22 7 142516580 142669655 142593117.5 153075
RP11-811J9 7 142598468 142802162 142700315 203694
RP11-119F21 7 142704281 142763109 142733695 58828
RP11-165B5 7 142740171 142769533 142754852 29362
RP11-407F8 7 142967914 143186365 143077139.5 218451
RP11-137A1 7 143095419 143267019 143181219 171600
RP11-703N5 7 143182512 143354063 143268287.5 171551
RP11-634011 7 143317949 143356258 143337103.5 38309
RP11-466J6 7 143317195 143511372 143414283.5 194177
RP11-714J20 7 143471913 143646353 143559133 174440
RP11-340G20 7 143652126 143846769 143749447.5 194643
RP11-136L16 7 143675486 143835792 143755639 160306
RP11-353H9 7 143806339 143954406 143880372.5 148067
RP11-466N22 7 143863302 144056081 143959691.5 192779
RP11-621J17 7 144003818 144192912 144098365 189094
RP11-747D17 7 144110019 144269719 144189869 159700
RP11-409M7 7 144165741 144322766 144244253.5 157025
RP11-37M18 7 144267725 144436499 144352112 168774
RP11-177L17 7 144289468 144441284 144365376 151816
RP11-597H23 7 144312586 144497195 144404890.5 184609
RP11-185G4 7 144381491 144529157 144455324 147666
RP11-252P1 7 144492756 144644877 144568816.5 152121
455RP11-67908 7 144534763 144701553 144618158 166790
RP11-158G24 7 144633984 144785573 144709778.5 151589
RP11-599M4 7 144701554 144863493 144782523.5 161939
RP11-266G14 7 144777237 144933173 144855205 155936
RP11-204B17 7 144837454 144994137 144915795.5 156683
RP11-107N5 7 145047033 145207126 145127079.5 160093
RP11-711K12 7 145126903 145295731 145211317 168828
RP11-48E17 7 145178445 145322952 145250698.5 144507
RP11-593N14 7 145248588 145439519 145344053.5 190931
RP11-178F1 7 145412559 145588197 145500378 175638
RP11-6J19 7 145530487 145678627 145604557 148140
RP11-328C18 7 145590883 145754644 145672763.5 163761
RP11-141D5 7 145721003 145894012 145807507.5 173009
RP11-161H9 7 145804753 145979323 145892038 174570
RP11-739B3 7 146076031 146277183 146176607 201152
RP11-620C13 7 146198804 146395379 146297091.5 196575
RP11-643A21 7 146381733 146533429 146457581 151696
RP11-699J3 7 146487826 146647058 146567442 159232
RP11-162A9 7 146593600 146755135 146674367.5 161535
RP11-773G19 7 146724436 146880186 146802311 155750
RP11-284J17 7 146833262 147024350 146928806 191088
RP 11-56404 7 146958966 147139262 147049114 180296
RP11-99G19 7 147107321 147284112 147195716.5 176791
RP11-79K23 7 147191958 147343032 147267495 151074
CTD-2025B7 7 147323173 147488874 147406023.5 165701
RP11-89P11 7 147485335 147638644 147561989.5 153309
RP11-76511 7 147532537 147724448 147628492.5 191911
456RP11-323L17 7 147622223 147844328 147733275.5 222105
RP11-801N1 7 147808606 148034588 147921597 225982
CTD-2415L21 7 147928119 148125855 148026987 197736
RP11-185C24 7 147944912 148122806 148033859 177894
RP11-794E21 7 148300593 148469198 148384895.5 168605
RP11-279B9 7 148375225 148520704 148447964.5 145479
RP11-603M10 7 148461442 148664636 148563039 203194
RP 11-749022 7 148499421 148690806 148595113.5 191385
RP11-478H20 7 148761390 148943299 148852344.5 181909
RP11-263017 7 148862483 149037741 148950112 175258
CTD-2140124 7 148984195 149122596 149053395.5 138401
RP11-474L2 7 149018936 149117281 149068108.5 98345
RP11-58609 7 148998753 149157307 149078030 158554
RP11-318D10 7 149011517 149157307 149084412 145790
RP11-728K20 7 149020484 149169295 149094889.5 148811
RP11-473L10 7 149106042 149247375 149176708.5 141333
RP11-544F18 7 149146769 149368311 149257540 221542
RP11-676P18 7 149340017 149499017 149419517 159000
RP11-620K21 7 149417269 149605924 149511596.5 188655
RP11-7P1 7 149638777 149808332 149723554.5 169555
RP11-64C23 7 149763561 149941148 149852354.5 177587
RP11-126M15 7 149807794 150002372 149905083 194578
RP11-684M7 7 149924997 150090017 150007507 165020
RP11-445P2 7 149962182 150275694 150118938 313512
RP11-119F18 7 150172852 150350523 150261687.5 177671
RP11-552G14 7 150219969 150440807 150330388 220838
RP11-717G15 7 150297453 150468061 150382757 170608
457RP11-428M3 7 150360689 150605358 150483023.5 244669
RP11-193C16 7 150468062 150675792 150571927 207730
RP11-60D3 7 150586755 150756902 150671828.5 170147
RP11-113A18 7 150709360 150875049 150792204.5 165689
RP11-639C15 7 150803631 150979651 150891641 176020
RP11-381K9 7 150910300 151092509 151001404.5 182209
RP 11-79612 7 150959344 151131820 151045582 172476
RP11-146E20 7 151134086 151294605 151214345.5 160519
RP11-137021 7 151211236 151395090 151303163 183854
RP11-343L6 7 151253666 151420996 151337331 167330
RP11-208G20 7 151365120 151531931 151448525.5 166811
RP13-507K23 7 151370060 151540322 151455191 170262
RP11-658C6 7 151482865 151649593 151566229 166728
RP11-170E21 7 151593007 151792433 151692720 199426
RP11-1211F5 7 151593007 151805654 151699330.5 212647
RP11-31J9 7 151753465 151895564 151824514.5 142099
RP11-364L19 7 151753465 151900946 151827205.5 147481
RP11-452J20 7 151744858 151951495 151848176.5 206637
RP11-753N9 7 151791192 152030326 151910759 239134
RP11-1137J16 7 151953981 152115488 152034734.5 161507
RP11-399E23 7 152057131 152236516 152146823.5 179385
RP11-349M19 7 152200048 152401585 152300816.5 201537
RP11-715L6 7 152327290 152513240 152420265 185950
RP 11-2616 7 152438821 152598400 152518610.5 159579
RP11-103E18 7 152480190 152641769 152560979.5 161579
RP11-138K3 7 152574934 152741364 152658149 166430
RP 11-794122 7 152617487 152836204 152726845.5 218717
458RP11-354C19 7 152783136 152936999 152860067.5 153863
RP11-737G12 7 152783236 153002753 152892994.5 219517
RP11-135F23 7 152872498 153054474 152963486 181976
RP11-732N20 7 153035961 153190158 153113059.5 154197
RP11-30J12 7 153036456 153195879 153116167.5 159423
RP11-564B10 7 153161824 153322470 153242147 160646
RP13-620M21 7 153220028 153397424 153308726 177396
RP13-862B20 7 153379129 153511918 153445523.5 132789
RP13-500D13 7 153402959 153549213 153476086 146254
RP11-389118 7 153418445 153586933 153502689 168488
RP11-79K9 7 153441322 153586968 153514145 145646
RP11-641017 7 153437393 153619711 153528552 182318
RP11-446021 7 153437393 153626868 153532130.5 189475
RP11-422E4 7 153511919 153706971 153609445 195052
RP11-232A2 7 153816356 153965944 153891150 149588
RP11-476H24 7 153933858 154141084 154037471 207226
RP11-51M20 7 154155007 154319485 154237246 164478
RP11-448D3 7 154155214 154356493 154255853.5 201279
RP11-799A21 7 154155214 154376481 154265847.5 221267
RP11-295N1 7 154208705 154415465 154312085 206760
RP11-317A13 7 154265817 154458618 154362217.5 192801
RP 11-279022 7 154298853 154449825 154374339 150972
RP11-143006 7 154341891 154504352 154423121.5 162461
RP13-553J3 7 154366740 154483393 154425066.5 116653
RP13-559G12 7 154396881 154482253 154439567 85372
CTD-2014I17 7 154651263 154792424 154721843.5 141161
RP11-60D5 7 154729457 154893855 154811656 164398
459RP11-61K21 7 154729921 154901700 154815810.5 171779
RP11-265E13 7 154761099 154935115 154848107 174016
RP11-6903 7 155000392 155154956 155077674 154564
RP11-451N23 7 155091298 155274533 155182915.5 183235
RP11-134M1 7 155248338 155411612 155329975 163274
RP11-264P5 7 155371524 155542400 155456962 170876
RP11-459H7 7 155514709 155739542 155627125.5 224833
RP11-691F21 7 155658864 155839469 155749166.5 180605
RP11-728F9 7 155846192 156008086 155927139 161894
RP11-133G9 7 155881752 156086853 155984302.5 205101
RP11-776L17 7 155922117 156121832 156021974.5 199715
CTD-2008L1 7 155979854 156120116 156049985 140262
RP11-693K11 7 156058580 156225616 156142098 167036
RP11-798G13 7 156203928 156352462 156278195 148534
RP11-333G1 7 156256187 156451285 156353736 195098
RP11-51L24 7 156336152 156484531 156410341.5 148379
RP13-508B4 7 156451286 156610548 156530917 159262
RP11-80N17 7 156587049 156681068 156634058.5 94019
RP11-527G9 7 156587049 156748116 156667582.5 161067
RP11-172F22 7 156568073 156782288 156675180.5 214215
RP11-637M7 7 156660000 156877064 156768532 217064
RP11-732K4 7 156791707 156979406 156885556.5 187699
RP11-666K15 7 156882549 157089996 156986272.5 207447
RP11-815G4 7 156999684 157238725 157119204.5 239041
RP11-50D7 7 157105012 157315334 157210173 210322
RP11-452C13 7 157103817 157328557 157216187 224740
CTD-2041J20 7 157203152 157325773 157264462.5 122621
460RP13-965C1 7 157203152 157350018 157276585 146866
RP11-599B11 7 157422158 157552466 157487312 130308
RP11-711A5 7 157430294 157585876 157508085 155582
RP 11-68314 7 157507520 157585876 157546698 78356
RP11-434G15 7 157485044 157663102 157574073 178058
RP11-744K13 7 157575793 157760598 157668195.5 184805
RP 13-967121 7 157760858 157800439 157780648.5 39581
RP13-613J3 7 157763325 157865942 157814633.5 102617
RP11-582J15 7 157825922 157983696 157904809 157774
RP11-106C11 7 157933821 158104642 158019231.5 170821
RP11-240J1 7 158077275 158252830 158165052.5 175555
RP11-664B5 7 158211184 158402685 158306934.5 191501
CTD-2031M22 7 158343036 158377124 158360080 34088
RP11-129F1 7 158343036 158493889 158418462.5 150853
RP11-133J16 7 158343435 158496543 158419989 153108
RP11-83D3 7 158413174 158594317 158503745.5 181143
RP13-1052O2 7 158466998 158612807 158539902.5 145809
CTD-2319F20 7 158498002 158624831 158561416.5 126829
RP11-45519 8 119194110 119373058 119283584 178948
RP 11-45519 8 119194110 119373058 119283584 178948
RP11-167H17 11 28573327 28607450 28590388.5 34123
RP11-439P15 12 13717255 13919901 13818578 202646
RP13-839K18 12 39645817 39775948 39710882.5 130131
RP11-41P11 14 62953734 62995830 62974782 42096
RP11-611C24 16 7700099 7794509 7747304 94410
RP11-297H14 16 32404379 32439725 32422052 35346
RP11-20L17 19 32534541 32639571 32587056 105030
461CTD-2276I11 - 0 0 0 0
RP 11-252121 - 0 0 0 0
RP11-253J2 - 0 0 0 0
RP11-256G7 - 0 0 0 0
RP11-274A2 - 0 0 0 0
RP11-435D24 - 0 0 0 0
RP 11-470121 - 0 0 0 0
RP11-522C18 - 0 0 0 0
RP11-574E17 - 0 0 0 0
RP11-753N11 - 0 0 0 0
462A. 3 Drosophila background hybridisation controls
Eight BAC clones from Drosophila melanogaster were selected as
background hybridisation controls. These clones were purchased from the 
BACPAC resource centre at Oakland Children’s Hospital, Oakland, CA, USA. 
Clones were hybridised to normal human chromosomes by Fluroescnce in-situ 
hybridisation (FISH) and found not to hybridise to human chromosomes.
Clone ID Drosophila Chromosome 
mapping
FISH result against 
human
RP98-10P9 3L-66E4 No hybridisation
RP98-5L4 X No hybridisation
RP98-38L1 X No hybridisation
RP98-3G6 3L No hybridisation
RP98-33N24 X No hybridisation
RP98-44K7 3L-74C1 No hybridisation
RP98-9C21 3L-9C21 No hybridisation
RP98-7P15 X No hybridisation
463